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Summary 
Pharmacovigilance plays an important role in monitoring adverse drug reactions 
(ADRs) resulting from an intervention related to medicinal products. Due to the 
frequencies and potentially serious consequences, ADRs pose a considerable 
economic and clinical burden. Patients with an underlying risk factor or 
established cardiovascular disease (CVD) are usually on long-term treatment, thus 
it is important to monitor the efficacy and safety of drugs prescribed. Modern 
antihypertensive drugs have been showed to effectively reduce high blood 
pressure (BP) hence prevents the development or complications of CVD in high-
risk patients. However, there is evidence from clinical trials and observational 
studies suggesting the association between antihypertensive drugs and risk of 
cancer. Furthermore, these observations are inconsistent and the majority of 
clinical trials were directed towards cardiovascular outcomes.  
The thesis is divided into five main result chapters (4 to 8) based on the 
antihypertensive drug classes evaluated for risk of cancer in the systematic review 
and meta-analyses. Altogether, 90 randomised controlled trials (RCTs) enrolling 
390,750 participants with an average follow-up of 3.5 years were included for 
qualitative and quantitative analysis.   
Angiotensin converting enzyme inhibitor (ACEI) and risk of cancer: ACEI lowers 
BP through preventing the conversion of angiotensin 1 to angiotensin II by ACE in 
the renin-angiotensin system (RAS) pathway. In the present study, no significant 
association between ACEI and risk of cancer incidence or cancer-related death is 
reported. Factors such as tissue binding capacity, comparator used, clinical 
settings, age, and study duration do not affect the risk of cancer overall.  
Angiotensin receptor blockers (ARB) and risk of cancer: In the RAS pathway, 
ARB acts directly on the angiotensin type 1 (AT1) receptor to inhibit downstream 
signalling which results in downregulation of sympathetic activity and lowering of 
BP. The present meta-analysis has reported no association between ARB use and 
risk of cancer incidents or cancer-related mortality. Subgroup assessment 
indicates that valsartan has a cancer protective effect, particularly against lung 
cancer. Patients’ clinical settings, age, and study duration do not influence the 
risk of cancer in relation to ARB overall.  
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Calcium channel blockers (CCB) and risk of cancer: As a class, CCBs are potent 
vasodilators and are recommended for use as first or second-line drugs in treating 
hypertension. This study has reported a marginally increased risk of cancer 
incidents (P=0.06) but not cancer-related death overall in relation to CCB use. 
DHP-CCB is associated with a 9% increased risk for cancer compared to controls 
(P=0.05). A positive relationship is also observed with older patients and in 
patients with longer exposure to CCB. Therefore, a properly designed further 
research into the risk of a specific type of cancer with use of DHP CCB is warranted 
to detect a safety signal.    
Beta-blockers (BB) and risk of cancer: Inhibition of stress mediators from 
activating beta-adrenoceptors has been proposed to be the underlying mechanism 
by which BB lower the risk of cancer. This study has found no evidence of an 
association between BB and the risk of cancer or cancer-related death. Factors 
such as cardioselectivity, treatment indication, age and study duration do not 
have an impact on cancer risk altogether. 
Thiazide diuretics (TZ) and risk of cancer: TZ induces diuresis at the distal 
convoluted tubule and a great number of studies had attempted to link TZ and 
risk of renal cancer. No evidence of an association between TZ and the risk of 
cancer or cancer mortality is reported in the present study. Chemical structure 
differences, clinical settings, age, and study duration does not significantly 
influence the risk of cancer in relation to TZ use. 
Strengths and limitation: The strengths of the systematic review and meta-
analyses conducted in this thesis include; only RCTs were included, a 
comprehensive search strategy spanning over 60 years with no language 
restrictions, and a sufficiently large sample size of over 390,000 trial participants 
from various clinical settings with an average 3.5 years follow-up duration. Lack 
of individual-level data and non-standard reporting of cancer in RCTs are the main 
limitations.  
Future recommendations: All RCT evaluating drug intervention should pre-
identify cancer as one of the study outcomes as part of drug safety monitoring.
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1 Introduction 
1.1 Pharmacovigilance  
 Definition for pharmacovigilance 
The World Health Organization (WHO, 2002) defined pharmacovigilance as “the 
science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem”. A similar 
definition is adopted by the International Council for Harmonisation (ICH) and 
Council for International Organizations of Medical Science (CIOMS) The field of 
drug safety monitoring also involves issues such as substandard medicine, 
medication error, lack of efficacy reports, abuse and misuse of drugs, adverse 
drug-substance interactions (e.g. chemicals, food, other medicine), and drug-
related mortality assessment (WHO, 2002). Over the years, safety concerns have 
widened to include herbal products, traditional and complementary medicines, 
blood products, biologicals, medical devices, and vaccines. According to the WHO 
(2002), the main goals of pharmacovigilance are 1) to improve patient care, public 
health and safety with regards to use of medicines; 2) to contribute to assessment 
of drug safety and efficacy and 3) to support public health programmes by 
providing reliable and balanced information to the public.  
1.2 Historical perspective of pharmacovigilance 
The WHO Programme for International Drug Monitoring was initiated following a 
worldwide response to the infamous thalidomide disaster. The 16th World Health 
Assembly held in 1963 had called for a resolution (WHA 16.36)(WHO, 1963) to 
systematically collect information on serious adverse drug reactions (ADR) during 
drug development and post-marketing which subsequently led to the creation of 
WHO Pilot Research Project for International Drug Monitoring in 1968 (WHO, 
2002). The rationale of this programme was to develop a system, applicable 
internationally, to identify rare ADR that could not be detected through clinical 
trials (Olsson, 1998). Following the pilot project in the United States (US), an 
international database (also known as VigiBase) was set up in Geneva in 1971 and 
subsequently moved to Uppsala in 1968, hence managed by UMC (Uppsala 
Monitoring Centre, 2017).    
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As of 2017, 125 countries are full members of the WHO Programme for 
International Drug Monitoring (Uppsala Monitoring Centre, 2017). Member States 
of this programme would collect, evaluate, and submit reports of suspected 
adverse drug reactions associated with medicinal products from individual case 
histories to VigiBase. These are known as individual case safety reports (ICSRs). 
UMC is responsible for validating this data judiciously and consequently 
disseminate the outcomes with member countries.  
1.3 International collaboration and regulatory authorities 
The following section describes the important organisations that play a key role 
in the global administration of pharmacovigilance.   
 The World Health Organization (WHO)  
WHO is a United Nation (UN) agency that specialized in global public health. The 
WHO work in areas encompasses health system development; communicable and 
non-communicable diseases treatment and prevention; health promotion through 
life-course; preparedness, surveillance, and response during emergencies; and 
corporate services (WHO, 2017). The WHO Department of Essential Medicines and 
Health Products (EMP) in collaboration with the UMC promote pharmacovigilance 
at the country level. UMC is an independent, non-profit organization associated 
with WHO. Based in Sweden, UMC supports and coordinates the WHO Programme 
for International Drug Monitoring since 1978.  
 The International Council for Harmonization (ICH) 
The ICH is a global organisation with the main goal is to produce, recommend and 
disseminate global standards for development and registration of medicines. 
Originally known as the International Conference on Harmonisation, this 
organisation was founded in 1990 bringing together regulatory agencies and 
industry associations of Europe, US, and Japan which are acknowledged as the 
founding regulatory members (ICH, 2017). In the first decade of its establishment, 
some of the important work undertaken included the Medical Dictionary for 
Regulatory Activities (MedRA) and the Common Technical Document (CTD).  The 
new ICH association was established on 23rd October 2015 with attention directed 
towards extending the benefits of harmonisation beyond its founding regions. As 
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of June 2017, its members comprised regulatory authorities from Singapore, 
China, Brazil and Republic of Korea and industrial associations such as 
Biotechnology Innovation Organization (BIO), World Self-Medication Industry 
(WSMI), and International Generic and Biosimilar Medicines Association (IGBA) 
(ICH, 2017). The ICH members actively support adherence to ICH guidelines, 
appoint experts in Working Groups, and support the aims of the ICH association. 
Non-voting observers also included regulatory bodies from other countries such as 
Australia, India, Russia, and many others who may contribute input to the ICH 
activities. 
 The Council for International Organizations of Medical 
Science (CIOMS) 
The CIOMS is an international, independent, non-profit organization established 
jointly by WHO and the United Nations Educational, Scientific and Cultural 
Organization (UNESCO) in 1949 (CIOMS, 2017). The main mission is to embolden 
and promote global biomedical scientific activities in conjunction with United 
Nation agencies by gathering representative of biomedical scientific community 
worldwide. One of the core activities of CIOMS includes the drug development and 
use programme which results in important works in pharmacovigilance (CIOMS, 
2017). The first Working Group on pharmacovigilance was commissioned in 1986 
which was known as the Working Group on International Reporting of Adverse Drug 
Reactions (CIOMS Working Group, 1987). Following the first work, several 
numbered and unnumbered Working Groups have been launched to address 
important topics in pharmacovigilance (CIOMS, 2017). Several CIOMS Working 
Group guidelines have served as a basis for several ICH guidelines. For example, 
the ICH E2 Clinical Safety Data Management-Definitions and standards for 
expedited reporting (ICH, 1994) was based on the CIOMS Working Group I and II 
reports (CIOMS, 2017). 
 Regulatory authorities in states member 
Drug regulatory authorities play an important role in observing pharmacovigilance 
at the national or regional level. For example in the US, the Food and Drug 
Administration (FDA) is the agency responsible in ensuring the safety and 
effectiveness of human and veterinary drugs, vaccines, biological products and 
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medical devices intended for human uses apart from food products (FDA, 2018). 
The regulation set up by FDA extends to all 50 states in the US and other US 
territories and possessions including Columba, Puerto Rico, Guam, Virgin Islands, 
and American Samoa. In Europe, the European Medicines Agency (EMA) 
coordinates pharmacovigilance activities in 28 member states of the European 
Union (EU) as well as European Economic Area (EEA) (EMA, 2017). The main 
responsibilities of EMA are to facilitate development and access to medicines, 
evaluate an application for marketing authorisation, monitor the safety of 
medicines, and provide information to healthcare professionals and the public 
(EMA, 2017).  
For the remaining non-EU European countries, pharmacovigilance is regulated by 
specific governmental agencies. For example, Swissmedic is the agency 
responsible for authorisation and oversight of medicinal products in Switzerland 
(Swissmedic, 2017). Likewise in Asia and the rest of the world, regulation and 
authorization of pharmaceutical products are managed by individual regulatory 
agencies specific to the country. In Japan, the regulatory framework for 
pharmaceutical products and medical devices is governed by the Pharmaceuticals 
and Medical Devices Agency (PMDA) which is supported by the Japan Ministry of 
Health, Labour and Welfare (MHLW) (Okada et al., 2015). These national centres 
vary in term of activities, source and funding with most are partly funded by 
ministries of health. 
1.4 The importance of pharmacovigilance 
Pharmacovigilance and all drug safety issues are relevant for all whose life is 
affected in any way by medical interventions. The wide range of stakeholders 
involved comprised policy makers, healthcare practitioners, pharmaceutical 
industries and scientists, health epidemiologist, health economist, health 
administrators, consumer groups, and patients among others (WHO, 2002). The 
main focus of pharmacovigilance concerned with only two outcomes and that is 
safety and efficacy (Siramshetty et al., 2016). Therefore, pharmacovigilance is 
important in ensuring patients’ safety throughout the entire drug development 
cycle as well as when the drug is readily available in the market. Additionally, 
pharmacovigilance activities allow drug safety officials or related authorities to 
recommend that a drug development process be suspended or an approved drug 
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is pulled from the market whenever a concern arises. In a nutshell, 
pharmacovigilance is important in improving drug safety and the prevention of 
adverse events related to adverse drug reactions (ADR).  
  Definitions and terminologies associated with ADR  
1.4.1.1 Side effect 
According to the WHO International Drug Monitoring Programme, the side effect 
is defined as “any unintended effect of a pharmaceutical product occurring at 
doses normally used in man, which is related to the pharmacological properties of 
the drug” (Edwards and Biriell, 1994). This effect can be therapeutic or adverse. 
Occasionally, certain drugs or procedures are prescribed specifically for their side 
effect. In this situation, the effect is no longer known as a side effect but the 
intended effect. For instance, sildenafil which was originally intended for the 
treatment of hypertension and angina was subsequently found to be more 
effective in inducing an erection in men (Ghofrani et al., 2006). Following this 
discovery, sildenafil is currently used for the treatment of erectile dysfunction.  
1.4.1.2 Adverse event  
The WHO had defined an adverse event as “any untoward medical occurrence in 
a patient or clinical investigation subject administered a pharmaceutical product 
and which does not necessarily have to have a causal relationship with this 
treatment” (EMA, 1995). Meanwhile, Aronson and Ferner (2005) proposed the 
definition of an adverse event as “any abnormal sign, symptom, laboratory test, 
a syndromic combination of such abnormalities, untoward or unplanned 
occurrence (e.g. an accident or unplanned pregnancy), or any unexpected 
deterioration in a concurrent illness.” In the context of drug safety, an adverse 
event can be any unfavourable sign, symptom, or disease that patient experienced 
temporarily while taking a drug which may or may not be related to the treatment. 
All adverse drug effects are an adverse event, but not all adverse events are drug-
induced. For example, hospital admission due to pneumonia whilst a patient is on 
drug therapy is identified as an adverse event but the event may or may not be 
caused by the drug intake.  
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1.4.1.3 Adverse drug reactions (ADRs) 
According to WHO (1972), a drug is defined as any substance or product that is 
used or intended to be used to modify or explore physiological systems or 
pathological states for the benefit of the recipients. From a medical perspective, 
the term “drug” and “medicine” are often interchangeably used and they have a 
synonymous meaning. In clinical settings, drugs are usually prescribed either to 
help diagnose, treat, cure, or prevent disease or any abnormal conditions; to 
alleviate pain or suffering; or to control any physiological or pathological 
condition. Prescribers and patients expect the approved drug to be “safe and 
effective” in term of intended drug reactions; therefore, any unwanted, 
unintended, and toxic effects of drugs are termed “adverse drug reactions.” 
An adverse drug reaction (ADR) is defined as “a response to a drug which is noxious 
and unintended, and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the modifications of 
physiological function” (WHO, 1972). The WHO’s definition, however, was vague 
as it does not suggest the scale of reactions where inclusion of minor or 
insignificant reaction would defeat the surveillance system as they currently 
operate. Hence to overcome this ambiguity, a more recent definition was 
proposed by Edwards and Aronson (2000) : “An appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, 
which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product.” 
The terms “adverse reaction” and “adverse effect” are commonly used 
interchangeably. The differences between these two terms are distinguished by 
considering the emergence of ADR. An ADR arises from an interaction between an 
extrinsic component (e.g. a drug or metabolite, a contaminant) and an intrinsic 
factor (e.g. tissue protein such as a receptor, ion channel, or enzyme) which are 
distributed at the same site leading to an adverse outcome and subsequently 
adverse reaction (Aronson, 2013). An adverse effect is usually seen from the point 
of view of the drug. While ADRs are usually manifested as clinical signs or 
symptoms, adverse effects are usually detected by laboratory tests or clinical 
investigations such as gastrointestinal endoscopy or abdominal ultrasound 
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(Aronson, 2013). For example, prolonged treatment with glucocorticoid may lead 
to bone demineralisation also known as osteoporosis which is the adverse effect 
of therapy. The bone fracture caused by osteoporosis in patients taking 
glucocorticoid therapy is the adverse drug reaction. 
However, abnormal laboratory tests unaccompanied by signs or symptoms are not 
ADR or adverse effect. This is known as markers of adverse effects. 
1.4.1.4 Unexpected adverse drug reactions 
According to the standard definitions recommended by ICH (1994), unexpected 
ADR is defined as “an adverse reaction, the nature or severity of which is not 
consistent with the applicable product information.”  
1.4.1.5 Serious adverse event or adverse drug reaction 
It is important to clarify that the term ‘serious’ is not synonymous to ‘severe.’ 
Severity is us usually used to describe the intensity of a specific event such as 
mild, moderate, or severe (Aronson and Ferner, 2005). However, the event itself 
may not be relative to medical significant such as a severe headache or a severe 
cough. A serious event or reaction is usually associated with an occurrence which 
is life-threatening or where normal functioning of a patient is affected. Therefore, 
ICH (1994) had defined serious adverse event or ADR as” A serious adverse event 
(experience) or reaction is any untoward medical occurrence that at any dose:[1] 
results in death, or [2] is life threatening, or [3] requires inpatient hospitalisation 
or prolongation of existing hospitalisation, or [4] results in persistent or significant 
disability/incapacity, or [5] is a congenital anomaly/birth defect. As well as 
adding cancer to point [5], Aronson and Ferner (2005) had also put forward two 
additional serious adverse events or ADR: [6] requires medical or surgical 
intervention to preclude permanent impairment of a body function or permanent 
damage to a body structure, or [7] is any medical event that would be regarded 
as serious if it had not responded to acute treatment.  
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 Drugs withdrew after ADRs observed in patients with a long-
term medical condition 
In patients with chronic conditions such as diabetes and hypertension, treatments 
are generally life-long. Therefore, it is important to monitor the efficacy and 
safety of drug prescribed. Certain latent adverse reactions that were not detected 
during drug development and licensing could arise after decades of exposure such 
as cancer. Various events such as reported severe side effects or deaths, lack of 
efficacy, and regulatory or manufacturer’ business issues could be the reason a 
drug is withdrawn from the market post-approval (Fung et al., 2001, Siramshetty 
et al., 2016). Drugs withdrawn due to ADR can be triggered by various sources of 
evidence including anecdotal reports, case reports, clinical trials, observational 
studies, systematic reviews, or animal studies (Lortie, 1986, Onakpoya et al., 
2016). A systematic review of 462 medicinal products withdrawn showed that 
hepatotoxicity (18%) was the commonly reported ADR resulting in withdrawal and 
this was followed by immune-related reactions (17%), neurotoxicity (16%), 
cardiotoxicity (14%), carcinogenicity (13%), haematological toxicity (11%), and 
drug abuse and dependence (11%) (Onakpoya et al., 2016). Additionally, deaths 
contributed to 25% of reasons for drugs withdrawal. This review also demonstrated 
that drug withdrawals varied geographically with 43 (9.3%) products were 
withdrawn worldwide whereas the remaining 419 (90.7%) products were 
withdrawn in only one or two or more countries. The following sections describe 
the example of drugs used for chronic diseases which have been withdrawn from 
the market. 
1.4.2.1 Antidepressants 
Monoamine oxidase inhibitors (MAOIs) were the first class of antidepressant to be 
developed. It acts by elevating the level of norepinephrine, serotonin, and 
dopamine by inhibiting an enzyme known as monoamine oxidase. 
Phenoxypropazine and mebanazine belong to the MAOI class that was introduced 
to the market in the early 1960s. However, following reports of hepatotoxicity 
and drug interactions, both drugs were withdrawn from the UK market in 1966 and 
1975 respectively (Onakpoya et al., 2016). Around the same period, scientists had 
hypothesized that serotonin deficiency may be the aetiological factors for 
depression (Cowen and Browning, 2015) hence the recommendation to use L-
Chapter 1 Introduction 32 
tryptophan as an antidepressant and a natural hypnotic (Boman, 1988). This amino 
acid is a metabolic precursor to serotonin and was introduced into the market in 
1963 (Onakpoya et al., 2016). However, L-tryptophan was discontinued worldwide 
after more than 20 years in the market following report of deaths associated with 
eosinophilia-myalgia syndrome (Onakpoya et al., 2016). Zimelidine was another 
antidepressant that was withdrawn worldwide. It was one of the first selective 
serotonin reuptake inhibitor (SSRI) to be marketed for use in depression in 1982 
(Fagius et al., 1985, Onakpoya et al., 2016). Review of 13 case reports by the 
Swedish ADR committee had found that those receiving zimeldine had a 2.5 fold 
increased risk of developing Guillain-Barre syndrome (Fagius et al., 1985), a rare 
but serious autoimmune condition that leads to damage of the peripheral nervous 
system. These events had prompted the manufacturer to withdraw this drug from 
the market in 1983 (Onakpoya et al., 2016).  
1.4.2.2 Oral hypoglycaemic agents (OHA) 
Oral hypoglycaemic agents (OHA) or also known as anti-diabetic drugs also are 
used to treat type 2 diabetes mellitus (T2DM) by lowering blood glucose. The use 
of several OHA agents has been discontinued in a certain region or country due to 
ADR in the past decades. Biguanides are a class of OHA derived from a chemical 
compound known as guanidine which has hypoglycaemic properties but too toxic 
for clinical use (Quianzon and Cheikh, 2012). In the 1950s, three biguanides-
phenformin, buformin, and metformin- were introduced for the treatment of 
T2DM (Quianzon and Cheikh, 2012). Despite their potency in lowering blood 
glucose (Geldermans et al., 1975), phenformin and buformin were discontinued in 
many countries due to severe metabolic acidosis and hepatotoxicity (Fung et al., 
2001, Onakpoya et al., 2016).  
Thiazolidinedione is another class of OHA which acts by activating the peroxisome 
proliferator-activated receptors gamma (PPARγ), a nuclear receptor. Troglitazone 
was the first thiazolidinedione to be approved for clinical use in 1997 (Onakpoya 
et al., 2016). However, its use has been discontinued in the same year it was 
introduced in several countries including the UK, US, Canada, and Switzerland due 
to reports of hepatotoxicity (Fung et al., 2001, Onakpoya et al., 2016). Another 
member of thiazolidinedione, rosiglitazone which was introduced in 1999, was 
withdrawn from the European market in 2011 after reports of increased risk of 
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heart attacks as demonstrated in the Rosiglitazone evaluated for cardiovascular 
(CV) outcomes in oral agent combination therapy for type 2 diabetes (RECORD) 
study (Nissen and Wolski, 2007). In the US, rosiglitazone prescription was 
restricted to those who have shown good control and those with poor blood glucose 
control despite treatment with other OHA after consultation with their healthcare 
provider (FDA, 2011b). However, these restrictions were removed in 2013 and 
prescription of rosiglitazone was considered safe for the treatment of T2DM in the 
US after re-assessment of safety data (FDA, 2015). Meanwhile, recent longitudinal 
studies have demonstrated a small risk of bladder cancer associated with the use 
of another member of this class known as pioglitazone (Lewis et al., 2011, Piccinni 
et al., 2011). Correspondingly, the EMA had recommended contraindications and 
caution to the prescription of this agent in clinical settings as well as initiating a 
region-wide review to investigate this safety signal (EMA, 2011). 
1.4.2.3 Antihypertensive drugs    
Antihypertensive agents are one of the commonest cardiovascular (CV) drugs 
prescribed for long term therapy. Over the years, certain antihypertensive drugs 
have been withdrawn from the market for various reasons. Nitrates have been 
around for a very long time and it has been assumed to be the first 
antihypertensive drug discovered in the early 20th century (Wallace and Ringer, 
1909, Fye, 1986). Potassium nitrate or also known as saltpetre had demonstrated 
blood pressure (BP) lowering property in both human and animals (Reichert, 1880) 
by promoting nitric oxide synthesis hence causing a direct vasodilatory effect on 
the arteries. It was introduced into the market for the treatment of hypertension 
and ascites in 1901 (Onakpoya et al., 2016). However, its use has been 
discontinued in France, Egypt, and Venezuela effective in the 1980s due to 
potential carcinogenic risk observed in post-marketing surveillance (Onakpoya et 
al., 2016). Since the introduction of modern antihypertensive therapy, this 
particular agent has been rarely used. 
Beta-adrenergic blockade has been considered as a possible treatment for 
hypertension in the early 1960s (Black and Stephenson, 1962). Practolol, a 
selective beta-blocker (BB), was one of the earliest of its class to be developed 
and introduced into the market in 1970 for treatment of hypertension, angina, 
and cardiac dysrhythmias (Onakpoya et al., 2016). Following reports of a serious 
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delayed idiosyncratic oculo-mucocutanous syndrome associated with the use of 
this drug (Anonymous, 1975a), practolol was withdrawn from multiple markets 
including the UK in 1975 (Onakpoya et al., 2016). Meanwhile, the marketing of a 
non-selective BB known as dilevalol introduced in 1986, was discontinued 
worldwide due to hepatotoxicity reports (Fung et al., 2001, Onakpoya et al., 
2016). Nevertheless, there was no evidence to suggest that the other BB subclass 
is associated with risk of serious ADR. Alternatively, studies have linked BB therapy 
to increased risk of developing incident diabetes (Dahlöf et al., 2005, Elliott and 
Meyer, 2007).        
Calcium channel blockers (CCB) have been showed to be more effective than BB 
in lowering the risk of CV mortality (Chen et al., 2010). Mibefradil, a non-selective 
calcium antagonist, was introduced in 1997 for the treatment of hypertension and 
chronic angina pectoris (Onakpoya et al., 2016). However, less than a year after 
its approval, this agent was pulled off from the market in 38 countries by its 
manufacturer (Roche) (Bradbury, 1998). Combination therapy with mibefradil and 
certain lipid-lowering agents such as statins or other drugs have been shown to be 
associated with rhabdomyolysis as well as suppression of the sinoatrial node that 
could result in fatality (Anonymous, 1998). 
Above are just some examples of drugs intended for long-term therapy which use 
has been discontinued worldwide or certain countries. In summary, continuous 
post-marketing surveillance of drug safety is essential in the identification of 
adverse effects. Furthermore, the role of the pharmaceutical industry, 
academics, and regulatory authorities are undeniably important in the efforts of 
drug safety monitoring.  
1.5 Cardiovascular disease and hypertension 
 Epidemiology of cardiovascular disease 
Cardiovascular disease (CVD) is a term broadly used to describe disorders affecting 
the heart and blood vessels. This group of disorders includes coronary heart 
disease (CHD), cerebrovascular disease, peripheral arterial disease, rheumatic 
heart disease, deep vein thrombosis, and pulmonary embolism. According to the 
latest statistics from WHO, approximately 17.7 million people died from CVDs in 
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2015, representing 31.1% of deaths worldwide and an increment of 3.6% since the 
year 2000 (WHO, 2018b). Of these, CHD and stroke contributed the highest 
percentage of CVD mortality (15.5% and 11.1% respectively) consequently 
accounted for the top two cause of death worldwide. The most recent statistics 
from 2015 also showed CVD contributed 407.6 million disability-adjusted-life-
years (DALY) in 7.3 billion people from 185 countries, representing 15% of total 
DALYs and also the highest for non-communicable disease (WHO, 2018b). DALY is 
a time-based measure combining time live with a disability and time lost due to 
premature mortality (Anand S. and Hanson K., 1997). More importantly, CHD and 
stroke were the two leading causes of DALYs worldwide with 160 countries had 
one of these conditions as the leading cause of DALYs in that particular year (GBD 
2015 DALYs and HALE Collaborators, 2016).  
In the United Kingdom (UK), CVD is the caused of more than 26% of all deaths and 
premature deaths. This condition is common in the north of England, central 
Scotland, and the south of Wales (British Heart Foundation, 2017). The cost of 
treating CVD in the UK is estimated to be approximately £9 billion annually (British 
Heart Foundation, 2017). 
 Risk factors for CVD 
There are many risk factor associated with CVD and these attributes can be 
categorised into modifiable and non-modifiable risk factors. Modifiable risk 
factors include physical activity, cigarette smoking, dietary habit, socioeconomic 
status, hypertension, and obesity. Non-modifiable risk factors comprise age, 
gender, ethnicity, family history, and diabetes. Having one of these risk factors 
does not necessarily impose one to CVD, however, the presence of more risk factor 
will increase the likelihood. Apart from these classic clinical factors, recent 
research has also considered novel risk markers for developing CVD such as a lipid-
related marker, c-reactive protein, micro-RNA (miRNA), N-terminal–proBNP, 
coronary artery calcium score and plaque burden (Thomas and Lip, 2017). 
1.6 Hypertension 
Blood pressure (BP) is the force that is exerted by the blood upon the wall of blood 
vessels, especially the arteries. The overall BP is maintained by cardiac output 
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(CO) and peripheral vascular resistance. Cardiac output (CO) - the amount of blood 
pumped by the heart through the circulatory system per minute (ml/min) - is 
determined by the heart rate (HR) and stroke volume (SV). HR is the number of 
heart beats per minute whereas SV is the amount of blood pumped from the 
ventricle per beat. Peripheral vascular resistance – the resistance to the flow of 
blood in peripheral arterial vessels – is conditional on the functional and 
anatomical changes in the arteries and arterioles such as vessel diameter, the 
tone of vascular musculature and blood viscosity. Arterial pressure control is 
greatly determined by serum sodium and renal function which are important in 
fluid balance mechanism (Guyton et al., 1984). If any changes should occur to 
either salt intake or kidney function, the exact pressure level to which the arterial 
pressure will be controlled would be altered accordingly. Autoregulatory 
responses for local blood flow will instinctively adjust the blood vessel diameter 
to re-establish optimal tissue perfusion. Failure of autoregulation results in 
increased peripheral vascular resistance and consequently elevated BP. High BP 
or also known as hypertension is a long-term medical condition in which the BP in 
the arteries is persistently elevated. 
 Causes of hypertension 
A small number of patients have an underlying renal, adrenal or monogenic cause 
of elevated BP. However, the aetiology for high BP in the majority of patients 
remains unclear and no single identifiable cause is found and their condition is 
diagnosed as essential hypertension. There is growing evidence that the causes of 
hypertension are multifactorial meaning there are several factors when the 
effects are combined leads to the development of hypertension (Neutel and Smith, 
1999). Complex interaction among multiple environmental factors and multiple 
gene factors at various combinations play a crucial role in determining the risk of 
developing hypertension. From the genetic aspect, development of hypertension 
is attributable by many genes or gene combinations (Padmanabhan et al., 2015). 
Currently, over 60 loci associated with BP or hypertension were discovered from 
genome-wide association studies (GWAS) and candidate gene studies (Zheng et 
al., 2015). Meanwhile, various environmental factors involving components of 
lifestyle such as poor diet, physical inactivity, alcohol consumption, and 
psychological stress also affect BP in the majority of people (Whelton et al., 2017). 
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 Measurement and diagnosis of hypertension 
In the clinic, BP is classically measured non-invasively using a sphygmomanometer 
with the patients’ arm outstretched and supported. Measurement of BP at the 
upper arm is preferred and cuff and bladder dimensions should be adapted to the 
individual’s arm circumference. BP is conventionally measured in millimetre 
mercury (mmHg) and every BP reading consist of two numbers: systolic pressure 
(SBP), which represents the maximum pressure during contraction of the 
ventricles; diastolic pressure (DBP) is the minimum pressure recorded just prior to 
the next contraction. Table 1-1 summarizes the definition of hypertension 
according to methods of measurement in established scientific guidelines such as 
the National Institute for Health and Care Excellence (NICE, 2011), the European 
Society of Hypertension/ European Society of Cardiology (ESH/ESC) (Mancia et al., 
2013b), and the Eighth Joint National Committee (JNC 8) guideline (James et al., 
2014). Conventionally, hypertension is diagnosed when clinic BP is SBP 140 mmHg 
or higher and/or DBP 90 mmHg or higher according to many clinical guidelines. 
However, the recently published American College of Cardiology/ American Heart 
Association (ACC/AHA) guideline (Whelton et al., 2017) changed the definition of 
hypertension to SBP 130 mmHg or higher and/or DBP 80 mmHg or higher instead 
of SBP 140 and/or DBP 90 mmHg. This new definition would increase the 
proportion of people labelled as hypertensive especially in the US. In addition to 
clinic BP, most guidelines recommend monitoring of ambulatory BP (ABPM) or 
home BP monitoring (HBPM) as adjunct measurement and therefore should be used 
complementarily and not competitively in diagnosing hypertension. ABPM have a 
stronger predictive value for all-cause and CV mortality compared to office BP in 
a model that considered CV risk factors including age and sex (Banegas et al., 
2018). Furthermore, routine and formal cardiology assessment should be carried 
out to detect target organ damage, to identify comorbidities (e.g. diabetes 
mellitus, dyslipidaemia) and to exclude secondary causes for hypertension (e.g. 
renal diseases, endocrine diseases, drugs).  
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Table 1-1: Guidelines for definitions of hypertension based on the measurement techniques. 
NICE 2011- United Kingdom *   
Clinic SBP ≥140 and/or DBP ≥90 
ABPM (Daytime) SBP ≥135 and/or DBP ≥85 
HBPM SBP ≥135 and/or DBP ≥85 
ESH/ESC 2013 - Europe    
Clinic/Office SBP ≥140 and/or DBP ≥90 
ABPM   
Daytime SBP ≥135 and/or DBP ≥85 
Nightime SBP ≥120 and/or DBP ≥70 
24 –hour SBP ≥130 and/or DBP ≥80 
HBPM SBP ≥135 and/or DBP ≥85 
JNC 8 2014 -US †   
Clinic/office SBP ≥140 and/or DBP ≥90 
AHA/ACC 2017 – US 
Clinic/Office SBP ≥130 and/or DBP ≥80 
ABPM SBP ≥130 and/or DBP ≥80 
HBPM SBP ≥130 and/or DBP ≥80 
*Last updated November 2016 
†Definition of hypertension was not addressed, but thresholds for 
pharmacologic treatment were defined. The current definition is 
based on the JNC 7 report.   
 
1.7 Global burden of hypertension 
The current global burden of disease (GBD) estimates for hypertension is available 
for the year 2015 (WHO, 2018b) and the disease and injury outcomes caused by 
hypertension are measured as DALYs. Hypertension is an important public health 
problem and it was estimated that 7.8 million projected death (14% of total 
deaths) and 143 million DALYs were linked to hypertension (Forouzanfar et al., 
2017). Deaths due to CVD attributed by hypertension was estimated at 41%, among 
which 40.1% were related to ischaemic heart disease (IHD), and 40.4% were 
related to cerebrovascular diseases (Forouzanfar et al., 2017). Overall, the GBD 
2015 reported that high BP is the second and third leading risk factor for diseases 
in women and men respectively contributing to 7.8% and 9.2% of DALYs (GBD 2015 
Risk Factors Collaborators, 2016). DALYs attributable to high BP is largely 
associated with CVD followed by diabetes mellitus, urogenital, blood, and 
endocrine disease. 
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Furthermore, the number of adults with hypertension is projected to rise to a total 
of 1.56 billion by the year 2025 (Kearney et al., 2005). Compared to economically 
developed countries, the prevalence of hypertension in the lower income 
countries is currently in excess of 5% at the rate of approximately 40% (WHO, 
2018a) and this is predicted to increase in excess of 60% by 2025 (Kearney et al., 
2005).  
1.8 Hypertension management 
Prospective Studies Collaboration (2002) reported that lowering BP can 
substantially decrease CV morbidity and mortality as well as all-cause mortality. 
A reduction of 20 mmHg of usual SBP (or 10 mmHg equivalent to usual DBP) is 
associated with more than double the difference in the stroke mortality rate and 
with twofold differences in the death rates from IHD and from other vascular 
causes in middle age individuals. A review of observational and randomised studies 
using antihypertensive therapy demonstrated that lowering of DBP by 5 mmHg 
reduce the risk of IHD by 21% and the risk of stroke by approximately 34% 
regardless of baseline BP level (Law et al., 2003). Therefore, striving for good BP 
control is important in all type of population to prevent CV complications. 
Management of hypertension can be achieved by non-pharmacological as well as 
pharmacological means.  
 Non-pharmacological treatment 
A non-pharmacological intervention generally indicates lifestyle changes and this 
approach should be offered prior to initiating antihypertensive agents in a person 
undergoing assessment or periodical treatment for hypertension. Although 
appropriate lifestyle changes are the key to hypertension prevention, 
administration of BP lowering drugs should not be delayed in patients with high 
CVD risks. A practical and comprehensive lifestyle modification approach that 
have been shown to be effective in lowering BP in hypertensive patients are: [1] 
salt restriction, [2] moderation of alcohol consumption, [3] high consumption of 
vegetables, fruits, low-fat and other types of diet, [4] restriction of coffee and 
other caffeine-rich products consumption, [5] weight reduction and maintenance, 
[6] regular physical exercise, and [7] smoking cessation (NICE, 2011, Mancia et al., 
2013b). In pre-hypertensive and Stage 1 hypertension patients, multiple lifestyle 
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modifications have been shown to improved BP control subsequently prevents the 
risk of chronic diseases (Elmer et al., 2006). Nevertheless, antihypertensive agent 
initiation is essential in situations where BP target is not achieved with lifestyle 
changes alone and especially in those with one or more risks of developing CV 
events.  
 Pharmacological therapy 
There is unequivocal evidence from randomised controlled trials (RCTs) 
demonstrating the benefit of pharmacological BP reduction on the risk of major 
CV events and death. There are various classes of antihypertensive agents with 
new ones are being developed and tested by the pharmaceutical industry. 
However, agents that have been showed to reduce the risk of clinical events 
should be used preferably. The drug classes that are mainly prescribed in the 
primary care or hospital settings are angiotensin-converting enzyme inhibitors 
(ACEI), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), 
diuretics, or beta blockers (BB). These drugs act at one or more anatomical sites 
of BP controls namely resistance arterioles, capacitance venules, the heart and 
kidney. Meta-analyses of RCTs using these five major antihypertensive classes had 
been shown to prevent CVD as compared to placebo (Law et al., 2009, 
Thomopoulos et al., 2015). Consistently, established clinical guidelines such as 
NICE, ESH/ESC, and JNC recommended ACEI, ARB, CCB, and thiazide diuretics (TZ) 
for the initial management of hypertension. Most guidelines do not recommend BB 
as first-line therapy unless indicated. The Losartan Intervention For Endpoint 
reduction in hypertension (LIFE) study randomised 9193 patients with essential 
hypertension to either ARB (losartan)-based or BB (atenolol)-based therapy 
(Dahlöf et al., 2002). The study participants were followed for at least four years 
to assess for a composite of CV events. Results showed that treatment with BB 
had a higher frequency of the primary composite endpoints of CV death, stroke, 
and myocardial infarction (MI) compared to treatment with ARB. Additionally, a 
recent systematic review and network meta-analysis of RCTs conducted in 
conjunction of the new ACC/AHA guidelines showed that BB was significantly less 
effective than TZ diuretics (Reboussin et al., 2017). The NICE guideline has 
recommended initial therapy with BB only in younger patients who are either 
intolerance or contraindicated to ACEI or ARB, pregnant, and in those with 
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evidence of increased sympathetic drive (NICE, 2011). Table 1-2 summarises the 
initial drug therapy as recommended by the respective guidelines.  
Table 1-2: Guidelines recommendation for initial drug therapy 
Guidelines Recommended initial antihypertensive therapy 
NICE 2011 
ACEI or ARB for people age < 55 years. 
CCB for people age ≥ 55 years and black people of African or 
Caribbean origin of any age. Offer TZ diuretics if there is evidence 
of intolerance or heart failure (HF) or high risk of HF. 
ESH/ESC 
2013 
ACEI, ARB, CCB, diuretics, or BB are recommended for initiation of 
treatment or maintenance 
JNC-8 2014 
TZ, CCB, ACEI or ARB, alone or in combination for non-black 
people. 
TZ or CCB, alone or in combination for black people. 
ACC/AHA 
2017 TZ, CCB, ACEI or ARB are recommended for initiation of treatment 
 
Understanding the benefit of one antihypertensive agent versus another is 
important in determining the initial treatment for hypertension and in informing 
clinical decision. However, it is not uncommon for hypertension to co-exist with 
one or more chronic conditions, especially with increasing age. A retrospective 
observational study with a random sample of 86,100 patients age 20 years and 
older retrieved from the United Kingdom General Practice Research Database 
(GPRD) shown that hypertension commonly occurred with other conditions 
primarily CHD, CKD, and diabetes mellitus (Brilleman et al., 2013). Therefore, 
consideration of initial or maintenance of antihypertensive should also make 
allowance for the presence of comorbidities in the effort to achieve target BP 
control and at the same time promotes safe and effective pharmacotherapy. Table 
1-3 outlines the recommended first-line therapy for hypertensive patients with 
comorbidities based on established guidelines. 
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Table 1-3: First line treatment in a patient with hypertension and comorbidities 
Conditions First-line antihypertensive treatment  
Chronic kidney 
disease ACEI or ARB 
Type 1 diabetes ACEI or ARB 
Type 2 diabetes   
 Non-black ACEI or ARB 
 Black ACEI plus CCB/TZ or TZ 
Heart failure Patients already on ACEI/ARB plus BB should be given TZ
Ischaemic heart 
disease BB and/or CCB 
Atrial fibrillation ACEI or ARB plus BB or non-dihydropyridine CCB 
Peripheral artery 
disease ACEI or CCB 
Adapted from American Heart Association (2017), Cohen and Townsend (2017), Kennard 
and O’Shaughnessy (2016) and Mancia et al. (2013b). 
 
The main objective of antihypertensive therapy is to attain and maintain goal of 
BP therapy. Data from the US showed that, of those treated for hypertension, only 
approximately 50% are under control (Go et al., 2014). If control is not achieved, 
the dose of the initial drug or add a second drug from the drug class recommended 
for initial therapy (See Table 1-2). Current recommendations by guidelines such 
as NICE and JNC-8 emphasize stepwise dose increase and addition of a second (and 
third or fourth) drug. For example, the Anglo-Scandinavian Cardiac Outcomes 
Trial- Blood Pressure Lowering Arm (ASCOT-BPLA) study demonstrated that nine 
out of ten patients required two or more antihypertensive agents to bring their BP 
down to less than 140/90 mmHg (Dahlöf et al., 2005). 
A certain combination of antihypertensive drugs may exert an additive and 
protective effect. For example, the Systolic Evaluation of Lotrel Efficacy and 
Comparative Therapies (SELECT) study showed that CCB-amlodipine and ACEI-
benazepril combination therapy was significantly more effective in lowering SBP 
and pulse pressure than either monotherapy (p<0.001) after eight weeks of 
treatment in a group of elderly patients with systolic hypertension (Neutel et al., 
2005). Likewise, the Nifedipine and Candesartan Combination (NICE-Combi) Study 
demonstrated that CCB-nifedipine and ARB-candesartan combination therapy was 
superior to uptitrated ARB monotherapy in BP control (p<0.0001) and renal 
protection (p<0.05) after eight weeks of treatment in hypertensive patients 
(Hasebe et al., 2005). In addition, combination therapy has been showed to be 
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beneficial in lowering the risk of complications related to other conditions such as 
diabetes. The Action in Diabetes and Vascular disease: preterax and diamicron-
MR Controlled Evaluation (ADVANCE) trial reported that ACEI-perindopril and TZ 
diuretic-indapamide combination had significantly reduced risks of major vascular 
complications including death compared to placebo in T2DM patients followed for 
an average of 4.3 years (Patel, 2007). Surrogate renal endpoint such as 
microalbuminuria which is associated with CV events was also greatly reduced 
with ACEI/diuretic combination therapy versus placebo. This evidence shows that 
combination therapy is more effective in lowering BP and the prevention of 
related complications. 
However, a combination of two classes of renin-angiotensin system (RAS) blockers 
including ACEI and ARB is not recommended. In theory, a combination of ACEI and 
ARB should enhance RAS blockade. A dual blockade of the RAS pathway has been 
shown to be effective in lowering BP compared to either as monotherapy (Azizi et 
al., 2000, Mogensen et al., 2000, Stergiou et al., 2000). Despite the efficacy in BP 
reduction, there is evidence that the combination of ARB and ACEI is associated 
with increased risk of adverse events (The ONTARGET Investigators, 2008). A 
systematic review of 33 RCTs comparing dual RAS blockers with monotherapy with 
a mean duration of 52 weeks reported that dual therapy was associated with a 
55% increased risk of hyperkalaemia (p< 0.001), a 66% increase in the risk of 
hypotension (p< 0.001), a 41% increase in the risk of renal failure (p=0.01), and a 
72% increase in the risk of withdrawal from study due to adverse events (p<0.001) 
(Makani et al., 2013). All-cause mortality was significantly higher in the cohort 
without HF (p=0.04) whereas renal failure was significantly higher in the cohort 
with HF (P<0.001). Altogether, the risks of adverse effects outweigh the benefits 
of dual therapy hence not recommended in established clinical guidelines (NICE, 
2011, James et al., 2014). The Systolic Blood Pressure Intervention Trial (SPRINT) 
reported that in patients >50 years and at high risk of CVD, but without prevalent 
diabetes or history of stroke, an intensive BP target of ≤120 mmHg was associated 
with lower rates of CV events and death compared to the standard target of 140 
mmHg (The SPRINT Research Group, 2015) 
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1.9 Antihypertensive therapy (AHT) and risks of cancer: 
an overview 
 Historical perspective of AHT and risks of cancer 
The association between antihypertensive therapy (AHT) and risks of malignancy 
has been made over more than half a century ago, prior to the advent of modern 
day hypertension treatment. Reserpine (isolated from Rauwolfia serpentina), 
used as a sedative and treatment for insanity for centuries in India (Moser, 2006), 
was first used in the US in late 1940. A clinical trial by Vakil (1949) showed that 
reserpine is very safe and effective in treating patients with benign hypertension. 
Despite its safety, reserpine was the first antihypertensive agent to be associated 
with increased cancer risk. The Boston Collaborative Drug Surveillance Programme 
(1974) has found that women exposed to reserpine have three times increased the 
risk of developing breast cancer. Following this discovery, two retrospective case-
control studies also reported comparable findings around the same time. In 
Finland, 461 matched-pairs were assessed for risk of breast cancer in those 
exposed to reserpine and results showed a significant positive association between 
the two variables (Heinonen et al., 1974). Meanwhile, Armstrong et al. (1974) 
assessed 708 breast cancer cases and 1430 controls diagnosed with another type 
of cancer and reported a positive association between reserpine and breast 
cancer. Subsequent studies in the following years, however, found such an 
association was unlikely (Laska et al., 1975, Mack et al., 1975, O'Fallon et al., 
1975). These revelations have since ignited disputes and numerous studies relating 
CV drugs as a precursor to malignant neoplasms.  
Certain CV drugs have been implicated to either increase or decrease the risk of 
a certain type of malignancy. For example, aspirin was suggested to be protective 
of colorectal cancer. The Colorectal Adenoma/carcinoma Prevention Programme 
(CAPP2) trial was a large-scale trial assessing the antineoplastic effect of aspirin 
versus placebo in patients with major form of hereditary colorectal cancer and 
findings suggested lower rate of colorectal cancer incidence in those treated with 
long term high dose aspirin with (HR 0·4;P = 0.02) (Burn et al., 2011). In addition, 
studies showed that digoxin increases the risk of breast cancer. A large cohort 
study of postmenopausal women reported that long term use of digoxin was 
associated with 45% increased breast cancer risk among users versus non-user and 
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this relationship persistent even after adjustment for established breast cancer 
risk factors (Ahern et al., 2014). Table 1-4 summarises the type of CV therapy 
commonly associated with a certain type of cancer. Many of these researches were 
designed using cohorts and population-based studies whereas associations 
hypothesized from a limited number of clinical trials were derived from the sub-
study analysis. This subject remains controversial as no definitive conclusion can 
be made to this date. 
Table 1-4: Cardiovascular drugs and risks of cancer  
Cardiovascular drug Cancer site References
Increased risk 
Reserpine Breast 
(Armstrong et al., 1974, Boston Collaborative Drug 
Surveillance Programme, 1974, Heinonen et al., 
1974, O'Fallon et al., 1975) 
Digoxin Breast (Ahern et al., 2008, Biggar et al., 2011, Ahern et al., 2014) 
Antihypertensive agents:
ARB 
CCB 
TZ 
Lung 
Breast 
Kidney 
(Hiatt et al., 1994, Pahor et al., 1996, Fitzpatrick et 
al., 1997, Sipahi et al., 2010, Bangalore et al., 2011, 
Li et al., 2014b, Ni et al., 2017) 
Decreased risk 
Aspirin GI tract (Rothwell et al., 2010, Burn et al., 2011) 
Statin Any (Friis et al., 2005, Leung et al., 2013, Shi et al., 2014) 
 
 Antihypertensive drug class and risks of cancer 
Over the last few decades, almost every antihypertensive drug class has been 
implicated with increased cancer risk. The following section described the 
relationship between major antihypertensive drug classes and risk for cancer. 
Details on the underlying mechanism of cancer are described in individual drug 
class chapters. 
 RAS inhibitors and cancer risk 
There is evidence suggesting that several components in the renin-angiotensin-
aldosterone system (RAS) pathway such as angiotensin II may be involved with 
carcinogenesis (Ager et al., 2008). Therefore, it was hypothesized that RAS 
inhibitors such as ACEI and ARB could reduce cancer risk. More about the RAS 
pathway and its component is described in 4 Section 4.1.1(page 148).  
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1.9.3.1 What is the evidence? 
Earlier reviews highlighted a slightly higher incidence of malignancy in patients 
receiving ACEI compared to placebo in two RCTs (Felmeden and Lip, 2001, 
Grossman et al., 2001). The Study of Left Ventricular Dysfunction (SOLVD) trial 
which followed patients with congestive HF for 42.4 months reported an OR of 
1.59, with 95% CI ranged between 0.90 to 2.82 (The SOLVD Investigators, 1992).  
In another RCT of patients with renal insufficiency followed for three years 
(Maschio et al., 1996), a slightly higher risk for cancer in patients receiving 
benazepril was observed than did those who received placebo (OR 1.52, 95%CI 
0.45-5.42). In the more recent and larger-scale Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) enrolling 33,357 
hypertensive patients with a CVD risk factor for eight years, the odds for cancer 
was 1.02 with 95% CI 0.93 to1.12 for ACEI when compared to the diuretic arm (The 
ALLHAT Collaborative Research Group, 2002). 
Following these reports, subsequent trials using ARB have pre-specified cancer as 
one of their study outcomes. For example, the Losartan Intervention for Endpoint 
Reduction (LIFE) trial evaluated ARB-based versus BB-based therapy in 9,193 
hypertensive patients found that the OR for cancer was 1.09 (95% CI 0.93-1.27) 
for those in the ARB treatment group (Dahlöf et al., 2002). In the Telmisartan 
Randomised Assessment Study in ACE Intolerants Subjects with Cardiovascular 
Disease (TRANSCEND) study, 5,926 patients were randomised to either ARB or 
placebo and were followed for approximately five years (The TRANSCEND 
Investigators, 2008). The risk for cancer in ARB users versus placebo showed a 
trend towards a positive relationship with OR 1.23 (95% CI 0.99-1.52).    
Additionally, observational studies investigating the relationship between ACEI 
and risks of cancer have reported inconsistent outcomes. In a cohort study of 
17,897 patients with high risk of CVD, Friis et al. (2001) reported a relative risk of 
1.07 (95% CI 1.0-1.15) for overall cancer with use of ACEI. A similar relationship 
has also been reported by a larger study observing 149,417 cases and 597,668 
controls over a five year period (Hallas et al., 2012). This study reported an OR of 
1.17(95% CI 1.14-1.20) and 1.12(95% CI 1.06-1.18) for overall cancer risk among 
ACEI and ARB users respectively. In contrast, many epidemiological studies have 
found that ACEI exerts a protective effect against cancer. For example, a 
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retrospective cohort study of over five thousand hypertension patients based in 
Glasgow followed for over 15 years have found that ACEI users have a significantly 
lower risk for cancer incidence and fatal cancers compared to other 
antihypertensive users (Lever et al., 1998). In another study, Kedika et al. (2011) 
followed patients with adenomatous polyps (AP), a risk factor for colorectal 
cancer, for five years. The author reported that the risk for advance AP is 41% less 
likely in ACEI user compared to non-user, hence insinuating lower risk of colorectal 
cancer. Nevertheless, studies have also shown no evidence of overall or a specific 
type of malignancy with ACEI use. ACEI showed no significant effect on the risk of 
developing or protecting against breast cancer (Fryzek et al., 2006) and prostate 
cancer (Perron et al., 2004). Furthermore, two meta-analyses of RCTs, Bangalore 
et al. (2011) and Sipahi et al. (2011) demonstrated no significant association 
between ACEI and risks of cancer.  
Meanwhile, a meta-analysis by Sipahi et al. (2010) suggested a small but significant 
increase in cancer risk associated with ARB. Pooling of results from nine RCTs 
enrolling 94,570 using ARB as one its treatment arm gave an RR of 1.08 (95% CI 
1.01-1.15) for overall cancer risk among ARB user, with an increased occurrence 
of new lung cancer detected (RR 1·25, 1·05–1·49). Finding from this study ignited 
debate on the safety of ARB which led to a series of observational studies exploring 
the risk of cancer with ARB use. A preceding network meta-analysis had reported 
a weak association between ARB and cancer risk with multiple comparisons 
showed an OR of 1.12(95% CI 0.87-1.47) (Coleman et al., 2008). In a subsequently 
larger and more comprehensive systematic review and network meta-analysis of 
70 RCTs enrolling 324,168 participants, Bangalore et al. (2011) found no significant 
relationship between ARB and cancer risk. Instead, the author reported an 
increased risk of cancer with ARB and ACEI combination. Around the same time, a 
meta-analysis of 15 RCTs enrolling 138,769 conducted by the ARB Trialist 
Collaboration found no significant association between ARB or ACEI/ARB 
combination and risk of overall or site-specific cancer (Teo, 2011).  
Contrariwise, epidemiological studies have reported conflicting results. Several 
cohorts study reported no significant impact on cancer risk observed with ARB use. 
In a large nationwide Danish cohort study of new antihypertensive drug users 
followed for 2.5 years (Pasternak et al., 2011), use of ARB was not associated with 
risk of cancer overall with RR 0.99 (95% CI 0.95-1.03). A comparable result for 
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overall cancer (OR 1.03, 95% CI 0.99-1.06) was reported by a similarly designed 
study using the UK cohort followed for five years among new ARB users (Bhaskaran 
et al., 2012). Upon detail analysis, the increased risk was only observed for breast 
and prostate cancer. Additionally, the use of ARB is associated with increased 
breast cancer risk especially in pre-menopausal women (Gómez-Acebo et al., 
2016). However, the number of cases and controls exposed to ARB were very small 
which potentially resulted in an unstable estimate.   
A recent meta-analysis by Shen et al. (2016) evaluated 14 RCTs and 17 
observational studies enrolling a total of nearly 4 million participants. Pooling of 
results from RCTs showed the use of ARB or ACEI did not have any impact on cancer 
risk whereas combined estimated from observational studies demonstrated a 
decreased risk (OR 0.82,95% CI 0.73-0.93). In another meta-analysis of 
observational studies, the result showed no evidence of an association between 
RAS inhibitors and breast cancer risk (Ni et al., 2017).  
Overall, the risk of cancer related to RAS inhibitors is inconclusive. The evidence 
for an increased cancer risk or protective effect with ACEI use is insufficient with 
many of the studies refuting any link. An evaluation conducted by the US FDA 
(2011a) concluded that use of ARB is not associated with the potential risk of 
cancer. Nevertheless, further studies and data collection is needed to determine 
the active substances of the RAS blockers and the types of cancer that may be 
triggered, as well as to establish the exact relationship.   
 CCB and cancer risk 
Calcium antagonist, particularly dihydropyridines (DHP), is effective in reducing 
severe CV events in the hypertensive elderly (Gong et al., 1996). Clinical studies 
have also demonstrated that CCB is as effective as other antihypertensive drug 
class in preventing CV outcomes in high risk patients (Black et al., 2003, 
Muramatsu et al., 2012). 
1.9.4.1 What is the evidence? 
In the 1990s, two studies reported a positive association between CCB and cancer. 
A cohort of 750 elderly hypertensive age 71 years or older were followed for five 
years (Pahor et al., 1996). These patients were cancer free at baseline and were 
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using ACEI, BB, or CCB. In comparison to BB and ACEI, results showed that CCB 
significantly increased overall cancer risk with excess risk among verapamil (RR 
2.46, 95% CI 1.17-5.17) and nifedipine users (RR 2.34, 95% CI 1.09-5.03). In another 
study, postmenopausal women enrolled in the Cardiovascular Health Study (CHS) 
who were followed for five years have shown a significantly increased risk for 
breast cancer among CCB user versus non-user (Fitzpatrick et al., 1997). Similar 
observations have been reported by more recent studies. In a 12 year follow-up, 
Saltzman et al. (2013) observed a 1.6 fold increased risk (95% CI 1.0-2.5) for breast 
cancer in CCB user among 3,201 postmenopausal women. After stratification by 
formulation preparations, the increased risk was confined only to immediate 
release CCB (HR 2.4, 95% CI 1.3-4.5) whilst no significant association was observed 
with sustained release CCB. Meanwhile, Li et al. (2013) evaluated the risk of 
invasive breast cancer in 1,907 cases and 856 controls from a cohort of middle-
age and elderly women. Results showed that long-term use of CCB for 10 years or 
more was associated with increased risk for both invasive ductal and lobular breast 
carcinoma. These relationships, however, did not vary substantially between DHP 
and non-DHP CCBs. Furthermore, the recent Spanish Multi Case-control (MCC) 
Study reported an increase in breast cancer risk associated with CCB use especially 
in women who are menopaused and overweight (Gómez-Acebo et al., 2016). 
Similar associations were also observed in those taking CCBs for five years or more 
and in several subtypes of breast cancer.  
Contrariwise, many studies have found no significant association between CCB and 
cancer risk. In one of the earlier study, almost 18 thousand CCB users from the 
Danish prescription and health insurance database were followed for a duration 
of three years (Olsen et al., 1997). This study found no evidence of CCB affecting 
cancer risk overall or specific type of cancers. In a more recent and much larger 
study, Grimaldi-Bensouda et al. (2016) reported an adjusted HR of 0.88 (0.86 to 
0.89) and 1.01 (0.98 to 1.04) for all cancer comparing CCB cohorts to non-CCB and 
another antihypertensive class cohort respectively. Additionally, several meta-
analyses also reported consistent results. Grossman et al. (2002) evaluated the 
risk of cancer in meta-analyses of RCTs and observational studies. Pooling of eight 
RCTs showed an OR of 0.91 (0.80-1.04) indicating no significant relationship 
between CCB and cancer risk. Likewise, a meta-analysis of seven longitudinal 
studies showed a non-significant association. In a subsequent network meta-
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analysis of RCTs by Coleman et al. (2008), 15 of the 27 included trials used CCB as 
one its treatment group. Results showed no evidence of excess cancer risk related 
to CCB use in both multiple comparison and pair-wise analysis. Compared to the 
previous studies, Bangalore et al. (2011) reported an increased cancer risk 
associated with CCB use (P = 0.02) in a meta-analysis of 22 RCTs with modest 
heterogeneity. Stratification by subclasses showed an OR of 1.06 (95% CI 1.01-
1.12) and OR 1.02 (95% CI 0.90-1.15) for DHP- and non-DHP CCBs respectively 
suggesting DHP CCB may have an impact on cancer risk.  
Two meta-analyses of observational studies demonstrated comparable results 
regarding CCB and breast cancer risk. A meta-analysis of 17 studies (nine cohorts, 
eight case-control) enrolling 149,607 showed an OR of 1.02 (95% CI 0.94-1.11) for 
overall cancer risk comparing CCB user and non-user (Li et al., 2014b). Long term 
use of CCB of ten years or longer has been showed to increase cancer risk by 1.7 
fold but this estimation was derived from only two studies thus may not be 
accurate. No remarkable difference was observed between DHP- and non-DHP CCB 
with regard to breast cancer risk in comparison to the overall analysis. A more 
recent meta-analysis of 13 observational studies (seven cohorts, six case-control) 
showed an RR 1.07 (95% CI 0.99-1.16) (Ni et al., 2017). In their subgroup analysis, 
a meta-analysis of case-control studies showed a positive risk of breast cancer 
with RR 1.21(95% CI 1.08-1.35) whereas no significant association was observed 
with cohort studies. This observation could be the result of recall and selection 
bias commonly implicated with retrospective studies.  
The conflicting results reported by these studies merit further investigation into 
the potential carcinogenicity risk of CCB and the specific type of cancer that may 
be influenced by its use. 
  BB and cancer risk 
Although BB is no longer prescribed as first-line therapy in hypertension, its use 
remains as a standard of care for patients with CHD, especially after an MI episode 
(The CAPRICORN Investigators, 2001) and in patients with HF (Ponikowski et al., 
2016). The number of studies linking BB and the risk of malignancy is very limited 
while most randomised trials primarily focused on cardioselective BB such as 
atenolol.  
Chapter 1 Introduction 51 
1.9.5.1 What is the evidence? 
A randomised trial evaluating patients with MI, the Beta-blocker Heart Attack trial 
(BHAT) reported more patients in the propranolol group versus placebo were 
withdrawn for cancer although the exact rate was very little (0.2% versus 0.1% 
respectively) (Beta-blocker Heart Attack Trial Research Group, 1982). In a primary 
care setting where elderly hypertensive patients were recruited, Coope and 
Warrender (1986) observed a higher rate of cancer incidence in the atenolol group 
compared to control. They also recorded an excess of fatal lung cancers in the 
treatment group compared with control (OR 1.89, 95%CI 0.88-4.08). In the Medical 
Research Council’s randomised trial of elderly with hypertension, patients 
allocated to atenolol had the highest number of cancer deaths compared to 
diuretic or placebo (MRC Working Party, 1992). A similar finding has been observed 
in the United Kingdom Prospective Diabetes Study (UKPDS) of diabetic 
hypertensive patients in which those receiving atenolol showed an increased rate 
of cancer-related mortality compared to those receiving captopril or placebo (OR 
2.04, 95% CI 1.06-3.90) (UKPDS Investigators, 1998).  
On the contrary, epidemiological studies showed an inconsistent association 
between BB and cancer risks. Most of the studies observed a decreased risk of 
cancer. In the prospective studies, one study has found an increased risk of breast 
cancer. In 3,201 elderly women followed for 12 years, Saltzman et al. (2013) 
reported that ever exposure to BB during the period of observation increased 
breast cancer risk with a hazard ratio (HR) of 1.1 (95% CI 0.7-1.7). Meanwhile, 
history of exposure to BB for 2 years prior to study increased breast cancer risk by 
50% compared to those who were never exposed. However, the association 
estimated was not robust due to the small study size. In two larger studies 
enrolling approximately 50,000 patients from Denmark (Fryzek et al., 2006) and 
America (Wilson et al., 2016), results showed that BB did not affect the risk of 
breast cancer. In another case-control study of 1,736 breast cancer cases and 
1,895 healthy controls (Gómez-Acebo et al., 2016), the OR for breast cancer was 
1.11 (95% CI 0.75-1.63) in BB user. However, no significant association with breast 
cancer was observed after stratification by menopausal status and BMI.  
Meanwhile, a cohort of 1,340 diabetic patients initiating insulin therapy observed 
significantly reduced the overall risk of cancer with RR 0.33 (Monami et al., 2013). 
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In a more general population, Chang et al. (2015) suggested that BB has a potential 
anti-cancer effect and is protective against a specific type of cancer including 
head and neck cancers, the gastrointestinal tract (GIT) cancers, and prostate 
cancer. A preceding retrospective study agreed and found that BB users among 
men had a significantly lower incidence of prostate cancer (Perron et al., 2004), 
hence suggesting its cancer prevention potential. Most of the retrospective studies 
have utilised prescription or healthcare database which were not designed to 
detect cancer. Additionally, these databases may have a limitation in providing 
the variables required to control for risk of cancer such as BMI, smoking status, 
dietary habit, and physical activity.    
Three meta-analyses of RCTs demonstrated that BB does not influence the risk for 
cancers. A network meta-analysis of 27 RCTs enrolling 126,137 patients was 
comprised of 56 treatment arms (Coleman et al., 2008). Of these, only three trials 
used BB. Mixed-treatment comparison showed no difference in cancer risk 
between BB and control. None of the pairwise comparisons showed a significant 
association. A subsequent network meta-analysis included 70 trials comprising 
324,168 participants and 148 comparator arms (Bangalore et al., 2011). Of these, 
only seven trials used BB and results of direct comparison between BB and controls 
showed a trend towards lower risk of cancer incidence overall (OR 0.94, 95%CI 
0.88-1.00).  A comparable result has been reported by a subsequent meta-analysis 
including nine RCTs although with a smaller number of participants (Monami et 
al., 2013). Recently published meta-analyses of observational studies focused on 
the risk of breast cancer. Ni et al. (2017) have reported a marginally increased 
risk of breast cancer risk with BB use (OR 1.0, 95% CI 0.96-1.09) from a 
combination of 7 retrospective studies and 4 prospective studies. It is important 
to interpret this result with caution because observational studies are naturally 
prone to the risk of bias. 
Due to the limited number of available studies, it is difficult to determine 
whether BB does influent cancer risk with confidence. The likely mechanism by 
which BB may cause cancer is further discussed in Chapter 7 Section 7.1.3 BB 
and cancer. 
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 Diuretics and cancer risk 
Previous concerns have been about the metabolic problems associated with 
thiazides (TZ) use such as dyslipidaemia, insulin resistance and gout. However, 
these adverse effects have been shown to be mainly a dose-dependent effect. The 
possibility of diuretics promoting the development of cancer, particularly of the 
kidney, has been of concern since the 1980s. 
1.9.6.1 What is the evidence? 
Several prospective and retrospective studies had attempted to link diuretic use 
and cancer risk. Most of these studies had focused on diuretics as a whole and only 
the very small number of studies had looked into TZ specifically.  
One of the earliest studies to suggest the possible relationship between diuretics 
and risk of cancer was from a small interview-based study of 160 cases of renal 
cell carcinoma (RCC) with age, race, sex-matched controls (Yu et al., 1986). This 
study found that diuretic use was associated with RCC especially in women. A 
consistent finding has been reported in a subsequent similarly designed but larger 
study of 495 cases and 697 controls (McLaughlin et al., 1988). In addition to the 
higher risk in women, this study also suggested that the risk for RCC is independent 
of high BP. In a prospective study of 192,133 Danish patients discharged from the 
hospital for hypertension, HF, or oedema, results showed that those exposed to 
diuretics had a greater increased risk for RCC and the risk was higher in women 
(Mellemgaard et al., 1992). Although utilisation of patients’ discharge register 
could potentially reduce the risk of recall bias, this study failed to adjust for 
confounding factors such as smoking, and BMI thus could not clarify the observed 
association. Moreover, these studies did not distinguish the different type of 
diuretics used. Hiatt et al. (1994) have investigated the use of TZ and risk of RCC 
in 257 cases and an equal number of controls using patients data retrieved from a 
medical programme records. Multivariate analysis controlled for hypertension, 
smoking, BMI, and history of kidney infection showed a significantly elevated risk 
of RCC among women but not in men. In the same study population, Weinmann et 
al. (1994) evaluated the risk of RCC in a different type of diuretics including TZ, 
a loop diuretic, a potassium-sparing diuretic, and chlorthalidone in 206 cases and 
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292 controls. The investigators have reported that diuretics increased the risk of 
RCC in both genders and the association was not restricted to one class of diuretic.  
Contrariwise, Chow et al. (1995) found that diuretics did not significantly affect 
the risk of RCC in a study of 691 cases and an equal number of controls. Instead, 
use of other unspecified antihypertensive medication was associated with two-
fold excess risk. In the International Renal-cell Cancer study of 1732 cases and 
2309 controls from Australia, US, and three European countries, results showed 
that there was no different in risk in diuretic user compared to another 
antihypertensive drug user after adjustment for hypertension (McLaughlin et al., 
1995). However, long term diuretic use (more than 15 years) was associated with 
a 60% increased risk (RR 1.6, 95% CI 1.0-2.5). In keeping with much earlier studies, 
the finding of a meta-analysis of 13 observational studies (10 case-controls and 3 
cohorts) by Grossman et al. (2002) also showed a positive association between 
diuretic use and risk of RCC overall and in both retrospective and prospective 
studies.  
Another type of malignancies has also been evaluated but more literature or 
additional observation is required to confirm the reliability of the association. One 
of the most commonly studied types of cancer is breast cancer. In a multicentre 
cohort study of 3,198 elderly women followed for five years, no association was 
observed between diuretic use and risk of breast cancer after controlling for age, 
race, parity, age at menopause, and diabetes (Fitzpatrick et al., 1997). 
Conversely, a case-control study among elderly women found that diuretic use 
significantly elevated risk of breast cancer and the risk increased with increase 
duration (Largent et al., 2006). In a subsequent study of 114,549 women in the 
California Teachers Study cohort, ever use of diuretic did not have a significant 
impact on invasive breast cancer risk (Largent et al., 2010). However, the risk 
increased with the diuretic use of ten years or longer especially for the oestrogen-
receptor positive subtype (RR 1.26, 95% CI 1.10-1.45). Like former studies, many 
of these studies did not report breast cancer risk specifically for TZ. By 
distinguishing the categories of diuretics, Coogan et al. (2008) found no significant 
association between TZ use and risk of breast cancer among 4,653 cases and 4,269 
controls. A recent study reported a comparable result showing no significant 
association between diuretics and breast cancer risk in a multivariate analysis 
supporting the results of previous studies (Gómez-Acebo et al., 2016). Still, recall 
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bias and misclassification of exposure were likely as information was ascertained 
by self-report. Furthermore, a most recently published meta-analysis of 13 
observational studies showed a trend towards a significantly positive association 
between diuretics and breast cancer risk with RR 1.05 (95% CI 0.99-1.12; P = 
0.004). Nonetheless, the presence of substantial heterogeneity between the 
included studies renders a caution interpretation of this study conclusion. Also, 
the risk of bias with observational studies must be acknowledged and a causal role 
of diuretic in causing carcinogenicity cannot be automatically derived from these 
studies’ conclusions.  
A network meta-analysis of 70 RCTs enrolling 324,168 participants with 148 
comparator arms has shown that TZ is not associated with the risk of cancer 
incidence overall (Bangalore et al., 2011). Multiple comparisons for TZ against 
other class of antihypertensive also showed no significant association to risk of 
cancer. Likewise, a meta-analysis of seven RCTs with data from 61,450 
participants showed no significant association to risk of cancer mortality. 
1.10 Summary of literature review and rationale for the 
present study 
Pharmacovigilance activity is important in ensuring the efficacy and safety of 
medicinal-related products. Signals from epidemiological studies should be 
investigated and follow-up accordingly particularly of a serious or potentially 
serious nature such as malignancies. Recent epidemiological studies and meta-
analyses have been critical in exploring whether there is a true relationship 
between antihypertensive drugs and cancer risk. On the basis of the results from 
these studies, the presence of an association for most antihypertensive drug class 
is very unlikely. Currently, there is no clear indication that antihypertensive 
therapy results in greater risk of malignancy. However, most antihypertensive 
drugs trials are directed towards CV outcomes hence evaluation of cancer risks is 
performed as a post-hoc analysis. It is likely that these factors contribute to the 
inconsistencies in the results observed. These inconsistencies raise a research 
question which forms the basis of the specific aims of this thesis. 
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1.11 Aim and objectives of the thesis 
 Aim 
To investigate the association between exposure to major AHT drug classes and 
risks of cancer. 
 Objectives 
1) To assess the relationship between exposure to RAS inhibitors and the risk 
of cancer and cancer-related death. 
2) To assess the association between exposure to CCB and the risk of cancer 
and cancer-related death. 
3) To evaluate the relationship between exposure to BB and the risk of cancer 
and cancer mortality. 
4) To evaluate the association between TZ and the risk of cancer and cancer 
mortality. 
Chapter 2 Materials and Methods 57 
2 Materials and Methods 
2.1 Systematic review and meta-analysis 
This section describes the strategies and methods applied to systematically review 
the five main classes of antihypertensive agents used in RCTs in order to identify 
the association between antihypertensive drugs and the risks of cancer. This 
systematic review has been written in accordance with the protocol set forth by 
the Cochrane guidelines on the effects of healthcare interventions (2011). The 
protocol for this review is registered with PROSPERO (ID: CRD42016039801). 
 Eligibility criteria 
The criteria for considering and excluding studies for this review was conducted 
in accordance with the Population Intervention Comparison Outcome Study 
(PICOS) design framework (Santos et al., 2007). The PICOS strategy grouped search 
terms into thematic groups in order to identify medical literature for systematic 
reviewing. Standard search strategies of the antihypertensive agent's review, with 
supplementary terms, were used to identify the relevant works. 
2.1.1.1 Population 
Men and non-pregnant women aged 18 years and over who could be either 
previously treated with BP-lowering agents or untreated. All population receiving 
out-patient antihypertensive therapy as specified in the search strategy was 
included in this review.  
Pregnant women, patients with existing cancers, pre-malignant cancers, benign 
tumours or high cancer risk (e.g. liver cirrhosis, hepatitis B or C,  retrovirus 
infection, autoimmune disease, chronic inflammation etc.) ,organ transplant 
recipients, patients with underlying genetic disorders (e.g. Marfan’s syndrome, 
Down’s syndrome etc.) or studies with missing information about population 
characteristics or healthcare setting were excluded from this review. 
2.1.1.2 Intervention and comparator 
This review included adults who were treated with the five major classes of 
antihypertensive agents namely ACEI, ARB, BB, CCB, and TZ in different doses and 
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sub-classes as monotherapy whether in a stepped-care approach or not. As the 
primary pathway of action of ACEI and ARB was similar and the paucity of trials 
which used both ACEI and ARB combination after ONTARGET (The ONTARGET 
Investigators, 2008), for this review, the only combination allowed is ACEI plus 
ARB. The interventions of interest were compared against other classes of AHT 
(ACEI, ARB, CCB, BB, TZ) in different doses and sub-classes as monotherapy. Other 
comparators such as conventional BP lowering therapy (e.g., centrally-acting 
drugs, alpha-blockers, vasodilators, and another type of diuretics), placebo or no 
active treatment were also included. In addition, drug doses should be mentioned 
in both the intervention and the comparator arms or, at least, in the intervention 
arm. The intervention and comparator drugs must be administered orally and 
continue to be taken as outpatients if patients were hospitalized. Supplemental 
drugs from other classes were allowed as part of the stepped therapy which had 
to be pre-specified and follow the same protocol in both arms. 
While treatment provider and trial participants are followed according to a 
stringent trial protocol, issues related to compliance or adherence reporting is not 
uncommon concerning long- and short-term studies. In a review of non-adherence 
to treatment protocol published in 100 randomised controlled trials, Dodd et al. 
(2012) demonstrated that only 25 trials were deemed to be adequate in term of 
treatment initiation and completeness report. Furthermore, ambiguous terms 
were often used in describing non-adherence to treatment which does not provide 
explicit information on the completeness of treatment.      
Comparisons between drugs that belong to the same class were excluded. 
Combination of antihypertensive drugs classes, drugs other than the classes as 
listed in the search strategy, administration route other than oral (intravenous, 
intramuscular, intracoronary, intrathecal, sublingual, transdermal patch, 
ophthalmic solution), or studies with missing information about AHT class and dose 
in treatment arms were excluded. This review also excluded studies that used 
other pharmacological protocols (e.g. hormonal therapy, supplements, vitamins), 
or non-pharmacological approach (e.g. diet, lifestyle changes, exercise, surgical 
procedures). 
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2.1.1.3 Outcome 
Studies included in this review should be able to report on cancer outcomes in 
term of the number of cancers and/or cancer-related deaths observed among 
participants on studied AHT compared with those who are on a different type of 
treatment, or placebo. Cancer outcomes include all malignancies regardless of 
type and site. The outcome of interest is defined as malignant neoplasms that 
comply with International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9CM 140.xx-208.xx) and/or International Classification of 
Diseases, Tenth Revision (ICD-10 C00-97). 
Malignancies occurring specifically after transplantation and secondary cancers 
that have arisen after treatment of a primary malignancy were excluded in this 
review. In a few cases, insufficient data were found and authors of the studies 
were contacted for further information. Studies with insufficient information were 
excluded from this review and analysis. 
2.1.1.4 Study design 
Only randomised-controlled trials (RCTs) were included in this review which 
satisfied the following criteria: [1] parallel design with random allocation to 
treatment groups comparing the drugs as listed in the search strategy in humans, 
[2] randomised at least 100 participants per treatment arm, and [3] followed the 
study participants for at least 52 weeks or one year of active treatment. RCTs with 
the factorial design were allowed in this review. 
This review excluded studies where the unit of randomisation was not at the 
individual level (cluster-randomized),  when the same individual acts as control 
(cross-over studies), quasi-experimental designs where participants were not 
randomly allocated to study treatment, and all types of observational studies 
(cohorts, case control, cross-sectional, case-reports, editorials, commentaries, 
opinions). Clinical trials that randomized less than 100 participants per treatment 
arm and/ or followed participants for less than 52 weeks or one year of active 
treatment were also excluded.  Studies that utilize human sample in a controlled 
environment outside of the human body (in vitro) were excluded. Any study design 
involving animals were ineligible.  
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2.1.1.5 Geographical context 
This review included studies conducted in other countries as the five main classes 
of AHT are commonly prescribed worldwide. Therefore, there was no language 
restriction applied for this review. 
 Search strategy for identification of relevant studies 
2.1.2.1 Electronic searches 
The success of a systematic review depends on the ability to locate and retrieve 
the relevant literature. A thorough literature search of all available sources is 
crucial to ensure a complete and robust review. The Medical Literature Analysis 
and Retrieval System Online (MEDLINE (OVID)), the Excerpta Medica database 
(EMBASE (OVID)), and Cochrane Central Register of Controlled Trials (CENTRAL) 
were searched for published articles between 1950 and December 2015 (last 
search performed on 11th August 2016).  
Search filters are commonly used as a strategy to identify the higher quality 
evidence from a considerable amount of literature indexed in the selected 
databases. Search filters also help in focusing the disease, type of studies and 
health care settings in question in order to achieve a manageable quantity of 
records (Beale et al., 2014). A comprehensive search for studies was sought using 
a combination of the keywords “antihypertensive”, ”angiotensin converting 
enzyme inhibitor”, “ACE inhibitors”, “angiotensin receptor blockers”, 
“angiotensin receptor antagonist”, “ beta adrenergic antagonist”, “beta 
blockers”, “calcium channel blockers”, “calcium channel antagonists”, 
“diuretics” , “thiazides”, “randomized controlled trial”, “randomized”, 
“randomly”, and “trial”  in human beings. The Scottish Intercollegiate Guidelines 
Network or SIGN (Scottish Intercollegiate Guidelines Network, 2016) search filters 
were also applied to focus and assist with literature searches in this review. The 
SIGN search filters lay emphasize on specificity rather than sensitivity. The 
detailed search strategy is shown in Appendix (Page 313). The literature search in 
the current review spanned over the last 65 years as the first modern 
antihypertension (TZ) was introduced in the late 1950s (Freis et al., 1958, Freis, 
1995, Moser and Feig, 2009). One of the main limitations of using data spanning a 
long period of time includes a change in rates on risk factors related to cancer. 
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For example,  increasing age increases the risk of cancer and this is evident from 
the current prolonged life expectancy compared to the olden days. Moreover, 
cancer treatment discovery has led to a higher rate of cancer survivorsa .  The 
increase in cancer incidence rates over time may be contributed by increased 
surveillance and detection implemented in study protocols.   
 Searching other resources 
Clinical trial register such as www.ClinicalTrials.gov was searched for relevant 
study by drug names and/ or classes. ClinicalTrials.gov is an internet-based 
registry and results database of publicly and privately supported clinical studies 
of human participants conducted around the world. In addition, references from 
identified articles including reviews and meta-analyses were also reviewed to look 
for eligible trials. Authors were contacted via email for studies that did not report 
the outcome of interest. A second email was sent after one or two weeks of no 
response and whenever possible, other investigators were contacted in cases 
where the email address is not valid. The following reviews and meta-analyses 
were searched for eligible study: 
Aung and Htay (2011) ; Bangalore et al. (2011); Chen et al. (2010) ; Ghamami et 
al. (2014); Heran et al. (2008a); Heran et al. (2008b);Hines and Murphy (2011); Li 
et al. (2014a); Monami et al. (2013); Musini et al. (2014); Perez et al. (2009); Teo 
(2011); Wiysonge et al. (2017); Wong et al. (2014); Wong and Wright (2014); Wong 
et al. (2016). 
 Managing references 
Records or references yield from the chosen electronic databases were imported 
and collated into reference manager software in the form of a bibliographic 
library. The EndNote version X7 by Thomson Reuters Corporation was used to 
manage citations imported from the searched electronic databases in Research 
Information Systems, Incorporated (RIS) or endnote export (.enw) format. 
Duplicates (studies that appeared in more than one database) identified using 
EndNote X7 deduplication tool were removed and saved in a separate bibliographic 
library for safekeeping. Manual identification of duplicates was also carried out 
by scanning the references sorted by title. Following removal of duplicates, a 
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group for eligible references was created in the library for ease of full-text search. 
Only the main author (Nur Aishah Che Roos) of this review was responsible for the 
maintenance and amendment of the bibliographic library. 
Subsequently, references from the bibliographic library were exported into 
Microsoft Excel (version 2013) spreadsheet for coding. Study inclusion or exclusion 
coding was performed according to the PICOS strategy as described previously in 
Section 2.1.1. A categorical coding stating “Yes” and “No” was used when 
considering references against the inclusion criteria. 
 Process for study selection and quality assessment 
2.1.5.1 Screening of titles and/ or abstract 
The primary author, Nur Aishah (NA), independently screened the titles and/or 
abstracts of studies against the predetermined inclusion criteria outlined above 
(Section 2.1.1). During the screening, the reasons and number of rejected articles 
were documented for record keeping purposes. The rejected references were 
classified into two categories; those that are clearly not relevant to the review 
question and those that address the topic of interest but fail on one or more 
criteria. When a definite decision could not be made based on the title and/or 
abstract alone, the full paper was obtained for detailed assessment against 
inclusion criteria. 
The full text of potentially eligible studies was retrieved and independently 
assessed for eligibility by two reviewers, Safaa Alsanosi (SA) and Mohammed 
Alsieni (MA). SA has completed her Doctorate Degree in Cardiovascular Sciences 
at the University of Glasgow whereas MA has completed his Masters of Science in 
Clinical Pharmacology and is currently a doctorate candidate at the University of 
Glasgow. 
2.1.5.2 Obtaining documents 
The full-text articles were obtained from the University of Glasgow Library’s print 
and online resources. Articles were also requested from ArticleReach Direct (ARD) 
for journal articles that were not held by the library. ARD is a consortium of 
academic libraries offering authorized users from participating institution's free 
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automated request for journal articles (ArticleReach Direct, 2017). Whenever 
necessary, the inter-library loan was requested and most of the articles were 
obtained from the British Library Document Supply Centre. An additional search 
was also conducted via the Internet using ‘Google’ search engine by typing the 
title of the article or name of the journal for full-text articles. The full-text search 
tool which is available on the EndNote toolbar was also utilised by highlighting the 
required references and clicking the search icon. 
2.1.5.3 Risk of bias assessment 
The methodological risk of bias of included studies was assessed and reported in 
accordance with the Cochrane Handbook (Higgins, 2011) which recommends the 
explicit reporting of the following individual elements for RCTs: [1] random 
sequence generation; [2] allocation sequence concealment; [3] blinding of 
participants and personnel; [4] blinding of outcome assessment; [5] completeness 
of outcome data; [6] selective outcome reporting; and [7] other sources of bias 
[source of funding]. Each domain was judged as being at high, low or unclear risk 
of bias as set out in the criteria provided by Higgins (2011) and a justification for 
judgement of each item was reported in the risk of bias table (See Chapter 3 
Section 3.3.6, Page 119). Studies will be deemed to be at the highest risk of bias 
if they are scored as at high or unclear risk of bias for either the [1] sequence 
generation, [2] allocation concealment, [3] blinding of participants and personnel 
or [4] blinding of outcome assessment domains based on growing empirical 
evidence that these factors are particularly important potential sources of bias 
(Egger M, 2003, Higgins, 2011).  
In all cases, two authors (MA and SA) independently assessed the risk of bias of 
included studies, with any disagreements resolved by discussion to reach 
consensus. Study authors were contacted for additional information about the 
included studies, or for clarification of the study methods as required. 
 Data extraction 
Two reviewers (NA and SA) independently decided whether a trial was included. 
They also extracted and verified data entry from included studies. Discrepancies 
were resolved by discussion. Any uncertainty identified was resolved through 
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discussion with supervising author (Prof Sandosh Padmanabhan) where necessary. 
Missing data especially on cancer outcomes were requested from study authors by 
email though not all responded.  
The data collection form was designed after taking into consideration how much 
information should be collected. A standardised Microsoft Excel 2010 worksheet 
was used to extract data from the included studies for assessment of study quality 
and evidence synthesis. The detail of the study quality assessment was described 
previously in Section 2.1.5.3. Information extracted for evidence synthesis was 
collected according to the PICOS framework: [1] population, [2] intervention and 
comparators, [3] outcome measures and [4] study design.  
For the study population: [1] Overall number of study participants (N); [2] study 
population clinical settings; [3] N of randomised patients in each treatment arm; 
and [4] baseline characteristics (mean age in years, percentage of male, 
percentage of current smokers, percentage of participants with history of cancer). 
For the study intervention and comparator: [1] Class of the drug; [2] the generic 
name of the drug; [3] Doses of the drug; [4] Duration of treatment; [5] Percentage 
of adherence to therapy; and [6] Supplemental agents. 
For the outcome measures: [1] Cancer as a pre-specified outcome; [2] Number of 
incidence cancer and/ or cancer mortality in each treatment arm; [3] Cancer 
diagnosis adjudication; and [4] Source of cancer data (published or unpublished). 
For study type: [1] Study acronym; [2] Study name; [3] First author’s name; [4] 
Publication year; [5] Journal published;[6] Study duration (total, mean or 
median); and [7] Primary and secondary outcome measures. 
For studies with multiple treatment arms (more than two intervention group), only 
the directly relevant treatment arms were included. If a study was comparing 
different AHT and a number of them had different doses (e.g., the study had four 
treatment arms, irbesartan 150mg vs irbesartan 300mg vs amlodipine 5mg vs 
amlodipine 10mg), cancer outcomes for the treatment arm were combined to 
corresponding AHT classes (e.g., ARB vs CCB). Similarly, if the study was 
comparing different AHT and a number of them belong to the same class with 
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different doses (e.g., the study had four treatment arms, irbesartan 150mg vs 
losartan 100mg vs olmesartan 40mg vs amlodipine 10mg), cancer outcomes for the 
treatment arm were combined to corresponding AHT classes (e.g., ARB vs CCB). 
 Meta-analysis 
Data were processed in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins, 2011); data synthesis and analyses were 
performed using the RevMan 5 software. 
2.1.7.1 Meta-analysis software 
RevMan 5 (Review Manager, 2014)is a software recommended for preparing and 
maintaining Cochrane Reviews developed by the Cochrane Collaboration Group. It was 
developed to facilitate literature reviews ( both protocol and full review) and meta-
analyses (Cochrane Community). It is available free for Cochrane author and academic 
use. 
Analysis methods contained in Revman 5 includes Peto, Mantel-Haenszel, and inverse 
variance for meta-analysis. This software can be used to calculate ratios of effect 
measure (e.g. odds ratio, risk ratio, hazard ratio, ratio of means) expressed on a log-
scale , ‘difference’ measure of effect (risk difference, differences in means) 
expressed on their natural scale (Deeks, 2010), heterogeneity and sensitivity analysis. 
For statistical models, both the fixed-effect (FE) model and random-effect (RE) model 
are included in the RevMan.  
2.1.7.2 Fixed-effect (FE) model meta-analysis 
The assumptions under the FE model is that there is only one true effect size that 
is shared by all the studies in the analysis and that differences in effect estimates 
observed are due to sampling error (Borenstein et al., 2010). The combined effect 
estimate generated from the FE meta-analysis reflects this one true effect size. 
The null hypothesis for this common effect is zero for a difference or one for a 
ratio (Borenstein et al., 2010). Distribution of points observed in the meta-analysis 
indicates sampling error and within-study error is reduced by assigning weights to 
each study in the analysis. 
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2.1.7.3 Random-effects (RE) model meta-analysis 
Under the RE model, we assumed that different studies in the meta-analysis are 
estimating study-specific true effect (Borenstein et al., 2010). Therefore, the 
summary effect generated from the RE model estimates the mean of all the true 
effects. The null hypothesis for the summary is that the mean of these effects is 
0.0 for a difference and 1.0 for the ratio (Borenstein et al., 2010). The RE model 
measures the mean of the distribution and thereby requires consideration of two 
sources of variance: 1) within study error, and 2) variation in the true effects 
across studies. Both sources of variance are minimized by assigning weight to each 
study. 
For RE models, DerSimonian and Laird random-effects models are used. This is the 
most common RE model used in the majority of meta-analyses.  Revman also allows 
presentation of analysis graphically such as analysis flow diagram, forest plots, funnel 
plots, and risk of bias graph and summary. 
2.1.7.4 Data synthesis 
Study participants were analysed in the group to which they were randomised, 
regardless of which or how much treatment they actually received. The 
aggregated data on cancer incidences and/ or cancer mortality obtained from 
included studies were treated as dichotomous variables and were presented in a 
2x2 table giving the numbers of a participant who do or do not experience the 
event in each of the two groups as in Table 2.1. A traditional meta-analysis for 
individual drug classes was conducted using Revman 5 (version 5.3.5). The Mantel-
Haenszel method was used in the estimation of odds ratio (OR) and confidence 
interval (CI) which have been shown to have better statistical properties when 
there are few events (Higgins, 2011). The value of 0.5 was added in the 2x2 cells 
in situations where no events occurred (corrected automatically by RevMan 5). In 
these analyses, an OR below 1 indicates lower odds in the treatment containing 
arm, whereas an OR above 1 indicates lower odds in the comparator. 
Heterogeneity was evaluated using the Q statistic for heterogeneity and I2 
statistics. Small p-values (< 0.05) and a large I2 ratio (≥50%) signify evidence of 
heterogeneity and suggests study-specific OR should be reported instead of 
performing a meta-analysis. When homogeneity was not rejected, the Mantel-
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Haenszel OR in an FE meta-analysis was reported. Publication bias was evaluated 
using funnel plot. 
Table 2-1: Nomenclature for 2 x 2 table of events by treatment 
 Events Non-Events
Treatment A B n1
Control C D n2
2.1.7.5 Heterogeneity assessment  
Heterogeneity in a systematic review is defined as any kind of variability between 
included studies (Higgins, 2011). This variability may be due to clinical diversity 
(difference in participants, interventions, exposures or outcomes studied), and/ 
or methodological diversity (difference in study design and risk of bias). Statistical 
heterogeneity results when there is variability in the true treatment or risk factor 
effects as a consequence of clinical diversity, methodological diversity or both 
(Higgins and Thompson, 2002, Higgins, 2011). 
Heterogeneity can be identified and measured by statistical tests. One of the 
common methods to assess heterogeneity is with Cochran’s chi-square test or also 
known as the Q-statistic for heterogeneity (Higgins and Thompson, 2002). Q is 
defined as 
𝑄 ൌ  ෍ 𝑊𝑖ሺ𝑌𝑖 െ 𝑀ሻଶ
௞
௜ୀଵ
, 
where  
 Wi is the study weight 
 Yi is the study effect size  
 M is the study effect 
 K is the number of studies. 
Q is a standardised measure indicating that it is not affected by the metric of the 
effect size index, but simply is the degrees of freedom (df), 
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𝑑𝑓 ൌ 𝑘 െ 1, 
where k is the number of studies. 
Therefore, the excess variation attributed to differences in the true effects 
between studies is computed as 𝑄 െ 𝑑𝑓. 
It tests the null hypothesis that all included studies have the same effect on the 
population. This review considers a p-value of <0.05 as statistically significant for 
the presence of heterogeneity. It is noteworthy that the Q-statistic has a poor 
power especially in the availability of sparse data and excessive power of 
detecting clinically unimportant heterogeneity when there are many studies 
(Hardy and Thompson, 1998). To overcome this drawback, we also used I squared 
(I2) statistics to quantify inconsistencies between studies. 
According to Higgins (2011), I2 statistics described the percentage of variability in 
the effect estimates that is due to heterogeneity rather than chance. It is 
computed as 
𝐼ଶ ൌ ൬𝑄 െ 𝑑𝑓𝑄 ൰  ൈ 100% 
that is the ratio of excess dispersion to total dispersion.  
The I2 value ranges between 0% (indicate no observed heterogeneity) and a 
maximum of 100% (larger values indicate increasing heterogeneity). Tentatively, 
I2 can be interpreted as follows (Higgins, 2011): 
    0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity. 
 
If there are very little variations between studies, the I2 will be low and the FE 
model is more appropriate. The FE model assumes that there is one true effect 
size that underlies all the studies in the analysis and that all differences in 
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observed effects are due to sampling error (Borenstein et al., 2010). By way of 
explanation, the only difference between studies is their power to detect the 
outcome of interest. 
Significant heterogeneity is typically considered if I2 is 50% or more. It is worth 
noting that I2 is not a measure of absolute heterogeneity and it does not provide 
information on the dispersion of true effects (Borenstein, 2009). It cannot reliably 
tell us which of two meta-analyses shows more heterogeneity in true effects. 
Therefore, I2 should be used together with the observed effects to give the 
reviewers a sense of the true effects.   
In the presence of statistically significant heterogeneity, one analytical approach 
is to incorporate it into a RE mode. The RE model does not fix heterogeneity, on 
the other hand, it allows for differences in the treatment effect from study to 
study (Riley et al., 2011) as it assumes that there is a distribution of true effect 
sizes. The RE model used the tau-squared (Τ2) statistics to estimate between study 
variance from the observed effects. It is computed as 
𝛵ଶ ൌ  𝑄 െ 𝑑𝑓𝐶  
 Where  
𝐶 ൌ  ෍ 𝑊௜  െ ∑𝑊௜
ଶ
∑𝑊௜  
The Τ2 estimates were used to assigned weights under the RE model, where the 
weight assigned to individual study is computed as  
𝑊௜∗  ൌ  1𝑉௒௜∗  ൌ  
1
𝑉௒௜  ൅  𝛵ଶ 
With  𝑉௒ ∗  is the sum of the within study variance (VY) and the between study 
variance (Τ2).  
Heterogeneity is further explored with reference to the characteristics of the 
studies included in the meta-analysis by performing sensitivity analysis through 
conducting subgroup analysis, repeating the analysis, and substituting alternate 
decisions if any were arbitrary or unclear. 
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2.1.7.6 Publication bias assessment  
Publication bias is the failure to include all relevant trials because they were not 
published and hence, not accessible. Publication bias can be measured by 
comparing published and unpublished studies addressing the same question. In this 
review, publication bias was estimated visually by funnel plots. Funnel plots are 
primarily used as a visual tool in the exploration of publication and another type 
of bias in the meta-analysis (Sterne et al., 2006). A funnel plot is a simple scatter 
plot of the intervention effect estimates from individual studies against a measure 
of study size (Sterne et al., 2006, Higgins, 2011). The effect estimates of studies 
were plotted on the horizontal axis while the measure of a studies size was plotted 
on the vertical axis. Hence, results from small studies scattered at the bottom of 
the graph, with the spread narrowing among larger studies. Funnel plots were only 
used if there were at least ten studies included in the meta-analysis otherwise, 
the power of the tests is too low to differentiate chance and real asymmetry 
(Higgins, 2011). The plot approximately resembled a symmetrical inverted funnel 
in the absence of bias. 
2.1.7.7 Sensitivity analysis 
Sensitivity analyses were done by exclusion (when applicable) of trials in which 
the patients were also receiving other study treatment in a factorial designed RCT, 
rendering any attribution of cancer risk to one class of medication problematic. 
Additionally, the treatment effects were also assessed according to quality 
domains (concealed treatment allocation, blinding of patients and caregivers, 
blinded outcome assessment) and study sample size to explore the degree to 
which this systematic review was affected by changes in its methods or in the data 
used from individual studies.  
2.1.7.8 Subgroup analysis  
Subgroup analyses are typically undertaken to explore heterogeneity. In this 
review, subgroup analyses were conducted to explore the average effect of 
treatment when compared to control on the odds of cancer incidence considering 
[1] variant of intervention and comparators and [2] characteristic of the studies.  
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For variant of intervention and comparators subgroup analysis: [1] 
antihypertensive drug subclasses (e.g. DHP CCB and non-DHP CCB) [2] 
antihypertensive class vs placebo and antihypertensive class vs another 
antihypertensive class or active treatment. 
For characteristic of studies subgroup analysis: [1] Mean age 65 years or older and 
mean age below 65, [2] Different health care settings (e.g., hypertension, a 
composite of CVD, and T2DM) and [3] duration of study (e.g., less than five years 
and five years or longer). The different type of clinical settings included 
hypertension, a composite of CVD (CHD, HF, arrhythmia, and stroke), and diabetes 
mellitus. High-risk hypertensive was defined as hypertension with one or more risk 
factor for CV events.  
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3 Antihypertensive therapy and risks of cancer: 
Systematic Review – Screening and Eligibility 
 
3.1 Aim 
This chapter described the systematic review search result (literature searching, 
excluded and included studies, and risk of bias in included studies) for RCTs 
studying the main antihypertensive agents to identify BP-lowering drug classes 
and risks of cancer as per protocol. 
3.2 Results of the search  
Literature searching resulted in 35 696 citations identified through multiple 
sources. After removal of duplicates, 27 235 records were screened for eligibility. 
The detail of the search strategy and review of the literature identified is 
summarized in the PRISMA study flow (Figure 3.1). 
After removal of duplicates, 27, 235 citations and/or abstracts were screened for 
eligibility criteria. Just over 98% (26,772) of these were excluded based on title 
or abstract as pre-determined by this review PICOS criterion. The remaining 463 
publications were assessed for eligibility and only 258 met the eligibility criteria. 
The 205 ineligible studies were excluded because less than 100 participants were 
enrolled per treatment arm and/ or follow-up of less than one year. 
Finally, 90 RCTs enrolling 390,750 participants were included in this review and 
meta-analysis. Details of the excluded and included studies are described in 
Section 3.2.1Description of excluded studies and Section 3.2.2 Description of 
included studies. 
Altogether, 26 studies in language other than English were screened and excluded 
after translation of their abstract or full-text as they did not meet the inclusion 
criteria: nine Russian studies (one was not a randomised study, one did not specify 
the duration of follow-up, two were observational studies, two had follow-up less 
than one year, three had no cancer outcomes), five French studies (four were non-
RCTs and one had follow-up less than one year), five German studies (three were 
non-RCTs, one had used combined therapy, while the other one had enrolled less 
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than 100 participants per treatment arm), four Chinese studies (one was non-RCT, 
two had enrolled less than 100 participants per treatment arm, while the other 
had no cancer outcome), two Italian studies (both had follow-up less than 52 
weeks), and one Portuguese study (enrolled less than 100 participants per 
treatment arm and had less than one year of follow-up). 
 Description of excluded studies 
Overall, a total of 168 RCTs were excluded after a thorough screening of their full-
text for eligibility.  
Four studies (COOPERATE; JIKEI; KYOTO HEART; VART) were retracted due to 
ethical misconduct and unreliable data (Sawada, 2009, The Editors, 2009, 
Asayama et al., 2013, Takano et al., 2014). Different AHT class combination was 
used as an intervention in one study (HSCHG ) and as a comparator in two studies 
(CLEVER; OSCAR).  
One study (Tepel) reported overall cancer mortality but not according to AHT 
class. Meanwhile, cancer incidence was reported collectively the ATTEST study 
and not according to treatment group. Cancer events were not well-defined in 
two studies (Lund-Johansen; HDPAL) as they were reported as either malignant 
processes or cancer-related complications. 
The majority of studies were excluded because of failure to report cancer 
outcomes. The reasons for exclusion for each trial are provided in Table 3-1.  
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Figure 3-1 PRISMA Study flow diagram 
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Table 3-1: Reasons for exclusion of eligible RCTs (Ordered by study ID) 
Study ID 1 Reason for exclusion Reference 
4C  No data on cancer available (Kondo et al., 2003)
AASK  No data on cancer available (Wright Jr et al., 2002)
Aberg  No data on cancer available (Aberg, 1995)
Agardh  No data on cancer available (Agardh, 1996)
AIRE  No data on cancer available (Cleland, 1997)
AIREX  No data on cancer available (Hall, 1997) 
ANBP-2  No data on cancer available (Wing et al., 1997)
Andersen  No data on cancer available (Andersen, 1979)
Andrews  No data on cancer available (Andrews, 2000)
ANZHF  No data on cancer available (Anonymous, 1997)
APSI  No data on cancer available (Boissel, 1990)
Aronow  No data on cancer available (Aronow, 1994)
ASSIST  No data on cancer available (Pepine et al., 1994)
ATTEST  Reported cancer as an adverse drug reaction but 
did not specify to which treatment group. 
(Katayama, 2008)
AVER  No data on cancer available (Esnault et al., 2008)
Barber  No data on cancer available (Barber, 1976)
Barnett  No data on cancer available (Barnett, 2004)
BENEDICT  No data on cancer available (Ruggenenti et al., 2004)
BENEDICT-B No data on cancer available (Ruggenenti et al., 2011)
BEST  No data on cancer available (Eichhorn, 2001)
Beta-PRESERVE  No data on cancer available (Zhou, 2010) 
Bremner  No data on cancer available (Bremner, 1997)
Breyer  No data on cancer available (Breyer, 1996)
CAPPP  No data on cancer available (Hansson et al., 1999)
CAPRICORN  No data on cancer available (The CAPRICORN 
Investigators, 2001) 
CARMEN  No data on cancer available (Remme et al., 2004)
CARP  No data on cancer available (Okada et al., 2011)
CASE-J  No data on cancer available (Ogihara, 2008)
CATS  No data on cancer available (Van Den Heuvel, 1997)
Cheng  No data on cancer available (Cheng, 1997)
Chiariello  No data on cancer available (Chiariello, 1991)
CIBIS  No data on cancer available (Anonymous, 1994b)
CIBIS-II  No data on cancer available (Anonymous, 1999)
Cice  No data on cancer available (Cice, 2010) 
CITAS  No data on cancer available (Campeanu, 2001)
CLEVER   Combined drug classes were used as an active 
comparator (ACEI vs the combination of ACEI and 
BB 
(Miller, 2010)
CONSENSUS  No data on cancer available (Kjekshus, 1988)
Colluci  No data on cancer available (Colucci et al., 1996)
COOPERATE Publication retracted due to invalid data (Nakao, 2003)
COPERNICUS  No data on cancer available (Packer et al., 2002)
CORD  No data on cancer available (Spinar, 2009)
COSMO-CKD No data on cancer available (Ando et al., 2014)
CRIS  No data on cancer available (Rengo et al., 1996)
CVIP  No data on cancer available (Schneider et al., 2004)
Daae  No data on cancer available (Daae, 1998) 
Derosa  No data on cancer available (Derosa et al., 2014)
Derosa  No data on cancer available (Derosa et al., 2011)
DETAIL  No data on cancer available (Barnett, 2006)
DIAL  No data on cancer available (Dalla Vestra, 2004)
DREAM  No data on cancer available (The DREAM Trial 
Investigators, 2006) 
DUTCH TIA  No data on cancer available (Anonymous, 1993)
EIS  No data on cancer available (Anonymous, 1984)
ELSA  No data on cancer available (Zanchetti et al., 2002)
ENCORE II  No data on cancer available (Luscher et al., 2009)
EUCLID  No data on cancer available (Chaturvedi, 1997)
EUROPA  No data on cancer available (Fox, 2003) 
FAMIS  No data on cancer available (Borghi, 1997)
                                         
1 For studies acronyms (see ‘list of abbreviations, Acronyms and symbols) 
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Fogari  No data on cancer available (Fogari et al., 2006)
Fogari  No data on cancer available (Fogari et al., 2008)
Fogari  No data on cancer available (Fogari et al., 2002)
Fogari  No data on cancer available (Fogari et al., 2012a)
Fogari  Combined therapy (ARB or ACEI added on to 
CCB/TZ combination 
(Fogari et al., 2012b)
FOSIDIAL  No data on cancer available (Zannad, 2006)
GISSI-3  No data on cancer available (Anonymous, 1994a)
GLANT  Not a randomized study. (Matsuoka, 1995)
Goldman  No data on cancer available (Goldman, 1980)
Goteborg Metoprolol 
Trial 
No data on cancer available (Herlitz, 1984)
HANE  No data on cancer available (Philipp, 1997)
HAPPHY  No data on cancer available (Wilhelmsen et al., 1987)
HDPAL  Reported cancer-related complications. No data on 
incident cancer and/ or cancer-related mortality 
was available. 
(Agarwal et al., 2014)
HOMED-BP  No data on cancer available (Noguchi et al., 2013)
HSCHG  Different drug class combination was used as an 
intervention (0.5 mg deserpidine combined with 5 
mg methyclothiazide in each tablet).  
(Hypertension-Stroke 
Cooperative Study Group, 
1974) 
HYVET  No data on cancer available (Beckett et al., 2008)
HYVET-ex  No data on cancer available (Beckett et al., 2012)
HYVET-P  No data on cancer available (Bulpitt et al., 2003)
IMAGINE  No data on cancer available (Rouleau et al., 2008)
INNOVATION  No data on cancer available (Makino, 2007)
IPPPSH  No data on cancer available (Anonymous, 1985)
JAMP  No data on cancer available (Ueshima et al., 2004)
J-DHF  No data on cancer available (Yamamoto et al., 2013)
J-ELAN  No data on cancer available (Hori, 2006) 
Jikei Heart  Publication retracted due to unreliable data and 
ethical misconduct (data were intentionally 
altered).
(Mochizuki et al., 2007)
JIMIC-B  No data on cancer available (Yui et al., 2010)
J-MIND  No data on cancer available (Baba et al., 2001)
J-RHYTHM 2  No data on cancer available (Yamashita et al., 2011)
Keilich  No data on cancer available (Keilich, 1997)
Kumar  No data on cancer available (Kumar et al., 2015)
Kyoto Heart  Publication retracted due to unreliable data 
( critical problems existed with some of the data 
reported in this study) 
(Sawada et al., 2009)
Lee  No data on cancer available (Lee et al., 2011)
Lewis  No data on cancer available (Lewis, 1993)
Lin  No data on cancer available (Lin et al., 2013)
LIT  No data on cancer available (LIT Research Group, 1987)
LIVE  No data on cancer available (Gosse et al., 2000)
LOMIR-MCT-IL  No data on cancer available (Yodfat, 1993)
Lund-Johansen  Reported malignant processes but no details were 
available.  
(Lund-Johansen, 1981)
MACB  No data on cancer available (Anonymous, 1995)
MACH-1  No data on cancer available (Levine et al., 2000)
Maclean  No data on cancer available (Maclean, 1993)
MDC  No data on cancer available (Waagstein et al., 1993)
MDPT  No data on cancer available (Anonymous, 1988)
MIAMI  No data on cancer available (Herlitz, 1990)
MITEC  No data on cancer available (Baguet, 2009)
MOSES  No data on cancer available (Schrader et al., 2005)
NORDIL  No data on cancer available (Hansson et al., 2000)
OLIVUS  No data on cancer available (Hirohata et al., 2010)
OLIVUS-Ex  No data on cancer available (Hirohata et al., 2012)
Olsson  No data on cancer available (Olsson, 1986)
Olsson  Duplicate survey (Olsson, 1984)
Omvik  No data on cancer available (Omvik, 1993)
ORIENT  No data on cancer available (Imai et al., 2011)
OSCAR  Combined drug classes used as an active 
comparator (ARB vs the combination of ARB and 
CCB) 
(Kim-Mitsuyama et al., 
2013) 
Ott  Duplicate survey (Ott, 2003) 
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Pacifico  No data on cancer available (Pacifico, 1999)
Packer  No data on cancer available (Packer, 1996)
Packer  No data on cancer (Packer et al., 2001)
Pantoni  No data on cancer available (Pantoni et al., 2005)
PART-2  No data on cancer available (MacMahon et al., 2000)
PATS  No data on cancer available (PATS Collaborating Group, 
1995) 
PEACE  No data on cancer available (Braunwald et al., 2004)
Peng  No data on cancer available (Peng et al., 2015)
PEP-CHF  No data on cancer available (Cleland, 2006)
Perez-Stable  No data on cancer available (Perez-Stable et al., 2000)
POST  No data on cancer available (Sheldon et al., 2006)
PRAISE-2  No data on cancer available (Packer et al., 2013)
PREAMI  No data on cancer available (Ferrari, 2006)
PRESERVE  No data on cancer available (Devereux, 2001)
PREVEND-IT No data on cancer available (Asselbergs, 2008)
PROGRESS  No data on cancer available (PROGRESS Collaborative 
Group, 2001)
PROTECT  No data on cancer available (Stumpe, 1995b)
PUTS  No data on cancer available (Stumpe, 1993)
QUIET  No data on cancer available (Pitt et al., 2001)
RASS  No data on cancer available (Mauer et al., 2009)
REIN  No data on cancer available (Ruggenenti, 2003)
ROAD  No data on cancer available (Fan, 2007) 
ROADMAP  No data on cancer available (Haller et al., 2011)
Salathia  No data on cancer available (Salathia, 1985)
Schmieder  No data on cancer available (Schmieder et al., 2009)
SENIORS  No data on cancer available (Flather et al., 2005)
Sever  No data on cancer available (Sever, 1997)
Shaifali  No data on cancer available (Shaifali et al., 2014)
Shanghai Study  No data on cancer available (Shen, 1996) 
STONE  Not RCT. The alternate allocation was used. (Gong et al., 1996)
Stumpe  A study duration of less than 52 weeks (30 weeks) (Stumpe, 1995a)
Shanghai Study  Duplicate publication of the Shanghai Study. (The 
same study population published in two different 
journals) 
(Xu, 1998) 
SHELL  No data on cancer available (Malacco et al., 2003)
Shen  No data on cancer available (Shen et al., 2012)
SHEP  No data on cancer available (Kostis et al., 1997)
SHEP-PS  No data on cancer available (Perry Jr et al., 1989)
Sjӧland  No data on cancer available (Sjoland, 1995)
STAR-CAST  No data on cancer available (Sasamura et al., 2013)
TAIM  No data on cancer available (Wylie-Rosett et al., 1993)
Talseth No data on cancer available (Talseth, 1990)
TEST  No data on cancer available (Eriksson S., 1995)
Tepel  Cancer outcome reported not according to the 
drug class 
(Tepel, 2008)
TIBET  No data on cancer available (Fox, 1996) 
TOHMS  No data on cancer available (Neaton et al., 1993)
Trimarco  No data on cancer available (Trimarco et al., 2012)
UK Lacidipine  No data on cancer available (The UK Lacidipine Study 
Group, 1991) 
USPHSH  Treatment arm comprised of HCTZ plus reserpine 
combination or hydralazine. The exact number of 
patients randomized to HCTZ plus reserpine not 
given 
(Smith, 1977)
VA COOP  No data on cancer available (Materson et al., 1993)
VA NEPHRON-D  No data on cancer available (Fried et al., 2013)
VAL-CARP  No data on cancer available (Ikeda, 2006)
VART  Publication retracted due to unreliable data and 
problems with management of conflict of interest
(Takano et al., 2014)
VESPA  No data on cancer available (Bestehorn et al., 2004)
VHAS  No data on cancer available (Rosei et al., 1997)
V-HeFT III  No data on cancer available (Cohn et al., 1997)
Waters  No data on cancer available (Waters et al., 1987)
Woo  No data on cancer available (Woo et al., 2009)
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 Description of included studies 
In accordance with the PRISMA statement recommendations, this review included 
90 studies enrolling 390,750 participants with an average follow-up of 3.5 years. 
The characteristics of the study design, participants and interventions used of the 
included studies are summarised in Section 3.2.2.1. Additionally, selected 
characteristics of interest are tabulated in (Appendix). 
Five studies (ACTIVE I; HOPE; NAVIGATOR; PRoFESS; SCAT) used partial or 2-by-2 
factorial design while the rest of the included studies were of parallel design. 
Geographical characteristics: Majority of the included studies were conducted in 
the western world which includes Europe, America, Australia, New Zealand, and 
Israel. 11 studies were conducted in Asia with nine studies (CASE-J Ex; E-COST; 
HIJ-CREATE; Kanamasa; NHS; NICS-EH; OCTOPUS; Otsuka; Suzuki) from Japan and 
two studies (FEVER; Syst-China) from China. All the studies were published in 
English. 
Clinical settings: 21 studies enrolled hypertensive patients without co-morbidities 
(ALPINE; ANBP; E-COST; EWPHE; HEP; LIFE; MAPHY; MIDAS; MRC; MRCOA; NICS-
EH; OSLO; PHYLLIS; PREVER-Treatment; SCOPE; SHEP; STOP-HTN2; Syst-China; 
Syst-Eur; VA COOP II; VERDI).   
The remaining 69 included studies enrolled hypertensive and non-hypertensive 
patients with the presence of specific co-morbidities as an entry criterion. In 
seven studies, hypertensive participants with at least one risk factor for CVD were 
enrolled (ALLHAT; ASCOT-BPLA; CASE-J Ex; CONVINCE; FEVER; INSIGHT; VALUE). 
CHD was the most common comorbidity or illness in 18 studies (ACTION; APSIS; 
BHAT; CAMELOT; DAVIT II; HIJ-CREATE; INTACT; INVEST; Kanamasa; OPTIMAAL; 
Otsuka; Practolol Study; PREVENT; SCAT; SPRINT; SMT; TRACE; Wilcox). This was 
followed by HF in 13 studies (CHARM Added; CHARM Alternative; CHARM 
Preserved; I-PRESERVE; MERIT-HF; PARADIGM-HF; PRAISE; SAVE; SOLVD-P; SOLVD-
T; Val-HeFT; VALIANT; V-HeFT II). Meanwhile, atrial fibrillation (AF) was the main 
comorbidity studied in three studies (ACTIVE I; ANTIPAF; GISSI-AF). 
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T2DM was the main health setting in 10 studies (DEMAND; DIABHYCAR; DIRECT-
Protect 2; FACET; IDNT; IRMA-2; NHS; NESTOR; RENAAL; UKPDS). Participants with 
Type 1 DM and impaired glucose tolerance (IGT) were studied in three RCTs 
(DIRECT-Prevent; DIRECT-Protect I; NAVIGATOR).  
CKD was the main health setting in five studies (AIPRI; ESPIRAL; OCTOPUS; REIN-
2; Suzuki). Four studies (HOPE; ONTARGET; PAT; PRoFESS) investigate participants 
with vascular diseases (including stroke). Two studies (PHARAO; TROPHY) enrolled 
participants with pre-hypertension and one study (LaCroix) enrolled healthy 
adults.  
Participants with baseline cancer: Eight studies (ACTION; CHARM Added; CHARM 
Alternative; CHARM Preserved; GISSI-AF; INVEST; Kanamasa; OCTOPUS) included 
participants with a history of cancer at baseline ranging from 0.4% to 7.5% of total 
study population. 17 studies (AIPRI; CASE-J Ex; EWPHE; HIJ-CREATE; INTACT; 
IRMA-2; LaCroix; MAPHY; MRCOA; OSLO; REIN-2; SHEP; SOLVD-T; SPRINT; TRACE; 
VA COOP II; VERDI) excluded patients with a history of malignancy. The remaining 
63 included studies did not report a history of cancer at baseline. 
Cancer pre-specified as an outcome: 14 studies (ALLHAT; CONVINCE; FACET; HEP; 
INVEST; Kanamasa; LIFE; MIDAS; MRC; MRCOA; ONTARGET; SCAT; TRANSCEND; 
UKPDS) pre-specified cancer as an outcome. However, the remaining 76 studies 
did not pre-specified cancer as a clinical end-point.  Diagnosis of cancer or cancer-
related deaths were centrally-adjudicated in 27 studies (ALLHAT; ASCOT-BPLA; 
BHAT; CONVINCE; FACET; HIJ-CREATE; IDNT; INSIGHT; INVEST; I-PRESERVE; LIFE; 
MAPHY; MIDAS; MRC; MRCOA; NHS; ONTARGET; OPTIMAAL; PARADIGM-HF; PAT; 
Practolol Study; PREVENT; SCOPE; SHEP; Syst-China; Syst-Eur; TRANSCEND) while 
four studies (FEVER; Otsuka; V-HeFT II; Wilcox) were site-reported by treating 
physicians. The remaining 59 studies did not report on the method of cancer 
diagnosis adjudication. 
Source and type of cancer outcomes: 86 included studies have published cancer 
outcomes. Of these, cancer outcomes from 20 studies (ACTIVE 1; ALPINE; ASCOT-
BPLA; CAMELOT; CHARM Added; CHARM Alternative; CHARM Preserved; DIRECT-
Prevent; DIRECT-Protect 1; DIRECT-Protect 2; HOPE; IDNT; IRMA-2; NAVIGATOR; 
ONTARGET; PRoFESS; REIN-2; SCOPE; Val-HeFT; VALUE) were retrieved from 
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published systematic review and meta-analyses. Cancer outcomes were 
collectively reported for six studies (CHARM Added; CHARM Alternative; CHARM 
Preserved; DIRECT-Prevent; DIRECT-Protect 1; DIRECT-Protect 2) as CHARM 
Overall and DIRECT Overall. Conversely, cancer outcomes were unpublished in 
only four studies (DIABHYCAR; MERIT-HF; PARADIGM-HF; PREVER-Treatment) and 
the outcome of interest was provided by the study authors.  
For type of cancer outcomes, 32 included studies (ACTIVE 1; ALLHAT; ALPINE; 
ANTIPAF; ASCOT-BPLA; CHARM Overall; CONVINCE; DEMAND; DIRECT Overall; 
FACET; GISSI-AF; HEP; I-PRESERVE; IRMA-2; Kanamasa; LIFE; NHS; NAVIGATOR; 
NICS-EH; OCTOPUS; ONTARGET; PHARAO; PREVER-Treatment; PRoFESS; RENAAL ; 
SCOPE; Syst-Eur ; TRANSCEND; VERDI) have reported both incident cancer and 
cancer-related deaths . 34 studies (ABCD; ACTION; AIPRI; BHAT; CAMELOT; CASE-
J Ex; DAVIT II; ESPIRAL; EWPHE; FEVER; HIJ-CREATE; HOPE; INSIGHT; INVEST; 
LaCroix; MERIT-HF; MIDAS; NESTOR; NICOLE; PARADIGM-HF; PHYLLIS; PRAISE; 
PREVENT; SCAT; SOLVD-P; SOLVD-T; STOP-HTN2; TRACE; TROPHY; Val-HeFT; 
VALIANT; VALUE; VA COOP II) reported incident cancer alone and 24 studies 
(APSIS; ANBP; DIABHYCAR; E-COST; IDNT; INTACT; MAPHY; MRC; MRCOA; 
OPTIMAAL; OSLO; Otsuka; PAT; Practolol Study; REIN-2; SAVE; SHEP; SPRINT; SMT; 
Suzuki; Syst-China; UKPDS; V-HeFT II; Wilcox)  only reported cancer-related 
deaths.   
BP-lowering agents: Overall, 55,294 were randomised to ACEI, 86,558 to ARB, 
40,115 to BB, 73, 627 to CCB, and 32, 534 to TZ, as shown in Table 3.1. 
ACEI was used in 27 studies (ABCD; AIPRI; ALLHAT; CAMELOT; CHARM Added ; 
DEMAND; DIABHYCAR; ESPIRAL; FACET; HOPE; NESTOR ; ONTARGET; OPTIMAAL; 
Otsuka; PARADIGM-HF; PHARAO; PHYLLIS; SAVE; SCAT; SOLVD-P; SOLVD-T; STOP-
HTN2; TRACE; UKPDS; Val-HeFT; VALIANT; V-HeFT II). The ACEI subclasses were 
further categorised into tissue ACEI and non-tissue ACEI. Four tissue ACEI 
(benazepril, quinapril, ramipril, and trandolapril) and five non-tissue ACEI 
(captopril, delapril, enalapril, fosinopril, and lisinopril) were used. However, two 
studies (CHARM Added; Val-HeFT) did not specify the ACEI subclass used. Among 
the ACEI subclasses, ramipril was mostly used as it was allocated to 31.3% of the 
patients randomised to the ACEI arm in four studies (DIABHYCAR; HOPE; 
ONTARGET; PHARAO).  
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ARB was used in 32 studies (ACTIVE I; ALPINE; ANTIPAF; CASE-J Ex; CHARM 
(Overall); DIRECT (Overall); E-COST; GISSI-AF; HIJ-CREATE; IDNT; I-PRESERVE; 
IRMA-2; LIFE; NHS; NAVIGATOR; OCTOPUS; ONTARGET; OPTIMAAL; PREVER-
Treatment; PRoFESS; RENAAL; SCOPE; TRANSCEND; TROPHY; Val-HeFT; VALIANT; 
VALUE). Overall, six ARB subclasses (candesartan, irbesartan, losartan, 
olmesartan, telmisartan, and valsartan) were used in these studies. Of these, 
telmisartan was commonly used as it was allocated to 34.8% of the patients 
randomised to the ARB arm in three studies (ONTARGET; PRoFESS; TRANSCEND).     
CCB was used in 30 studies (ABCD; ACTION; ALLHAT; APSIS: ASCOT-BPLA; 
CAMELOT; CASE-J Ex; CONVINCE; DAVIT II; ESPIRAL; FACET; FEVER; IDNT; INSIGHT; 
INTACT; INVEST; Kanamasa; MIDAS; NHS; NICOLE; NICS-EH; PRAISE; PREVENT; 
REIN-2; SPRINT; STOP-HTN2; Syst-China; Syst-Eur; VALUE; VERDI). 
With regards to CCB subclasses, seven DHP agents (amlodipine, felodipine, 
isradipine, nicardipine, nifedipine, nisoldipine, and nitrendipine) and two non-
DHP agents (diltiazem and verapamil) were used. Amlodipine was commonly used 
as it was allocated to almost half (42.5%) of the total patients randomised to the 
CCB arm in ten studies (ALLHAT; ASCOT-BPLA; CAMELOT; CASE-J Ex; FACET; IDNT; 
NHS; PRAISE; PREVENT; VALUE). 
Diuretics were used in 18 studies (ALLHAT; ALPINE; ANBP; EWPHE; INSIGHT; La 
Croix; MAPHY; MIDAS; MRC; MRCOA; NESTOR; NICS-EH; OSLO; PHYLLIS; PREVER-
Treatment; SHEP; VA COOP; VERDI).  
For diuretics subclasses, four TZ (bendroflumethiazide, chlorothiazide, HCTZ, and 
tricloromethiazide) and two TZ-like diuretics (chlorthalidone and indapamide) 
were used. In between the diuretics, chlorthalidone was mostly used as it was 
allocated to more than half (55.2%) of the total participants randomised to the 
diuretics arm in three studies (ALLHAT; PREVER-Treatment; SHEP).  
BB was used in 16 studies (APSIS; ASCOT-BPLA; BHAT; HEP; INVEST; LIFE; MAPHY; 
MERIT-HF; MRC; MRCOA; PAT; Practolol Study; SMT; UKPDS-38; VA COOP II; 
Wilcox). The BB subclasses included three cardioselective (atenolol, metoprolol, 
and practolol) and one non-cardioselective (propranolol). Atenolol was commonly 
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used as it was allocated to 68.1% of the total patients randomised to the BB arm 
in six studies (ASCOT-BPLA; HEP; INVEST; LIFE; MRCOA; UKPDS-38). 
Treatment adherence: A total of 57 studies reported participants’ adherence to 
study treatments ranging from 31% to 100% while the remaining 33 studies (ABCD; 
AIPRI; ANTIPAF; APSIS; CAMELOT; DEMAND; DIRECT (Overall); ESPIRAL; EWPHE; 
HIJ-CREATE; IDNT; INSIGHT; INTACT; Kanamasa; MAPHY; NHS; NICS-EH; OSLO; 
PHYLLIS; Practolol Study; PREVER-Treatment; REIN-2; SHEP; Suzuki Syst-China; 
Syst-Eur; TROPHY; Val-HeFT; VA COOP II; VERDI; Wilcox) did not provide any 
information on adherence.  
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Table 3-2: Summary of BP-lowering agents used in RCTs included in this systematic review.  
Red highlights indicate the highest N or %. 
AHT class
N of RCTs 27 32 30 18 16
N of participants 51,681 86,558 73, 627  32,534 40,115
% of participants 13.18 22.09 18.78 8.3 10.24
AHT subclasses
Benazepril 0.58% Candesartan 16.07% Amlodipine 42.94% Bendroflumethiazide 13.21% Atenolol 68.61%
Quinapril 0.25% Irbesartan 8.74% Felodipine 9.78% Chlorothiazide 5.29% Metoprolol 10.37%
Ramipril 31.29% Losartan 9.73% Isradipine 0.60% Hydrochlorothiazide 24.8% Practolol 3.80%
Trandolapril 1.70% Olmesartan 0.52% Nicardipine 0.29% Trichloromethiazide 0.65%
Telmisartan 34.83% Nifedipine 12.42% Propanolol 17.22%
Captopril 17.72% Valsartan 29.90% Nisoldipine 0.87% Chlorthalidone 55.18%
Delapril 0.25% Nitrendipine 4.96% Indapamide 0.87%
Enalapril 22.55% ARB 0.21%
Fosinopril 0.86% Diltiazem 0.00
Lisinopril 17.52% Verapamil 0.28
ACEI 7.29%
ACEI ARB BBCCB Diuretics
Non‐specific
Non‐specific 
Non‐tissue ACEI
Non‐cardioselective
AT‐II receptor antagonists CardioselectiveDHP
Non‐DHP
Tissue ACEI Thiazide
Thiazide‐like
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3.2.2.1 Characteristics of included studies (ordered by study ID) 
ABCD 2 (1998) (Estacio et al., 1998)
Design: Prospective, randomized, double-blind, parallel trial.
Mean duration of follow-up: 5.6 years  
Participants: 470 participants with NIDDM and hypertension
Age range: 40-74 (mean: 57.5 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment group
CCB: nisoldipine 5-40mg/day vs ACEI: enalapril10-60mg/day 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (Metoprolol 
and HCTZ) 
Primary and secondary outcomes: 24-hour creatinine clearance, CV events, end-organ damage, 
urinary albumin excretion and LVH.
Funding Source: Bayer Pharmaceuticals
 
ACTION (2006);(Poole-Wilson et al., 2006)  
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 4.9 years   
Participants: 7665 participants with treated stable symptomatic coronary artery disease (stable 
angina). 
Age range : 35-older (mean: 63.5yrs) 
Hypertensive patients (%): 52 
Baseline cancer(%): 4.4 
Intervention:  2 treatment group
CCB: nifedipine GITS 60mg/day or Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (except CCB) 
Primary and secondary outcomes: Major CV event-free survival, combined endpoint for safety, 
any CV event; death, or procedure; and any vascular event or procedure. 
Funding Source: Bayer Healthcare AG, Wuppertal, Germany
 
ACTIVE I (2011); (The ACTIVE I Investigators, 2011)
Design: Multicentre, partial factorial, randomized, double-blind, placebo-controlled trial
Mean duration of follow-up: 4.1 years  
Participants: 9016 participants with a history of a risk factor for stroke and permanent AF or had 
at least two episodes of intermittent AF in the last 6 months. 
Age range: 75-older (mean: 69.6 yrs.) 
Hypertensive patients (%): 88 
Baseline cancer(%):Not reported 
Intervention: 2 treatment group
ARB: irbesartan 300mg/day vs Placebo 
Co-intervention: ACTIVE W: clopidogrel plus aspirin vs anticoagulants; ACTIVE A: clopidogrel vs 
placebo 
Primary and secondary outcomes: First occurrence of stroke, MI, vascular death, and 
hospitalization for HF. 
Funding Source: Bristol-Myers Squibb and Sanofi-Aventis2
 
AIPRI (1996);(Maschio et al., 1996)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 3 years 
Participants: 583 patients with renal insufficiency caused by various disorders 
                                         
2 For studies acronyms (see ‘list of abbreviations, Acronyms and symbols) 
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Age range: 18‐70 (mean: 51 yrs.) 
Hypertensive patients (%): 82 
Baseline cancer(%): None 
Intervention: 2 treatment group
ACEI: Benazepril 10 mg/day vs Placebo 
Co-intervention: No other BP lowering agents were added 
Primary and secondary outcomes: time from the initiation therapy to a doubling of the serum 
creatinine concentration or the need for dialysis; changes over time in the values for serum 
creatinine, urinary protein excretion, and diastolic pressure; adjustments in antihypertensive 
therapy 
Funding Source: Boehringer Ingelheim, Bayer Schering Pharma and GSK 
 
ALLHAT (2002) (The ALLHAT Collaborative Research Group, 2002) 
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 4.9 years  
Participants: 33 357 hypertensive patients with at least one risk factor for CHD events.
Age range: 55-older (mean: 67 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 3 treatment groups
ACEI: Lisinopril 10-40 mg/day vs CCB: amlodipine 2.5-10 mg/day vs TZ: chlorthalidone 25 mg/day 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added consecutively 
(atenolol, reserpine, clonidine, or hydralazine) 
Primary and secondary outcomes: fatal CHD or non-fatal MI combined, all-cause mortality, 
stroke, combined CHD, and combined CVD 
Funding Source: Pfizer 
 
ALPINE (2003) (Lindholm et al., 2003)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 1 year  
Participants: 392 participants with hypertension.
Age range: Not reported (mean: 55 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: Candesartan cilexetil 16mg/day vs TZ: HCTZ 25mg/day 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added consecutively 
(felodipine was added to the candesartan group and Atenolol was added to the HCTZ group) 
Primary and secondary outcomes: glucose and lipoprotein metabolism, electrolytes, BP, and 
subjective symptoms  
Funding Source: Department of Public Health and Clinical Medicine, Umea˚ University, Sweden 
together with AstraZeneca R&D, Molndal, Sweden and Hassle Lakemedel AB, Sweden. 
 
 
ANBP (1980);(The ANBP Study Commitee, 1980)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 4.1 years  
Participants: 3427 participants with mild hypertension
Age range: 30-69 (mean: 50.5 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer (%): Not reported 
Intervention: 2 treatment groups
TZ: Chlorothiazide 500mg - 1g/ day vs Placebo
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Co-intervention: if BP goal was not achieved, other BP-lowering agents were added consecutively 
(methyldopa, propranolol, pindolol, hydralazine or clonidine). 
Primary and secondary outcomes: Death from any cause, peripheral vascular events, TIA, MI, 
other IHD, HF, dissecting aneurysm of the aorta, retinal haemorrhages, hypertensive 
encephalopathy, and onset of renal failure. 
Funding Source: National Health and Medical Research Council of Australia, the Life Insurance 
Medical Research Fund of Australia and New Zealand, the Victorian Government, the Clive and 
Vera Ramaciotti Foundations, and the Raine medical Research Foundation of Western Australia 
 
ANTIPAF (2012)(Goette et al., 2012)  
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 1 year 
Participants: 430 participants with paroxysmal AF.
Age range: 18-older (mean: 61.5 yrs.) 
Hypertensive patients (%): 49 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB: olmesartan 40mg/day vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (diuretics, 
CCBs, and antiadrenergic agents. 
Primary and secondary outcomes: Percentage of days with documented episodes of paroxysmal 
AF, time to the first occurrence of AF, number of hospitalizations for AF and stroke, quality of 
life.  
Funding Source: German Ministry of Research and Education. Daiichi Sankyo Deutschland GmbH 
(Munich, Germany) 
 
APSIS (1996);(Rehnqvist et al., 1996)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 3.4 years  
Participants: 809 patients with stable angina pectoris
Age range: 70 or younger (mean: 59 yrs.) 
Hypertensive patients (%): 27 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
BB: metoprolol 25-200 mg/day vs CCB: verapamil 40-240 mg twice/day  
Co-intervention: No other BP lowering agents were added 
Primary and secondary outcomes: Death, CV events, cerebrovascular events, peripheral vascular 
events, psychological variables reflecting the quality of life. 
Funding Source: Swedish Heart Lung Foundation, the Swedish Research Medical Council, Knoll 
AG, Germany and Astra Hassle, Sweden. 
 
ASCOT-BPLA (2005) (Dahlöf et al., 2005)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE)  
Mean duration of follow-up: 5.7 years  
Participants: 19,257 participants with hypertension and had at least three other CV risk factors
Age range: 40-79 (mean: 63 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
CCB: 5-10mg/day with 4-8mg/day  vs BB: 50-100mg/day atenolol  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added as required 
(perindopril was added to CCB-based therapy and bendroflumethiazide was added to BB-based 
therapy). 
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Primary and secondary outcomes: non-fatal MI and fatal CHD, all-cause mortality, total stroke, 
primary end point minus silent MI, all coronary events, total CV events and procedures, CV 
mortality, non-fatal and fatal HF, CHD, PVD, life-threatening arrhythmias, development of T2DM, 
development of renal impairment 
Funding Source: Pfizer 
 
BHAT (1982) (Anonymous, 1982)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 2.1 years 
Participants: 3837 participants who had at least one documented MI
Age range:  30-69 (mean: 54.8 yrs.) 
Hypertensive patients (%): 41 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
BB: Propanolol hydrochloride 180-240 mg/day vs Placebo 
Co-intervention: No other BP lowering agents were added 
Primary and secondary outcomes: All-cause mortality, CHD mortality, sudden cardiac death, 
CHD mortality plus non-fatal MI. 
Funding Source: National Heart, Lung, and Blood Institute (NHLBI)
 
CAMELOT (2004); (Nissen et al., 2004)
Design: Prospective, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2 years  
Participants: 1997 participants with angiographically documented CAD  and DBP 100 mm Hg
Age range:  30-79 (mean: 57.7 yrs.) 
Hypertensive patients (%): 60.4 
Baseline cancer(%): Not reported  
Intervention: 3 treatment groups
CCB: amlodipine 5mg/day + 1 tab placebo vs ACEI: enalapril 10mg/day + 1 tab placebo vs Placebo 
Co-intervention: No other BP lowering agents were added 
Primary and secondary outcomes: Incidence of adverse CV events, the incidence of adverse 
events for enalapril treatment versus placebo and comparison of the amlodipine treatment group 
versus enalapril group, all-cause mortality and the incidence of revascularization in vessels that 
had undergone previous stent placement 
Funding Source: Pfizer 
 
CASE-J Ex (2011); (Ogihara et al., 2011)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Mean duration of follow-up: 4.5 years  
Participants: 4703 with high-risk hypertension (at least one risk factor for CVD) 
Age range:  25-85 (mean: 63.9 yrs.) 
Hypertensive patients (%): 100 
Baseline cancer(%): None 
Intervention: 2 treatment groups
ARB: Candesartan 4-12 mg/day vs CCB: Amlodipine 2.5- 10 mg/day 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: Sudden death, cerebrovascular events, cardiac events, renal 
dysfunction, all deaths, left ventricular MI, the proportion of the subjects who withdrew from the 
allocated treatment 
Extension study primary and secondary outcomes: Fatal/non-fatal CV events, all-cause death, 
CV death, new-onset diabetes 
Funding Source: Takeda Pharmaceutical and Pfizer Japan.
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CHARM-Added (2003); (McMurray et al., 2003)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 3.4 years  
Participants: 2548 patients with NYHA class II-IV and left ventricular EF= 40% or lower, and who 
are being treated with ACEI. 
Age range: 18-older (mean: 64.1 yrs.) 
Hypertensive patients (%): 48 
Baseline cancer(%): 6 
Intervention: 2 treatment groups
ARB: Candesartan 4-32mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: All-cause and CV death, unplanned admission to hospital for 
the management of worsening CHF, non-fatal MI, non-fatal stroke, or coronary revascularization, 
development of new diabetes. 
Funding Source: Astra-Zeneca
 
CHARM-Alternative (2003) (Granger et al., 2003)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 2.8 years 
Participants: 2028 patients with NYHA class II-IV and left ventricular EF= 40% or lower, and who 
are intolerance to ACEI. 
Age range: 18-older (mean: 67 yrs.) 
Hypertensive patients (%): 50 
Baseline cancer(%): 6.6 
Intervention: 2 treatment groups
ARB: Candesartan 4-32mg/day or Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: All-cause and CV death, unplanned admission to hospital for 
the management of worsening CHF, non-fatal MI, non-fatal stroke, or coronary revascularization, 
development of new diabetes. 
Funding Source: Astra-Zeneca
 
CHARM-Preserved (2003); (Yusuf et al., 2003)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 3.1 years  
Participants:  3023 patients with NYHA functional class II–IV and had LVEF higher than 40%
Age range: 18-older (mean: 67.2 yrs.) 
Hypertensive patients (%): 64 
Baseline cancer(%): 7.5 
Intervention: 2 treatment groups
ARB: Candesartan 4-32mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: All-cause and CV death, unplanned admission to hospital for 
the management of worsening CHF, non-fatal MI, non-fatal stroke, or coronary revascularization, 
development of new diabetes. 
Funding Source: Astra-Zeneca
 
CONVINCE (2003) (Black et al., 2003)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 3 years 
Participants: 16602 participants with hypertension and had 1 or more additional risk factors for 
CVD. 
Age range: 55-older (mean: 65.6 yrs.) 
Hypertensive patients (%): 100 
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Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: COER verapamil 180 mg/day vs non-CCB :Atenolol 50 mg/day or HCTZ 12.5 mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added as step 2 
(HCTZ and atenolol). Any additional open-labelled BP-lowering agents (except a non-DHP CCB, TZ, 
or BB) could be added as a step 3 if needed. 
Primary and secondary outcomes: first occurrence of stroke, MI, or CV disease-related death, 
hospitalizations for CVD end-points, all-cause mortality, cancer, hospitalizations for bleeding 
(excluding haemorrhagic stroke), the incidence of primary end points occurring between 6 AM and 
noon.   
Funding Source: G.D. Searle & Co and Pharmacia
 
DAVIT II (1999) (Sajadieh et al., 1999)  
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 1.3 years 
Participants: 1775 patients with the diagnosis of acute MI (post MI 2 weeks) 
Age range: 76 or younger (mean: 60.7 years) 
Hypertensive patients (%): 14 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: verapamil 120 mg three times/day vs Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: total mortality and first major event (i.e., death or 
reinfarction). 
Funding Source: Knoll Aktiengesellschaft
 
DEMAND (2011) (Ruggenenti et al., 2011)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 3.8 years  
Participants: 380 participants with hypertension and T2DM (with albuminuria <200mg/min)
Age range: 40-older (mean: 61.2 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 3 treatment groups
CCB+ACEI: manidipine 10 mg/day  plus delapril 30mg/day vs ACEI: delapril 30 mg/day vs Placebo 
Co-intervention: Additional antihypertensive agents were allowed in the following steps: (1) 
HCTZ, indapamide, or furosemide (2) β- or α-β blockers; and (3) doxazosin, prazosin, clonidine 
hydrochloride or α-methyldopa. 
Notes: For this review, only the monotherapy arms were considered. 
Primary and secondary outcomes: Rate of GFR decline, composite end-point of death from CV 
causes, sudden death; non-fatal MI or stroke; coronary revascularization; amputation; vascular 
surgery for peripheral atherosclerotic artery disease; new-onset, progression, or regression of 
retinopathy and peripheral neuropathy. 
Funding Source: Independent academic trial
 
DIABHYCAR (2004) (Marre et al., 2004)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 4 years  
Participants: 4912 patients with T2DM who use oral antidiabetic drugs and have persistent 
microalbuminuria or proteinuria, and serum creatinine ≤ 150 μmol/l. 
Age range: 50-older (mean: 65.1 years) 
Hypertensive patients (%): 56 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
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ACEI: ramipiril 1.25mg/day vs Placebo
Co-intervention: On top of usual treatment 
Primary and secondary outcomes: incidence of CV death, fatal and non-fatal MI, stroke, HF, 
leading to hospital admission, and ESRF; all-cause death; any revascularisation procedure on 
coronary or other arterial vessels, transient neurological ischaemic episodes, doubling of the 
serum creatinine concentration, loss of vision in one eye, and amputation above the 
metatarsophalangeal joint. 
Funding Source: Avantis (Paris) and the French Health Ministry
 
DIRECT-Prevent 1 (2008) (Chaturvedi et al., 2008)
Design: Prospective, randomized, double-blinded, parallel trial
Median duration of follow-up: 4.7 years  
Participants: 1421 participants with normotensive, normoalbuminuric type 1 diabetes without
retinopathy 
Age range: 18-50 (mean: 29.7  years) 
Hypertensive patients (%): None 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: candesartan 32 mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: incidence and progression of retinopathy.  
Funding Source: AstraZeneca and Takeda
 
DIRECT-Protect 1 (2008) (Chaturvedi et al., 2008)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 4.8 years  
Participants: 1905 participants with normotensive, normoalbuminuric type 1 diabetes with 
retinopathy 
Age range: 18-55 (mean: 31.7  years) 
Hypertensive patients (%): None 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: candesartan 32 mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: incidence and progression of retinopathy.  
Funding Source: AstraZeneca and Takeda
 
DIRECT-Protect 2 (2008) (Sjølie et al., 2008)
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 4.7 years  
Participants: 1905 participants with normoalbuminuric, normotensive, or treated hypertensive 
people with T2DM with mild to moderately severe retinopathy. 
Age range: 37-75 (mean: 56.9 years) 
Hypertensive patients (%): 62 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: candesartan 32 mg/day vs placebo 
Co-intervention: no other BP-lowering agents were added 
Primary and secondary outcomes: incidence and progression of retinopathy.  
Funding Source: AstraZeneca and Takeda
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E-COST (2005) (Suzuki and Kanno, 2005)
Design: Prospective, randomized, open-label, parallel trial
Mean duration of follow-up: 3.1 years 
Participants:  2048 participants with essential hypertension
Age range: 35-79 (mean: 67 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: candesartan 4-8mg/day  vs Control: Conventional therapy 
Co-intervention: Other antihypertensive drugs were added as necessary (not specified) 
Primary and secondary outcomes: Stroke, MI and CHF, which included fatal and non-fatal 
incidence 
Funding Source: Not reported
 
ESPIRAL (2001) (Marin, 2001)
Design: Prospective, multicentre, randomized, open-label, parallel study 
Mean duration of follow-up: 3 years 
Participants: 241 participants with hypertension and chronic renal failure. 
Age range: 24-74 (mean: 56 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ACEI: fosinopril 10-30 mg/day vs CCB: nifedipine GITS 30-60 mg/day  
Co-intervention: Additional antihypertensive agents were allowed in the following steps: 
(1)Furosemide, (2) atenolol (3) doxazosin 
Primary and secondary outcomes: Time elapsed until the serum creatinine values doubled, or 
the need to enter the dialysis programme; CV events, proteinuria evolution and serum creatinine 
values 
Funding Source: Not reported
 
EWPHE (1985)(Amery et al., 1985)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.7 years  
Participants: 840  elderly participants with hypertension
Age range:  60-older (mean: 72 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None
Intervention: 2 treatment groups
TZ: HCTZ 25 mg/day plus triamterene 50mg/day vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added 
(methyldopa).  
Primary and secondary outcomes: Deaths; CV morbidity (non-fatal cerebral or subarachnoid 
haemorrhage, development of hypertensive retinopathy grade III or IV, dissecting, aneurysm, 
CHF) 
Funding Source: Belgian National Research Foundation (NFWO) and through grants from Merck, 
Sharpe and Dohme, and Smith, Kline, and French.  
 
FACET (1998) (Tatti et al., 1998)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Mean duration of follow-up: 2.9 years   
Participants: 380 participants with hypertension and T2DM
Age range:  Not reported (mean: 63.1 years) 
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Hypertensive patients (%): 100
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ACEI: fosinopril 20mg/day vs CCB: amlodipine 10 mg/day  
Co-intervention: If BP was not controlled on monotherapy, the other study drug was added at full 
dose (not specified). 
Primary and secondary outcomes: Blood examination test; all-cause mortality; any major 
vascular events or procedure; cancer. 
Funding Source: Bristol-Myers Squibb
 
FEVER (2005) (Liu et al., 2005)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.3 years  
Participants: 9711 Chinese participants with hypertension and one or two additional CV risk 
factors or disease 
Age range:  50-79 (mean: 61.5 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention:  2 treatment groups
CCB:  Felodipine 5mg/day vs Placebo 
Co-intervention: Background therapy of HCTZ 12.5 mg/day throughout the trial in both 
treatment arms. If BP was not controlled, further 12.5 mg HCTZ dose given as open label was 
allowed and subsequently other AHT agents (except CCB). 
Primary and secondary outcomes: Time to the first stroke; all CV events, cardiac events, all-
cause death. 
Funding Source: National Science and Technology Ministry, China and partly by Beijing 
Hypertension League Institute, and Shanxi Kangbao Pharmaceutical Company. 
 
GISSI-AF (2009) (The GISSI-AF Investigators, 2009)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1 year 
Participants: 1442 patients with AF.
Age range: 40-older  (mean: 68 years) 
Hypertensive patients (%): 85 
Baseline cancer(%): 3.1 
Intervention: 2 treatment groups
ARB: valsartan 80-320mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added.  
Primary and secondary outcomes: time to the first recurrence of AF; the proportion of patients 
who had more than one episode of AF over the 1-year follow-up period; total number of episodes 
of AF per patient, hospitalization for any reason and for a CV event, the composite of death and 
thromboembolic events, the number of patients in sinus rhythm at the time of each study visit, 
the duration of and ventricular rate at the first recurrence of AF, and a safety profile. 
Funding Source: Novartis
 
HEP (1986) (Coope, 1986)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Mean duration of follow-up: 4.4 years  
Participants: 884 elderly participants with hypertension
Age range: 60-79  (mean: 68.8  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
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BB: 100mg/day atenolol vs Control: no treatment
Co-intervention: Additional antihypertensive agents were allowed in the following steps: (2) 
bendrofluazide or (3) α-methyldopa. 
Primary and secondary outcomes: Any CV events, clinical gout, T2DM, non-fatal cancer, vertigo 
and dizzy spells, all-cause death 
Funding Source: Imperial Chemical Industries
 
HIJ-CREATE (2012) (Kasanuki et al., 2009, Sugiura et al., 2012)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Median duration of follow-up: 4.3 years  
Participants: 2049 hypertensive participants with angiographically documented CAD
Age range: 20-80 (mean: 64.8 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None 
Intervention: 2 treatment groups 
ARB: candesartan 4–12 mg/day  vs Control: Non-ARB 
Co-intervention: Additional antihypertensive agents were allowed (exclude ACEI). 
Primary and secondary outcomes: time to a first major adverse cardiac event, angioplasty, 
stenting or coronary artery bypass grafting; new onset diabetes. 
Funding Source: Japan Research Promotion Society for CV Diseases
 
HOPE (2002) (The HOPE Study Investigators, 2000)
Design: Prospective, randomized,  double-blind, two-by-two factorial, placebo-controlled trial
Mean duration of follow-up: 5 years 
Participants: High risk patients with CAD, stroke, peripheral vascular disease or diabetes plus at 
least one other CV risk factor 
Age range: 55-older (mean: 66 years) 
Hypertensive patients (%): 47 
Baseline cancer(%): Not reported 
Intervention: 2  treatment groups
ACEi: 10 mg/day ramipiril vs Placebo 
Co-intervention: no other BP-lowering agents were added. 
Notes:  Additional randomised treatment: Vitamin E 400 IU vs Placebo 
Primary and secondary outcomes: Composite of MI, stroke or CV mortality, all-cause mortality, 
revascularization, hospitalization for CV morbidity and complications related to diabetes 
Funding Source: Medical Research Council of Canada, Hoechst-Marion Roussel, AstraZeneca, King 
Pharmaceuticals, Natural Source Vitamin E Association and Negma, and the Heart and Stroke 
Foundation of Ontario research Chair. 
 
I-PRESERVE (2010) (Zile et al., 2010)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.1 years  
Participants: 4128 participants with HF and preserved LVEF ≥ 45%.
Age range:  60 – older (mean: 72  years) 
Hypertensive patients (%): 64 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: irbesartan 75-300mg/day  vs  Placebo 
Co-intervention: no other BP-lowering agents were added. 
Primary and secondary outcomes: Time to first occurrence of the composite outcome of death 
or CV hospitalization, CV death; all-cause mortality, combined vascular endpoint, combined HF 
endpoint, HF mortality or hospitalizations; quality of life, change in NYHA functional class, 
change in patient global assessment of symptoms, N-terminal B-type natriuretic peptide levels in 
blood. 
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Funding Source: Bristol-Myers Squibb and Sanofi-Aventis
 
IDNT (2003) (Berl et al., 2003)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Median duration of follow-up:  2.6 years  
Participants:  1715 participants ( treatment, control) with hypertension and T2DM nephropathy
Age range:  30-70 (mean: 59  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 3 treatment groups
ARB: Irbesartan 300mg/day vs CCB: Amlodipine 10 mg/day vs  Placebo 
Co-intervention: if BP goal was not achieved, other open BP-lowering agents were added 
(excluding ACEI, ARB, and CCB).  
Primary and secondary outcomes: time to a composite end-point of doubling of baseline serum 
creatinine, ESRD, and death; time to a composite end-point of fatal or non-fatal CV events  
Funding Source: Bristol-Myers Squibb Pharmaceutical Research Institute and Sanofi-Synthelabo
 
INSIGHT (2000) (Brown et al., 2000)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Median duration of follow-up: 2.6 years 
Participants: 6321 participants with hypertension and at least one additional CV risk factor
Age range: 55-80 (mean: 65 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
CCB: nifedipine: 30 mg/day vs TZ:  amiloride + HCTZ: 2.5 mg/day + 25 
g/day 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (including 
atenolol and enalapril, excluding CCBs and diuretics) 
Primary and secondary outcomes: CV death, MI, HF, or stroke
Funding Source: Bayer AG.
 
INTACT (1990) (Lichtlen, 1987, Lichtlen, 1990)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3 years 
Participants: 425 participants showing mild CAD on arteriography.
Age range: 65 or younger (mean: 53.1years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
CCB: nifedipine 80 mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added.    
Primary and secondary outcomes: Changes in pre-existing stenosis (percentage and diameter of 
progression or regression) 
Funding Source: Not reported
 
INVEST (2003) (Pepine et al., 2003)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Mean duration of follow-up: 2.7  years 
Participants: 22576 participants with hypertension and CAD patients. 
Age range: 50-older (mean: 66.1 years) 
Hypertensive patients (%): 47 
Baseline cancer(%): Not reported 
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Intervention: 2 treatment groups
CCB: Verapamil Sustained Release 240-360mg/day vs BB: Atenolol 50-100mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (including 
trandolapril and HCTZ).  
Primary and secondary outcomes: the first occurrence of death from any cause, non-fatal MI, or 
non-fatal stroke; all-cause death, non-fatal MI, non-fatal stroke, CV death, angina, CV 
hospitalisations, BP control, cancer, Alzheimer’s disease, Parkinson’s disease, gastro-intestinal 
bleeding 
Funding Source: Abbot Laboratories
 
IRMA-2 (2001) (Parving et al., 2001)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Median Mean duration of follow-up: 2  years 
Participants: 590 participants with hypertension, T2DM and microalbuminuria. 
Age range: 30-70 (mean: 58 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None
Intervention: 3 treatment groups
ARB: irbesartan 150mg/day vs ARB: irbesartan 300mg/day vs  Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (excluding 
DHPs and ACEI). 
Primary and secondary outcomes: Time from the base-line visit to the first detection of overt 
nephropathy, changes in the level of albuminuria, changes in creatinine clearance, and the 
restoration of normoalbuminuria by the time of the last visit. 
Funding Source: Sanofi–Synthelabo and Bristol-Myers Squibb
 
Kanamasa et al (1998);  (Ishikawa et al., 1997, Kanamasa et al., 1999) 
Design: Prospective, randomized, open-label, clinical trial
Mean duration of follow-up: 2.2 years  
Participants: 1054 patients with healed MI
Age range: Not reported (mean: 60 years) 
Hypertensive patients (%): 46 
Baseline cancer(%): 0.4 
Intervention: 2 treatment groups
CCB: nifedipine 10-30mg/day short-acting and short-acting diltiazem 30-90mg/day  vs Control: 
Non-CCB 
Co-intervention: no other BP-lowering agents were added.    
Primary and secondary outcomes: Cardiac death and nonfatal, recurrent MI, cancer 
Funding Source: Not reported
 
LaCroix et al (2000);  (LaCroix, 2000)
Design: Prospective, single centre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3  years  
Participants: 320 healthy, normotensive elderly participants
Age range: 60-79 (mean: 68 years) 
Hypertensive patients (%): None 
Baseline cancer(%): None
Intervention: 3 treatment groups
TZ: HCTZ12.5mg/day vs TZ: HCTZ 25mg/day vs  Placebo 
Co-intervention: no other BP-lowering agents were added.     
Primary and secondary outcomes: Change in bone mineral density at the total hip, spine, and 
total body. 
Funding Source: Ciba-Geigy and  the National Institute of Health
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LIFE (2002) (Dahlöf et al., 1997, Dahlöf et al., 2002)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.8 years  
Participants: 9193 participants with essential hypertension and LVH 
Age range:  55–80 (mean: 67 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB:  losartan 50-100mg/day vs BB: atenolol 50-100mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (HCTZ 12.5-
25mg/day, excluding ARB, ACEI and BB). 
Primary and secondary outcomes: CVD mortality and mortality, total mortality, angina pectoris 
or CHF requiring hospital admission  
Funding Source: Merck 
 
MAPHY (1988)(Wikstrand, 1988)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Median Mean duration of follow-up: 4.2  years 
Participants: 3234 participants with essential hypertension.
Age range:  40-64 (mean: 52.6 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None 
Intervention: 2 treatment groups
TZ:  HCTZ 50mg/day or bendroflumethiazide 5 mg/day vs BB: metoprolol 200 mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (hydralazine, 
spironolactone, or others but not BB or TZ). 
Primary and secondary outcomes: Total mortality, sudden cardiac death, pooled incidence of 
fatal and nonfatal coronary events, stroke. 
Funding Source: Swedish National Association Against Heart and Chest Diseases (Stockholm) and 
the Astra Cardiovascular Research Laboratories (Molndal). 
Notes: This multicentre study was a subset of the HAPPHY trial. The analysis takes into 
consideration only 1 of the 2 BBs (metoprolol). 
 
MERIT-HF (1999) (MERIT-HF Study Group, 1999)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1  year 
Participants: 3991 participants with chronic HF (ejection fraction 40% or less). 
Age range: 40-80  (mean:63.8 years) 
Hypertensive patients (%): 44 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
BB: metoprolol CR/XL 12.5-200mg/day  vs  Placebo 
Co-intervention: no other BP-lowering agents were added.     
Primary and secondary outcomes: Total mortality, combined endpoint of all-cause mortality and 
all-cause hospitalization); Pooled incidence of cardiac death and nonfatal acute MI; the number 
of hospitalizations due to HF and other CV causes 
Other: 
(1)Combined endpoint of all-cause mortality, hospitalizations due to HF, and emergency 
department visits due to HF (time to the first event) 
(2) Tolerability, defined as overall discontinuation of treatment and discontinuation due to 
worsening of HF 
(3) NYHA functional status 
Funding Source: Astra Hassle AB, Molndal
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MIDAS (1996) (Borhani et al., 1996)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3 years 
Participants: 883 participants with hypertension.
Age range:  40 –older (mean: 58.5  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: isradipine 5-10 mg/day  vs TZ: 25-50 mg/day HCTZ  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (enalapril 
2.5-10 mg twice/day). 
Primary and secondary outcomes: the rate of progression in mean maximum intimal media 
thickness (IMT) of carotid focal points 
Funding Source: Sandoz Pharmaceuticals
 
MRC (1985) (MRC Working Party, 1985)
Design: Prospective, multicentre, randomized, single-blinded, parallel trial 
Mean duration of follow-up: 4.9 years 
Participants: 17 354 participants with hypertension. 
Age range: 35-64 (mean: 52 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 3 treatment groups
BB: 240 mg/day propranolol vs TZ: 10 mg/day bendrofluazide vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (methyldopa)  
Primary and secondary outcomes: Fatal or non-fatal stroke, coronary events, fatal and non-fatal 
MI, other CV events and death from other cause. 
Funding Source: Imperial Chemical Industries Ltd and Merck Sharp and Dohme. 
 
MRCOA (1992) (MRC Working Party, 1992)
Design: Prospective, multicentre, randomized, single-blinded, parallel trial 
Mean duration of follow-up: 5.8 years 
Participants: 4396 participants with hypertension.
Age range:  65-74 (mean: 70.3 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None 
Intervention: 3 treatment groups
BB: 50 mg/day atenolol vs TZ: 50 mg/day HCTZ and 5 mg/day amiloride (single tablet) or 25 
mg/day HCTZ and 2.5 mg/day amiloride vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added in the 
following steps- (1) nifedipine up to 20 mg/day or matching placebo and (2) other 
antihypertensive drugs). 
Primary and secondary outcomes: Fatal or non-fatal stroke, coronary events, fatal and non-fatal 
MI, other CV events and death from other cause. 
Funding Source: Merck, Sharp and Dohme, Imperial Chemical Industries, and Bayer 
 
NHS (2012) (Muramatsu et al., 2012)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Median Mean duration of follow-up: 3.2  years 
Participants: 1150 participants with hypertension and T2DM or IGT.
Age range:  30-75 (mean: 63  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
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ARB: valsartan 80 -160mg/day vs CCB: amlodipine 5 -10mg/day 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (diuretics, β-
blockers, or α-blockers could be added after 8 weeks as needed). 
Primary and secondary outcomes: a composite of CV morbidity and mortality 
Funding Source: Nagoya University Graduate School of Medicine
 
NAVIGATOR (2010) (The NAVIGATOR Study Group, 2010)
Design: Prospective, multicentre, randomized, double-blinded trial with a 2-by-2 factorial design.
Mean duration of follow-up:  5 years 
Participants: 9306 patients with impaired glucose tolerance and established CVD or CV risk 
factors 
Age range: 18-older (mean: 63.7 years) 
Hypertensive patients (%): 75 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: valsartan 80-160 mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added.     
Notes: Additional randomised treatment: nateglinide vs placebo 
Primary and secondary outcomes: (1) incidence of T2DM, (2) a composite of death from CV
causes, nonfatal MI, nonfatal stroke, hospitalization for HF, arterial revascularization, or 
hospitalization for unstable angina, (3) core CV outcome  
Funding Source: Novartis Pharma
 
NESTOR (2004) (Marre, 2003, Marre, 2004)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1  year 
Participants:  570 patients with T2DM and hypertension
Age range: 35-80  (mean: 60 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
TZ: indapamide SR 1.5 mg/day vs ACEI: enalapril 10 mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (amlodipine 
5-10 mg/day  and atenolol 50-100mg/day)  
Primary and secondary outcomes: (1) Microalbuminuria (2) BP measurements and variability 
following treatment (3) Ambulatory BP measurements (4) Potential genetic markers for 
albuminuria and CV risk. 
Funding Source: Institut de Recherches Internationales Servier
 
NICOLE (2003) (Dens et al., 2003)
Design: Prospective, single centre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3 years 
Participants: 826 participants with CAD who underwent successful single or multiple vessel PTCA 
Age range: 75 or younger (mean: 60  years) 
Hypertensive patients (%): 41 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: nisoldipine SR  20-40mg/day vs  Placebo 
Co-intervention:  no other BP-lowering agents were added.     
Primary and secondary outcomes: (1) Angiographic: angiographic progression of non-dilated 
coronary arterial lesions (2) Clinical: CV events, including death, stroke, acute MI, repeat PTCA, 
PTCA of a new or progressive lesion, or coronary artery bypass grafting (CABG). 
Funding Source: Bayer AG, Wuppertal, Germany
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NICS-EH (1999) (NICS-EH Study Group, 1999)
Design: Prospective, randomized, double-blinded, parallel trial
Median Mean duration of follow-up:  4.6 years 
Notes: In total, 15 participants were withdrawn, but the intention-to-treat analysis was not used 
Participants: 429 elderly participants with hypertension and no history of CV complications.
Age range: 60-older (mean: 69.8  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
CCB: nicardipine HCL  SR 40 mg/day  vs TZ: trichlormethiazide 2 mg/day 
Co-intervention: no other BP-lowering agents were added.     
Primary and secondary outcomes: CV complications and other non-CV end-points 
Funding Source: Not reported
 
OCTOPUS (2013) (Iseki et al., 2013)
Design: Multicentre, prospective, randomized, open-label, blinded-endpoint trial (PROBE)
Mean duration of follow-up: 3.5 years 
Participants: 469 participants with hypertension and ESRD
Age range: 20-79  (mean: 59.5 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): 5.3 
Intervention: 2 treatment groups
ARB: Olmesartan 10-40mg/day vs Control: Non-ARB (excluding ACEI) 
Co-intervention: no other BP-lowering agents were added.     
Primary and secondary outcomes: (1) All causes of death (2) CVD (3) HMBP to evaluate the 
relationship between CVD (4) Blood access troubles requiring an operation. 
Funding Source: Own fund and donation
 
ONTARGET(2008) (The ONTARGET Investigators, 2008, Teo, 2011) 
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.7 years 
Participants: 25620 patients with coronary, peripheral, or cerebrovascular disease or diabetes 
with end-organ damage. 
Age range:  55 or older (mean: 66.4 years) 
Hypertensive patients (%): 69 
Baseline cancer(%): Not reported
Intervention: 3 treatment groups
ARB: 80mg/day telmisartan vs ACEI: 5-10mg/day ramipiril vs ARB+ACEI: 80mg/day telmisartan 
plus 5-10mg/day ramipiril   
Co-intervention: No information on further titration or background therapy 
Primary and secondary outcomes: Death from CV causes, nonfatal MI, nonfatal stroke,
hospitalization for congestive HF 
Funding Source: Boehringer Ingelheim and  the Heart and Stroke Foundation of Ontario
 
OPTIMAAL (2002) (Dickstein and Kjekshus, 2002)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.7  years 
Participants: 5477 participants with confirmed acute MI and HF
Age range:  50 or older (mean: 67.4  years) 
Hypertensive patients (%): 36 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
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ARB: losartan 12.5-50 mg/day vs ACEI: captopril 37.5-150 mg/day 
Co-intervention: No information on further titration or background therapy 
Primary and secondary outcomes: All-cause mortality
Funding Source: Merck, Sharp and Dohme Research Laboratories
 
OSLO (1980) (Helgeland, 1980)
Design: Prospective, randomized, parallel trial
Mean duration of follow-up: 5.5 years 
Participants: 785 men with hypertension 
Age range:  20-49 (mean: 45.3  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None
Intervention: 2 treatment groups
TZ: HCTZ 50 mg/day vs Control: No treatment 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (methyldopa 
500mg-1g/day or propranolol 80-320 mg/day). 
Primary and secondary outcomes: CV events
Funding Source: Not reported
 
Otsuka et al (1982) 
Design: Prospective, randomized, open, and non-placebo controlled trial 
Mean duration of follow-up: 4.8 years 
Participants: 253 patients with coronary artery disease post PCI
Age range: 18-79 (mean: 63 years) 
Hypertensive patients (%): 46 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ACEI: 10-20 mg/day quinapril vs Control: Non-ACEi 
Co-intervention: no other BP-lowering agents were added. 
Notes: Aspirin and ticlopidine were administered as an adjunct pharmacologic therapy. 
Primary and secondary outcomes: Death, MI, CVA and revascularization 
Funding Source: Not reported
 
PARADIGM-HF (2014) (McMurray et al., 2014)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.3  years 
Participants: 8442 patients with class II, III, or IV HF and an ejection fraction of 40% or less
Age range: 18-older (mean: 63.8 years) 
Hypertensive patients (%): 35 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ACEI: enalapril 20 mg/day vs  Control: LCZ696 400 mg/day (ArNi)  
Co-intervention: no other BP-lowering agents were added.  
Primary and secondary outcomes: composite of death from CV causes or a first hospitalization 
for HF; the time to death from any cause, the change from baseline to 8 months in the clinical 
summary score on the Kansas City Cardiomyopathy Questionnaire (KCCQ), the time to a new onset 
of AF, and the time to the first occurrence of a decline in renal function 
Funding Source: Novartis Pharmaceutical
 
PAT (2002) (The Propranolol Aneurysm Trial Investigators, 2002)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.5 years 
Participants: 548 patients with asymptomatic small abdominal aortic aneurysm 
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Age range: Not reported (mean: 68.9 years)
Hypertensive patients (%): 36 
Baseline cancer(%): Not reported 
Notes: 4 randomized patients were excluded from analysis as they did not meet the eligibility 
criteria. 
Intervention: 2 treatment groups
BB: propranolol 160-240 mg/day vs  Placebo 
Co-intervention: no other BP-lowering agents were added. 
Primary and secondary outcomes: the Growth rate of an aneurysm, mortality, elective resection 
of an aneurysm, reasons for permanent withdrawal from study medication, quality of life  
Funding Source: Canadian Institute of Health Research
 
PHARAO (2008); (Lüders et al., 2008)
Design: Multicentre, prospective, randomized, open-label, blinded-endpoint trial (PROBE)
Mean duration of follow-up: 3 years 
Participants: 1008 participant with high-normal office BP
Age range:  50-85 (mean: 62.3 years) 
Hypertensive patients (%): None 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ACEI: ramipiril 5 mg/day vs Control 
Co-intervention: no other BP-lowering agents were added. 
Notes:  It was not reported whether participants in the control group were given alternative 
antihypertensive or no treatment. 
Primary and secondary outcomes: development of hypertension, reduction in CVA events and CV
events, overall mortality, reasons for admissions to hospital, the occurrence of pathological 
fasting glucose levels in serum/pathological HbA1c levels. 
Funding Source: Sanofi Aventis Pharma GmbH
 
PHYLLIS (2004) (Zanchetti et al., 2004)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.6 years 
Participants: 508 patients with hypertension, hyperlipidaemia, and asymptomatic carotid 
atherosclerosis 
Age range: 45-70 (mean: 58.4 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 4 treatment groups
TZ: HCTZ 25 mg/QD plus placebo vs ACEI: Fosinopril 20 mg/QD plus placebo vs TZ+Statin: HCTZ 
25 mg/QD plus pravastatin vs ACEI+statin: Fosinopril 20 mg/QD plus pravastatin 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (Nifedipine 
GITS 30-60 mg/QD). 
Notes: For this review, only the TZ and ACEI arm were considered.   
Primary and secondary outcomes: Rate of change in maximum intimal media thickness (IMT) of 
the coronary artery wall, changes in BP, changes in lipid level and other laboratory variables 
Funding Source: Bristol-Myers Squibb and Menarini
 
Practolol Study (1975) (Anonymous, 1975b)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1.2  years 
Participants: 3038 participants recovering from acute MI.
Age range: 69 or younger (mean: 55 years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): Not reported
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Intervention: 2 treatment groups
BB: practolol 400 mg/day vs Placebo 
Co-intervention: No information on further titration or background therapy. Drugs considered to 
interact with beta-adrenoceptor antagonists were not permitted. 
Primary and secondary outcomes: All-cause mortality, reinfarction, effects of treatment on BP, 
angina pectoris, and arrhythmia, causes of treatment withdrawal. 
Funding Source: Not reported
 
PRAISE (1996) (Packer et al., 1996)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1.2 years 
Participants: 1153 participants with severe chronic HF and ejection fractions of less than 30 
percent.  
Age range: Not reported (mean: 64.7 years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: amlodipine 5-10mg/day vs  Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: Mortality from all causes and CV morbidity. 
Funding Source: Pfizer Central Research
 
PREVENT(2000) (Pitt et al., 2000)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3  years 
Participants: 825 participants with coronary artery disease.
Age range: 30-80 (mean: 56.9 years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
CCB: amlodipine 20-40mg/day vs Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: change in the mean minimal diameter of early atherosclerotic 
segments and reduction in the rate of coronary disease progression. 
Funding Source: Pfizer, Inc./US Pharmaceuticals Group
 
PREVER-Treatment (2016) (Fuchs et al., 2016)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1.5 years 
Participants: 655 participants with stage I hypertension and no current use of BP-lowering 
medication. 
Age range: 30-70 (mean: 54 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
TZ: chlorthalidone/amiloride 12.5/2.5 mg/day vs ARB: losartan 50 mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added in the 
following steps- (1) amlodipine up to 10 mg/day (2) propranolol up to 80 mg/day 
Primary and secondary outcomes: mean BP between the two treatment groups, fatal and 
nonfatal major CV events. 
Funding Source: Department of Science and Technology (DECIT), Health Ministry; National 
Council of Research (CNPq) and Agency for Funding of Studies and Projects (FINEP), Science and 
Technology Ministry; National Institute of Health Technology Assessment (IATS); and Funding of 
Incentive to Research (FIPE), Hospital de Clinicas de Porto Alegre, all in Brazil 
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PRoFESS (2008); (Yusuf et al., 2008)
Design: Prospective, randomized,  double-blind, 2x2 factorial, placebo-controlled trial
Mean duration of follow-up: 2.5 years 
Participants: 20,332 patients with recent ischaemic stroke
Age range: 50-older (mean: 66.2 years) 
Hypertensive patients (%): 74 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB: telmisartan 80mg/day vs Placebo 
Co-intervention: No information on further titration or background therapy. 
Notes: Other randomized drugs included aspirin and dipyridamole extended release vs clopidogrel 
Primary and secondary outcomes: Recurrent stroke of any type and total vascular events 
Funding Source: Boehringer Ingelheim, with additional support from Bayer Schering Pharma and 
GlaxoSmithKline 
 
REIN-2 (2005) (Ruggenenti et al.)
Design: Multicentre, prospective, randomized, open-label, blinded-endpoint trial (PROBE)
Mean duration of follow-up: 1.6 years 
Participants: 338 patients with non-diabetic proteinuric nephropathy with background ACEI 
treatment 
Age range:  18-70 (mean: 53.4 years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): None
Intervention: 2 treatment groups
Conventional BP control: ramipiril 5 mg/day and concomitant antihypertensive therapy vs 
Intensified BP control: felodipine 5-10 mg/day and concomitant antihypertensive therapy 
Co-intervention: No information on other antihypertensive therapy. 
Notes: Combined therapy approach 
Primary and secondary outcomes: Time to ESRD.
Funding Source: Aventis Pharma SA
 
RENAAL (2002) (Brenner  et al., 2001)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.4 years 
Participants: 1513 patients with T2DM and nephropathy
Age range: 31-70 (mean: 60 years) 
Hypertensive patients (%): 94 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: 50-100mg/day Losartan vs Placebo 
Co-intervention: Open-label conventional antihypertensive therapy excluding ARBs and ACEIs 
were given along with the randomized treatment. 
Primary and secondary outcomes: composite of a doubling of the base-line serum creatinine 
concentration, ESRD, or death and composite of morbidity and mortality from CV causes, 
proteinuria, and the rate of progression of renal disease. 
Funding Source: Merck and Company.
 
SAVE (1992) (Pfeffer et al., 1992)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.5 years 
Participants: 2231 patients with acute MI and left ventricular dysfunction (EF 40% or less)
Age range: 21-80  (mean: 59.4 years) 
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Hypertensive patients (%): 43
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ACEI: captopril 25-50 mg/TID vs  Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: CV mortality and morbidity, all-cause mortality, development 
of overt HF, hospitalization to treat congestive HF. 
Funding Source: Bristol-Myers Squibb
 
SCAT (2000) (Teo et al., 2000)
Design: Prospective, randomized,  double-blind, 2x2, placebo-controlled trial 
Mean duration of follow-up: 4 years 
Participants: 460 patients with CAD and normal or mildly elevated cholesterol. 
Age range: 21-older (mean: 61 years) 
Hypertensive patients (%): 36 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ACEI: Enalapril 2.5 -10 mg/ BID vs Placebo 
Co-intervention: no other BP-lowering agents were added. 
Notes: Other randomized drugs included simvastatin vs placebo.  
Primary and secondary outcomes: Quantitative coronary angiography (QCA) measures and 
clinical events (death, MI, stroke, hospitalization for angina, revascularization, and cancer). 
Funding Source: Merck Frost Canada and Company
 
SCOPE (2003) (Lithell et al., 2003)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial  
Mean duration of follow-up: 3.7 years 
Participants: 4964 elderly patients with hypertension and a Mini Mental State Examination (MMSE) 
test score >=24. 
Age range:  70–89 (mean: 76.4 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ARB: candesartan 8 – 16 mg/day vs Placebo 
Co-intervention: Other antihypertensive drugs, except ACEI or AT1-receptor blockers, could be 
added later 
Primary and secondary outcomes: Major CV events, CV death, non-fatal stroke, non-fatal MI, 
cognitive function measured by the MMSE and dementia.  
Funding Source: AstraZeneca
 
SHEP (1991) (SHEP Cooperative Research Group, 1991)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 5 years 
Participants: 4736 elderly patients with systolic hypertension.
Age range: 60-older (mean: 71.6 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None
Intervention: 2 treatment groups
TZ: chlorthalidone 12.5-25 mg/day vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added  (atenolol 25-
50 mg/day or reserpine 0.05-0.1 mg/day) 
Notes: Potassium supplements were given to all participants who had potassium serum level 
below 3.5 mmol/L  
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Primary and secondary outcomes: total stroke, sudden cardiac death, rapid cardiac death, fatal 
and non-fatal MI, left ventricular failure, other CV death, TIA, coronary artery therapeutic 
procedures and renal dysfunction. 
Funding Source: National Heart, Lung, and Blood Institute and the National Institute on Ageing. 
Drugs were supplied by the Lemmon Co, Sellersville, Pa; Wyeth Laboratories, AH Robins Co, and 
Studart Pharmaceuticals 
 
SOLVD-P (1992) (The SOLVD Investigators, 1992)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.1 years 
Participants: 4228 patients with severe congestive HF (LVEF < 35%, with no overt HF)
Age range: Not reported (mean: 59.1 years) 
Hypertensive patients (%): 37 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
ACEI: enalapril 2.5 - 10 mg/BID vs Placebo 
Co-intervention: Patients were allowed to receive diuretics for hypertension, digoxin for current 
or past AF, and nitrates for angina. 
Primary and secondary outcomes: overall mortality and morbidity, quality of life, changes in 
clinical and functional status, hospitalizations, adherence to study drug, side effects 
Funding Source: National Heart, Lung, and Blood Institute and Merck, Sharp and Dohme
 
SOLVD-T (1991) (The SOLVD Investigators, 1991)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.5 years 
Participants: 2569  patients with severe congestive HF (LVEF < 35%, with overt HF) 
Age range: 80 or younger (mean: 60.9 years) 
Hypertensive patients (%): 42 
Baseline cancer(%): None
Intervention: 2 treatment groups
ACEI: enalapril 2.5 - 10 mg/BID vs Placebo 
Co-intervention: In patients with worsening symptoms of congestive HF, an increase in the dose 
of diuretics or the addition of vasodilators was recommended.  
Primary and secondary outcomes: overall mortality and morbidity, quality of life of patients, 
changes in clinical and functional status, hospitalizations, adherence to study drug, side effects 
Funding Source: National Heart, Lung, and Blood Institute and Merck, Sharp and Dohme
 
SPRINT (1988) (The Israeli SPRINT Study Group, 1988, Jonas et al., 1998) 
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 5 year 
Notes: The primary study followed patients up to 1 year 
Participants: 2127 survivors of acute MI
Age range: 30-74  (mean: 57.5 years) 
Hypertensive patients (%): 27 
Baseline cancer(%): None 
Notes: The primary trial reported 2276 patients underwent randomisation however baseline 
characteristics for only 2149 patients were reported as one study centre failed to supply complete 
baseline data. The current analysis used the total number of patients reported in the 5-year 
mortality follow-up. 
Intervention: 2 treatment groups
CCB: 30 mg/day nifedipine vs Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: total mortality and non-fatal recurrent acute MI, CV events 
cardiac surgery. 
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Funding Source: Bayer AG
 
SMT (1985) (Olsson, 1985)
Design: Prospective, single, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3 years 
Participants: 301 survivors of acute MI
Age range: 70 or younger (mean: 59.7 years) 
Hypertensive patients (%): 26 
Baseline cancer(%): Not reported 
Intervention: 2 treatment groups
BB: 100 mg/day metoprolol vs  Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: total mortality, non-fatal recurrent acute MI, other ischaemic 
manifestations. 
Funding Source: Swedish National Association Against Heart and Chest Diseases and AB Hassle, 
Molndal, Sweden 
 
STOP-HTN2 (2001) (Hansson et al., 1999, Lindholm et al., 2001)
Design: Prospective, randomized, open-label, blinded-endpoint trial (PROBE) 
Mean duration of follow-up: 5 years 
Participants: 6614 elderly participants with hypertension 
Age range:  70-84 (mean:  years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported 
Intervention:  3 treatment groups
ACEi : enalapril 10mg/day or lisinopril 10mg/day vs CCB: felodipine 2.5mg/day or isradipine 
2.5mg/day vs Control: Conventional therapy (atenolol 50 mg/day; metoprolol 100mg/day; 
pindolol 5mg/day or  HCTZ+amiloride 25/2.5mg) 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (Patients on 
BBs were given HCTZ; patients on HCTZ were given any of the BBs; patients on ACEI were given 
HCTZ 12.5-5.0 mg/day; patients on CCB were given any of the BBs). 
Primary and secondary outcomes: Combined endpoint of fatal and non-fatal stroke, fatal MI, and 
other fatal CVD. 
Funding Source: AstraZeneca, Merck Sharp and Dohme, and Sandoz (later Novartis)
 
Suzuki et al. (2008) 
Design: Multicentre open-labelled randomized trial
Mean duration of follow-up: 3 years 
Participants: 366 patients with end-stage renal disease on haemodialysis 
Age range:  30-80 (mean: 59.6 years) 
Hypertensive patients (%): 93 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB: losartan 50-100mg/day or  candesartan 8-12mg/day or  valsartan80-160mg/day vs Control: 
Non-ARB 
Co-intervention: No details on concomitant antihypertensive therapy allowed. 
Primary and secondary outcomes: the development of fatal and nonfatal CV events, all-cause 
death 
Funding Source: Own fund
 
Syst-China (1998)(Liu et al., 1998)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4 years 
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Participants: 2391 elderly patients with systolic hypertension
Age range: 60 or older (mean: 66.5 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention:  2 treatment groups
CCB: nitrendipine 10-40mg/day vs Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (captopril 
12.5-50mg/day or HCTZ 12.5-50mg/day) 
Primary and secondary outcomes: Death, stroke, retinal haemorrhage or exudates, MI, 
congestive HF, dissecting aortic aneurysm, renal insufficiency, and all other events.  
Funding Source: State Planning Commission of the People's Republic of China. The study analysis 
was facilitated through a fellowship granted by Bayer AG, Wuppertal, Germany, to Dr Ji Guang 
Wang 
 
Syst-Eur (1997) (Staessen et al., 1997)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2 years 
Participants: 4695 elderly participants with isolated systolic hypertension 
Age range:  60 or older (mean: 70.3 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
CCB: 10-40 mg/day nitrendipine vs  Placebo 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (captopril 
12.5-50mg/day or HCTZ 12.5-50mg/day) 
Primary and secondary outcomes: stroke, MI, congestive HF, cardiac events, renal insufficiency.
Funding Source: European Union and Bayer AG, Wuppertal, Germany 
 
TRACE (2005) (The TRACE Study Group, 1994, Kober, 1995, Buch et al., 2005) 
Design: Prospective, multicentre, randomized, double-blinded, parallel trial  
Mean duration of follow-up: 5.6 years 
Participants: 1749 participants with MI and left ventricular dysfunction (ejection fraction <= 35%)
Age range:  18 or older (mean: 67.5 years) 
Hypertensive patients (%): 23 
Baseline cancer(%): None
Intervention: 2 treatment groups
ACEI: trandolapril 2-4 mg/day vs Placebo 
Co-intervention: No information on further titration or background therapy.  
Primary and secondary outcomes: total mortality, CV mortality, sudden death, reinfarction, 
severe congestive HF, left ventricular function. 
Funding Source: Roussel-Uclaf and Knoll
 
TRANSCEND (2008) (The TRANSCEND Investigators, 2008)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.7 years 
Participants: 5926 patients with a history of CVD or T2DM with end-organ damage  intolerant to 
ACE inhibitors 
Age range: Not reported (mean: 66.9 years) 
Hypertensive patients (%): 76 
Baseline cancer(%): 4.9 
Intervention: 2 treatment groups
ARB: 80mg/day telmisartan vs  Placebo 
Co-intervention: No information on further titration or background therapy. 
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Primary and secondary outcomes: CV death, MI, stroke, hospitalisation for HF, new HF, 
development of T2DM, AF, cognitive decline or dementia, nephropathy, and revascularisation. 
Funding Source: Boehringer Ingelheim.
 
TROPHY (2006) (Julius et al., 2006)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 3.6 years 
Participants: 809 participants with BP on study entry in the high-normal range (pre-hypertension)
Age range: 30-65 (mean: 48.5 years) 
Hypertensive patients (%): None 
Baseline cancer(%): Not reported
Intervention: 2 treatment group
ARB: 16 mg/day candesartan vs Placebo 
Co-intervention: no other BP-lowering agents were added. 
Primary and secondary outcomes: Development of clinical hypertension. 
Funding Source: AstraZeneca
 
UKPDS-38 (1998) (Anonymous, 1998, UKPDS Investigators, 1998)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 9 years 
Participants: 1148 hypertensive patients with T2DM
Age range:  Not reported (mean: 56.8 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): Not reported
Intervention: 3 treatment groups
ACEI: Captopril 25- 50 mg/BID vs BB: Atenolol 50-100 mg/day vs Control: Non-ACEI/BB 
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added in the 
following steps: (1) Frusemide 20 mg/day (max 40 mg/bid) (2) Nifedipine SR 10 mg (max 40 mg)/ 
bid 
(3) Methyldopa 250 mg ( max 500 mg)/ bid (4) Prazosin 1 mg ( max 5 mg) / TID   
Primary and secondary outcomes: Time to occurrence of (1) first clinical end point related to 
diabetes (2) death related to diabetes (3) All-cause mortality. Macrovascular and microvascular 
complications. 
Funding Source: MRC, British Diabetic Association, the Department of Health, the National Eye 
Institute, and the National Institutes of Health (USA), the British Heart Foundation, Novo-Nordisk, 
Bayer, Bristol Myers Squibb, Hoechst, Lilly, Lipha, and Farmitalia Carlo Erba. 
 
 
VA COOP II (1982) (Anonymous, 1982)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1 year 
Participants: 394 patients with mild to moderate hypertension
Age range: 21-65 (mean: 50 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None 
Intervention: 2 treatment groups
BB: 80-640 mg/day propranolol vs TZ: 50-200 mg/day HCTZ 
Co-intervention: no other BP-lowering agents were added   
Primary and secondary outcomes: Treatment efficacy, and adverse effects. 
Funding Source: Ayerst Laboratories Inc.
 
Val-HeFT (2001) (Cohn and Tognoni, 2001)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
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Mean duration of follow-up: 1.9 years
Participants: 5010 patients with HF
Age range: 18 or older (mean: 62.7 years) 
Hypertensive patients (%): 6.7 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB: valsartan 80-320 mg/day vs Placebo 
Co-intervention: no other BP-lowering agents were added     
Primary and secondary outcomes: mortality and morbidity, CV outcomes, NYHA functional class, 
quality-of-life scores, and signs and symptoms of HF. 
Funding Source: Novartis Pharmaceuticals
 
VALIANT (2003) (Pfeffer et al., 2000, Pfeffer et al., 2003)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.1 years 
Participants: 14,703 patients with HF and/or left ventricular systolic dysfunction (LVSD) after MI.
Age range: 18 or older (mean: 64.8 years) 
Hypertensive patients (%): 55 
Baseline cancer(%): Not reported
Intervention: 3 treatment groups
ACEI: captopril  150 mg/day vs ARB: valsartan 320 mg/day vs ACEI+ARB: 150/320 mg/day 
Co-intervention: no other BP-lowering agents were added     
Primary and secondary outcomes: all-cause mortality, CV death, acute coronary syndromes 
(fatal and nonfatal), CV morbidity, revascularization procedures, CV procedures, hospitalization. 
Funding Source: Novartis Pharmaceuticals
 
VALUE (2004) (Julius et al., 2004)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 4.2 years 
Participants: 15,245 participants with treated or untreated hypertension and a high risk of 
cardiac events 
Age range: 50 or older (mean: 67 years) 
Hypertensive patients (%): 92 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ARB: Valsartan 80 - 160mg/day vs CCB: Amlodipine 5 - 10mg/day  
Co-intervention: if BP goal was not achieved, other BP-lowering agents were added (excluding 
ACEI) 
Primary and secondary outcomes: Time to first cardiac event, Fatal and non-fatal MI, fatal and 
non-fatal HF, and fatal and non-fatal stroke, all-cause mortality, new-onset diabetes. 
Funding Source: Novartis Pharma AG
 
VERDI (1989) (Holzgreve et al., 1989)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 1 year 
Participants: 369 untreated hypertensive patients
Age range: 22-71 (mean: 50.5 years) 
Hypertensive patients (%): 100 
Baseline cancer(%): None
Intervention: 2 treatment groups
TZ: HCTZ 12.5-25mg/day vs CCB: sustained release verapamil 120-240mg/day  
Co-intervention: no other BP-lowering agents were added     
Primary and secondary outcomes: BP determined with a device permitting automatic repeated 
measurements with printouts. 
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Funding Source: Knoll AG
 
V-HeFT II (1991) (Holzgreve et al., 1989, Cohn et al., 1991)
Design: Prospective, multicentre, randomized, double-blinded, parallel trial 
Mean duration of follow-up: 2.5 years 
Participants: 804 men with chronic HF
Age range: 18-75 (mean: 60.5 years) 
Hypertensive patients (%): 48 
Baseline cancer(%): Not reported
Intervention: 2 treatment groups
ACEI: enalapril 5-20 mg/day vs Control: hydralazine 37.5-300 mg/day plus isosorbide dinitrate 40-
160 mg/day  
Co-intervention: No information on further titration or background therapy.  
Primary and secondary outcomes: exercise tolerance, cardiothoracic ratios, measurement of 
ejection fraction, quality of life, all-cause death. 
Funding Source: Cooperative Studies Program of the Medical Research Service, Department of 
Veterans Affair Central Office. 
 
Wilcox et al. (1980) 
Design: Prospective, randomized, double-blinded, parallel trial
Mean duration of follow-up: 1 year 
Participants: 388 patients with suspected MI. 
Age range: No age limit (average: 55 years) 
Hypertensive patients (%): Not reported 
Baseline cancer(%): Not reported
Intervention: 3 treatment groups
BB: propranolol 120 mg/day vs BB: atenolol 100 mg/day vs Placebo 
Co-intervention: No information on further titration or background therapy. 
Primary and secondary outcomes: Mortality at 6 weeks and one year. 
Funding Source: Imperial Chemical Industries Limited.
 
 Discussion 
This chapter described the protocol for identification of studies that were used in 
a systematic review for antihypertensive drugs and risk of cancer. In addition to 
lowering elevated BP, antihypertensive drugs are also commonly used in treating 
other conditions such as congestive HF, cardiac dysrhythmia, and renal 
insufficiency. In this review, more than half (59%) of the included trials are non-
intentional BP lowering studies where studied antihypertensive therapy was 
investigated for other indications and outcomes. The majority (76.7%) of the 
included RCTs of major antihypertensive drugs class enrolled patients with 
comorbidities especially heart diseases and metabolic disorder namely T2DM. High 
risk hypertensive, CHD, and HF contributed 42.2% of study participants in this 
review. These comorbidities are not unprecedented complications of hypertension 
as long-term elevated BP is known to cause alteration to arterial conductance and 
resistance, hence jeopardizing vital organ integrity.  
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3.2.3.1 Treatment strategy and agents 
Established clinical guidelines (NICE, 2011, Mancia et al., 2013a, James et al., 
2014) has outlined a common general principle on hypertension treatment 
initiation. Majority of the included study initiated treatment by monotherapy and 
added another drug (sometimes more than one) in a stepped care approach in 
some patients. Great detail on antihypertensive therapy strategy is described in 
1, Section 1.8.2.  
The RAS inhibitors, specifically ARB and ACEI, were used in 22.1% and 13.2% of 
participants enrolled in this review respectively. Both classes of drugs are amongst 
the widely used antihypertensive treatment and are generally well-tolerated. 
Equally, ACEIs and ARBs offers similar clinical benefits which includes BP lowering 
(LIFE, SCOPE, VALUE), alleviating CHF symptoms (CHARM Alternative, Val-HeFT, 
VALIANT), inhibition of diabetic renal disease (IDNT, RENAAL), and possibly 
preventing new onset of T2DM (Gillespie et al., 2005) and AF (Healey et al., 2005). 
However, one of the disadvantages commonly associated with ACEIs is chronic dry 
cough which is not dose-dependent (Yesil et al., 1994) and subsequently makes 
ARBs as the preferable alternative in patients who are ACEI-intolerant. Several 
meta-analyses have suggested that ACEIs is inferior in preventing stroke when 
compared to other classes (Blood Pressure Lowering Treatment Trialists' 
Collaboration, 2003, Law et al., 2009) while ARBs are inferior to ACEIs in reducing 
MI and CV deaths (Strauss and Hall, 2006, Strauss and Hall, 2017).  
In this review, 31.3% of participants randomised to ACEI were given ramipril which 
makes it the most used ACEI. The HOPE study showed that when added to 
concomitant therapy, ramipril is beneficial on the primary combined endpoints of 
CV death, non-fatal MI, and non-fatal stroke (RR reductions 22%, p<0.001) as well 
as associated with lower rates of incident T2DM (RR 0.66, p<0.001) compared to 
placebo  in patients with high CV risk. A comparable finding was reported for the 
ramipiril treatment arm in the ONTARGET study who recruited participants of 
similar characteristics. Conversely, similar protective effects against CV risk and 
diabetic nephropathy was not seen in patients with underlying T2DM (Marre, 
2004). The DREAM trial also reported an insignificant reduction in incident 
diabetes in participants with IGT. The possible explanation could be due to the 
different characteristics of the study population, a lower dose of ramipiril used, 
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and shorter study duration. All the major studies have reported a higher rate of 
discontinuation or adverse effect due to dry cough in the ramipril treatment arm.   
On the other hand, telmisartan was the most used ARB (34.8%) as it was studied 
in three large key RCTs (ONTARGET, PRoFESS, and TRANSCEND). It was approved 
by the US FDA in November 1998 (FDA, 1998) for the treatment of hypertension 
and as an alternative to ACEI. Among the Angiotensin II antagonists, telmisartan 
is the most lipophilic, thus shows excellent oral absorption and tissue penetration 
(Wienen et al., 2000). Trials comparing telmisartan and ramipril (ONTARGET, 
VALIANT) have demonstrated that telmisartan is not inferior to ramipril when used 
in patients with high CV risk. A parallel finding was also reported by Li et al. 
(2014a) in a meta-analysis of RCTs comparing ARB vs ACEI for primary 
hypertension. 
CCBs is the second most used antihypertensive in this review with DHP-CCBs 
predominates over non-DHP CCBs. Amlodipine was used in ten major trials 
contributing to 42.9% of participants enrolled in this review. Major trials have 
shown that CCBs are at least equally effective if not superior (ALLHAT, VALUE) in 
lowering BP. However, several controlled trials (ABCD, FACET, and ALLHAT) have 
exhibited trends toward higher CV events with CCBs. On the contrary, large trials 
enrolling high-risk hypertensives (CAMELOT, INVEST, VALUE) have demonstrated 
that CCBs are as clinically effective as other drug classes in reducing major CV 
events. In addition, the combination of CCB and other drug class have proven 
beneficial in improving patients’ outcomes.  
The decision on which drug class is to be prescribed first is still controversial. In 
clinical practice, the management of hypertension varies greatly due to factors 
which included: patients’ non-compliance and non-adherence; switching or 
addition of another drug; and difficulties to achieve adequate BP control with 
monotherapy even after the dose is optimised. Hence, dose titration plus 
additional drug treatment approach is not uncommon in more than 90% of RCTs 
included in this review and study drugs administered as second-line of therapy has 
been investigated in several key trials (ASCOT-BPLA, CONVINCE, FEVER). Data 
from ASCOT-BPLA have shown that amlodipine plus perindopril was more effective 
than atenolol plus bendroflumethiazide. The FEVER study has demonstrated that 
CCB added-on to diuretic was well-tolerated and was directed towards a lower 
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incidence of major CV events. Meanwhile, the combined therapy arm in the 
DEMAND study showed that delapril plus manidipine safely reduced CV risk and 
stabilized insulin sensitivity. However, not all drug combinations proved to be 
beneficial and most major scientific hypertension guidelines do not recommend 
initial treatment with combination therapy because of concern about the 
excessive reduction in BP, increased side effects, and the difficulty of attributing 
adverse events to one drug. Many clinical guidelines have discouraged the 
combination of two different RAAS blockers. Two large key trials (ONTARGET and 
VALIANT) have suggested that ARB plus ACEI combinations had no increase in 
benefit but was associated with more adverse effects namely ESRD and stroke. 
Quite the opposite, the CHARM-Added and Val-HeFT trials have demonstrated that 
combined ARB and ACEI therapy was superior to placebo in reducing 
hospitalizations for HF. These differences in findings were probably due to the 
different patient's characteristics where patients studied in the CHARM-Added and 
Val-HeFT had symptomatic HF on ACEI therapy and variable doses of ACEI was used 
although there was no attempt to titrate the ACEI to the maximum dose. 
3.2.3.2 Cancer reporting in clinical trials 
Monitoring for adverse or unwanted effects is routinely conducted during phase II 
and phase III of clinical trials. The FDA (1995), EMA (1995) and ICH (1994) have 
outlined a guideline on reporting serious adverse event or ADR. According to the 
guidelines, cancer or malignancy is classified as a serious ADR because it requires 
hospitalisations and results in persistent or significant disability or capacity. 
Moreover, the carcinogenic study is recommended for any pharmaceutical product 
whose clinical use is continuous for at least six months (ICH Expert Working Group, 
1995). 
All included trials in this review lasted at least one year with the longest mean 
duration of follow-up was nine years (APSIS, UKPDS-38). An extensive period of 
study follow-up is essential for cancer detection because most human 
malignancies grow at a slow and steady rate for a long period of time during the 
clinically measurable phase. A study on human malignant tumour kinetics by 
Friberg and Mattson (1997) has found that a cancerous tumour has consumed more 
than half of its lifespan when it became detectable by the diagnostic method. For 
example, an approximate size 10 μmeter in diameter breast tumour with an 
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average doubling time of 280 days took more than eighteen years to produce a 
detectable tumour with a 2 mm diameter (Friberg and Mattson, 1997); where the 
lowest level of detection by mammography is stated to be 2.1 mm (Spratt et al., 
1986). Though, different tumour types vary in term of growth rate and detection 
methods.  
Of the included studies, only 14.4% has pre-specified cancer as a clinical endpoint. 
There was no difference in term of the year these studies were carried out as it 
was fairly ranged between the 1990s to the 2000s and it is of interest to note that 
these trials compared new AHT against older agents (BB or TZ) or placebo. TZ has 
been used as a reference group in many observational studies because it has not 
been convincingly linked to the risk of any cancer. It is also likely that these trials 
predefined cancer as one of their outcome of interest due to the increasing 
numbers of literature attempting to tie AHT to the risk of cancers.   
Almost all the included studies (97.7%) published cancer outcomes where cancer 
incidence was reported as a serious adverse effect in safety analysis, the reason 
for treatment discontinuation or cause of deaths. Conversely, the main reason for 
92% of the excluded studies is no cancer outcome reported or available. Although 
unpublished data were received from the remaining trials, the list is neither 
extensive nor complete and is probably biased because of selective data sharing. 
3.2.3.3 Limitations 
One limitation of this review is it is restricted to published trials and it is possible 
that smaller trials are missing. The grey literature was not searched due to the 
sheer volume of citations identified from electronic databases and time 
constraint. Searching for grey literature can be time-consuming because they are 
not usually included in the bibliographic database. Although data from the grey 
literature may be used to overcome publication bias, the quality of information is 
variable. However, this review is unlikely to miss any RCTs based on the extensive 
search strategy that has been implemented. Additionally, a different type of 
cancer incidence is more common in a certain part of the world. This factor could 
be contributed by the different ecological, environmental, genetic and 
socioeconomic variables. The inclusion of trial such as the FEVER and NHS study 
which enrolled only Chinese and Japanese participants respectively may not 
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reflect the true risk associated with antihypertensive treatment. For example, 
cancer of the nasopharynx, oesophagus, stomach and liver shows higher incidence 
rate in China than in the USA (Wang et al., 2012).       
3.3 Risk of bias in included studies 
The method used in the assessment of the risk of bias across all studies were 
described in Chapter 2, Section 2.1.5.3 (page 63). All included studies were stated 
to be RCTs (See ‘Methodological quality of included studies’, Section 3.3.6). The 
risk of bias is summarized in Figure 3.2 presented as percentages across all 
included studies. Another bias is defined as the source of funding. 
 
Figure 3-2: Risk of bias graph.  
Review authors’ judgements about each risk of bias item presented as percentages across all 
included studies. 
 Randomisation and allocation 
Random sequence generation method was reported adequately in 59 (65.6%) of 
the included studies. We judged 30 (33.3%) included studies (ABCD; AIPRI; ALPINE; 
APSIS; ANBP; ESPIRAL; EWPHE; HOPE; INSIGHT; INTACT; IRMA-2; Kanamasa; 
MAPHY; NICOLE; NICS-EH; OCTOPUS; OSLO; Practolol Study; PRAISE; PREVENT; 
RENAAL; SCAT; SMT; STOP-HTN2; Suzuki; Syst-China; Val-HeFT; VA COOP II; VERDI; 
Wilcox) as unclear risk of bias as the method of randomisation was not reported.  
One study (E-COST) was judged reporting of the random sequence generation as 
high risk of bias. 
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The allocation domain was adequate in 54 (60%) of the included studies. The 
allocation concealment method was not reported in the remaining 34 studies 
(ABCD; AIPRI; ALPINE; APSIS; ANBP; CAMELOT; DAVIT II; ESPIRAL; EWPHE; FACET; 
HIJ-CREATE; INSIGHT; INTACT; IRMA-2; MAPHY; MIDAS; MRC; MRCOA; NICOLE; 
NICS-EH; OCTOPUS; OSLO; Otsuka; PRAISE; PREVENT; RENAAL; SCAT; SPRINT; SMT; 
STOP-HTN2; Suzuki; Syst-China; Val-HeFT; VA COOP) and was judged as unclear 
risk of bias. Two studies (E-COST; Kanamasa) were deemed as high risk of bias due 
to inadequate allocation concealment method. 
 Blinding 
More than half (68 studies) of the included trials reported blinding of both 
participants and personnel where the active or study drugs and the placebo or 
control drugs were usually described as externally indistinguishable. Hence, these 
studies were considered to have a low risk of performance bias. However, there 
was a high risk of performance bias in 20 open-label studies (ASCOT-BPLA; CASE-
J Ex; E-COST; ESPIRAL; FACET; HEP; HIJ-CREATE; INVEST; Kanamasa; MAPHY; NHS; 
OCTOPUS; OSLO; Otsuka; PHARAO; REIN-2; STOP-HTN2; Suzuki ; UKPDS-38; V-HeFT 
II) as both participants and personnel were aware of the assigned treatment.  The 
risk of performance bias was unclear in two single-blind studies (MRC; MRCOA) 
where the treatment assignments were known to the doctors and nurses but not 
to the participants. 
Blinding of outcome assessment was deemed adequate in more than half (73%) of 
included studies. Prospective, randomized, open-label, blinded-endpoint (PROBE) 
design was implemented in 14 of these studies (ASCOT-BPLA; CASE-J Ex; FACET; 
HEP; HIJ-CREATE; INVEST; NHS; OCTOPUS; OSLO; PHARAO; REIN-2; STOP-HTN2; 
UKPDS-38; V-HeFT II). The PROBE design was used mainly to avoid the introduction 
of bias in open-label clinical trials. Though, the risk of detection bias was unclear 
in 24 studies (AIPRI; ALLHAT; ANTIPAF; APSIS; ASCOT-BPLA; E-COST; ESPIRAL; 
GISSI-AF; INTACT; Kanamasa; LaCroix; MAPHY; NESTOR; NICOLE; Otsuka; Practolol 
Study; SAVE; SCAT; SPRINT; Suzuki; TROPHY; VA COOP II; VERDI; Wilcox) as 
blinding of outcome assessment was not described . 
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 Incomplete outcome data  
Eleven studies (ALPINE; DEMAND; MERIT-HF; NESTOR; OSLO; Otsuka; PHARAO; 
PRAISE; PREVENT; STOP-HTN2; Suzuki) have complete outcome data and no 
participant was lost to follow-up. The loss to follow-up was negligible in 57 studies 
where the attrition rate was between 0.02% and 15% (less than 20%). In these 
studies, the rate of discontinuation was generally low and equal between study 
arms. Four trials were judged to have high risk of bias for the following reasons: 
[1] high attrition rate of 19% (MRC) and 25% (MRCOA), [2] data of withdrawn 
participants were not included and per protocol analysis was used (NICS-EH), and 
[3] data presented in the study did not represented all randomized participants as 
one of the study centre failed to supply complete data and reason for failure was 
not stated (SPRINT).  
The remaining 21 studies (ABCD; ACTION; AIPRI; ANTIPAF; APSIS; DAVIT II; 
ESPIRAL; IDNT; Kanamasa; MAPHY; MIDAS; PHYLLIS; Practolol Study; SCAT; SHEP; 
SMT; TROPHY; VA COOP II; VERDI; V-HeFT II; Wilcox) evidently accounted for all 
participants in each study arm, although participants loss to follow-up was not 
reported, and intention-to-treat (ITT) analysis was performed. Therefore, we 
judged these studies to be at low risk of attrition bias. Four studies (E-COST; HEP; 
INTACT; Val-HeFT) were judged to have an unclear risk of bias due to inadequate 
description of outcome data. 
 Selective reporting 
Overall, 85 of the included studies (94%) reported outcomes as stated in the 
methodology section or the respective study protocols where available. Only five 
studies were judged to have an unclear risk of reporting bias. Four of these studies 
(HEP; VA COOP II; V-HeFT II; Wilcox) did not pre-specify study outcomes in the 
method section and we had no access to the respective study protocols. One study 
(VALIANT) failed to report revascularization procedures outcome as pre-specified 
in its method section. 
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 Other potential sources of bias 
3.3.5.1 Source of funding 
Source of funding for each individual study was considered as a potential source 
of bias.  In total, 72 studies have received various forms of support and sponsorship 
(e.g. financial, drugs provision, data analysis) from the pharmaceutical industries. 
Six studies (ANBP; BHAT; HIJ-CREATE; PAT; PREVER-Treatment; V-HeFT II) were 
supported by governmental bodies’ research grant and/ or non-profit 
organizations such as the National Institute of Health, National Medical Council, 
NHBLI, Heart and Stroke Foundation etc. Four studies (DEMAND; NHS; OCTOPUS; 
Suzuki) were independent academic research while the remaining eight studies 
(E-COST; ESPIRAL; INTACT; Kanamasa; NICS-EH; OSLO; Otsuka; Practolol Study) 
have inadequate information on the funding source.   
More than half of the included studies (57%) were judged to have an unclear risk 
of bias as the role and extend of sponsors’ involvement was inadequately 
reported. In 37 of the included studies (ACTION; ACTIVE I; ALLHAT; ANBP; ASCOT-
BPLA; DAVIT II; DEMAND; DIRECT (Overall); GISSI-AF; HIJ-CREATE; HOPE; I-
PRESERVE ; INVEST; IRMA-2; LaCroix; LIFE; MRCOA; NHS; OCTOPUS; OPTIMAAL; 
PAT; PHARAO; PREVER-Treatment; REIN-2; SAVE; SCOPE; SHEP; SOLVD-P; SOLVD-
T; Suzuki; Syst-China ; Syst-Eur; TRACE; TRANSCEND; UKPDS-38; VALIANT; V-HeFT 
II ), the risk of bias was judged to be low as the respective study sponsors were 
not directly involved in the planning of studies, collection, analysis, and 
interpretation of data. Conversely, two studies (TROPHY; Val-HeFT) were judged 
to have a high risk of bias because the sponsors were directly involved in 
organizing, data collection and analysis of the clinical trials. 
Overall, 50 of the included studies (55.6%) were judged to be at high risk of bias 
whereas the remaining 40 studies (ACTION; ACTIVE I; ASCOT-BPLA; BHAT; CASE-J 
Ex; CHARM (Overall); CONVINCE; DEMAND; DIABHYCAR; DIRECT (Overall); FEVER; 
HEP; IDNT; INVEST; I-PRESERVE ; MERIT-HF; NHS; NAVIGATOR; ONTARGET; 
OPTIMAAL; PARADIGM-HF; PAT; PHYLLIS; PREVER-Treatment; PRoFESS; REIN-2; 
SCOPE; SHEP; SOLVD-P; SOLVD-T; Syst-Eur; TRACE; UKPDS-38; VALIANT; VALUE; 
V-HeFT II) were deemed to be at low risk of bias (See Chapter 2, Section 2.1.4.3). 
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 Methodological quality of included studies (ordered by 
study ID) 
ABCD 
Bias 3 Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described 
Allocation concealment  Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Sponsor's role or involvement was not reported.
 
 
ACTION 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Randomisation was blocked and stratified by 
centre. 
Allocation concealment  
 Low risk 
The chair of the safety monitoring committee 
prepared the random allocation list. 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Role of sponsor restricted to study medication supply and on-site monitoring. 
 
ACTIVE I 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Central randomisation service through an 
automated voice response system (AreS) 
Allocation concealment  
 Low risk Allocated through AreS. 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blinded outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsors had no direct role in the collection, analysis, or interpretation of study data
                                         
3 The six domains assess the risk of bias in each individual studies for: [1] Random sequence 
generation and allocation concealment method assess for risk of selection bias; [2] Blinding of 
participants and personnel assess the risk of performance bias; [3] Blinding of outcome 
assessment assess for risk of detection bias; [4] Incomplete outcome data assess for risk of 
attrition bias; [5] Selective reporting of outcome assess for risk of reporting bias; and [6] Other 
bias assess the risk of source of funding bias.   
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AIPRI 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Randomisation was balanced for disease severity 
at each centre. The exact method of 
randomisation was not described. 
Allocation concealment  
 Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Unclear risk 
A quality-control and end-point–evaluation 
committee confirmed all the diagnoses and all 
the instances in which end points were reached. 
It was not stated whether they were blinded.
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Sponsor's role or involvement was not described
 
ALLHAT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified by the centre and blocked in random 
block sizes of 5 or 9 
Allocation concealment  
 Low risk 
Generated by a computer, implemented at the 
clinical trials centre
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Unclear risk Not described. 
Incomplete outcome data  Low risk 
Two sites and their patients originally reported 
were excluded, which might impact on the 
results, although it was because of their poor 
documentation of informed consent. But an ITT 
analysis was performed 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
Industrial sponsors had no direct role in the 
collection, analysis, or interpretation of study 
data.
 
ALPINE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described 
Allocation concealment  
 Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
Not indicated whether reasons for missing
outcome data were similar across treatment 
groups. Modified ITT analysis was performed 
including all randomised patients who had 
completed the study and had taken at least one 
dose of study drug
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
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ANBP 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Stratified by age and sex. The exact method of 
randomisation was not described 
Allocation concealment  Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
3931 were randomized but 504 participants were 
not given study medication as their BP fell before 
tablets were due and never again reached the 
threshold to qualify them to start tablets. 
Therefore, the trial population was made up of 
3427 patients. All randomized patients were 
reported or analysed in the group to which they 
were allocated by randomisation. Lost to follow-
up: 0.2% 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsored by government bodies or non-profit organizations
 
ANTIPAF 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Used internet-based e-Trial Management System 
(XTrial™). 
Allocation concealment  
 Low risk 
Used internet-based e-Trial Management System 
(XTrial™). 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Unclear risk Not described. 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described.
 
APSIS 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described 
Allocation concealment  Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Unclear risk Not described. 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described.
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ASCOT-BPLA 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer generated optimum allocation 
Allocation concealment  Low risk Computer generated optimum allocation
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
Two centres with 85 patients were excluded
after randomisation, but missing data were 
equal between the treatment groups, and an 
ITT analysis was performed 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsors had no direct role in the collection, analysis, or interpretation of study data
 
BHAT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified by clinical centre and was carried out 
in a block fashion (groups size of 4,6, and 8)
Allocation concealment  
 Low risk 
Central allocation. The assignment made by the 
Coordinating Centre and transmitted to the 
Clinical Centre by telephone 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
CAMELOT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
The randomisation code was generated using a 
block size of 6. 
Allocation concealment  Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk 
Sponsor participated in discussions regarding 
study design and protocol development and 
provided logistic support. 
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CASE-J Ex 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Computer-generated lists of permutation blocks 
stratified by 9 regional blocks and complication 
of T2DM
Allocation concealment  
 Low risk 
The allocation results were immediately 
transmitted to the collaborating physicians 
through the Internet and/or facsimile. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
CHARM Overall 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified by site and component trial, and 
provided through a coordinating telephone centre
Allocation concealment  
 Low risk 
Computer generated assignment and provided 
through a coordinating telephone centre. The 
assignment code was held at an independent 
centre and by the data safety monitoring board. 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk 
The sponsor of the study managed the data, and 
their representatives were involved in the data 
analysis and data interpretation. 
 
CONVINCE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
The Interactive Voice Response System (IVRS) was 
used 
Allocation concealment  
 Low risk 
Allocation via a trans-telephonic interactive voice 
response system
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
Participants from 2 sites (n=126; 62 randomized 
to COER verapamil) were excluded because of 
data integrity concerns, and its impact on results 
was unclear, but ITT analysis was performed in 
this systematic review 
Selective reporting  Low risk Outcomes listed in the methods were all reported
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Other bias Unclear risk 
Sponsor participated in designing and monitoring 
of the study. All analyses were carried out 
independent of the sponsor. 
 
DAVIT II 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Permutation blocks of 10 at each centre. 
Allocation concealment  Unclear risk The method was not described 
Blinding of participants 
and personnel  Low risk Participants and personnel were blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Role of sponsor restricted to study drug supply.
 
DEMAND 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Block of 6 patients assigned to each therapy with 
a 1:1:1 ratio.
Allocation concealment  
 Low risk 
Computer-generated and randomisation numbers 
were blindly assigned 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Independent academic trial 
 
DIABHYCAR 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified by centre and balanced by blocks of 
two treatments, using a computer generated 
random number list.
Allocation concealment  
 Low risk Centralised allocation. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Partly sponsored by a pharmaceutical company
 
DIRECT Overall 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Random assignment was done centrally, using an 
interactive voice-response system 
Allocation concealment  Low risk Central allocation
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Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial    
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsors did the statistical analysis, validated by an independent statistician. 
 
E-COST 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  High risk 
The envelope method. The names of subjects 
were written on slips of paper, and the physician 
randomly placed the slips of paper into envelopes 
representing the different group assignments.
Allocation concealment  High risk Inadequate.
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk Not described. 
Incomplete outcome data  Unclear risk 
All randomized patients were reported or 
analysed in the group to which they were 
allocated by randomisation. However, the details 
on numbers and reasons for withdrawal and loss 
to follow-up were not reported. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Funding source not reported 
 
ESPIRAL 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Funding source not reported 
 
EWPHE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial    
Selective reporting  Low risk Outcomes listed in the methods were all reported
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Other bias Unclear risk 
Supported by a grant from pharmaceutical 
companies who prepared active and placebo 
tablets. Yearly meetings were sponsored by a 
pharmaceutical company. 
 
FACET 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer generated randomisation list. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
FEVER 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list. 
Allocation concealment  Low risk Allocation by phone or fax after verified eligibility.
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Partly sponsored by a pharmaceutical company
 
 
 
GISSI-AF 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list. 
Allocation concealment  
 Low risk 
By means of a computerized, telephone 
randomisation system, with the group 
assignments concealed 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
An independent end-point committee 
adjudicated all reports of primary end points, 
deaths, and hospitalizations. Not described 
whether they were blinded to assigned treatment 
or not. 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The sponsor had no role in the design or conduct of the trial.
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HEP 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Prepared by a random number tables 
Allocation concealment  
 Low risk 
By opening an opaque envelope supplied in 
sequence supplied by the trial instructor 
Blinding of participants 
and personnel  Unclear risk Not described 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Unclear risk 
Not indicated whether reasons for missing
outcome data were similar across treatment 
groups
Selective reporting  Unclear risk No access to the protocol 
Other bias Unclear risk Role of the sponsor was not described
 
HIJ-CREATE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The sponsor played no role in the study design, 
data collection, data analysis, data 
interpretation, or writing of the report.
 
HOPE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Central randomisation (2 x 2 factorial design),
no description of the random sequence 
generation
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsored by government bodies or non-profit organizations
 
I-PRESERVE  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Automated, central randomisation system 
permuted block and stratified by site and by use 
of ACE inhibitors at baseline. 
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Allocation concealment  
 Low risk Via an interactive voice-response system. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The sponsor collected the trial data which were then analysed independently of the sponsor. 
 
IDNT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list. 
Allocation concealment  
 Low risk 
To minimize any centre effect, randomisation
was blocked by the centre 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
INSIGHT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
254 patients (132 and 122 patients in each
group) were excluded after randomisation 
from centres withdrawn for misconduct, and they 
were not included in the analysis 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
INTACT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
Blinding of outcome assessment was not 
described 
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Incomplete outcome data  Unclear risk 
77 patients were excluded from the final report 
as they had no or slight study deviations and 
completed the study. The final analysis only 
included 348 patients who underwent a second 
angiogram.
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported. 
 
INVEST 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk An Internet-based management system was used. 
Allocation concealment  Low risk Central allocation.
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
Missing data were equal between the treatment
groups, and an intention-to-treat 
analysis was performed 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
Sponsor provided financial support for all study 
medications. The sponsors have played no role in 
editorial or data management. 
 
IRMA-2 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The steering committee included two nonvoting 
members from the sponsoring company who 
oversaw the study design, the conduct of the 
trial, and the management and analysis of the 
data 
 
Kanamasa  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Determined according to the fifth digit of their 
hospital identification number. 
Allocation concealment  
 High risk 
Inadequate. Allocation based on the odd number 
or even number
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk 
Blinding of outcome assessment was not 
described
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Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported. 
 
LaCroix  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
A complete randomized list was prepared with 
study identifiers stratified by sex and used equal 
allocation with blocking size of nine 
Allocation concealment  
 Low risk 
The blocking size was known only to the 
statistician. A complete randomized list was 
prepared with study identifiers indicated and 
each vial of medication was labelled by pharmacy 
staff. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
Study statistician and data monitoring committee 
saw unblinded data but none had any contact 
with study participants. 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
Financially sponsored by government and study 
tablets were sponsored by a pharmaceutical 
company.
 
LIFE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated allocation sequence 
Allocation concealment  Low risk Adequate. Central allocation. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
Study data are in the sponsor’s database who 
provided the study steering committee with free 
access to all data. Data interpretation and 
analysis, paper writing and publication was 
independent of the sponsor. 
 
MAPHY 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk Not described 
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Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Partly sponsored by a pharmaceutical company
 
MERIT-HF 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer generated randomisation list. 
Allocation concealment  Low risk Allocation by the interactive voice recording system. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
MIDAS 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
The randomisation process was stratified
and blocked by clinic 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
MRC 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Randomisation was in a stratified block of eight 
within each sex and clinic 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Unclear risk Single blind 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  High risk 
All randomized patients were reported or 
analysed in the group to which they were 
allocated by randomisation. Lost to follow-up: 
19%
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
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MRCOA 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Randomisation was in a stratified block of eight 
within each sex and clinic 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Unclear risk Single blind 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  High risk 
All randomized patients were reported or 
analysed in the group to which they were 
allocated by randomisation. Lost to follow-up: 
25%
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Study drugs supplied by sponsor 
 
 
NAVIGATOR 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Computer generated stratified according to 
centre, with a block size of eight within each 
centre. 
Allocation concealment  
 Low risk Central allocation. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
212 patients were excluded after randomisation
because of protocol deficiencies at the site and 
they were not included in the final analysis. ITT 
analysis was performed. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk 
Data were collected, managed, and analysed by 
the sponsor, with oversight from the executive 
committee, and the analyses were replicated by 
an independent academic statistician.
 
NESTOR 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer generated 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
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NHS  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Minimization method with five factors of baseline 
characteristics. 
Allocation concealment  
 Low risk 
Automatically performed by a host computer 
system
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Independent academic study 
 
NICOLE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk Seven patients were excluded from the ITT population as they did not take any study tablet. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
NICS-EH 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk 
It was stated as double-dummy, but details
was not described
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  High risk Data of withdrawn patients were not included.PP analyses were used 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Status of study funding not reported
 
OCTOPUS 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
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Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was supported by own fund and donation
 
ONTARGET 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified according to the site with the use of 
permuted blocks 
Allocation concealment  Low risk Central automated telephone service
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Partly sponsored by a pharmaceutical company
 
OPTIMAAL 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Block randomisation was used at each centre 
Allocation concealment  Low risk Computer generated allocation 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The sponsor provided data management 
assistance and two non-voting members of the 
steering committee. The scientific conduct of the 
study and manuscript preparation was 
independent of the sponsor. 
 
OSLO 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Randomisation performed by a "random number 
table". However, the table was not adjusted for 
the actual numbers, which is the reason for the 
difference between groups. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Unclear risk 
No description of whether drug administration 
was performed open or blinded. 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported 
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Otsuka 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Minimization method controlling for the following 
four factors.
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported 
 
PARADIGM-HF 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk The randomisation list was produced by the IVRS. 
Allocation concealment Low risk Interactive voice response system 
 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
PAT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list 
Allocation concealment  
 Low risk Centrally allocation 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
4 patients were excluded from analysis as they 
were randomized in error and did not meet 
eligibility criteria. An ITT analysis was 
performed. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk Sponsored by a government body 
 
 
PHARAO 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation list. 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
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Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors
 
PHYLLIS 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated in a block size of 4 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
Practolol Study 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Randomized code of numbers was used. The 
exact method was not described. 
Allocation concealment  
 Low risk 
Sealed envelope and sequentially numbered 
containers
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk 
Patients information or data collection were 
incomplete as a few physicians had not finally 
reviewed all patients by the cut-off date. Missing 
data were unlikely to alter the results and 
conclusion 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported 
 
PRAISE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The exact method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported 
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PREVENT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The exact method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Source of funding not reported 
 
PREVER-Treatment 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated list. 
Allocation concealment  Low risk Via a 24-h web-based automated system.
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Unclear risk Withdrawals were not included in the analysis. No indication of ITT analysis performed. 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The sponsors had no participation in the design 
and conduct of the study, preparation and 
approval of the manuscript. 
 
 
PRoFESS 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Central telephone randomisation system. 
Allocation concealment  Low risk Central allocation.
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk 
The trial was sponsored by pharmaceutical 
companies and was designed by the steering 
committee, which included representatives of 
the sponsor 
 
REIN-2 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Minimisation method 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Chapter 3 Systematic review 138 
 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk 
3 patients were excluded from analysis post-
randomisation as they never took the study 
tablet. ITT analysis was performed.
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The sponsors had no participation in the design 
and conduct of the study, preparation and 
approval of the manuscript. 
 
RENAAL  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
SAVE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Computer-generated stratified according to 
centre
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The sponsor was not involved in the acquisition or 
management of data and did not have access to 
unblinded information. 
 
SCAT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
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SCOPE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation schedule 
Allocation concealment  Low risk Central allocation.
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
The study data were entered in the sponsor’s 
database. The Executive and Steering 
Committees had full-access to all data and were 
free to suggest analyses, interpret results, and 
write paper independently of the sponsor
 
SHEP 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Randomisation stratified by clinical centre and by 
antihypertensive status at initial contact. The 
exact method was not described. 
Allocation concealment  Low risk Central allocation 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk 
Financially sponsored by government and study 
tablets were sponsored by pharmaceutical 
companies.
 
SOLVD-P 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors 
 
SOLVD-T 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation  
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Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors
 
SPRINT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Block size of six divided randomly into triplet 
according to the intervention arm 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
Blinding of outcome assessment was not 
described 
Incomplete outcome data  High risk 
Data presented in the study did not represent all 
randomized participants as one of the study 
centres failed to supply complete baseline data 
(n= 127). Reason for failure not stated.
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
SMT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Stratified according to the type of ventricular
arrhythmias, age, and estimated infarct size. The 
method was not reported 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Partly sponsored by the pharmaceutical company
 
STOP-HTN2 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
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Other bias Unclear risk Role of the sponsor was not described
 
Suzuki 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Dynamic allocation method after stratification by 
sex, age, SBP, and diabetes 
Allocation concealment  Unclear risk The method was not described. 
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data Low risk No patients were lost to follow-up 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was supported by own fund
 
Syst-China  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Stratification by centre, sex, and previous CV
complications. The exact method was not 
described.
Allocation concealment  
 Unclear risk 
Each clinical centre received supplies of the 
three active study drugs, all labelled ‘A’, and the 
three matching placebos, all labelled ‘B. The first 
patient of each of the four strata was always 
assigned to type ‘A’ medication. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors 
 
Syst-Eur 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated scheme 
Allocation concealment  Low risk Central allocation
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors
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TRACE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated assignment scheme  
Allocation concealment  
 Low risk 
Computer-generated using separate 
randomisation lists at each centre 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors
 
TRANSCEND 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Randomisation was stratified according to the 
site with the use of permuted blocks. 
Allocation concealment  Low risk Via a computerized voice-activated telephone call
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors 
 
TROPHY 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Automated randomisation system according to 
study sites in blocks of four 
Allocation concealment  Low risk Automated randomisation system  
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
Blinding of outcome assessment was not 
described 
Incomplete outcome data  Low risk 
One centre (n=24 participants) were excluded 
from the study post-randomisation because of 
inadequate record keeping. Of those included in 
the safety population, data on BP were not 
available for 13 participants. However, missing 
values were imputed by using the last-
observation-carried-forward method
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias High risk The sponsor provided funding and organized the study. 
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UKPDS-38 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Stratified for those with or without previous 
treatment for hypertension was performed by the 
coordinating centre
Allocation concealment  Low risk Sealed opaque envelopes were used
Blinding of participants 
and personnel  High risk Study drugs were administered open-label 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Low risk The study was conducted independently of all sponsors
 
VA COOP II  
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk 
Only patients who entered the long term 
treatment phase were included in this review. All 
withdrawals were accounted. 
Selective reporting  
 Unclear risk 
Outcomes were not pre-specified in the method 
section and no access to study protocol.
Other bias Unclear risk Role of the sponsor was not described
 
Val-HeFT
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk 
Stratified according to whether or not they were 
receiving BB as background therapy. The exact 
method was not described. 
Allocation concealment  
 Unclear risk The method was not described. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Unclear risk 
Missing outcome data i.e. total hospitalisations. 
All randomised patients who discontinued 
prematurely included in the analysis
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias High risk 
Site monitoring, data collection, and data 
analysis were performed by Novartis 
Pharmaceuticals. 
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VALIANT 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Automated randomisation scheme  
Allocation concealment  Low risk Allocated via IVRS 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Unclear risk 
Information from 105 patients at one site was 
censored before un-blinding because of adequate 
informed consent process could not be ensured. 
Study medications were not administered to 77 
patients. It was not indicated whether ITT 
analysis was performed. 
Selective reporting  
 Unclear risk 
Not all outcomes listed in the method section 
were reported i.e. Revascularization procedures
Other bias Low risk The study was conducted independently of all sponsors
 
VALUE 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk Computer-generated randomisation scheme 
Allocation concealment  
 Low risk Central allocation 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Unclear risk 
68 patients in 9 centres were excluded after
randomisation because of good clinical 
practice deficiencies and they were 
not included in intention-to-treat analyses, 
which might lead some bias 
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
 
VERDI 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  Low risk Central allocation. 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk Not described 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  Low risk Outcomes listed in the methods were all reported
Other bias Unclear risk Role of the sponsor was not described
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V-HeFT II
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Low risk 
Used a randomized six-subject permuted-block 
stratified according to the medical centre and 
patients' participation/non-participation in V-
HeFT I
Allocation concealment  
 Low risk Central allocation 
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Low risk Blind outcome assessment 
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  
 Unclear risk 
Outcomes were not pre-specified in the method 
section and no access to study protocol.
Other bias Low risk Supported by a government body 
 
Wilcox 
Bias Authors' judgement Support for judgement 
Random sequence 
generation  Unclear risk The method was not described. 
Allocation concealment  
 Low risk 
Predetermined randomized code for each 
hospital
Blinding of participants 
and personnel  Low risk Participants and personnel blinded 
Blinding of outcome 
assessment  Unclear risk 
Blinding of outcome assessment was not 
described
Incomplete outcome data  Low risk Missing data were unlikely to have an impact on the results of the trial   
Selective reporting  
 Unclear risk 
Outcomes were not pre-specified in the method 
section and no access to study protocol. 
Other bias Unclear risk Role of the sponsor was not described
 
 
3.4 Discussion 
According to the hierarchy of study designs to assess the effects of interventions, 
RCT is acknowledged as the gold standard. Although all the included studies are 
RCTs, the method of conduct differs greatly between individual studies; 
consequently the variable quality of studies. More than half (60%) of the included 
studies were published after the establishment of the Consolidated Standards of 
Reporting Trials (CONSORT) statement. The CONSORT statement was first 
published in 1996 (Begg et al., 1996) and was revised in 2001 (Moher et al., 2001) 
with the latest update published in 2010 (Schulz et al., 2010). It provides guidance 
for reporting of RCTs, though it emphasizes more on individually randomised, two 
groups, parallel trials. Despite the improvement in the reporting quality of RCTs, 
Chapter 3 Systematic review 146 
 
many studies in this review remain inadequately reported and this may introduce 
bias leading to underestimation or overestimation of the true intervention effect.  
Selection bias refers to systematic differences between the baseline 
characteristics of the individuals, groups or data that are compared (Higgins, 2011) 
hence not representing the intended study population. Approximately 40% of the 
included studies have a dubious risk of selection bias as they have inadequate or 
failed to report the method used for the random allocation process. Of these 
studies, 68.4% were published prior to 2000. Random allocation consists of two 
steps: [1] random sequence generation, and [2] allocation concealment. When 
done correctly in a large enough sample, the random allocation is effective in 
reducing the risk of bias. The studies were judged as unclear or high risk of 
selection bias when one or both steps were not reported. 
The optimal strategy to minimize the likelihood of differential treatment or 
assessments of outcomes is to blind as many individuals as possible in a trial. 
Performance bias refers to systematic differences between groups in the care that 
is provided, or in exposure to factors other than the interventions of interest 
(Higgins, 2011). Performance bias may occur when the person delivering and 
receiving the treatments being compared are aware of which participants received 
which treatment. Detection bias refers to systematic differences between groups 
in how outcomes are determined (Higgins, 2011) and the risk for this type of bias 
can be reduced by blinding the outcome assessors. Simply over half of the included 
studies (57%) were adequately blinded to reduce the risk of both performance and 
detection bias. Some of the studies utilized the PROBE design which offers 
advantages such as lower cost and greater similarity to the standard clinical 
practice compared to the classical double-blind design. A meta-analysis comparing 
the double-blind placebo-controlled and the PROBE design in hypertension trial 
has found that the result was statistically equivalent (Smith et al., 2003).   
Attrition bias refers to systematic differences between groups in withdrawals from 
a study (Higgins, 2011). Attrition bias may be introduced from the exclusion of 
participants from analysis or results. Ideally, an intention-to-treat (ITT) analysis 
is preferable as it included all randomized participants regardless of status at the 
end of a study follow-up. The ITT approach is considered as the gold standard 
because it preserved randomisation (Fergusson et al., 2002, Glasser and Howard, 
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2006), limits from arbitrary inferences, focuses on greater accountability, limit 
type I error and allows for greater generalisability (Fergusson et al., 2002). The 
overall attrition rate from all the included studies in this review ranged from 0.02% 
to 25%. The trials judged with high attrition bias tend to be older trials and has a 
longer duration of follow-up. Majority of included studies reported outcome as 
described in the method section or study protocols where available. Only a few 
studies were judged as unclear risk of reporting bias and the access to protocol 
was not available. Some of these studies were published more than 20 years ago 
and receiving a response from authors are very unlikely. 
Another factor considered as a potential source of bias was the source of funding 
for each included studies. Majority of the included studies (80%) received 
assistance in the form of financial support, trial organization or simply study drugs 
provision from pharmaceutical industries and most of these trials were conducted 
in Europe and North America. Industry-sponsored studies in this review showed a 
slight preference for comparing study drugs against a placebo (56.9%) than against 
similarly effective drugs (43.1%). However, only half (50%) of the industry-
supported study explicitly reported the role of the sponsor during the trials. One 
of the main reasons for concern in industry-funded trials is that the quality of 
study sponsored by profit-making firms may be poor. Dieppe et al. (1999) had 
found that 88% of pharmaceutical-sponsored studies reported a significant 
beneficial effect of the intervention tested compared to only 69% of studies with 
other or unknown source of funding. Studies of poor quality could overestimate 
therapeutic benefit by about 34% (Moher, 1999). Another reason is that the 
industry only sponsors studies that will produce positive results. This situation 
could subject a potential problem as when new drugs are approved for marketing 
but the sponsors have failed to disclose all of their potential benefits or risks. 
Furthermore, withholding the publication of unfavourable result contributes to 
the risk of publication bias.
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4 Association between angiotensin-converting 
enzyme inhibitors (ACEI) and risks of cancers 
4.1 Introduction 
 The renin-angiotensin system (RAS) 
The renin-angiotensin system (RAS) plays an important role in CV homeostasis by 
regulating blood volume and systemic vascular resistance, hence influence cardiac 
output and arterial pressure. Figure 4-1 depicts the classical RAS pathway and its 
inhibitory agents that are useful in controlling elevated BP. When renal blood flow 
is reduced, juxtaglomerular cells in the kidney convert prorenin into renin and 
secrete it into the circulation. Angiotensinogen, the primary hormone in the RAS 
and the only known substrate for renin, is catalytically cleaved to produce 
angiotensin I in the event of low BP (Sparks et al., 2014). Subsequently, 
angiotensin-converting enzyme (ACE) cleaves two amino acids from the C-
terminus of the inactive angiotensin I converting it into the vasoactive peptide 
angiotensin II. Angiotensin II is the main effector molecule of the RAS pathway and 
its biological effect is mediated by the angiotensin II (AT) receptors, which is 
further categorised into AT receptor type 1 (AT1) and AT receptor type 2 (AT2). 
Most of the effects classically related to the function of RAS are mediated by the 
AT1 including smooth muscle cell contraction, renal tubular sodium reabsorption, 
the release of aldosterone from the renal adrenal glomerulosa, and the release of 
antidiuretic hormone (ADH) from the posterior pituitary (Sparks et al., 2014).  
In addition to angiotensin I, bradykinin is also one of the most important active 
substrates for ACE. Bradykinin is a potent vasodilator and its activation is also 
important in inflammatory reactions (Hornig et al., 1997, Golias et al., 2007). 
Bradykinin exerts its vasodilatory effect by acting on a specific endothelial B2 
receptor leading to the release of prostacyclin, nitric oxide (NO) and endothelium-
derived hyperpolarizing factor (EDHF) (Hornig et al., 1997). In the kinin-bradykinin 
system, the ACE degrades bradykinin into inactive bradykinin components. Thus, 
it has been suggested that inhibition of the RAS pathway enhanced the 
vasodilatory effect of kinin-bradykinin cascade which consequently assists in 
lowering BP.   
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Characterization of the RAS was concluded in the 1950s with the identification of 
angiotensinogen, angiotensin I and II, and ACE (Skeggs et al., 1956). Apart from 
its BP regulatory function, inappropriate activation of RAS has many deleterious 
effects including vasoconstriction, cell proliferation, inflammatory responses, 
oxidative stress, prothrombotic effects, and increased insulin resistance 
(Tomiyama et al., 1994, Brown et al., 1998, Lévy, 2004). 
 Pharmacokinetics of ACEI 
Table 4-1: summarises the pharmacologic characteristics of the various ACEI. All 
the ACEI shares the same basic structure, however, they can be categorised based 
on their functional binding group: sulphydryl, carboxyl, or phosphinyl. Of the three 
groups, carboxyl-containing ACEI tends to be more potent due to the better 
strength of binding to the zinc-ligand. Only captopril and lisinopril do not require 
activation through hepatic metabolism to form its active metabolite. The ability 
of ACEI to bind to tissue ACE is considerably variable. The relative potency and 
ability to bind tissue ACE of ACE inhibitors is: quinaprilat = benazeprilat > 
ramiprilat > perindoprilat > lisinopril > enalapril > fosinopril > captopril 
(Konermann et al., 1998, Lala and McLaughlin, 2008). Fosinopril has the greatest 
lipophilicity thus longer half-life while lisinopril has the least for both variables. 
Most of the ACEI are eliminated via the kidney and only a few are excreted through 
the liver or faeces. The ACE inhibitors are generally well tolerated, with 
hypotension, cough, and hyperkalaemia being the most frequently reported 
adverse effects for the entire class.  
 Mechanism of action 
Figure 4-1demonstrates the classical RAS pathway and the site for RAS inhibitors. 
ACEI acts mainly by inhibiting the converting enzyme that hydrolyses angiotensin 
I to angiotensin II, hence depleting the agonist for angiotensin II receptors. At the 
same time, inhibition of the ACE also generates excess bradykinin which is a 
potent vasodilator. Meanwhile, blockade of the angiotensin II receptors 
specifically at the AT1 by ARB results in the dilatation of vasculature preferentially 
in the vital organs namely the heart, kidney, and brain (Timmermans, 1993). 
Unlike ACEI, ARBs have no effect on bradykinin metabolism and they are selective 
blockers of angiotensin effects. Inhibition of the RAS results in reduce arterial 
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pressure thereby reduce preload and afterload on the heart. Furthermore, 
blockade of the AT1 receptors and aldosterone secretion from the zona 
glomerulosa of the adrenal cortex promotes renal excretion of sodium and water. 
In the same time, sympathetic activity is down-regulated through blockade of 
angiotensin II effects on the sympathetic nerve.  
 ACEI and cancer risk 
There is evidence suggesting several components of RAS, particularly expressed in 
tissues, may be involved in carcinogenesis (Ager et al., 2008). Angiotensin II is 
important in regulating tissue angiogenesis, proliferation, apoptosis, and 
inflammation (Deshayes and Nahmias, 2005) which is primarily induced by AT1 
receptors. Inhibition of ACE prevents generation of angiotensin II and downstream 
signalling activated via AT1 receptors; hence reduce angiogenesis and cell 
proliferation. However, there is some evidence that signalling via AT2 receptors 
can also be pro-angiogenic (Sarlos et al., 2003) and pro-inflammatory (Wolf et al., 
2002). Several experimental studies have shown that modulation of the RAS 
pathway by ACEI conferred antineoplastic effects. In-vitro studies of captopril 
have shown to inhibit cancer cell growth in pancreatic ductal cancer cells (Reddy 
et al., 1995), ductal breast carcinoma (Small et al., 1997), and human 
neuroblastoma (Chen et al., 1991) by modulation of mitosis and gene expression. 
In a study using a murine model of hepatocellular carcinoma, perindopril had 
significantly inhibited tumour development and angiogenesis independent of AT1 
receptor blockade (Yoshiji et al., 2001). This observation was also accompanied 
by the suppression of vascular endothelial growth factor (VEGF), a potent 
angiogenic factor. 
Furthermore, the metabolism of angiotensin I form heptapeptide angiotensin (1-
7) by endopeptidases such as neprilysin, prolyl endopeptidase, and thimet 
oligopeptidase.  Angiotensin (1-7) is a biologically active peptide hormone with a 
vasodilator, antiproliferative, and antithrombotic properties (Ferrario, 2005). 
Administration of ACEI, in one way, could promote conversion of angiotensin I to 
angiotensin (1-7) via an alternative pathway. An in-vivo experiment by Soto—
Pantoja and colleague (2009) has observed reduced tumour angiogenesis in 
athymic mice bearing human lung cancer xenografts that were administered 
angiotensin (1-7). In addition, tumour growth was significantly reduced in treated 
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mice compared to control. Therefore, the purported underlying mechanism by 
which ACEI may be protective of carcinogenesis is by reducing angiogenesis and 
cellular proliferation. Evidence of ACEI and the risk of cancer from epidemiological 
studies are described in Chapter 1 Section 1.9.3 (page 45).  
This chapter aims to systematically review and report the meta-analysis of RCTs 
using ACEI as one of its treatment and its association with risks of cancer.  
Table 4-1: Summary of pharmacologic characteristics of various ACEI 
Group type 
Generic 
name 
Active 
metabolite 
% of 
inhibition 
of tissue 
ACE 
Protein-
bound 
fraction 
(%) 
Elimination 
half-life 
(h) 
Excretion 
Suphyhydryl-
containing 
Captopril None NA 25-30 _ 
Urine (>95%)
Dicarboxylate
-containing 
Enalapril Enalaprilat 2.3 20-89 1.3 Urine
Benazepril Benazeprilat 27 97 1.5-2 
Urine (88%), bile 
(11-12%) 
Lisinopril None 6 0 _ Urine (100%)
Ramipril Ramiprilat 11 73 9-18 Urine (60%)
Quinapril Quinaprilat 33 97 2 Urine (61-96%)
Perindopril Perindoprilat 17 60 3-10 
Urine (75%)
Trandolapril Trandolaprilat NA 65-94 6-10 
Faeces (66%), 
Urine (33%) 
Phosphinyl-
containing 
Fosinopril Fosinoprilat NA ≥ 95 12 Faeces (50%), 
Urine (50%) 
Abbreviations: ACE, angiotensin-converting enzyme, NA, not available.
Data adapted from (Konermann et al., 1998, Lala and McLaughlin, 2008, Saha et al., 2008) 
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Figure 4-1 The renin-angiotensin system (RAS). 
RAS are executed through high affinity binding of angiotensin II to specific angiotensin receptors. These receptors belong to the large family of 
G-protein coupled receptors (GPCRs) and can be separated into two pharmacological classes, AT1 and AT2, each with distinct functions linked 
to specific intra-cellular signaling pathways. Inappropriate activation of the RAS may lead to deleterious effects. Two pharmacological agents, 
ACEI and ARB, are the main inhibitors of this pathway and they act by 1) preventing the conversion of angiotensin I to angiotensin II, 2) 
generation of bradykinin, and 3) blockade of the angiotensin II type 1 (AT1) receptors, hence inhibiting downstream signalling. ACE, 
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AT, angiotensin II receptor. 
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4.2  Methodology 
 Systematic review 
Full descriptions of the methods used for this systematic review and meta-analysis 
have been described previously in Chapter 2, Section 2.1 (page 57).  
Data for four studies were extracted from the ARB Trialists Collaboration meta-
analysis (Teo, 2011) because of availability of data either as individual data 
(ONTARGET) or tabulated data (CHARM-Added 2003, Val-HeFT, VALIANT) on 
cancer outcomes. Data for PARADIGM-HF was supplied by the primary author 
(Professor John J.V. McMurray of the University of Glasgow). Data for the 
remaining studies were either published in the primary study or in post-hoc 
analyses. 
 Meta-analysis  
For data synthesis, see Chapter 2 Section 2.1.7.4 (page 66). 
Sensitivity analyses were done by exclusion of trials with: [1] factorial design; [2] 
poor methodological quality; and [3] small sample size with the number of total 
participants less than 1000. 
For incident cancer, the following subgroups category were conducted: [1] 
subclass; [2] comparator; [3] clinical setting; [4] mean age; and [5] duration of 
follow-up  
4.3 Results 
Overall, the search has identified 27 eligible ACEI trials enrolling 135,037 
participants with an average follow-up of 3.6 years (range 1 to 9 years). The 
average patients’ age across all studies is 64 years old.  
The searching and identification process of trials was summarised in Figure 3-1 
(Page 74). I have excluded 63 studies from the total of 90 included RCTs from the 
main systematic review primarily because they do not consist of an ACEI treatment 
arm. The full characteristics and risk of bias of studies included in this review have 
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been described previously (See Chapter 3, Section 3.2.2.1 and Section 3.3.6. 
correspondingly). 
Majority of the studies were published in the 21st century with the latest study 
published in 2014. Three studies (ALLHAT, ONTARGET, and VALIANT) enrolled 
more than 10,000 total participants, thus contributed the most number of 
participants in this review. Majority of the studies have recruited patients with 
underlying risk factors for or existing CVD including hypertension, T2DM, CHD, and 
HF. The AIPRI trial recruited patients with chronic renal insufficiency caused by 
various diseases which may not be of CV origin. Meanwhile, the PHARAO trial 
enrolled participants with high-normal BP (SBP less than 140 mmHg and DBP less 
than 90 mmHg) who were not on any antihypertensive treatment.  
Overall, approximately 38.3% of patients across all studies were randomised to 
treatment with ACEI. Of these, just over half of the patients (52.4%) were assigned 
to tissue ACEI. The ACEI treatment arm in the STOP-HTN2 study consisted of both 
tissue- (enalapril) and non-tissue ACEI (Lisinopril). Only two studies (CHARM-Added 
and Val-HeFT) did not fall into either category as the type of ACEI used was not 
specified.  
Most of the included RCTs compared ACEI to active controls including ARB, BB, 
CCB, TZ, and conventional antihypertensive therapy. One study (PARADIGM-HF) 
has compared ACEI to a new drug class, an angiotensin II receptor blocker 
neprilysin inhibitor (ARNI), which is a novel drug for treatment of HF that is likely 
to be a useful antihypertensive drug. Ten trials compared ACEI to placebo as either 
one of or the only comparator arm. Meanwhile, three studies contained a 
combination therapy as one of its treatment group. Two studies (ONTARGET, and 
VALIANT) randomised patients to ACEI, ARB and ARB plus ACEI. These trials were 
regarded as ACEI monotherapy versus ARB monotherapy and ACEI plus ARB 
combination. The DEMAND study has randomised patients to ACEI, ACEI plus CCB 
combination, and placebo. Only data from the ACEI monotherapy and placebo 
treatment arm were considered in this review and meta-analysis. 
Furthermore, the CHARM-Added trial investigated the use of ARB versus placebo 
in HF patients already receiving an ACEI. Similarly, the Val-HeFT trial which tested 
the strategy of ARB versus placebo, more than 90% of patients were receiving 
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background ACEI therapy in both groups. Therefore, these two trials were 
regarded as a trial of ACEI versus ARB plus ACEI.  
All the included studies implemented a double-blind design except for five studies. 
Two studies (ESPIRAL and Otsuka) were conducted as open-label while the 
remaining three studies (FACET, PHARAO, and STOP-HTN2) have only the outcome 
assessors blinded. A great number of studies consisted of two parallel treatment 
group. Seven studies have three treatment groups while two studies have 
implemented a 2-by-2 factorial design.  
All the studies were followed for at least one year with the UKPDS-38 study 
followed the longest. The mean age for patients across all studies is over 50 years. 
Almost all of the included studies have majority male participants except for the 
PHYLLIS study with an excess of ten percent female participants. Conversely, the 
V-HeFT II study consists of male-only patients. The reporting of current smokers 
is inconsistent across studies, though only one study (SAVE) reported more than 
50% of patients were current smokers. 
The selected characteristics of interest extracted from the 27 included studies are 
summarised in Table A-3 (Page 321). The reporting of all these variables was 
inconsistent across all studies.   
In the CHARM-Added study, patients with baseline cancer (6% of total participants) 
were allowed to participate in the trial whereas patients with cancer or 
malignancy were excluded in the AIPRI, SOLVD-T, and TRACE trials. Majority of 
the trials did not pre-specified cancer as an outcome and the adjudication of 
cancer diagnosis varies across studies. Only seven studies had malignancy either 
centrally or site-adjudicated.  Likewise, the rate of adherence to treatment was 
not reported consistently across trials. The loss to follow-up ranged from 0 to 
3.2%. 
4.4 ACEI and risks of incident cancer  
 Overall 
Altogether, 21 RCTs were eligibly fulfilling all criteria for the comparison between 
ACEI and other agents for incident cancer. Data were available from 117, 560 
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(97.5%) of the 120,602 patients who were enrolled in the 21 studies. Figure 4-2 
shows the meta-analysis of ACEI and risk of cancer incidence in a fixed-effect (FE) 
model. According to randomised allocation, cancer incidence was 5.87% in 
patients assigned to the ARB group versus 6.32% assigned to non-ACEI treatment. 
The meta-analysis result was mainly influenced by data from the ALLHAT and 
ONTARGET trials with the most weight assigned to these studies at 31.7% and 
27.1% respectively. Majority of the remaining studies were assigned a weight of 
less than five percent. A fairly equal number of studies has reported an OR of 
either more or less than 1 with 95% CI overlapping 1. From the forest plot, CIs for 
all the studies crossed the line of no effect indicating a lack of statistical 
significance at the study level. Consequently, the combined OR was 0.99 with 95% 
CI between 0.94 and 1.05 (P-value = 0.82). The diamond that represents the 
pooled effect estimates is narrow and it overlaps the line of no effect indicating 
the absence of statistical significance at the meta-analysis level. 
In the random effects (RE) model depicted in Figure 4-3, slightly more weight was 
assigned to the ALLHAT (32.1%) while weight for the ONTARGET study reduced by 
1.2%. The combined effect estimates yielded an OR 1.00 (95% CI 0.95-1.05; P = 
0.85) coming close to the FE model. 
Assessment of heterogeneity in both FE and RE model showed a chi-square P-
value of 0.58 and I2 statistics of 0% indicating no statistical differences between 
studies. 
Visual inspection of the funnel plot (Appendix Figure A-1) shows fairly equal 
distribution of studies on both sides of the diagram. No outlier was detected.
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Figure 4-2 Forest plot of incident cancers by ACEI vs. non-ACEI controls [FE model].  
Odds ratios and 95% confidence interval overall and in 21 trials. The overall effect represents the 
pooled estimate of odds for incident cancers.*Included were patients with no history of cancer or 
active cancer at baseline.  
 
 
Figure 4-3 Forest plot of incident cancers by ACEI vs non-ACEI controls [RE model]. 
Odds ratios and 95% confidence interval, overall and in 21 trials The overall effect represents the 
pooled estimate of odds for incident cancers.* Included were patients with no history of cancer or 
active cancer at baseline.
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 Sensitivity analyses 
Exclusion of two trials (HOPE and SCAT) with factorial design did not affect the 
risk of cancer with OR 1.00 (95% CI 0.95-1.06; Figure 4-4) and P-value of 0.98. 
Likewise, this result is mainly influenced by the ALLHAT and ONTARGET trial. Chi-
square test for heterogeneity yields a P-value of 0.48 and I2 statistics is observed 
at 0% indicating low heterogeneity between studies. Figure 4-5 shows the meta-
analysis results after exclusion of eight trials with small sample sizes. Similarly, 
no difference was observed after exclusion of these trials giving an OR of 1.00 
(95% CI 0.95-1.05; P-value = 0.87). Assessment of heterogeneity showed a chi-
square test P-value of 0.41 and an I2 statistics of 4% indicating a statistically 
insignificant difference between studies. The trivial heterogeneity observed is 
most likely due to clinical and methodological diversity of the PARADIGM-HF (a 
non-conventional comparator was used) and PHARAO (pre-hypertension 
participants) study. 
Exclusion of twelve trials with poor methodological quality is shown in Figure 4-6 
with OR 0.97, 95% CI 0.90-1.04 (P-value = 0.38). The direction of the combined 
effect estimates was largely influenced by ONTARGET study with 65.9% of the 
overall weight. Chi-square test for heterogeneity yields a P-value of 0.09 and I2 
statistics is observed at 42%. The moderate heterogeneity observed is most 
probably due to the methodological diversity of the CHARM-Added (patients in the 
ACEI treatment arm were originally randomised to placebo), DEMAND ( a three 
arm parallel study containing a combination arm), ONTARGET (a three arm parallel 
study containing a combination arm), and PARADIGM-HF (a non-conventional 
comparator was used) study. 
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Figure 4-4 Forest plot of incident cancers by ACEI vs control [Sensitivity analysis: 
Exclusion of trials with factorial design]. 
The overall effect represents the pooled estimate of odds for incident cancers.* Included were 
patients with no history of cancer or active cancer at baseline. 
 
 
Figure 4-5 Forest plot of incident cancers by ACEI vs controls [Sensitivity analysis: Study 
size]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 4-6: Forest plot of incident cancers by ACEI vs. controls [Sensitivity analysis: 
Methodological quality].  
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
 
 Subgroup analyses 
Table 4-2 summarises the results of subgroup analyses performed for ACEI and 
cancer risk. 
4.4.3.1 By subclasses: tissue ACEI and non-tissue ACEI 
Only six RCTS enrolling 36,885 participants had used tissue ACEI as one of the 
study treatment. In this analysis, tissue ACEI included benazepril, delapril, and 
ramipiril whereas non-tissue ACEI comprised captopril, enalapril, and fosinopril. 
Cancer incidence was 7.51% in the tissue ACEI group versus 7.99% in the control 
group with OR 0.94 (95% CI 0.87-1.02). As shown in Figure 4-7, this analysis is 
mainly influenced by the ONTARGET study followed by the HOPE study, each 
assigned 63.9% and 29.3% of the overall weight respectively. The chi-square test 
P-value was 0.33 and the I2 statistics of13%. The minimal heterogeneity observed 
is likely due to clinical and methodological diversity of the DEMAND (a three arm 
parallel study containing a combination arm) and ONTARGET (a three arm parallel 
study containing a combination arm) study. 
For non-tissue ACEI, data were available from 13 RCTs with a total of 75,434 
patients. Cancer incidence was 5.01% in the ACEI treatment group versus 5.63% in 
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the control group. The result of this study was greatly driven by the ALLHAT study 
carrying over 50% of the overall weight (Figure 4-7). The combined effect 
estimates resulted in OR 1.03 (95% CI 0.96-1.10).  Assessment of heterogeneity 
showed a chi-square P-value of 0.70 and I2 statistics at 0% indicating no statistical 
difference between studies.   
4.4.3.2 By type of comparator 
Overall, 12 RCTs compared ACEI to active controls with data available from 91,025 
patients. Cancer incidence was 5.93% in the ACEI treatment group versus 6.45% in 
the active control group. Pooling of effect estimates from the 12 studies yields an 
OR of 0.99 (95% CI 0.93-1.05) with P-value = 0.77 (Figure 4-8). The ALLHAT and 
ONTARGET study has the biggest influence in this analysis as they carry 41.6% and 
35.5% of the overall weight correspondingly. The chi-square test resulted in a P-
value of 0.83 and the I2 statistics of 0% indicating no statistical heterogeneity 
between studies. 
Two RCTs have compared ACEI to ARB and data were available from 25,792 
patients. Cancer incidence was 5.34% in the ACEI treatment group versus 5.56% in 
the ARB treatment group. Both included studies (ONTARGET and VALIANT) with 
OR less than 1 and their 95% CI overriding 1. Combined effect estimates resulted 
in OR 0.96 (95% CI 0.86-1.07; P-value = 0.42). This result was mainly influenced 
by the ONTARGET study as it carried the most weight overall at 87.4% (Figure 
4-8). Assessment of heterogeneity showed a chi-square P-value of 0.95 and I2 
statistics is observed at 0% indicating no statistical difference between studies. 
For comparison with ACEI and ARB combination, four RCTs were included with 
data available from 33,129 patients. Cancer incidence was 5.32% in the ACEI 
treatment group versus 5.48% in the combination treatment group with OR 0.97 
(95% 0.88-1.07; P-value = 0.52). The ONTARGET study was assigned the heaviest 
weight of 73.2% overall and eventually had a major influence in the direction of 
the combined OR (Figure 4-8). The chi-square test resulted in a P-value of 0.03 
and the I2 statistics of 66% signifying evidence of a difference between studies. 
The observed heterogeneity observed is most likely due to methodological 
diversity of the Val-HeFT (ARB versus placebo study) and VALIANT (a three arm 
parallel study containing a combination arm) study.  
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Likewise, four RCTs used CCB as one of its randomised treatment with data 
available from 22,724 patients. Cancer incidence was 8.15% in the ACEI treatment 
group versus 8.16% in the CCB treatment group with OR 1.00 (95% CI 0.91-1.10; P-
value = 0.98). This analysis was greatly influenced by the ALLHAT study which 
carries 76.9% of the overall weight (Figure 4-8). Three (ALLHAT, ESPIRAL, FACET) 
of the four included studies yields OR less than 1 with 95% CI overlapping 1. 
Assessment of heterogeneity showed a chi-square P-value of 0.94 and I2 statistics 
is observed at 0% indicating no statistical difference between studies. 
For placebo, data were available from 17,391 patients enrolled in six RCTs. Cancer 
incidence was 5.62% in the ACEI treatment group versus 5.68% in the placebo group 
with OR 0.99 and 95% CI ranging from 0.87 to 1.13 (P-value = 0.88). From Figure 
4-8, it is clear that the HOPE study had influenced the direction of the pooled 
effect estimates with assigned study weight of 80.3% overall. Assessment of 
heterogeneity showed a chi-square P-value of 0.23 and I2 statistics is observed at 
28%. The observed moderate heterogeneity is most probably due to the 
methodological diversity of the DEMAND (a three arm parallel study containing a 
combination arm), HOPE (factorial design), and SCAT study (factorial design).  
4.4.3.3 By population clinical settings 
Data for patients with high-risk hypertension were available from 74,582 enrolled 
in nine RCTs. Cancer incidence was 7.78% in the ACEI treatment group versus 8.03% 
in the control group. Combined effect estimates resulted in OR 0.97 with 95% CI 
ranged between 0.92 and 1.03 (P-value = 0.34). Majority of the studies’ OR lies on 
the left side of the plot favouring ACEI. Furthermore, the overall result was mainly 
driven by the ALLHAT study (39.6%) followed by the ONTARGET study (33.8%) as 
demonstrated by the weight assigned to each study (Figure 4-9). Assessment of 
heterogeneity showed a chi-square P-value of 0.48 and I2 statistics is observed at 
0% indicating no statistical difference between studies. 
For patients with underlying T2DM, data were available from 1,673 patients 
enrolled in four RCTs. Cancer incidence was 1.32% in the ACEI treatment group 
versus 2.50% in the control group with OR  0.53 with a very wide 95% CI from 0.26-
1.09 (P-value = 0.08). From Figure 4-9, the ORs for three of the four studies are 
located on the left side with the wide 95% CI depicted as a wide-edged diamond 
Chapter 4 ACEI and risk of cancer 163 
 
in the forest plot. Moreover, this analysis was mainly driven by the FACET and 
DEMAND study as they carried the most weight overall (41.1% and 37.6% 
respectively). The chi-square test resulted in a P-value of 0.50 and the I2 statistics 
of 0% signifying no statistical heterogeneity between studies. 
Meanwhile, data for patients with underlying CKD were available from 824 
patients enrolled in two RCTs (Figure 4-9). Cancer incidence was 2.10% in the 
ACEI treatment group versus 1.52% in the control treatment group with OR 1.41 
and a very wide 95% CI from 0.50 to 3.99 (P-value = 0.52). The AIPRI study has a 
major influence in this analysis with an assigned weight of 82.5%. The chi-square 
test resulted in a P-value of 0.71 and the I2 statistics of 0% signifying no statistical 
heterogeneity between studies.   
For patients with established CVD which includes CHD with or without congestive 
HF, data were available from 41,146 patients enrolled in nine RCTs. Cancer 
incidence was 3.43% in the ACEI treatment group versus 2.82% in the control 
group. From Figure 4-9, the majority of the included studies’ effect estimates lie 
on the right side of the forest plot favouring control. The combined effect 
estimates yield an OR 1.09 (95% CI 0.97-1.22) with a P-value of 0.16 for the overall 
effect. The chi-square test resulted in a P-value of 0.53 and the I2 statistics of 0% 
signifying no statistical heterogeneity between studies. 
4.4.3.4 By mean age groups 
For studies with patients’ mean age of 65 years or older, data were available from 
74,404 enrolled in five RCTs. Cancer incidence was 8.07% in the ACEI treatment 
group versus 8.13% in the control group with OR 0.98 (95% CI 0.93-1.04; P-value = 
0.51). The direction of this analysis was mainly influenced by the ALLHAT and 
ONTARGET study (Figure 4-10). The chi-square test resulted in a P-value of 0.40 
and the I2 statistics of 1%. The trivial difference between studies observed is most 
likely due to clinical and methodological diversity of the ONTARGET (a three arm 
parallel study containing a combination arm) and TRACE (post-MI patients) study. 
On the other hand, data for studies with a younger mean age (< 65 years) were 
available from 43,156  patients enrolled in 16 RCTs. Cancer incidence was 3.01% 
in the ACEI treatment group versus 2.60% in the control group with combined OR 
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of 1.05 and a wide 95% CI ranging from 0.94 to 1.18 (P-value = 0.40; Figure 4-10). 
None of the studies had principally influenced this analysis because none of the 
individual study weight was more than 50%. Assessment of heterogeneity showed 
a chi-square P-value of 0.61 and I2 statistics of 0% indicating no statistical 
difference between studies. 
4.4.3.5 By duration of follow-up 
Data for studies with mean patients’ follow-up < 3 years were available from 
30,948 patients enrolled in seven RCTs. Cancer incidence was 3.12% in the ACEI 
treatment group versus 2.49% in the control group. Combined effect estimates 
resulted in OR of 1.10 (95% CI 0.96-1.26; P-value = 0.18). The individual OR for 
the majority of the included study is more than 1 with the PARADIGM-HF, Val-
HeFT, and VALIANT study heavily influenced the direction of this analysis (Figure 
4-11). Assessment of heterogeneity showed a chi-square P-value of 0.97 and I2 
statistics is observed at 0% indicating no statistical difference between studies. 
Meanwhile, studies with patients’ mean follow-up duration of three years or 
longer were available from 86,612 patients enrolled in 14 RCTs. Cancer incidence 
was 7.01% in the ACEI group versus 7.56% in the control group. Combined effect 
estimates resulted in OR of 0.98 with 95% CI ranged between 0.93 and 1.03 (P-
value = 0.45; Figure 4-11). None of the studies has principally influenced this 
analysis because all the studies were weighted less than 50%. The chi-square test 
resulted in a P-value of 0.34 and the I2 statistics of 11%. The observed 
heterogeneity between studies is most likely due to clinical and methodological 
diversity of the DEMAND and ONTARGET study (a three arm parallel study 
containing a combination arm). 
For studies with patients’ mean follow-up duration of five years or longer, data 
were available from 17,523 patients enrolled in four RCTs. Cancer incidence was 
8.72% in the ACEI group versus 8.98% in the control group with OR 1.01 (95% CI 
0.91-1.13; P-value = 0.81). This analysis was mainly driven by the HOPE trial with 
an assigned weight of 54.7% (Figure 4-11). The chi-square test resulted in a P-
value of 0.39 and the I2 statistics of 1% indicating a small difference between 
studies was present. 
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Table 4-2 Angiotensin-converting enzyme inhibitors and risk of cancer: Subgroup analyses 
Subgroup analysis No. of study 
No. of 
participants
Cancer incidence 
(%) OR (95% CI) P-value I2 (%) 
ACEI Control 
Overall 
effect FE model 21 117560 5.87 6.32 0.99 [0.94, 1.05] 0.82 0 
Subclass 
Tissue ACEI 6 36885 7.51 7.99 0.94 [0.87, 1.02] 0.14 13 
Non-tissue ACEI 13 75434 5.01 5.63 1.03 [0.96, 1.10] 0.46 0 
Type of 
comparator 
Active 12 91025 5.93 6.45 0.99 [0.93-1.05] 0.77 0 
ARB 2 25792 5.34 5.56 0.96 [0.86-1.07] 0.42 0 
ACEI plus ARB 4 33129 5.32 5.48 0.97 [0.88-1.07] 0.52 66
CCB 4 22724 8.15 8.16 1.00 [0.91-1.10] 0.98 0
Placebo 6 17391 5.62 5.68 0.99 [0.87-1.13] 0.88 28
Clinical 
setting 
High-risk 
hypertension 
9 74582 7.78 8.03 0.97 [0.92, 1.03] 0.34 0 
T2DM 4 1673 1.32 2.50 0.53 [0.26, 1.09] 0.08 0 
CKD 2 824 2.10 1.52 1.41 [0.50, 3.99] 0.52 0 
Established CVD 9 41146 3.43 2.82 1.09 [0.97, 1.22] 0.16 0 
Mean age 
≥ 65 years 5 74404 8.07 8.13 0.98 [0.93, 1.04] 0.51 1 
< 65 years 16 43156 3.01 2.60 1.05 [0.94, 1.18] 0.40 0 
Duration of 
follow-up 
< 3 year 7 30948 3.12 2.49 1.10 [0.96, 1.26] 0.18 0 
≥ 3 years 14 86612 7.01 7.56 0.98 [0.93, 1.03] 0.45 11 
≥ 5 years 4 17523 8.72 8.98 1.01 [0.91, 1.13] 0.81 1 
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Figure 4-7: Forest plot of incident cancers by ACEI subclasses [FE model]. 
1) Tissue ACEI vs. controls in 6 trials; 2) Non-tissue ACEI vs. controls in 13 trials. The subtotal 
effect represents the pooled estimate of odds for incident cancers for each subclass. *Included 
were patients who were cancer free at baseline. 
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Figure 4-8: Forest plot of incident cancers by comparators [FE model]. 
1) Active controls; 2) ARBs; 3) ARB plus ACEI; 4) CCB and 5) Placebo. The subtotal effect 
represents the pooled estimate of odds for incident cancers for each comparator. *Included were 
patients who were cancer free at baseline. 
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Figure 4-9: Forest plot of incident cancers by population clinical setting [FE model]. 
1) High risk hypertension; 2) T2DM; 3) CKD; 4) Established CVD. The subtotal effect represents 
the pooled estimate of odds for incident cancers for each clinical setting. *Included were patients 
who were cancer free at baseline. 
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Figure 4-10: Forest plot of incident cancers by mean age [FE model]. 
1) ≥ 65 years; 2) < 65 years. The subtotal effect represents the pooled estimate of odds for incident 
cancers for each criterion. *Included were patients who were cancer free at baseline. 
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Figure 4-11: Forest plot of cancer incident by mean duration of follow-up [FE model]. 
1) Follow-up < 3 years; 2) Follow-up ≥ 3 years; 3) Follow-up ≥5 years. The subtotal effect 
represents the pooled estimate of odds for cancer incidence for each criterion. 
 
4.5 ACEI and risks of cancer-related death 
Altogether, 14 RCTs were included for comparison between ACEI and other 
antihypertensive agents for risk of cancer-related death. Data on cancer-related 
death were available from 80,440 (99.7%) of 80,653 patients who were enrolled in 
the 14 studies. Figure 4-12 shows the meta-analysis of these studies in an FE 
model. According to the assigned treatment arm, cancer-related death was 1.96% 
Chapter 4 ACEI and risk of cancer 171 
 
in the ACEI group versus 2.32% in the non-ACEI group, OR 0.97 with 95% CI 0.88 – 
1.08 (P = 0.62).  
The main analysis was mainly influenced by the ALLHAT study as it was assigned 
the most weight overall at 55.9% which is clearly depicted as the largest blue 
square in the forest plot. The weight assigned to the majority of the 13 remaining 
individual studies is less than 10%.  Four studies recorded an OR more than 1 
ranging from 1.01 to 3.00. On the other hand, seven studies observed an OR less 
than 1 ranging from 0.70 to 0.99 whereas three studies have OR equal to 1. The 
95% CI for all the studies includes 1 which are displayed as CIs crossing the vertical 
line of no effect in the forest plot. Therefore, none of the individual studies is 
statistically significant at the study level. When the results of all the 14 studies 
were pooled together, the combined effect showed an OR of 0.97 with 95% CI 
ranged between 0.88 and 1.08 (P-value = 0.62) and the diamond that represents 
the combined effect estimate in the forest plot encroaches the line of no effect. 
This result indicates that no statistical significance is observed at the meta-
analysis level. 
Random effects (RE) model (Figure 4-13) shows an additional 1.3% weight was 
assigned to the ALLHAT study (57.2%). Similarly, the ALLHAT study carries the most 
weight overall giving an OR 0.98 and 95% CI 0.88 to1.08 (P = 0.67) which is 
comparable to the result of the FE model.   
Assessment of heterogeneity in both FE and RE model showed a chi-square test P-
value of 0.78 and I2 statistics of 0%. These values indicate no evidence of 
statistically significant heterogeneity between the difference studies.  
Appendix Figure A-2 shows the distribution of the 14 studies in a funnel plot. There 
is a missing study at the bottom right of the plot. No outlier is observed and the 
plot appears fairly symmetry.  
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Figure 4-12: Forest plot of cancer-related deaths by ACEI versus non-ACEI controls [FE 
model]. 
Odds ratios and 95% confidence interval, overall and in 14 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death.   
 
 
Figure 4-13: Forest plot of cancer-related deaths by ACEI vs non-ACEI controls [RE model]. 
Odds ratios and 95% confidence interval, overall and in 14 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death.  
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4.6 Discussion 
Results of this study have demonstrated no evidence of significant association of 
cancer incidence with use of ACEI (OR 0.99, 95% CI 0.94-1.05). This result is 
unlikely due to type II error because of the narrow 95% CI and lack of heterogeneity 
ratio. Sensitivity analyses also showed that the inclusion of studies with a different 
design, sizes, and quality did not affect the risk of cancer. Likewise, for cancer-
related death, no increase in risk was observed with summary OR 0.97 (95% CI 0.88 
– 1.08).  
An earlier case report described the relationship between the use of ACEI and 
malignancy by induction of an autoimmune disease of the skin and mucous 
membrane known as pemphigus vegetans (Bastiaens et al., 1994). Review of three 
patients presented with pemphigus vegetans has shown that this condition was 
possibly induced by enalapril and was associated with lung cancer. This finding 
was consistent with a preceding report that had described a statistically increased 
in cancer incidence associated with pemphigus (Younus and Ahmed, 1990). In 
another case report of an elderly heterosexual man free of retrovirus infection, 
captopril was implicated with the development of a rare type of cancer identified 
as Kaposi’s sarcoma (Puppin et al., 1990). It is believed that inhibition of the 
enzyme dipeptidylcarboxypeptidase by ACEI leading to rising kinin level was 
responsible for the various cutaneous reactions observed. Additionally, two RCTs 
reported increased cancer incidence associated with ACEI therapy. The SOLVD-T 
study has followed HF patients for an average 3.5 years and found that those 
receiving enalapril has a slightly higher incidence of cancer compared to placebo 
(OR 1.59,95% CI 0.90-2.82) (The SOLVD Investigators, 1991). In the AIPRI study, 
patients with renal insuffiency caused by various aetiology were followed for an 
average of three years (Maschio et al., 1996). The trial investigators reported 
higher cancer incidence in those randomised to benazepril treatment versus 
placebo (OR 1.52, 95% CI 0.49-4.71). In spite of that, assessment of different ACEI 
subclasses categorised into tissue and non-tissue ACEI in a subgroup analysis of the 
present study found no significant association to risk of cancer in comparison to 
non-ACEI controls.  The varied ACEI effect may be related to differences in 
inhibition of tissue versus plasma ACE, thus may affect their clinical therapeutic 
effects. Erman et al. (1991) assessed the range of ACE activity in human serum 
and tissue samples and inhibition effects of short-term oral ramipiril. This study 
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reported that ACE activity in the renal cortex was >600 times that of the heart, > 
500 times that of the veins, and >150 times that of the arteries. ACE activity in 
renal cortex and arteries were almost completely inhibited by ramipiril whereas 
ACE activity in the heart and veins was inhibited to a lesser extent. Meanwhile, a 
recent meta-analysis by Sun et al. (2016) assessed the efficacy and safety of 
different ACEI in HF patients. Although they have found that enalapril might be 
the best option considering factors associated with HF, it has the highest incidence 
of cough, gastrointestinal disturbance, and greater renal function deterioration. 
Lisinopril ranked the worst for both efficacy and safety profile as it did poorly in 
lowering both systolic and diastolic BP and was associated with the highest 
incidence of all-cause mortality. As for trandolapril and ramipiril, both had better 
efficacy and safety profile.  
ACEIs are also associated to dry cough, which is a class phenomenon and attributed 
to an increase in bradykinin and/or other vasoactive peptides. In an experimental 
study using human lung carcinoma cell line and rat lung cancer model, Papp et al. 
(2002) demonstrated that angiotensin II mediated alveolar epithelial cells 
apoptosis via AT1 receptor. Based on this mechanism, several studies tried to link 
ACEI and lung cancer. A cohort study of 5207 hypertensive patients on 
antihypertensive therapy followed for up to ten years reported a significant 
reduction in lung cancer incidence amongst those on ACEI (Lever et al., 1998). 
However, this study was insufficiently powered to detect different types of cancer 
in subgroup analyses.  In a much larger study,  Friis et al. (2001) retrospectively 
observed cancer incidence among 17,897 patients on ACEI treatment with a 3.7 
years follow-up. This study found no difference in lung cancer risk between ACEI 
users and other antihypertensive users (OR 1.0, 95% CI 0.7-1.03). A similar finding 
was reported in a post-hoc analysis of the STOP-HTN2 (Lindholm et al., 2001) trials 
where patients who were on ACEI did not have increased risk compared to CCB 
and conventional drugs. Then again, the STOP-HTN2 trial was not designed to 
detect cancers. Results from these studies disproved the hypothesis that ACEI is 
associated with increased lung cancer risk. Moreover, inhibition of ACE could lead 
to decreased production of angiotensin II and increased the formation of 
angiotensin (1-7) which can potentially prevent cancer development. Increase 
detection of lung cancer in patients on ACEI is likely due to increased screening 
for patients presenting with a chronic cough in clinical settings. 
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Apart from lung cancer, several studies have also investigated the relationship 
between ACEI and colorectal cancer (Lever et al., 1998, Kedika et al., 2011, Makar 
et al., 2014). Experimental studies suggested that ACEI used in conjunction with 
non-steroidal anti-inflammatory drugs (NSAIDs) is protective against colorectal 
cancer. Upregulation of cyclooxygenase-2 (COX-2) messenger ribonucleic acid 
(mRNA) was markedly increased in most human colorectal cancers (Eberhart et 
al., 1994); thus inhibition of COX-2 activity is thought to be one of the mechanisms 
by which NSAIDs exert its antineoplastic effects. However, the use of specific COX-
2 inhibitors, as well as conventional NSAIDs, have side-effects such as gastric 
ulcers or CV complications in predisposed patients. In addition to COX-2, insulin-
like growth factors type II (IGF-II) acting on IGF receptor type I (IGF-IR) is also 
implicated in the tumorigenesis of colorectal cancer (Manousos et al., 1999, 
Vigneri et al., 2015)  In an in-vivo study using mouse and human colon cancer cells, 
Yasumaru et al. (2003) reported that concurrent use of NSAIDs and ACEI decreased 
IGF-IR expression level and had significantly reduced tumour growth. 
Interestingly, the use of either agent separately did not have a significant effect 
as compared to control.  
The RAS pathway is blocked at different levels by ACEI and ARB. A meta-analysis 
of nine ARB trials enrolling total 94,579 participants by Sipahi et al. (2010) 
proposed increased malignancy risk associated with ARB. Contrariwise in a meta-
analysis of 14 RCTs evaluating ACEI, Sipahi et al. (2011) reported that ACEI did not 
significantly influence the risk for cancer. Although ACEI acts in the same pathway 
as ARB, their mechanism of action is very different. However, the subgroup meta-
analysis conducted in this review indicates that there is no difference in cancer 
risk between ACEI and ARB. Similarly, the risk of cancer between ACEI 
monotherapy and ACEI and ARB combination did not differ significantly. Then 
again, this observation should be interpreted with caution due to the limited 
number and variability of studies included in this analysis. Nevertheless, no 
significant difference is observed with other comparators.  
The inhibition of ACE have proven to be safe and effective in controlling BP and 
preventing major CV outcomes in patients with hypertension, high risk or 
established CVD as demonstrated in clinical trials. The ABCD trial followed 
hypertensive patients with T2DM for an average of 5.6 years and found a lower 
incidence of fatal and non-fatal MI in those receiving ACEI versus CCB (Estacio et 
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al., 1998). In a similar clinical setting, Tatti et al. (1998) reported a lower risk of 
major CVD events in those randomised to ACEI versus CCB despite similar effects 
in biochemical parameters in hypertensive patients with T2DM followed for an 
average three years. In patients with established CVD or high risk for diabetes, 
treatment with ACEI was as effective as ARB (The ONTARGET Investigators, 2008). 
Treatment with ACEI also protects against the progression of renal insufficiency in 
patients with CKD (Maschio et al., 1996). Current clinical guidelines are 
recommending ACEI as one of the primary treatment for hypertension (NICE, 2011, 
Mancia et al., 2013a, James et al., 2014) and left ventricular dysfunction (Hunt et 
al., 2005, Swedberg et al., 2005, NICE, 2010). However, it is important to consider 
whether different clinical settings or disease severity have any impact on cancer 
risk. In a subgroup analysis, no significant increase in cancer risk was detected in 
a different population with different clinical settings. Owing to the limited 
number of study available, cancer risk observed in patients with T2DM or CKD is 
not conclusive with OR 0.53 (0.26-1.09) and OR 1.41 (0.50, 3.99) respectively. 
Additionally, no significant difference in cancer risk was observed in patients older 
versus younger than 65 years.  
The relationship between ACEI therapy and risk of cancer-related death was 
assessed in this review. Cancer-related mortality differs from cancer incidence 
because cancer deaths inform us of the effect of ACEI on cancer progression hence 
survival in cancer patients. Results from the current study correspond to the 
results of previous systematic review and meta-analysis that shows ACEIs have no 
effect on cancer-related mortality (Bangalore et al., 2011, Sipahi et al., 2011, 
Teo, 2011). In a systematic review of ten studies (two interventional, eight 
observational) with total 4,178 patients with cancer of various type, use of ACEI 
or ARB have been showed to improve outcomes in term of recurrence, distant 
metastasis and overall survival rate in cancer patients (Mc Menamin et al., 2012). 
A recent and larger meta-analysis including 55 studies has reported that use of 
RAS blockers was associated with better outcomes in term of cancer progression 
and survival (Sun et al., 2017). Compared to non-user, RAS inhibitors significantly 
improved overall survival (HR  0.82, 95% CI 0.77–0.88), progression-free survival 
(HR  0.74, 95% CI 0.66–0.84) and cancer-free survival (HR  0.80, 95% CI 0.67–0.95). 
This study also found that overall cancer survival was influenced by the type of 
cancer and RAS inhibitors. Improvement of overall survival was only observed in 
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solid cancers but not cancers of the blood such as leukaemia and multiple 
myeloma. The underlying mechanism by which ACEI or RAS inhibitors affect the 
progression of solid cancer is still not clearly understood. However, it has been 
postulated that ACEI disrupts tumour angiogenesis by suppressing VEGF formation 
independent of the AT1 blockade (Yoshiji et al., 2001). 
 Strength and limitations 
This review incorporates all data publicly available reported to date and this is 
the largest meta-analysis of RCTs observing ACEI and risk of cancer overall. Only 
RCTs were included thus decreasing the effects of confounding variables. An OR 
of 0.99 with a very narrow 95% CI obtained makes a false-negative result unlikely. 
The absence of statistical heterogeneity also supported the pooling of outcomes 
from all of the included studies.  
Nevertheless, this review has several important limitations. Majority of the 
included trials were not designed to detect cancer outcomes as a primary 
outcome. Adjudication of the incidence of cancer was unknown and they are 
frequently reported as serious adverse events. Majority of the RCTs have a short 
average duration of follow-up ranging from one to nine years. Hence, the analyses 
only can rule out the effect on late preclinical stage cancers. The risk of site-
specific cancer was not reported due to inadequate access to such data. Many 
trials were excluded from the analysis due to the lack of cancer outcome 
reporting. Therefore, this meta-analysis is subject to outcome reporting bias. 
Lastly, access to individual-patient data from the included RCTs was not available, 
thus it is not possible to perform a time-to event analysis. Additionally, it is 
possible to introduce ascertainment bias in this review during data collection. 
However, the risk of ascertainment bias is reduced by implementing independent 
data abstraction and quality review as well as sensitivity and subgroup analyses. 
4.7 Conclusion  
There is no evidence that ACEI significantly increases or decrease the risk of any 
cancer or cancer-related death. These data add to the growing body of evidence 
suggesting these agents do not affect the risks of cancer. 
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5 Association between angiotensin receptor 
blockers (ARB) and risks of cancer  
5.1 Introduction 
The RAS is described in more detail in Chapter 4 Section 4.1.1. ARBs is one of the 
earliest pharmacological inhibitors to target the RAS pathway in BP control. The 
characteristics of different ARB types are summarised in Table 5-1. Currently, 
only seven orally active ARB has been approved by the FDA for the treatment of 
hypertension. Among the ARBs, irbesartan has the best bioavailability with 
approximately 70% of the drug reaches circulation following oral administration, 
whereas eprosartan had the least oral bioavailability. The active metabolite for 
losartan, EXP 3174, when administered via the intravenous route is more potent 
and has a longer duration of action than the parent drug (Burnier and Brunner, 
2000). However, the EXP 3174 has poor oral bioavailability, thus losartan is in the 
market. Meanwhile, candesartan is administered orally as a prodrug, candesartan 
cilexetil, which is rapidly converted to candesartan during absorption in the 
gastrointestinal tract. The remaining ARBs are either directly active and have no 
active metabolite. Telmisartan has the longest half-life allowing a once a day 
regime, while losartan has the shortest half-life of approximately two hours. All 
ARBs are highly bound to plasma protein and they are mainly excreted via the 
biliary system with a lesser fraction are excreted through the kidney. The 
mechanism of action for ARBs is described in Chapter 4, Section 4.1.4 and Figure 
4-1. 
 ARB and cancer risk 
The underlying mechanism where blockade of angiotensin type 2 (AT2) receptors 
by ARB leads to cancer formation is still unclear. As described earlier, angiotensin 
II is known to regulate angiogenesis thereby plays a role in carcinogenesis (See 4 
Section 4.1.4(page 150). In an in-vivo study, sarcoma and fibrosarcoma cells were 
implanted in mice treated with candesartan, lisinopril, or control (Fujita et al., 
2002). This experiment demonstrated that treatment with candesartan or 
lisinopril inhibited angiogenesis, growth, and metastasis of a tumor, hence 
suggesting that blockade of the AT2 receptors may become a potential target in 
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tumor chemoprevention strategy. Evidence from epidemiological studies is 
discussed in Chapter 1, Section 1.9.3.1(page 46).   
This chapter aims to systematically review and report the meta-analysis of RCTs 
using ARB as one of its treatment and its association with risks of cancer. 
Table 5-1 Pharmacokinetics of angiotensin receptor blockers (ARB) 
Drug name Bioavailability Active metabolite Half-life (h) 
Protein 
binding 
(%) 
Elimination 
route 
Losartan 33 EXP 3174 2 98.7 Bile (90%), 
renal (10%) 
Valsartan 25 No 9 95 Bile (70%), 
renal (30%) 
Irbesartan 70 No 11-15 90-95 Bile (80%), 
renal (20%) 
Candesartan 
cilexetil 
42 Candesartan 3-11 99.5 Bile (40%), 
renal (60%) 
Telmisartan 43 No 24 > 99 Bile (99%), 
renal (1%) 
Eprosartan 15 No 5-7 98 Bile (90%), 
renal (10%) 
Olmesartan 29 No 14-16 > 99 Bile (90%), 
renal (10%) 
Azilsartan   
Adapted from Brunner (2002), Burnier and Brunner (2000), and Brousil and Burke (2003). 
 
5.2 Methodology 
 Systematic review 
Full descriptions of the methods used have been described previously in Chapter 
2 Section 2.1 (page 57). 
Majority of the included trials have published cancer outcomes in their primary 
study or as a post-hoc analysis. In eleven trials (ALPINE, CHARM Overall, DIRECT 
Overall, IDNT, ONTARGET, TRANSCEND, and VALIANT), cancer outcomes were 
reported in two earlier meta-analyses (Bangalore et al., 2011, Teo, 2011). Cancer 
outcomes for the PREVER-Treatment study were supplied by the trial primary 
author (Dr Flávio D. Fuchs of Hospital de Clinicas de Porto Alegre, Brazil).  
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 Meta-analysis 
For data synthesis, see Chapter 2 Section 2.1.7.4 (page 66). 
For incident cancer, sensitivity analyses were done by exclusion of trials with: [1] 
factorial design; [2] poor methodological quality; [3] small sample size with the 
number of total participants less than 1000; and [4] inclusion of patients with 
baseline cancer. 
Additionally, the following subgroup analyses were performed: [1] by subclass;[2] 
by the comparator; [3] by clinical setting; [4] by mean age; and [5] by the duration 
of follow-up.  
Furthermore, individual patient data for the four major valsartan trials (VALUE, 
Val-HeFT, VALIANT and NAVIGATOR) was provided by Novartis, a pharmaceutical 
company, through Professor John J.V. McMurray of the University of Glasgow. The 
analysis of these trials was designed and performed by the authors in conjunction 
with Statistics Collaborative Incorporated (SCI). They also reviewed these data to 
identify all cancers (except basal cell cancers) reported as adverse events or 
deaths. 
Data from the four major valsartan trials were analysed for risk of fatal and non-
fatal lung, breast and prostate cancer. Additionally, focus was given to the 
following treatment comparison: [1] valsartan vs. placebo, [2] valsartan vs. CCB, 
[3] valsartan vs. non-RAS blocker comparator, [4] valsartan plus ACEI vs ACEI alone 
(data from Val-HeFT and two of the three arms of VALIANT), [5] valsartan  vs ACEI 
(data from two of the three arms of VALIANT), [6] valsartan plus ACEI (“more 
intense” RAS blockade) vs. either ACEI or ARB monotherapy (“less-intense” RAS 
blockade) using data from Val-HeFT and all three arms of VALIANT), and [8] 
valsartan monotherapy vs. any comparator (placebo, ACEI, or CCB). 
The analysis for valsartan and risks of cancer, in particular, was conducted by SCI. 
Only within study OR estimates and 95% CIs were reported for comparison [1], [2], 
and [5]. The heterogeneity for the combined analyses [3, 4, and 6] was assessed 
using the Breslow-Day test (a chi-square test with one degree of freedom). The 
analysis was performed using R 2.9.2. 
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5.3 Results  
The searching and identification process of trials was summarised in Figure 
3-1(Page 74). Altogether, 63 studies were excluded from the total of 90 included 
RCTs from the main systematic review primarily because they do not consist of an 
ARB treatment arm. In total, 32 RCTs enrolling 160,063 participants with an 
average follow-up of 3.3 years (range 1 to 5 years) were included in the overall 
ARB cancer-risk meta-analysis. The average patients’ age across all studies is 61.5 
years old.  
The characteristics and risk of bias of the 32 studies included in this review have 
been described previously (See Chapter 3, Section 3.2.2.1 and Section 3.3.6). All 
the included studies were published in the 21st century with the most recent study 
was published in 2016. Four trials (ONTARGET, PRoFESS, VALIANT, and VALUE) 
have enrolled more than 10,000 total participants consequently contributed the 
largest number of patients in this review. More than half of the total participants 
(65.2%) have underlying CVD such as AF, CHD, and HF. Meanwhile, the TROPHY 
study enrolled participants with BP within the high-normal range (SBP between 
130-139 mmHg and DBP between 85-89 mmHg) who were never treated for 
hypertension.  
Overall, over half (54.1%) of the total participants were assigned treatment with 
ARB and telmisartan was the most prescribed (34.8%) among another type of ARB. 
Whilst the majority of the study has used one type of ARB, Suzuki et al. (2008) 
have used candesartan, losartan and valsartan in its ARB treatment arm versus no 
ARB. Most of the included trials compared ARB to active controls including ACEI, 
BB, CCB, TZ, and conventional antihypertensive therapy. The CHARM-Added trial 
investigated the use of ARB versus placebo in HF patients already receiving an 
ACEI, hence was regarded as a trial of ARB versus ACEI. Two studies (ONTARGET 
and VALIANT) randomised patients to ACEI, ARB and ARB plus ACEI combination. 
In these studies, both the ARB monotherapy arm and combination arm were 
considered as the ARB treatment arm. Henceforth, these trials were regarded as 
ARB versus ACEI monotherapy. 
In this review, CHARM Overall comprised three separate studies, CHARM-Added, 
CHARM-Alternative, and CHARM-Preserved. Similarly, cancer outcomes for 
Chapter 5 ARB and risk of cancer 182 
 
DIRECT-Prevent 1, DIRECT-Protect 1, and DIRECT-Protect 2 were collectively 
reported as DIRECT Overall. 
All the included studies are randomised trials. Majority of the studies have 
implemented blinding to both trial personnel and patients in a parallel design. It 
is noteworthy that all the included Japanese trials have instigated either the 
PROBE design (CASE-J Ex, HIJ-CREATE, NHS, and OCTOPUS) or open label design 
(E-COST, Suzuki). Two trials applied a double-blind, two-by-two factorial design. 
In the NAVIGATOR study, patients with IGT and established CVD were randomised 
to valsartan or matching placebo and nateglinide or matching placebo in addition 
to lifestyle modification. Meanwhile, PRoFESS randomised stroke patients to 
telmisartan or placebo and aspirin-dipyridamole combination or clopidogrel. All 
the study participants were followed for at least one year with the longest follow-
up was five years. The mean age for patients across all studies was over 50 years. 
The selected characteristics of interest extracted from the 32 included studies are 
summarised in Table A-3 (page 321). The reporting of all these variables was 
inconsistent across all studies. Almost all of the included studies enrolled at least 
50% or more male participants except for the SCOPE study with more than 60% of 
participants were made up of women. The reporting of current smokers is 
inconsistent across studies, yet none of the percentage reported was remarkable. 
Only six of the included studies (CHARM Overall, GISSI-AF, OCTOPUS, and 
TRANSCEND) have allowed participation of patients with baseline cancer whereas 
three studies (CASE-J Ex, HIJ-CREATE, and IRMA-2) reported exclusion of such 
patients. Most of the trials did not pre-specified cancer as an outcome. Eight 
studies have cancer outcomes adjudicated centrally whereas the remaining 
studies lacked such information. The loss to follow-up ranged between nil to 9.7% 
which was tolerable. 
5.4 ARB and risk of incident cancer 
 Overall 
For risk of incident cancer, 25 RCTs comparing ARB against active control or 
placebo were available. Data on cancer incidence were available from 148, 275 
(97.4%) of the 152,172 patients who were enrolled in the 25 studies.  
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Figure 5-1 shows the meta-analysis of ACEI and risk of cancer incidence in a fixed-
effect (FE) model.  Altogether, cancer incidence was 5.78% in patients assigned 
to the ARB group versus 5.87% assigned to non-ARB treatment. This result was 
mainly influenced by the ONTARGET, VALUE and the NAVIGATOR study which 
carries 19%, 18.4%, and 11% of the overall weight correspondingly. The distribution 
of weight among the remaining 22 studies was less than 10% each.  
More than 50% of the studies reported an OR more than 1 but their 95% CI includes 
1. One study, DIRECT (Overall), generated an OR of 1.69 with 95% CI between 1.06 
and 2.71 indicating 69% increased risk in the ARB treatment group. Meanwhile, 
two studies generated an OR less than 1 with 95% CI not crossing 1. The OCTOPUS 
and VALUE study yields an OR of 0.39 (95%CI 0.16, 0.96) and 0.84 (95% CI 0.75, 
0.93) respectively. Apart from these four studies, CIs for all the studies crossed 
the line of no effect indicating a lack of statistical significance at the study level. 
Overall, the combined OR of all 25 studies yields an OR of OR 0.99 with 95% CI 
0.95 – 1.04 (P = 0.79). The diamond that represents the pooled effect estimates is 
narrow and it impinges the line of no effect indicating the absence of statistical 
significance at the meta-analysis level.   
In the random effects (RE) model (Figure 5-2), the weight assigned to both 
ONTARGET and VALUE study slightly reduced by approximately 6% each. The 
combined effect estimates yields an OR of 1.00 (95% CI 0.94-1.06; P = 0.96).   
Assessment of heterogeneity in both FE and RE model showed a chi-square P-value 
of 0.09 and I2 statistics of 28% indicating minimal differences between studies. 
The observed statistical heterogeneity is most likely due to clinical and 
methodological diversity of the OCTOPUS (PROBE design), ONTARGET (a three 
parallel arm study with a combination comparator arm), and VALUE (patients with 
high CVD risk). 
Visual inspection of the funnel plot (Appendix Figure A-1) shows a missing study in 
the middle and left side of the plot. No outlier was detected.
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Figure 5-1: Forest plot of incident cancers by ARB vs non-ARB controls [FE model]. 
Odds ratios and 95% confidence interval, overall and in 25 trials. The overall effect represents the 
pooled estimate of odds for incident cancers. * Included were patients with no history of cancer or 
active cancer at baseline.  
 
 
Figure 5-2: Forest plot of incident cancers by ARB vs. non-ARB controls [RE model]. 
Odds ratios and 95% confidence interval, overall and in 25 trials. The overall effect represents the 
pooled estimate of odds for incident cancers.* Included were patients with no history of cancer or 
active cancer at baseline.
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 Sensitivity analyses 
Exclusion of two trials (NAVIGATOR and PRoFESS) with factorial design yields an 
OR of 0.99 (95% CI 0.94-1.04; Figure 5-3) and P-value of 0.68. Similar to the 
primary meta-analysis, this result is mainly influenced by the ONTARGET and 
VALUE trial. Chi-square test for heterogeneity yields a P-value of 0.07 and I2 
statistics is observed at 33% indicating a moderate variation across studies is due 
to heterogeneity rather than chance.  
Figure 5-4 shows a meta-analysis after exclusion of six trials with small sample 
size. The ONTARGET, VALUE, and NAVIGATOR studies have greatly influenced the 
direction of this analysis as they carry the most weight overall (19.2%, 18.5%, and 
11.1% respectively). Combined effect estimates show an OR of 1.00 with 95% CI 
ranged from 0.95 to 1.04. Assessment of heterogeneity showed a chi-square test 
P-value of 0.06 and I2 statistics of 36% indicating the presence of moderate 
differences between studies. The moderate heterogeneity observed is most likely 
due to clinical and methodological diversity of the ONTARGET (a three parallel 
arm study with a combination comparator arm) and VALUE study (patients with 
high CVD risk). 
Meanwhile, exclusion of nine trials considered as low methodological quality as 
shown in Figure 5-5 yields an OR of 1.00 (95% CI 0.95-1.05). This result was mainly 
driven by the ONTARGET and VALUE study as they were assigned the highest 
weight proportion (20.3% and 19.5% respectively). Chi-square test for 
heterogeneity yields a P-value of 0.02 and I2 statistics is observed at 46% indicating 
a substantial presence of heterogeneity. The heterogeneity observed is probably 
due to clinical and methodological diversity of the ACTIVE (patients with AF) and 
VALUE (patients with high CVD risk) study.  
Furthermore, incorporation of patients with baseline cancer data in three trials 
(GISSI-AF, TRANSCEND and ONTARGET) resulted in OR 1.00 (95% CI 0.96-1.04; 
Figure 5-6). Similar to the primary analysis, the direction of this analysis was 
mainly driven by the ONTARGET and VALUE study. Assessment of heterogeneity 
showed a chi-square test P-value of 0.08 and I2 statistics of 30% indicating the 
presence of moderate differences between studies. The moderate heterogeneity 
observed is most likely due to clinical and methodological diversity of the 
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ONTARGET (a three parallel arm study with a combination comparator arm) and 
VALUE (patients with high CVD risk) study. 
 
Figure 5-3: Forest plot of incident cancers by ARB vs controls [Sensitivity analysis: 
Exclusion of trials with factorial design.] 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
 
Figure 5-4: Forest plot of incident cancers by ARB vs controls [Sensitivity analysis: Study 
size]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 5-5: Forest plot of incident cancers by ARB vs controls [Sensitivity analysis: 
Methodological quality]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
 
Figure 5-6: Forest plot of incident cancers by ARB vs controls [Sensitivity analysis: 
Inclusion of patients with baseline cancer]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline.
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 Subgroup analyses 
Table 5-2 summarises the results for subgroup analyses performed for ARB and 
cancer risk. 
5.4.3.1 By subclasses 
Figure 5-7 depicts the meta-analysis of ARB by subclasses. Three RCTs enrolling 
49,690 participants have used telmisartan as one of the study treatment. Cancer 
incidence was 6.33% in the telmisartan group versus 5.32 % in the control group 
with OR 1.07 (95% CI 0.99, 1.16). This analysis was mainly influenced by the 
ONTARGET which was assigned 60.6% of the overall weight. The chi-square test 
resulted in a P-value of 0.17 and the I2 statistics of 44%. The moderate 
heterogeneity observed is likely due to clinical and methodological diversity 
between the included trials. 
For irbesartan, data were available from four RCTs with a total of 14,890 patients. 
Cancer incidence was 6.56% in the irbesartan treatment group versus 7.34% in the 
control group. The direction of this study was greatly driven by the ACTIVE I study 
which carries over 60% of the overall weight. The combined effect estimates 
resulted in OR 0.91 (95% CI 0.80, 1.03). Assessment of heterogeneity showed a chi-
square P-value of 0.90 and I2 statistics is observed at 0% indicating no statistical 
difference between studies.  
Six RCTs enrolling 46,268 participants have used valsartan as one of the study 
treatment. Cancer incidence was 5.76% in the valsartan group versus 7.29% in the 
control group with OR 0.92 (95% CI 0.85, 0.99). This analysis was mainly influenced 
by the VALUE trial which was assigned 50.8% of the overall weight. The chi-square 
test resulted in a P-value of 0.22 and the I2 statistics of 29%. The small 
heterogeneity observed is likely due to methodological diversity of the NAVIGATOR 
study (factorial design). 
Seven RCTs enrolling 25,172 participants used candesartan as one of the study 
treatment. Cancer incidence was 4.08% in the candesartan group versus 3.78% in 
the control group with OR 1.08 (95% CI 0.95, 1.23). This analysis was mainly 
influenced by the CHARM (Overall) and SCOPE which was assigned 39.3% and 37.3% 
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of the overall weight correspondingly. The chi-square test resulted in a P-value of 
0.59 and the I2 statistics of 0% indicating no statistical difference between studies.  
Three RCTs enrolling 11,361 participants used losartan as one of the study 
treatment. Cancer incidence was 6.15% in the losartan group versus 5.63% in the 
control group with OR 1.09 (95% CI 0.93, 1.28). This analysis was mainly driven by 
the LIFE study which was assigned 98.7% of the overall weight. The chi-square test 
resulted in a P-value of 0.84 and the I2 statistics of 0% indicating no statistical 
difference between studies.  
Lastly, two RCTs enrolling 894 participants used olmesartan as one of the study 
treatment. Cancer incidence was 1.78% in the olmesartan group versus 3.82% in 
the control group with OR 0.47 (95% CI 0.20, 1.08). This analysis was mainly 
governed by the OCTOPUS study which was assigned 97.1% of the overall weight. 
The chi-square test resulted in a P-value of 0.23 and the I2 statistics of 30% 
indicating a moderate difference between studies.  
5.4.3.2 By type of comparator 
Figure 5-8 shows the meta-analysis of ARB by the different type of comparators. 
Altogether, 11 RCTs compared ARB to active controls with data available from 
77,873 patients. Cancer incidence was 5.96% in the ARB treatment group versus 
6.34% in the active control group. Pooling of effect estimates from the 11 studies 
yields an OR of 0.97 (95% CI 0.91, 1.03). The ONTARGET and VALUE study has the 
biggest influence in this analysis as they carry 34.9% and 33.7% of the overall 
weight correspondingly. The chi-square test resulted in a P-value of 0.03 and the 
I2 statistics of 46% indicating remarkable heterogeneity between studies. The 
heterogeneity observed is likely due to methodological and clinical diversity of 
the ONTARGET and VALUE study. 
Five RCTs compared ARB to ACEI and data were available from 42,403 patients. 
Cancer incidence was 5.23% in the ARB treatment group versus 5.26% in the ACEI 
treatment group. Combined effect estimates resulted in OR 1.06 (95% CI 0.97, 
1.16). This result was mainly influenced by the ONTARGET study as it carries the 
most weight overall of 57%. Assessment of heterogeneity showed a chi-square P-
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value of 0.96 and I2 statistics is observed at 0% indicating no statistical difference 
between studies. 
For comparison with ACEI and ARB combination, two RCTs were included with data 
available from 25,712 patients. Cancer incidence was 5.56% in the ARB treatment 
group versus 5.64% in the combination treatment group with OR 0.98 (95% CI 0.88, 
1.10). The ONTARGET study was assigned the heaviest weight of 91.6% overall and 
eventually had a major influence in the direction of the combined OR. The chi-
square test resulted in a P-value of 0.008 and the I2 statistics of 86% suggesting 
evidence of statistically significant difference between studies. The observed 
heterogeneity observed is most likely due to the clinical diversity between the 
ONTARGET (CVD or T2DM patients with target organ damage) and VALIANT (heart 
failure patients post MI) study. 
Three RCTs used CCB as one of their randomised treatment with data available 
from 21,051 patients. Cancer incidence was 6.61% in the ARB treatment group 
versus 7.74% in the CCB treatment group with OR 0.84 (95% CI 0.75, 0.93). This 
analysis was greatly influenced by the VALUE study which carries 96% of the overall 
weight. All the included RCTs have an OR less than 1 with 95% CI crossing 1 except 
the VALUE study. Assessment of heterogeneity showed a chi-square P-value of 0.89 
and I2 statistics is observed at 0% indicating no statistical difference between 
studies. 
For placebo, data were available from 65,958 patients enrolled in 14 RCTs. Cancer 
incidence was 5.56% in the ARB treatment group versus 5.48% in the placebo group 
with OR 1.02 (95% CI 0.96, 1.09). The direction of the combined effect estimate 
was greatly driven by the NAVIGATOR and ACTIVE I study which was assigned 25.5% 
and 20.4% respectively. Assessment of heterogeneity showed a chi-square P-value 
of 0.43 and I2 statistics is observed at 1%. The observed small heterogeneity is 
most probably due to the clinical diversity of the ACTIVE I (patients with AF) and 
TRANSCEND (patients with CVD or T2DM) study.  
5.4.3.3 By population clinical settings 
Figure 5-9 shows the meta-analysis of ARB by study population main clinical 
settings. Data for patients with underlying hypertension as the main clinical 
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setting were available from 40,494 enrolled in eleven RCTs. Cancer incidence was 
6.52% in the ARB treatment group versus 7.06% in the control group. Combined 
effect estimates resulted in OR 0.92 (95% CI 0.86, 1.00). Majority of the studies’ 
OR lies on the left side of the plot favouring ARB. The overall result was mainly 
influenced by the VALUE study which was assigned over 50% of the overall weight. 
Assessment of heterogeneity showed a chi-square P-value of 0.17 and I2 statistics 
is observed at 29% indicating a moderate difference between studies. The 
heterogeneity observed is likely due to the clinical diversity of the VALUE (patients 
with high CVD risk) study. 
Data for patients who were at high risk for CVD or with established CVD were 
available from 11 RCTs enrolling 111,375 patients. Cancer incidence was 5.88% in 
the ARB treatment group versus 6.05% in the control group. Combined effect 
estimates resulted in OR 0.99 (95% CI 0.94, 1.04). This analysis was mainly driven 
by the ONTARGET and VALUE study with an assigned weight of 24.9% and 24.1% 
respectively. The chi-square test resulted in a P-value of 0.04 and the I2 statistics 
of 47% suggesting evidence of a substantial difference between studies. The 
observed heterogeneity observed is most likely due to methodological and clinical 
diversity of the ONTARGET (a three parallel arm study with a combination 
comparator arm) and VALUE (patients with high CVD risk) study. 
Meanwhile, data for patients with AF were available from three RCTs with a total 
of 10,838 patients. Cancer incidence was 6.31% in the ARB treatment group versus 
6.90% in the control group. Combined effect estimates resulted in OR 0.91 (95% CI 
0.78, 1.06). This analysis was mainly driven by the ACTIVE I study which carries 
98.4% of the overall weight. Heterogeneity assessment showed a chi-square P-
value of 0.69 and the I2 statistics of 0% indicating no statistical difference was 
present between these studies. 
For patients with underlying T2DM, data were available from 4,411 patients 
enrolled in four RCTs. Cancer incidence was 2.43% in the ARB treatment group 
versus 2.80% in the control group with OR 0.90 (95% CI 0.62, 1.31). This analysis 
was mainly driven by the IDNT and NHS study as they carry the most weight overall 
(52% and 38.3% respectively). The chi-square test resulted in a P-value of 0.85 and 
the I2 statistics of 0% signifying no statistical heterogeneity between studies. 
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Lastly, data for patients with underlying nephropathy or CKD were available from 
3,122 patients enrolled in three RCTs. Cancer incidence was 2.30% in the ARB 
treatment group versus 3.27% in the control treatment group with OR 0.68 (95% CI 
0.44, 1.06). The IDNT study has a major influence in this analysis with an assigned 
weight of 60.6%. The chi-square test resulted in a P-value of 0.29 and the I2 
statistics of 20% signifying minimal statistical heterogeneity between studies. The 
observed heterogeneity observed is most likely due to the methodological 
diversity of the OCTOPUS trial (a PROBE trial).   
5.4.3.4 By mean age groups  
Figure 5-10 shows the meta-analysis of ARB by study population mean age groups. 
For patients age 65 or older, data were available from 10 RCTs enrolling a total of 
98,248 participants. Cancer incidence was 6.83% in the ARB treatment group 
versus 6.72% in the control group with OR 0.99 (95% CI 0.94-1.04). This analysis 
was mainly influenced by the ONTARGET and VALUE trial. The chi-square test 
resulted in a P-value of 0.01 and the I2 statistics of 56% indicating a statistically 
significant difference was present between studies. The observed heterogeneity 
observed is most likely due to clinical diversity of the ONTARGET (a three parallel 
arm study with a combination comparator arm), VALUE (a CCB was used as a 
comparator) and TRANSCEND (patients with CVD or T2DM) trial.  
Meanwhile, data for patients younger than 65 years were available from the 16 
trials with 50,027 participants. Cancer incidence was 3.76% in the ARB treatment 
group versus 4.16% in the control group with OR 1.02 (95% CI 0.93-1.12). This 
analysis was mainly driven by the NAVIGATOR study which carries 47.8% of the 
overall weight. Heterogeneity assessment showed a chi-square P-value of 0.41 and 
the I2 statistics of 4% indicating a minimal difference between studies. The 
observed heterogeneity observed is most likely due to clinical and methodological 
diversity of the CHARM Added (patients with background ACEI therapy) and 
OCTOPUS (homogenous patients with ESRD) trial. 
5.4.3.5 By duration of follow-up    
Figure 5-11 shows the meta-analysis of ARB by the mean duration of study follow-
up. Ten RCTs were followed for three years or less with a total of 45,897 
participants. Cancer incidence was 2.71% in the ARB treatment group versus 3.16% 
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in the control group with OR 0.95 (95% CI 0.85, 1.06). This analysis was mainly 
driven by the PRoFESS study which carries 50.4% of the overall weight. 
Heterogeneity assessment showed a chi-square P-value of 0.99 and the I2 statistics 
of 0% indicating no statistical heterogeneity between studies.  
The remaining 15 RCTs were followed-up for at least three years and data were 
available for 97,154 patients. Cancer incidence was 7.46% for ARB versus 7.40% 
for controls (OR 1.00, 95% CI 0.95-1.05). This analysis was mainly driven by the 
ONTARGET and VALUE study which carries 23% and 22.3% of the overall weight 
respectively. Heterogeneity assessment showed a chi-square P-value of 0.03 and 
the I2 statistics of 45% indicating a statistically significant difference among 
studies. The observed heterogeneity observed is most likely due to clinical and 
methodological diversity of the VALUE (patients with high CVD risk) trial. 
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 Table 5-2: Angiotensin receptor blockers and risk of cancer: Subgroup analyses 
 No. of study 
No. of 
participants 
Cancer incidence (%) OR (95% CI) P-value I2 (%) ARB Control 
Overall 
effect FE model 25 148275 5.78 5.87 0.99(0.95, 1.04) 0.96 28 
Subclass 
Telmisartan 3 49690 6.33 5.32 1.07 (0.99, 1.16) 0.10 44 
Irbesartan 4 14890 6.56 7.34 0.91 (0.80, 1.03) 0.13 0 
Valsartan 6 46268 5.76 7.29 0.92 (0.85, 0.99) 0.02 29 
Candesartan 7 25172 4.08 3.78 1.08 (0.95, 1.23) 0.22 0 
Losartan 3 11361 6.15 5.63 1.09 (0.93, 1.28) 0.26 0 
Olmesartan 2 894 1.78 3.82 0.47 (0.20, 1.08) 0.07 30 
Type of 
comparator 
Active controls 11 77873 5.96 6.34 0.97 (0.91, 1.03) 0.26 49 
ACEI 5 42403 5.23 5.26 1.06 (0.97, 1.16) 0.19 0 
ARB+ACEI 2 25712 5.56 5.64 0.98 (0.88, 1.10) 0.76 86 
CCB 3 21051 6.61 7.74 0.84 (0.75, 0.93) 0.001 0 
Placebo 14 65958 5.56 5.48 1.02 (0.96, 1.09) 0.52 1 
Clinical 
setting 
Hypertension 11 40494 6.52 7.06 0.92 (0.86, 1.00) 0.05 29 
High risk CVD 11 111375 5.88 6.05 0.99 (0.94, 1.04) 0.62 47 
AF 3 10838 6.31 6.90 0.91 (0.78, 1.06) 0.22 0 
T2DM 4 4411 2.43 2.80 0.90 (0.62, 1.31) 0.57 0 
Nephropathy or 
CKD 3 
3122 2.30 3.27 0.68 (0.44, 1.06) 0.09 20 
Mean age 
≥ 65 years 10 98248 6.83 6.72 0.99 (0.94, 1.04) 0.56 56 
< 65 years 16 50027 3.76 4.16 1.02 (0.93, 1.12) 0.62 4 
Duration of 
follow-up 
< 3 year 10 45897 2.71 3.16 0.95 (0.85, 1.06) 0.32 0 
≥ 3 years 15 97154 7.46 7.40 1.00 (0.95, 1.05) 0.93 45 
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Figure 5-7: Forest plot of cancer incident by ARB subclasses [FE model]. 
1) Telmisartan; 2) Irbesartan; 3) Valsartan; 4) Candesartan; 5) Losartan; and 6) Olmesartan in 25 
trials. The subtotal effect represents the pooled estimate of odds for incident cancers for each 
subclass. ** Included were patients with no history of cancer or active cancer at baseline.
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Figure 5-8: Forest plot of incident cancers by comparators [FE model]. 
1) Active controls; 2) ACEI; 3) ARB and ACEI combination; 4) CCB and 5) Placebo. The subtotal 
effect represents the pooled estimate of odds for incident cancers for each comparator. * Included 
were patients with no history of cancer or active cancer at baseline.
Chapter 5 ARB and risk of cancer 197 
 
 
Figure 5-9: Forest plot of incident cancers population clinical setting [FE model]. 
1) Hypertension; 2) High risk or established CVD ; 3) Atrial fibrillation;  4) Type 2 diabetes mellitus; 
and 5) Nephropathy or CKD. The subtotal effect represents the pooled estimate of odds for incident 
cancers for each healthcare setting. * Included were patients with no history of cancer or active 
cancer at baseline. 
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Figure 5-10: Forest plot of incident cancers by mean age [FE model]. 
1) ≥ 65 years; 2) < 65 years. The subtotal effect represents the pooled estimate of odds for incident 
cancers for each criterion. * Included were patients with no history of cancer or active cancer at 
baseline. 
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Figure 5-11 Forest plot of cancer incidence by study mean duration of follow-up [FE model]. 
1) Follow-up < 3 years; 2) Follow-up ≥ 3 years; 3) Follow-up ≥ 5 years. The subtotal effect 
represents the pooled estimate of odds for cancer incidence for each criterion. * Included were 
patients with no history of cancer or active cancer at baseline * 
 
5.5 ARB and risk of cancer-related death 
Overall, 25 RCTs were included for comparison between ARB and other 
antihypertensive drug class for risk of cancer-related death. In total, data from 
151,855 (98.23%) patients out of 154,588 patients were available for the analysis 
of ARB and risk of cancer mortality.  
Figure 5-12 shows the meta-analysis of ARB and cancer-related mortality in an FE 
model. According to the assigned treatment arm, cancer-related death was 1.79% 
in the ARB group versus 1.71% in the non-ARB group. This analysis was mainly 
influenced by the ONTARGET and VALUE study as they carry the most weight 
overall (19.4% and 13.1% respectively). The remaining studies were assigned less 
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than 10% of the overall weight individually. Distribution of studies with OR more 
or less than 1 is fairly equal. One study, CHARM (Overall), yields an OR 1.47 with 
95% CI ranged from1.05 to 2.05. Otherwise, the 95% CI for the rest of the studies 
includes 1 indicating a lack of statistical significance at the study level. 
Combination of the studies effect estimates yields an OR of 1.02 with 95% CI 0.94-
1.10 (P = 0.59). From the forest plot, the summary effect is represented by a 
narrow diamond that overlaps the line of no effect suggesting a lack of statistical 
significance at the meta-analysis level. 
Figure 5-13 shows the meta-analysis of ARB and cancer-related mortality in a RE 
model. In this analysis, the ONTARGET study was assigned an additional 0.5% 
(19.9%) whereas the weight assigned to the VALUE study was reduced by 0.2% 
(12.9%). Nevertheless, these two studies remain the biggest influence in the 
direction of this meta-analysis. The combined OR in this statistical model is 
comparable to the FE model analysis with OR 1.02 (95% CI 0.94-1.10).     
Assessment of heterogeneity in both FE and RE model showed a chi-square test P-
value of 0.94 and I2 statistics of 0%. These values indicate no evidence of 
statistically significant heterogeneity between studies.  
Figure A-2 (Appendix Page 324) shows the distribution of the 25 studies in a funnel 
plot. The dispersion of studies appears fairly symmetrical on both sides of the plot 
with no outlier observed. 
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Figure 5-12: Forest plot of cancer-related deaths by ARB vs non-ARB controls [FE model]. 
Odds ratios and 95% confidence interval, overall and in 25 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death. * Included were patients with no history of cancer 
or active cancer at baseline 
 
 
Figure 5-13: Forest plot of cancer-related deaths by ARB vs non-ARB controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 25 trials The overall effect represents the 
pooled estimate of odds for cancer-related death. * Included were patients with no history of cancer 
or active cancer at baseline 
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5.6 Valsartan and risk of cancer 
Figure 5-14 shows the meta-analysis of valsartan trials and risk of cancer. 
Altogether, six valsartan trials enrolling 41,947 participants with an average 
follow-up of 2.9 years (range 1-4.2) were included in the overall cancer risk meta-
analysis. In this analysis, only the ARB monotherapy versus ACEI monotherapy arm 
in the VALIANT study was considered. Cancer incidence was 6.23% in the valsartan 
treatment group versus 6.66% in the control group.  Three of the studies have OR 
less than 1 ranging from 0.85 to 0.95 whereas two studies have an OR more than 
1. With the exception of the VALUE trial, the 95% CI for all the studies includes 1. 
The direction of this analysis was mainly driven by the VALUE study as it was 
assigned 51.2% of the overall weight. Pooling of OR from all the studies yields an 
OR of 0.93 (95% CI 0.86-1.00) and a P-value of 0.07. Heterogeneity assessment 
showed a chi-square P-value of 0.23 and the I2 statistics of 28% indicating a 
minimal difference between studies. The observed heterogeneity observed is most 
likely due to the methodological diversity of the NAVIGATOR trial (the only study 
implementing factorial design in this meta-analysis). See Section 5.4.3.1, Figure 
5-7 for analysis incorporating the ARB and ACEI combination arm into the ARB 
monotherapy arm in the VALIANT study. 
 
Figure 5-14: Forest plot of incident cancers by valsartan versus non-ARB controls [FE 
model]. 
Odds ratios and 95% confidence interval, overall and in six trials. The overall effect represents the 
pooled estimate of odds for incident cancers. 
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5.7 Valsartan and risk of specific cancer  
The four RCTS with individual-patient data analysed included 44,544 patients of 
which 17,328 were assigned to valsartan monotherapy and 7,369 to combined 
valsartan and ACEI therapy.  
 Lung cancer 
Figure 5-15 shows the meta-analysis of valsartan trials and lung cancer risk. Lung 
cancer cases were 0.61% in the valsartan group versus 0.95% in the control group. 
This analysis was mainly influenced by the VALUE and NAVIGATOR study as they 
carried 45.5% and 29.9% of the overall weight respectively. Three of the studies 
lie on the left side of the forest plot favouring valsartan. The 95% CI for two of 
the studies (VALIANT and VALUE) did not cross the line of no effect suggesting 
statistical significance at the study level. Combined effect estimates yield an OR 
of 0.73 (95% CI 0.59-0.90) with P-value of 0.004. The marginally wide diamond 
representing summary effect lies on the right side of the forest plot indicating 
significance at the meta-analysis level. Heterogeneity assessment showed a chi-
square P-value of 0.17 and the I2 statistics of 41% indicating a moderate difference 
between studies. The observed heterogeneity observed is most likely due to the 
clinical diversity of the Val-HeFT trial (over 90% of participants in both treatment 
and control arm received ACEI therapy). 
 Breast cancer 
Data were available from 16,928 female participants across all four RCTs. Figure 
5-16 shows the meta-analysis of valsartan trials and breast cancer risk. Breast 
cancer cases were 1.33% in the valsartan group versus 1.52% in the control group. 
This analysis was mainly influenced by the VALUE and NAVIGATOR study as they 
carried 51.7% and 37.2% of the overall weight respectively. The 95% CI for all of 
the studies crosses the line of no effect suggesting a lack of statistical significance 
at the study level. Combined effect estimates yield an OR of 1.02 (95% CI 0.79-
1.32). The marginally wide diamond representing summary effect lies on the line 
of no effect indicating lack of significance at the meta-analysis level. 
Heterogeneity assessment showed a chi-square P-value of 0.56 and the I2 statistics 
of 0% suggesting no statistical difference between studies.  
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 Prostate cancer 
Data were available from 27,577 male participants across all four RCTs. Figure 
5-17 shows the meta-analysis of valsartan trials and prostate cancer risk. Prostate 
cancer cases were 1.64% in the valsartan group versus 2.04% in the control group. 
This analysis was mainly influenced by the VALUE and NAVIGATOR study as they 
carried 54.5% and 29.8% of the overall weight respectively. The 95% CI for all of 
the studies crosses the line of no effect suggesting a lack of statistical significance 
at the study level. Combined effect estimates yield an OR of 0.99 (95% CI 0.83-
1.18). The narrow diamond representing summary OR lies marginally on the left 
of the line of no effect indicating lack of significance at the meta-analysis level. 
Heterogeneity assessment showed a chi-square P-value of 0.18 and the I2 statistics 
of 39% suggesting a moderate difference between studies. The observed 
heterogeneity observed is most likely due to the clinical diversity of the Val-HeFT 
trial (over 90% of participants in both treatment and control arm received ACEI 
therapy. 
 
 
Figure 5-15: Forest plot of lung cancer incidence by valsartan vs. controls, overall and in 
four trials [FE model]. 
The overall effect represents the pooled estimate of odds for lung cancer incidence. 
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Figure 5-16 Forest plot of breast cancer incidence by valsartan vs. controls, overall and in 
four valsartan trials [FE model] 
The overall effect represents the pooled estimate of odds for breast cancer incidence. 
 
 
Figure 5-17 Forest plot of prostate cancer incidence by valsartan vs. controls, overall and in 
four valsartan trials [FE model]. 
The overall effect represents the pooled estimate of odds for prostate cancer incidence.  
 
 Valsartan trials and treatment comparison 
The results of the comparisons described in the Methods Section 5.2.2 are 
summarised in Table 5-3 (single trial comparison) and Table 5-4 (combined trial 
comparisons). 
Table 5-3 shows treatment comparisons in individual valsartan trials for risk of 
any or certain type of common cancers including lung, breast, and prostate 
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cancer. For risk of any cancer, two trials have shown an OR of less than 1 with 95% 
CI excluding 1. The VALUE study compared valsartan to CCB and the measure of 
association has shown an OR of 0.85 (95% CI 0.76, 0.95). Meanwhile, the VALIANT 
study compared combined valsartan and ACEI therapy (“more intense) to ACEI 
monotherapy or either RAS blocker as monotherapy (“less intense”). The measure 
of association showed an OR of 0.68 (95% CI 0.49, 0.94) and OR of 0.66 (95% CI 
0.49, 0.89) for the former and latter respectively. Likewise for lung cancer, the 
VALUE and VALIANT study have demonstrated statistical significance at study level 
with OR 0.70 (95%CI 0.51, 0.97) and OR 0.19 (95% CI 0.07, 0.56) respectively. The 
VALIANT study also showed an OR of less than 1 for “more intense” versus “less 
intense” therapy (OR 0.22, 95% CI 0.08, 0.61) for risk of lung cancer. Although 
most of the trials have shown a small OR for risk of any or certain type of cancers, 
they have a wide 955 CI spanning the null value of 1. 
Table 5-4 showed an analysis of cancer in combined trials with a common 
comparator. A noteworthy association has been observed with the risk of any or 
lung cancer in certain trial combination. For non-RAS blocker comparator, 
combined estimates from the NAVIGATOR and VALUE trial showed a notable result 
for risk of lung cancer with OR 0.71 (95% CI 0.55, 0.91). Risk of any cancer was 
not reported due to evidence of heterogeneity. For comparison between ARB plus 
ACEI combination and ACEI monotherapy, the combined estimate from the Val-
HeFT and VALIANT study showed an OR 0.79 (95% CI 0.65, 0.96) for risk of any 
cancer. The risk of lung cancer was not reported due to evidence of heterogeneity. 
Similarly, for “more intense” versus ”less intense” comparison, the combined 
estimate from the Val-HeFT and VALIANT  showed analogous association with an 
OR of 0.77 (95% CI 0.64, 0.93) for risk of any cancer. In addition, comparison with 
non-RAS blockers for risk of lung cancer was in favour of valsartan with OR 0.71 
(0.56, 0.90). The common estimates for risk of breast and prostate cancer showed 
mixed direction with fairly wide 95% CI across all combined analyses.   
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Table 5-3: Number of cancers (any, lung, breast, prostate) in major valsartan trials. 
 Odds ratios (95% confidence intervals) for treatment comparisons 
Comparison (for numbering, see 
methods) 
Any cancer Lung cancer Breast cancer Prostate cancer
 A B A B A B A B
1.Valsartan (A) vs. placebo (B) 
NAVIGATOR 
 
447 428 42 59 55 45 92 75
 1.06 (0.92, 1.22) 0.72 (0.48, 1.07) 1.27 (0.85, 1.89) 1.22 (0.89, 1.67)
2. Valsartan (A) vs. CCB (B) 
VALUE 
 
626 722 63 89 54 61 129 136
 0.85 (0.76, 0.95) 0.70 (0.51, 0.97) 0.88 (0.61, 1.27) 0.94 (0.73, 1.20)
4. Valsartan + ACEI (A) vs. ACEi (B)  
Val-HeFT 
 
120 137 25 20 7 9 14 25 
 0.87 (0.67, 1.11)
 
1.25 (0.69, 2.25) 0.77 (0.28, 2.08) 0.55 (0.29, 1.07)
VALIANT 61 90 4 21 1 3 8 10
 0.68 (0.49, 0.94) 0.19 (0.07, 0.56) 0.34 (0.04, 3.30) 0.79 (0.31, 2.02)
 
5. Valsartan (A) vs ACEi (B) 
VALIANT 
 
94 90 16 21 5 3 12 10
1.05 (0.78, 1.40) 0.76 (0.40, 1.46) 1.66 (0.40, 6.96) 1.20 (0.52, 2.79)
6. Valsartan + ACEI (A) vs ACEI or 
ARB monotherapy(B) 
Val-HeFT 
 
 
120 
 
137 
 
25 
 
20 
 
7 
 
9 
 
14 
 
25 
 1.05 (0.78, 1.40) 0.76 (0.40, 1.46) 1.66 (0.40, 6.96) 0.55 (0.29, 1.07)
  
VALIANT 61 184 4 37 1 8 8 22
 0.66 (0.49, 0.89) 0.22 (0.08, 0.61) 0.26 (0.03, 2.06) 0.72 (0.32, 1.62)
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Table 5-4 Analyses of cancer in the combined trial 
Comparison  
(for numbering, see methods) 
Breslow-Day P value Combined OR  
(95% CI) 
3. Valsartan monotherapy vs non-RAS 
blocker comparator 
 
NAVIGATOR + VALUE 
Any cancer 
Lung cancer 
Breast cancer 
Prostate cancer 
5.97 
0.007 
1.73 
1.71 
0.01 
0.93 
0.19 
0.19 
 
NR 
0.71 (0.55, 0.91) 
1.04 (0.08, 1.36) 
1.04 (0.86, 1.26) 
 
4. Valsartan + ACEi vs ACEi 
 
Val-HeFT + VALIANT 
Any cancer 
Lung cancer 
Breast cancer 
Prostate cancer 
1.36 
10.27 
0.42 
0.58 
0.24 
0.001 
0.52 
0.54 
 
0.79 (0.65, 0.96) 
NR 
0.66 (0.27, 1.62) 
0.62 (0.37, 1.06) 
 
6. Valsartan + ACEi vs ACEi or ARB 
monotherapy 
 
Val-HeFT + VALIANT 
Any cancer 
Lung cancer 
Breast cancer 
Prostate cancer 
1.86 
9.44 
0.92 
0.24 
0.17 
0.002 
0.34 
0.62 
 
0.77 (0.64, 0.93) 
NR 
0.58 (0.24, 1.38) 
0.62 (0.37, 1.03) 
 
7. Valsartan monotherapy vs. any non-ARB 
comparator 
 
NAVIGATOR, VALUE + VALIANT
Any cancer 
Lung cancer 
Breast cancer 
Prostate cancer 
6.57 
0.05 
2.13 
1.82 
0.04 
0.98 
0.34 
0.40 
 
0.94 (0.86, 1.02) 
0.71 (0.56, 0.90) 
1.06 (0.81, 1.38) 
1.05 (0.87, 1.26) 
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5.8 Discussion 
As demonstrated in the current meta-analysis, there is no evidence to suggest that 
the use of ARB as a class increased the risk of either cancer incidence or cancer-
related mortality. Fixed effect and random effects model evaluated relatively 
agree on the risk of cancer incidence with OR 0.99 (95% CI 0.95-1.04) and OR 1.00 
(95% CI 0.94-1.06) correspondingly. The consistencies of summary estimates, 
narrow CI, and minimal heterogeneity between studies observed validates the 
present study hypothesis that ARB does not influence the risk of any cancer 
overall. Furthermore, sensitivity analyses assessing study size, methodological 
quality, and incorporation of patients with baseline cancer all showed a consistent 
association with the primary meta-analysis. Similarly, no significant association 
was observed between ARB use and risk of cancer-related death.   
Evaluation of different ARB subtypes in a subgroup analysis has shown that 
valsartan has a significantly lower risk of cancer incidence (with OR 0.92 (95% CI 
0.85, 0.99; P = 0.02). A comparable association was reported by Teo (2011) in a 
meta-analysis of 15 ARB trials. The author reported a significantly lower risk of 
cancer for patients randomised to valsartan in four RCTs with OR 0.92 (95% CI 
0.85–0.99). Moreover, the assessment of individual patient data meta-analysis 
from the four major valsartan trials showed a significantly lower risk of lung cancer 
in those assigned to valsartan. Several studies have also reported evidence of 
lower lung cancer risk associated with ARB use. A systematic review and meta-
analysis of eight observational studies enrolling 433,1054 participants showed 
decreased lung cancer risk associated with ARB with OR 0.81 (95% CI 0.69-0.54) 
(Zhang et al., 2015). Likewise, a recent study by Shen et al. (2016) has also found 
a similar relationship between RAS blockers including ARB and lung cancer in a 
meta-analysis of six observational studies (OR 0.85, 95% CI 0.75-0.87) and nine 
RCTs (OR 0.88, 95% CI 0.79-0.99). However, the exact risk of lung cancer with ARB  
was not seen in this review. A recent cohort study of over one million participants 
using data from the American Veteran Affairs (VA) register reported a hazard ratio 
(HR) 0.74 (95% CI 0.67-0.83, P< 0.0001) for lung cancer in patients taking ARB 
compared to non-ARB (Rao et al., 2013).  
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Conversely, there are studies that have demonstrated evidence of ARB associated 
with an increased risk of lung cancer. In a meta-analysis of nine RCTs enrolling 
94,570 participants, Sipahi et al. (2010)  reported an excess risk for lung cancer 
in patients randomised to ARB for at least three years with a relative-risk (RR) 
estimate of 1.25 (P-value =0.01). Although statistically significant, the CI was wide 
ranging from 1.05 to 1.49 suggesting high dispersion hence the conclusion is less 
certain. Moreover, most of the patients in the meta-analysis received telmisartan 
as the study drug. Nonetheless, given the limited data, the author also failed to 
assess the risk of cancer associated with specific ARBs.  In another study, the 
Collaborative Transplant Study (CTS) which prospectively collects data on solid 
organ transplants reported increased risk of lung cancer in renal transplant 
recipients particularly in a subpopulation with history of smoking who received 
ACEI and ARB combinations (SIR 7.10, 95% CI 3.27-15.4, P-value<0.001) (Opelz and 
Döhler, 2011). Though, any cancer risk is readily observed in transplant recipients 
compared to the general population due to the immunosuppressive therapy they 
receive to prevent transplant rejection. Furthermore, the CTS observation is only 
applicable to ARB and ACEI combination therapy as they could not draw a 
particular influence of either class of agent. An experimental study demonstrated 
that apoptosis was induced in the alveolar epithelial cell of human lung carcinoma 
cell line and rat model by administration of purified angiotensin II (Papp et al., 
2002). Administration of AT1 selective antagonist blocked angiotensin-induced 
apoptosis. This finding suggests the role of ARB in lung carcinogenesis as an evasion 
of apoptosis is one of the hallmarks of cancer.    
The subgroup analyses also found no difference in the risk of cancer incidence 
between ARB and other antihypertensive drug classes or placebo except CCB. One 
subgroup analysis indicated that ARB has a significant cancer protective effect 
compared to CCB. A comparable observation is also seen in a single trial VALUE 
(Table 5-3). The risk of any or lung cancer was significantly lower in those 
receiving ARB versus CCB. The difference in risk could possibly be explained by 
the different pathways in which these drugs are involved. The pro-tumorigenic 
effects of the RAS pathway are prevented by blockade of the AT1 receptor by ARB 
leading to decreased VEGF and other pro-angiogenic factors expression hence 
impairing angiogenesis and cellular proliferation (Chen et al., 2013). Meanwhile, 
the disruption of cellular apoptosis as a result of decreased or increased 
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intracellular calcium induced by CCB leading to an increased potential for tumour 
growth has been hypothesized (Mason, 1999). Nonetheless, this observation should 
be regarded as hypothesis-generating only and not as a conclusion to a test. As 
ARB and CCB are not primarily prescribed for cancer prevention and the trial 
(VALUE) was not powered for this endpoint, it is difficult to conclude definitively 
that valsartan is protective or amlodipine is harmful due to the study design with 
two parallel arms. Including a placebo control arm would allow the investigators 
to capture the value of non-specific therapeutic or harmful effects that are 
common to all antihypertensive drugs. Therefore, most analyses including trials 
without a placebo comparator presented in this thesis may not be able to describe 
the precise risk of cancer. Both classes of drugs have been recommended as first 
choice therapy for the treatment of hypertension by established clinical 
guidelines. A meta-analysis of nine RCTs evaluating ARB versus CCB in total 25,084 
participants has shown that CCB is superior to ARB in reducing the incidence of 
stroke and MI overall (Wu et al., 2014). Nevertheless, the excellent safety and 
tolerability profile of ARB has improved the adherence to antihypertensive 
therapy and enhanced our ability to manage hypertension in those patients with 
sensitivities to other antihypertensive drug classes, including the ACE inhibitors.   
In a meta-analysis of two RCTs, Bangalore et al. (2011) reported an increased risk 
with ARB and ACEI combination therapy versus control (OR 1.14, 95% CI 1.04-1.24). 
The authors had also conducted a trial sequential analysis which suggested firm 
evidence of at least 10% increase risk for cancer with combined RAS blockers. 
Around the same time, a meta-analysis of seven RCTs found no significant 
association between combined ARB/ACEI therapy versus ACEI monotherapy with 
OR 1.01 (95% CI 0.94-1.10) (Teo, 2011). On the contrary, this review has observed 
a significantly lower risk of any cancer and lung cancer in particular with combined 
RAS blockers (“more intense”) versus monotherapy (“less intense”) (Table 5-4, 
Comparison 4). However, this observation is only limited to valsartan. This finding 
is consistent with experimental evidence that angiotensin II may act as an 
oncogenic agent (George et al., 2010). Though, the use of multiple RAS blockers 
concurrently is no longer recommended in clinical practice (NICE, 2011). Dual ARB 
and ACEI therapy showed no mortality benefit and did demonstrate increased non-
fatal adverse events. The ONTARGET study has shown that despite reducing 
progression of proteinuria, combined RAS blockers increased composite primary 
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renal outcome including dialysis, doubling of creatinine, and death (HR 1.09, 95% 
CI 1.09-1.84) (Mann et al., 2008). Whereas in the Aliskiren Trial in Type 2 Diabetes 
Using Cardio-Renal Endpoints (ALTITUTDE) trial, aliskiren versus placebo was 
added to a background therapy of either ACEI or ARB (Parving et al., 2012). This 
trial was prematurely terminated due to lack of benefit and increased risk of 
hyperkalaemia and hypotension.  
Findings from this review are different than Sipahi et al. (2010) and are in-line 
with recent meta-analyses that have reported comparable results (Bangalore et 
al., 2011, Teo, 2011, Shen et al., 2016, Zhao et al., 2016). In spite of that, the 
search and analyses of the current study are more comprehensive as RCTs 
published after 2010 were included with the most recent data available from the 
PREVER-Treatment study. Also, individual-patient level data used in the ARB 
Trialists Collaboration (ATC) (Teo, 2011) for ACTIVE 1, ONTARGET, TRANSCEND, 
and PRoFESS were incorporated in the current meta-analyses. Cancer data for the 
ACTIVE I and DIRECT-Overall study were only available from the ATC meta-
analysis. Furthermore, the data from JIKEI Heart Study (Mochizuki et al., 2007) 
and KYOTO Heart Study (Sawada et al., 2009) used in the Bangalore et al. (2011) 
meta-analysis were excluded because these studies were retracted from 
publication due to unreliable data and ethical misconduct. Thus, the result of the 
current meta-analysis is more precise in providing evidence for ARB and risk of 
cancer overall. 
The RAS pathway was extensively studied for its role in haemodynamic regulation, 
hence the pathogenesis of hypertension. Discussion of the RAS pathway is 
commonly centred on angiotensin II and its receptors. Results of several 
experimental studies have recognised angiotensin II as a potent mitogen where it 
is involved in cellular proliferation (Stoll et al., 1995, Arafat et al., 2007), 
angiogenesis (Herr et al., 2008), inflammation and tissue remodelling (Suzuki et 
al., 2003). Angiotensin II signalling through an angiotensin-type-I receptor (AT-1R) 
facilitates cellular proliferation and angiogenesis while stimulation of angiotensin-
type-II receptor (AT-2R) has anti-proliferative properties (George et al., 2010). 
Overexpression of AT-1R has been demonstrated in in-vitro studies of breast 
carcinoma cells (Herr et al., 2008, Rhodes et al., 2009), pancreatic 
adenocarcinoma cells (Arafat et al., 2007), hepatocarcinoma cells (Yoshiji et al., 
2001), and renal cell carcinoma (Dolley-Hitze et al., 2010). Despite its anti-
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proliferative effect, the AT-2R has been found to be overexpressed in several 
cancer-types such as astrocytomas (Arrieta et al., 2008) and lung tumours (Tamura 
et al., 2008). Thus, blockade of the RAS pathway suggests possible prevention and 
attenuation of cancer progression.    
 Strengths and limitations 
In comparison to the previous meta-analysis, the search for this review was 
extended to include trials published after 2010 rendering this study to be the most 
comprehensive and largest meta-analysis of ARB and risk of overall cancer. This 
study has also incorporated all data publicly available to date and only RCTs were 
included ensuring minimal selection bias and effects of confounding variables.  
Furthermore, the utilization of individual-patient data from four major valsartan 
studies provided a more precise OR for the risk of lung cancer. 
There are limitations to this study. Firstly, the majority of the RCTs were not 
designed to detect incident cancer and/ or cancer-related mortality a primary 
end-point. Apart from cancer-deaths, diagnosis of malignancy was variably 
adjudicated across the different studies. Second, only aggregate data reported as 
raw number (n/N) were available for most of the studies. Due to unavailability of 
individual-patient data, the time-to-event analysis was not conducted in this 
review. Availability of such information could better estimate the association of 
drug class studied to the occurrence of site-specific and overall cancer. Lastly, 
most of the studies were followed for an average short period of time ranging from 
one to five years.  As cancer development is a slow process, the results could only 
reflect late-detected cancers. 
 Conclusion 
In conclusion, ARB as an antihypertensive drug class does not influence the risk of 
cancer or cancer-related death overall. Valsartan, as a subclass, potentially have 
a protective effect against cancer, particularly lung cancer. Future studies 
investigating the prospect of valsartan use as a cancer-prevention in a high-risk 
population and as a targeted cancer therapy is warranted. 
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6 Association between calcium channel blockers 
(CCB) and risks of cancer 
6.1 Introduction 
The CCB, a drug class, exerts its effects through interaction with the voltage-
gated calcium channels (VGCC) in the heart and in smooth muscle of the 
peripheral arterioles and arteries. The pharmacological and electrophysiological 
diversity of calcium channels arises primarily from the existence of multiple α1 
subunits which determines the characteristics for the L-, P/Q-, N-, R-, and T-type 
VGCC (Bean and McDonough, 2001, Catterall et al., 2005, Ozawa et al., 2006). The 
CCBs used in CVD, namely hypertension, CHD, arrhythmias, and left ventricular 
dysfunction, inhibits mainly the L-type VGCC, although some of the CCB may 
possess other VGCC subtype blocking activity. Based on their chemical structures, 
CCBs are categorised into three subclasses: DHP, phenylalkylamines, and 
benzothiazepines. The phenylalkylamines and benzothiazepines CCBs are also 
collectively known as non-dihydropyridine CCB. Each of the CCB subclasses has its 
own particular binding site on the α1 subunit called the N, V, and D sites (Opie, 
1997). The DHP or N site appeared to be on the calcium channel pore while the 
benzothiazepine or D site is located on the α1 subunit. The phenylalkylamines 
binding site or V site is located on the α1 subunit in the C-terminal chain region 
adjacent to S6 helix. The DHP CCBs are potent vasodilators but they have minimal 
effect on cardiac conduction or heart rate. Conversely, non-DHP CCBs slow 
atrioventricular node conduction and decrease sinoatrial node automaticity 
resulting in decreased heart rate. Both DHPs and non-DHPs are indicated for the 
treatment of hypertension and angina pectoris. Additionally, verapamil is also 
used to treat cardiac arrhythmias. 
 CCB and cancer 
Apoptosis, a form of programmed cell death, regulates normal tissue mass and 
balances the production of growth and death factors that control mitosis and cell 
death. Earlier studies had demonstrated the crucial role of Ca2+ signalling where 
transient increase in cytosolic Ca2+ activates a cascade of events leading to cell 
death (Nicotera and Orrenius, 1998, Hajnóczky et al., 2003, Guo, 2009a)  
Disruption in apoptosis was proposed as one of the underlying cellular mechanism 
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by which CCB may promote carcinogenesis (Guo, 2009a). Connor and team (1988) 
had used a rat prostate gland model to study androgen-programmed cell death of 
the sexual accessory tissues following castration. Rats administered verapamil and 
nifedipine upon castration exhibited a significant delay in tissues regression 
compared to control. These findings were further corroborated in an in-vitro study 
by Escargueil-Blanc et al. (1997) using the human endothelial cell in a culture 
containing oxidised low-density lipoprotein (ox-LDL). The study demonstrated that 
in cultures treated with nifedipine or nisoldipine, increased Ca2+ concentration 
and deoxyribonucleic acid (DNA) fragmentation elicited by ox-LDL were inhibited. 
On the contrary, several studies demonstrated cell death not repressed by CCBs. 
Leszczynski et al. (1994) induced apoptosis in isolated non-transformed vascular 
smooth muscle cells (SMC) of rats with a number of cell proliferation inhibitors. 
Cell cultures treated with verapamil demonstrated no effect of apoptosis 
prevention. In an in-vivo study (Balakumaran et al., 1996), the effect of different 
CCBs (diltiazem, verapamil, nifedipine, and nicardipine) versus saline on apoptosis 
was assessed using rat thymus. A common effect was seen across all four types of 
CCB and higher apoptotic index was observed in CCBs compared to control. Thus, 
the effects of CCBs on apoptosis remains inconsistent. Evidence from 
epidemiological studies is described in Chapter 1, Section 1.9.4 (page 48). 
This chapter aims to systematically review and report the meta-analysis of RCTs 
using CCB as one of its treatment and its association with risks of cancer. 
6.2 Methodology 
 Systematic review 
Full descriptions of the methods used for this systematic review have been 
described previously in Chapter 2, Section 2.1(page 57). 
Except for the ASCOT-BPLA (Dahlöf et al., 2005) and REIN-2 (Ruggenenti et al.) 
study, cancer outcomes for all of the studies included in this review were 
published and available publicly. Cancer data for the ASCOT-BPLA and REIN-2 trial 
were available from a published meta-analysis (Bangalore et al., 2011). In 
addition, the number of cancer-related mortality in the NHS study (Muramatsu et 
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al., 2012) was provided by one of the trial investigator (Dr Toyoaki Murohara of 
Nagoya University, Japan). Pre-existing cancers before randomisation were not 
included in the analyses in ACTION (Poole-Wilson et al., 2006), INVEST (Pepine et 
al., 2003) Kanamasa (1999) and STOP-HTN2 (Lindholm et al., 2001).  
 Meta-analysis 
For data synthesis, see Chapter 2, Section 2.1.7.4 (page 66). 
For CCB and risk of incident cancer, a sensitivity analysis was performed by firstly 
excluding the FEVER trial (Liu et al., 2005) because it is also considered as a CCB 
and TZ diuretic combination therapy versus TZ monotherapy. The FEVER study was 
designed to assess the effects on CV outcomes of adding a low dose CCB felodipine 
versus placebo in hypertensive patients whose BP had already been reduced by a 
low dose TZ diuretic which was continued throughout the trial. Exclusion of the 
CAMELOT trial was also investigated as this study is detected as an outlier from 
the primary meta-analysis and funnel plot. Trials with the following criteria were 
also excluded trials with the following criteria: [1] small sample size with the 
number of total participants less than 1000; [2] poor methodological quality. 
Association robustness was assessed by including participants with baseline cancer 
available from four trials (ACTION, INVEST, Kanamasa, and STOP-HTN2).  
Additionally, subgroup analyses were also conducted on the following groups and 
treatment comparisons: [1] subclass; [2] comparator; [3] clinical setting; [4] mean 
age; and [5] duration of follow-up. 
6.3 Results 
A total of 60 trials were excluded from the 90 studies included in the primary 
systematic review mainly because they do not consist of CCB treatment arm. 
Details for reasons of exclusion and inclusion of studies are described in Chapter 
3, Section 3.2.1. Overall, identified 30 RCTs enrolling 165,811 patients with an 
average follow-up of 3.5 years (range between 1 and 9.1 years) were identified in 
the search. The average age for patients is 61.9 years across all trials. 
The full description of the studies’ characteristics is described in Chapter 3, 
Section 3.2.2.1 whereas the methodological quality is described in Chapter 3, 
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Section 3.3.6. The oldest study was published in 1989 (VERDI) while the most 
recent study was published in 2011 (CASE-J Ex). The largest study was the ALLHAT 
trial with 33,357 participants enrolled and this was followed by INVEST and VALUE 
with 22,576 and 15,245 participants enrolled correspondingly. The majority 
(88.6%) of the patients were hypertensive with more than half of these patients 
(65.6%) had risk factors for CV events e.g. T2DM, history of CHD such as angina 
pectoris and myocardial infarct. The remaining participants were mostly patients 
with established CHD.  
Across the 30 studies, only 44.4% of the total study population were randomised 
to the CCB treatment arm. Of these, the majority of the patients used DHP CCB 
(71.4%) while the rest used either verapamil (28.4%) or diltiazem (0.2%). Overall, 
21 RCTs compared CCB to active controls which include RAS inhibitors such as ACEI 
or ARB, CCB, and TZ. Two of these trials, Kanamasa and REIN-2, did not specify 
the active control used and the comparators were only described as non-CCB and 
conventional antihypertensive therapy respectively. Meanwhile, 12 RCTs 
randomised patients to placebo. 
All the included studies have a minimum duration of treatment at least one year 
with the longest mean follow-up was nine years. The mean or median age for the 
study participants was above 50 years across all 30 studies. However, two studies, 
STOP-HTN and Syst-Eur, recruited older patients with mean age above 70 years. 
Most of the studies recruited equal proportion or more than 50% males into each 
respective trial except for CONVINCE, INSIGHT, NICS-EH, and STOP-HTN2 (ranged 
between 33% and 46%). In the meantime, the proportion of active smokers was 
exceptionally high in two RCTs, INTACT and NICOLE (84% and 71.2% 
correspondingly).  
Four trials implemented more than two parallel treatment arms. Kanamasa has 
randomised patients to two CCB treatment arms (nifedipine and diltiazem) and 
non-CCB. Apart from ACEI, three trial has compared CCB to one additional active 
control (ALLHAT, STOP-HTN2) or placebo (CAMELOT). In addition, most of the 
trials have implemented a double-blind design. Seven trials blinded only the study 
endpoint assessors (ASCOT-BPLA, CASE-J Ex, FACET, INVEST, NHS, REIN-2, and 
STOP-HTN2). Two trials, ESPIRAL and Kanamasa, used an open-label design.  
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Table A-3 shows the selected characteristics of interest extracted from individual 
trials. On a whole, only four studies (ACTION, INVEST, Kanamasa, STOP-HTN2) 
have reported recruitment of patients with baseline cancer whereas five studies 
(CSE-J Ex, INTACT, REIN-2, SPRINT, VERDI) excluded such patients from their study 
protocol. Only seven trials had pre-specified cancer as one of the study outcomes 
while the remaining trials were not designed to detect cancer. Cancer 
adjudication varied across all studies with only 11 studies centrally adjudicated 
cancer outcomes and one study (FEVER) used site reports for cancer diagnoses. 
Reporting of treatment adherence and attrition was inconsistent across studies. 
Treatment adherence was reported to be between moderate to good in 17 studies 
ranging from 55% to 96%. As for attrition rate, three studies (PRAISE, PREVENT, 
STOP-HTN2) have not loss any patients throughout the individual study period. 
Meanwhile, 17 studies reported the number of patient loss to follow-up at the rate 
between 0.3% and 10%. Cancer outcomes for all the studies were available 
publicly. 
6.4 CCB and risks of incident cancer 
 Overall 
As a whole, 25 trials were included and data were available for 142,841 (89.4%) 
of the total 159,798 patients enrolled. Cancer incidence was 5.66% in patients 
assigned to CCB versus 5.34% in patients assigned to control. In the FE model as 
shown in Figure 6-1, the ASCOT-BPLA was given the most weight at 23.8% overall 
and this was immediately followed by the ALLHAT and VALUE trials (18.8% and 
17.3% respectively). The remaining weight was distributed variably between 22 
studies. Three studies (ACTION, CAMELOT, VALUE) have shown a significantly 
increased odds for cancer with OR ranging between 1.20 and 4.39 and 95% CI not 
including 1. In the forest plot, the CIs for CAMELOT and VALUE clearly did not cross 
the line of no effect and lies on the right side of the plot whereas the 95% CI lower 
limit for the ACTION study almost encroaching 1. Although many of the remaining 
studies showed increased odds for cancer while only a few showed OR less than 1, 
the 95% CI of all the studies overlaps 1. The CI of these studies crossed the line of 
no effect indicating no statistical significance at the study level. Nonetheless, the 
combined OR was 1.08 with 95% CI between 1.03 and 1.13 (P-value = 0.0007) and 
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the diamond that represents the pooled effect estimates lies to the right side of 
the forest plot indicating a statistical significance at the meta-analysis level. 
Figure 6-2 shows the RE model meta-analysis of the 25 trials included for the 
assessment of overall cancer risk. In this model, equal weight was assigned to 
ACTION, CAMELOT and VALUE at 11.4%, 11.0% and 11.0% correspondingly. The 
combined OR was 1.09 with 95% CI between 1.00 and 1.19 (P-value = 0.06). The 
diamond of pooled effect lies to the right side of the plot and is slightly wider with 
the left tips impinging the line of no effect showing a considerable trend towards 
significance.     
Both the FE and RE model showed a considerable presence of heterogeneity. The 
Chi-square test for heterogeneity showed a P-value of 0.002 indicating statistical 
evidence for differences between studies. In addition, the I2 statistic showed that 
51% variations across the studies are due to heterogeneity rather than chance. 
The observed statistical heterogeneity is most likely due to the methodological 
and clinical diversity of the CAMELOT and FEVER studies. Sensitivity analyses, 
without these studies, resulted in a narrower 95% CI and a marked decreased in I2 
statistics across studies (See Section 6.4.2.Sensitivity analyses).  
Finally, assessment of the funnel plot as shown in Appendix Figure A-1 (Page 323) 
demonstrated a fairly symmetrical distribution of studies at the top of the plot. 
However, small studies are missing on the left side of the funnel plot and there is 
an outlier on the top right. The outlier was identified as the CAMELOT study. The 
funnel plot asymmetry is most likely due to selective outcome reporting bias when 
located studies may not provide usable data for the outcome of interest. 
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Figure 6-1: Forest plot of incident cancers by CCB vs non-CCB controls [FE model]. 
Odds ratios and 95% confidence interval, overall and in 25 trials. The overall effect represents the 
pooled estimate of odds for incident cancers. *Included were patients with no history of cancer or 
active cancer at baseline. 
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Figure 6-2: Forest plot of incident cancers by CCB vs non-CCB controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 25 trials. The overall effect represents the 
pooled estimate of odds for incident cancers. *Included were patients with no history of cancer or 
active cancer at baseline. 
 
 Sensitivity analyses 
Exclusion of the FEVER study from the overall analysis in an FE model generated 
an OR 1.09 (95% CI 1.04-1.14) with a P-value of 0.0002 (Figure 6-3). Weight 
distribution between studies is comparable to the primary result. Chi-square test 
for heterogeneity yields a P-value of 0.007 indicating statistical evidence for 
differences between studies. The I2 statistics of 47% indicating a moderate amount 
of variation across studies is due to heterogeneity rather than chance. Meanwhile, 
the RE model yielded an OR of 1.11 with a wider 95% CI ranging from 1.02 to 1.21 
(Figure 6-4).  
Figure 6-5 shows the result of meta-analysis in an FE model after exclusion of the 
CAMELOT and FEVER study with an OR 1.08 (95% CI 1.03-1.13). Chi-square test for 
heterogeneity showed a P-value of 0.34 signifying no evidence of a difference 
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between studies. The I2 test had markedly decreased with its value observed at 
9% implying that the amount of variations across studies due to heterogeneity is 
trivial. The RE meta-analysis (Figure 6-6) yielded a similar pooled effect estimate 
as the FE model (OR 1.08, 95% CI 1.03-1.13). 
Exclusion of eight studies with small sample size resulted in OR 1.08 (95% CI 1.03-
1.13) with P-value of 0.001 (Figure 6-7). This result was mainly driven by the 
ALLHAT, ASCOT-BPLA, and VALUE studies as they were assigned the most and 
comparable weight each (11.4%, 11.8%, and 11.4% respectively. The presence of 
heterogeneity is evidenced by the Chi-square P-value of 0.0004 and the I2 statistics 
observed at 62%. The RE model showed an OR 1.09 with 95% CI between 0.99 and 
1.19 (P-value = 0.09; Figure 6-8) which is slightly wider. 
Exclusion of nineteen studies with high risk of bias left only six studies in the 
overall analysis (Figure 6-9). The FE model analysis resulted in a combined OR of 
1.10 (95% CI. 1.04-1.17; P-value = 0.002))The result was mainly influenced by the 
ALLHAT and VALUE trials as both trials carried equal weights and more than half 
of the weight combined for the overall meta-analysis. Test for heterogeneity 
yields a chi-square P-value of 0.17 and an I2 of 36%. Meanwhile, RE model analysis 
showed an OR of 1.10 with slightly wider 95% CI between 1.01 and 1.21 (P-value = 
0.03; Figure 6-10). 
In the meantime, the inclusion of patients with baseline cancer into the FE meta-
analysis yielded a combined effect estimate of OR 1.08, 95% CI 1.04-1.14 (P-value 
= 0.0006; Figure 6-11) which is comparable to the primary FE meta-analysis. 
Similarly, RE meta-analysis did not have any impact on the overall result as it gave 
a similar summary effect estimate and 95%CI to the main result (OR 1.09, 95% CI 
1.00-1.19; Figure 6-12).  
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Figure 6-3: Forest plot of incident cancers by CCB vs controls [Sensitivity analysis: 
Exclusion of the FEVER trial, FE model].  
The overall effect represents the pooled estimate of odds for incident cancers. *Included were 
patients with no history of cancer or active cancer at baseline 
 
Figure 6-4: Forest plot of incident cancers by CCB vs controls [Sensitivity analysis: 
Exclusion of the FEVER trial, RE model].  
The overall effect represents the pooled estimate of odds for incident cancers. *Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 6-5: Forest plot of incident cancers by CCB) vs non-CCB controls [Sensitivity 
analysis: Exclusion of the CAMELOT and FEVER trial, FE model]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
 
Figure 6-6: Forest plot of incident cancers by CCB) vs non-CCB controls [Sensitivity 
analysis: Exclusion of the CAMELOT and FEVER trial, RE model]. 
The overall effect represents the pooled estimate of odds for incident cancers. * Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 6-7: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: Study 
size, FE model]. 
The overall effect represents the pooled estimate of odds for incident cancers*Included were 
patients with no history of cancer or active cancer at baseline. 
  
 
Figure 6-8: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: Study 
size, RE model]. 
The overall effect represents the pooled estimate of odds for incident cancers*Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 6-9: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: 
Methodological quality, FE model]. 
The overall effect represents the pooled estimate of odds for incident cancers * Included were 
patients with no history of cancer or active cancer at baseline. 
 
 
Figure 6-10: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: 
Methodological quality, RE model]. 
The overall effect represents the pooled estimate of odds for incident cancers * Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 6-11: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: 
Inclusion of patients with baseline cancer, FE model]. 
The overall effect represents the pooled estimate of odds for incident cancers  
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Figure 6-12: Forest plot of incident cancers by CCB vs. controls [Sensitivity analysis: 
Inclusion of patients with baseline cancer, RE model]. 
The overall effect represents the pooled estimate of odds for incident cancers  
 Subgroup analyses 
Table 6-1 summarises the results for subgroup analyses that were carried out for 
CCB and cancer risk. Altogether, there are five subgroups analyses. 
6.4.3.1 By subclass 
Data for DHP CCB was available from 21 RCTs enrolling 118,173 patients. Cancer 
incidence was 6.47% in the DHP CCB treatment group versus 6.41% in the control 
group. The FE model estimates resulted in OR 1.08 (95% CI 1.03-1.13; P-value = 
0.002; Figure 6-13).Meanwhile, the RE model (Figure 6-14) estimated an OR 1.11 
with 95% CI between 1.00 and 1.23 and P-value of 0.05 at the edge of significance. 
The chi-square test resulted in a P-value of 0.001 and the I2 statistics of 55% 
indicating a substantial amount of heterogeneity between studies. The statistical 
heterogeneity observed is likely due to the inclusion of the CAMELOT (an outlier) 
and the FEVER trial (methodological diversity) in the analysis.   
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For non-DHP CCB, data were available from five RCTs enrolling 40,861 patients. 
Cancer incidence was 2.80% in the non-DHP CCB treatment group versus 2.76% in 
the control group with OR 2.76 (95% CI 0.90-1.14; P-value = 0.81). Test for 
heterogeneity resulted in a chi-square P-value of 0.56 and an I2 statistics of 0% 
signifying no observed heterogeneity. Both FE and RE meta-analysis agrees well 
with each other.   
6.4.3.2 By type of comparator 
Overall, 17 RCTs have compared CCB to active controls and data were available 
from 11,3998 patients. Cancer incidence was 6.09% in the CCB treatment group 
versus 5.84% in the non-CCB group. The summary effect estimate resulted in OR 
1.08 (95% CI 1.02-1.13; P-value = 0.004). The combined effect estimate was mainly 
influenced by the ALLHAT, ASCOT-BPLA, and VALUE trials as they carried the 
heaviest weight overall (21.1%, 27.5%, and 21.1% respectively; Figure 6-15). Test 
for heterogeneity resulted in a chi-square P-value of 0.76 and I2 statistics of 0% 
signifying no observed heterogeneity. The RE meta-analysis (Figure 6-16) agree 
well with the estimates derived from the FE model. 
Eight studies have compared ACEI or ARB to CCB and data were available from 
27,289 patients. Cancer incidence was 7.72% in the CCB treatment group versus 
6.82% in the RAS inhibitors treatment group with OR 1.14 (95% CI 1.04-1.26; P-
value = 0.004; Figure 6-15). The result of this analysis was greatly driven by the 
VALUE trial as it was given the heaviest weightage (73%). Test for heterogeneity 
resulted in a chi-square P-value of 0.67 and I2 statistics of 0% signifying no 
observed heterogeneity. Pooled estimates from the RE model is (Figure 6-16) is 
in agreement with the FE model. 
For placebo, data were available from eight studies enrolling 27,423 patients. 
Cancer incidence was 3.80% in the CCB treatment group versus 3.63% in the 
placebo group. The FE model (Figure 6-15) combined effect estimate resulted in 
OR 1.05 (95% CI 0.93-1.19; P-value 0.44). Meanwhile, the RE model yields a lower 
OR of 1.00 with wider 95% CI between 0.80 and 1.25 (P-value = 0.99). The chi-
square test resulted in a P-value of 0.05 and the I2 statistics of 49% indicating a 
considerable amount of heterogeneity between studies (Figure 6-16). The 
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statistical heterogeneity observed is likely due to methodological diversity of the 
FEVER (background TZ therapy) and DAVIT II (small study size) studies.  
6.4.3.3 By population clinical setting 
Data for patients with essential hypertension were available from five RCTs 
enrolling 12,383 patients. Cancer incidence was 4.34% in the CCB treatment group 
versus 6.88% in the control group (OR 0.98, 95% CI 0.84-1.15; P-value = 0.83; 
Figure 6-17). The combined effect estimate was mainly influenced by the STOP-
HTN2 trial which with 76.8% of the overall weight. The RE meta-analysis (Figure 
6-18) agree with the FE model estimates. Heterogeneity assessment shows a chi-
square P-value of 0.51 and an I2 statistics of 0% indicating no observed statistical 
heterogeneity. 
For hypertensive patients with one or more risk factor CV events, data were 
available from 11 RCTs enrolling 102,213. Cancer incidence was 5.50% in the CCB 
treatment group versus 5.15% in the control group. The FE model (Figure 6-17) 
yields an OR 1.06 (95% CI 1.01-1.12) with a P-value of 0.03 whereas the RE model 
results in a combined effect estimate of OR 1.04 with a wider 95% CI 0.94-1.15 (P-
value = 0.48; Figure 6-18). The result of this analysis was mainly influenced by 
the ALLHAT, ASCOT-BPLA, and VALUE studies which were assigned most of the 
overall weight. Heterogeneity test resulted in a chi-square P-value of 0.06 and I2 
statistics of 44%. The statistically moderate heterogeneity observed is most likely 
due to the methodological diversity of the CONVINCE (two comparators were used) 
and FEVER (background TZ therapy) trials.   
Data from seven RCTs enrolling 35,581 patients were available to assess the risk 
of incident cancer in patients with underlying CHD such as angina pectoris and 
myocardial infarct. Cancer incidence was 3.71% in the CCB treatment group versus 
3.17% in the control group with OR 1.17 (95% CI 1.04-1.31; P-value = 0.007; Figure 
6-17). The RE meta-analysis (Figure 6-18) showed a higher summary OR with wider 
95% CI (OR 1.31 (95% CI 0.95-1.80; P-value = 0.10). Significant differences between 
studies were observed with the I2 test of 79% (chi-square P-value <0.0001). The 
heterogeneity observed is most likely contributed by methodological diversity of 
the CAMELOT (an outlier) trial.  
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As for patients with underlying T2DM, data were available from four studies 
enrolling 3,715 patients. Cancer incidence was 3.19% in the CCB treatment group 
versus 2.38% in the control group. The combined FE estimate resulted in OR 1.28 
with 95% between 0.86 and 1.90 (P-value = 0.24; Figure 6-17). The RE meta-
analysis result (OR 1.27, 95% CI 0.85-1.89; P-value = 0.24; Figure 6-18) to a certain 
extend agrees with the FE estimates. This analysis was primarily influenced by the 
NHS study which carries 45% of the overall weight. The chi-square test yields a P-
value of 0.70 and the I2 statistics of 0% indicating no observed statistical 
heterogeneity.   
6.4.3.4 By mean age groups 
For studies with patients’ mean age of 65 years or older, data were available from 
eight RCTs enrolling 89,044 participants. Cancer incidence was 5.54% in the CCB 
treatment group versus 5.39% in the control group with OR 1.08 (95% CI 1.02 – 
1.14; P-value = 0.01; Figure 6-19). The RE model (Figure 6-20) estimates fairly 
agree with the FE model estimates resulting in OR 1.08 (95% CI 1.01-1.15; P-value 
= 0.02). The summary effect estimate was primarily driven by the ALLHAT and 
VALUE trials in which both studies combined carries more than half of the overall 
weight (27.9% and 28% respectively; Figure 6-20). Heterogeneity assessment 
between the eight studies yields a chi-square test P-value of 0.38 and an I2 
statistics of 7% indicating no observed statistical heterogeneity.  
Meanwhile, data for studies with patients’ mean age younger than 65 years were 
available from 17 RCTs enrolling 53,797 participants. Cancer incidence was 5.87% 
in the CCB treatment group versus 5.26% in the control group (OR 1.09, 95% CI 
1.02-1.18; P-value = 0.02). In this meta-analysis, the ASCOT-BPLA and ACTION 
trials carry the most weight overall with 62.7% and 18.3% correspondingly (Figure 
6-19). Meanwhile, the RE meta-analysis resulted in a larger OR and wider 95% CI 
(OR1.16, 95% CI 0.95-1.41; P-value = 0.16; Figure 6-20). Heterogeneity 
assessment observed with chi-square test (P-value = 0.0005) and I2 statistics (61%) 
suggests evidence of differences between studies. The heterogeneity observed 
was mainly contributed by methodological diversity of the CAMELOT and FEVER 
(background TZ therapy) trial. 
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6.4.3.5 By duration of follow-up 
Three subgroups analyses were carried out to assess the impact of duration of 
study follow-up on cancer risk. 
For studies with mean patients’ follow-up less than three years, data were 
available from nine studies enrolling 34,940 participants. Cancer incidence was 
2.34% in the CCB treatment group versus 2.14% in the control group with OR 1.11 
(95% CI 0.96-1.28; P-value = 0.16; Figure 6-21). The RE model showed a larger OR 
of 1.27 and a wider 95% CI between 0.90 and 1.79 (P-value = 0.18; Figure 6-22). 
This meta-analysis was mainly influenced by the ASCOT-BPLA, ALLHAT, and VALUE 
study as they carry the most weight overall (20.3%,17.9%, and 18.0% respectively; 
Figure 6-22). Heterogeneity assessment observed with the chi-square test (P-
value = 0.0003) and I2 statistics (73%) suggests evidence of differences between 
studies. The heterogeneity observed was primarily contributed by the CAMELOT 
trial probably due to methodological and clinical diversity. 
Data for studies with mean patients’ follow-up three years or longer were 
available from 16 RCTs enrolling 107,901. Cancer incidence was 6.72% in the CCB 
treatment group versus 6.39% in the control group (OR 1.08, 95% CI 1.03-1.13; P-
value = 0.002; Figure 6-21). The RE model estimates agree with the FE model to 
some extent (OR 1.08, 95% CI 1.01-1.15; P-value = 0.02; Figure 6-22). Similarly, 
the ASCOT-BPLA, ALLHAT, and VALUE study had the biggest influence in this meta-
analysis. Tests for heterogeneity resulted in a chi-square P-value of 0.21 and an I2 
statistics of 22% suggesting minimal differences between studies. 
Additionally, the risk of cancer in trials followed for five years or longer was 
assessed. Data were available from three studies enrolling 25,734 patients. Cancer 
incidence was 9.91% in the CCB treatment group versus 9.60% in the control group 
with OR 1.05 (95% CI 0.97-1.14; P-value = 0.26). The RE meta-analysis fairly agree 
with the FE estimates (OR 1.05, 95% CI 0.96-1.14; P-value = 0.26). The ASCOT-
BPLA study carried the most weight (77.2%) between the three studies hence had 
the biggest influence in this meta-analysis. Tests for heterogeneity results (chi-
square P-value= 0.52 and I2 = 0%) suggests no observed statistical heterogeneity 
between studies.   
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Table 6-1: Calcium channel blockers and risk of cancer: Subgroup analyses 
Subgroup analysis No. of study 
No. of 
participants
Cancer incidence 
(%) OR (95% CI) P-value I2 (%) 
CCB Control 
Overall 
effect 
RE model 25 142,841 5.66 5.34 1.09 (1.00-1.19) 0.06 51 
Subclass 
DHP 21 118,173 6.47 6.41 1.11 (1.00-1.23) 0.05 55 
Non-DHP 5 40,861 2.80 2.76 1.01 (0.90-1.14) 0.81 0 
Type of 
comparators 
Active 17 11,3998 6.09 5.84 1.08 (1.02-1.13) 0.004 0
RAS inhibitors 8 27,289 7.72 6.82 1.14 (1.04-1.25) 0.005 0
Placebo 8 27,423 3.80 3.63 1.00 (0.80-1.25) 0.99 49 
Clinical 
setting 
Hypertension 5 12,383 5.34 6.88 0.98 (0.84-1.15) 0.81 0 
High-risk 
hypertensive 11 102,213 5.50 5.15 1.04 (0.94-1.15) 0.48 44 
CHD 7 35,581 3.71 3.17 1.31 (0.95-1.80) 0.10 79 
T2DM 4 3,715 3.19 2.38 1.27 (0.85-1.89) 0.24 0 
Age 
≥ 65 years 8 89,044 5.54 5.39 1.08 (1.01-1.15) 0.02 7 
< 65 years 17 53,797 5.87 5.26 1.16 (0.95-1.41) 0.16 61 
Duration of 
follow-up 
< 3 years 9 34,940 2.34 2.14 1.27 (0.90-1.79) 0.18 73
≥ 3 years 16 107,901 6.72 6.39 1.08 (1.01-1.15) 0.02 22 
≥ 5 years 3 25,734 9.91 9.60 1.05 (0.96-1.14) 0.26 0 
Abbreviations: CCB, calcium channel blockers; CHD, coronary heart disease; DHP, dihydropyridine; RAS, renin-angiotensin system; 
RE, random-effect; T2DM, type 2 diabetes mellitus; OR, odds ratio; CI; confidence interval. 
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Figure 6-13: Forest plot of cancer incidence by CCB subclass [FE model]. 
1) DHP vs controls in 21 trials; 2) Non-DHP vs controls in 5 trials. The subtotal effect represents 
the pooled estimate of odds for cancer incidence for each subclass.* Included were patients with 
no history of cancer or active cancer at baseline. 
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Figure 6-14: Forest plot of cancer incidence by CCB subclass [RE model]. 
1) DHP vs controls in 21 trials; 2) Non-DHP vs controls in 5 trials. The subtotal effect represents 
the pooled estimate of odds for cancer incidence for each subclass.* Included were patients with 
no history of cancer or active cancer at baseline. 
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Figure 6-15: Forest plot of cancer incidence by comparators [FE model]. 
1) Active controls; 2) RAS inhibitors; 3) Placebo. The subtotal effect represents the pooled estimate 
of odds for cancer incidence for each comparator. * Included were patients with no history of 
cancer or active cancer at baseline. 
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Figure 6-16: Forest plot of cancer incidence by comparators [RE model]. 
1) Active controls; 2) RAS inhibitors; 3) Placebo. The subtotal effect represents the pooled estimate 
of odds for cancer incidence for each comparator. * Included were patients with no history of 
cancer or active cancer at baseline. 
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Figure 6-17: Forest plot of cancer incidence by clinical setting [FE model]. 
1) Hypertension; 2) High-risk hypertension; 3) Coronary heart disease; 4) Type 2 diabetes mellitus. 
The subtotal effect represents the pooled estimate of odds for cancer incidence for each clinical 
setting. * Included were patients with no history of cancer or active cancer at baseline. 
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Figure 6-18: Forest plot of cancer incidence by clinical setting [RE model]. 
1) Hypertension; 2) High-risk hypertension; 3) Coronary heart disease; 4) Type 2 diabetes mellitus. 
The subtotal effect represents the pooled estimate of odds for cancer incidence for each clinical 
setting. * Included were patients with no history of cancer or active cancer at baseline. 
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Figure 6-19: Forest plot of cancer incidence by mean age [FE model]. 
1) ≤  65 years; 2)  ≥ 65 years. The subtotal effect represents the pooled estimate of odds for cancer 
incidence for each criterion. * Included were patients with no history of cancer or active cancer at 
baseline. 
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Figure 6-20: Forest plot of cancer incidence by mean age [RE model]. 
1) ≤  65 years; 2)  ≥ 65 years. The subtotal effect represents the pooled estimate of odds for cancer 
incidence for each criterion. * Included were patients with no history of cancer or active cancer at 
baseline. 
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Figure 6-21: Forest plot of cancer incidence by study mean duration of follow-up [FE 
model]. 
1) Follow-up less < 3 years; 2) Follow-up ≥ 3 years 3) Follow-up ≥ 5 years. The subtotal effect 
represents the pooled estimate of odds for cancer incidence for each criterion. * Included were 
patients with no history of cancer or active cancer at baseline. 
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Figure 6-22: Forest plot of cancer incidence by study mean duration of follow-up [RE 
model]. 
1) Follow-up less < 3 years; 2) Follow-up ≥ 3 years 3) Follow-up ≥ 5 years. The subtotal effect 
represents the pooled estimate of odds for cancer incidence for each criterion. * Included were 
patients with no history of cancer or active cancer at baseline. 
  
6.5 CCB and cancer-related death 
Altogether, 15 trials were eligible and included in the meta-analysis of CCB and 
risk of cancer-related mortality. Data were available from 84,840 (99.2%) patients 
out of 85,535 patients enrolled in the fifteen studies. Based on randomised 
treatment allocation, cancer-related death was 2.23% in the CCB treatment group 
versus 2.64% in the control group. 
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In the FE model (Figure 6-23), the ALLHAT study contributed the biggest influence 
in this meta-analysis as it was given almost half of the overall weight (45.9%). This 
is followed by the ASCOT-BPLA study carrying 33.1% of the overall weight assigned 
between the fifteen included trials. Five trials (APSIS, CONVINCE, FACET, IDNT, 
INTACT) have observed non-significant increased odds for cancer in the CCB 
treatment arm whereas the MIDAS study is the only trial that had observed no 
different in cancer odds between treatment and control (OR 1.00, 95% CI 0.29-
3.47). All the remaining nine trials in the meta-analysis had recorded decreased 
OR for cancer in the CCB treatment arm. From the forest plot, the 95% CI of all 
the studies overlaps 1 as all the CIs cross the line of no effect indicating no 
statistical significance at the study level. The diamond representing the combined 
estimate was located to the left side of the forest plot with its right edge 
impinging the line of no effect indicating no statistical significance at 5% 
significance level. The combined effect estimate resulted in OR 0.95 with 95% CI 
between 0.86 and 1.04 (P-value = 0.25).   
Figure 6-24 showed the result of this meta-analysis in a RE model. The weighting 
of all fifteen studies was comparable to the weighting assigned in the FE model. 
Additionally, both FE and RE meta-analysis agreed on the combined OR of 0.95 
(95% CI 0.86-1.04). 
The chi-square statistic for heterogeneity recorded a P-value of 0.59 indicating no 
statistical evidence for a difference between the fifteen included studies. 
Additionally, the I2 statistics observed at the value of 0% suggests no statistical 
difference between the studies.       
Furthermore, the funnel plot as shown in the Appendix Figure A-2 demonstrates 
missing study in the middle left and bottom right side of the plot. No outlier study 
detected lying outside the triangular region within which 95% of studies are 
expected to lie in the absence of both biases and heterogeneity. The funnel plot 
asymmetry is most likely due to selective outcome reporting bias when located 
studies may not provide usable data for the outcome of interest.   
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Figure 6-23: Forest plot of cancer-related death by CCB versus non-CCB controls [FE 
model] 
Odds ratios and 95% confidence interval, overall and in 15 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death. 
  
 
Figure 6-24: Forest plot of cancer-related death by CCB vs non-CCB controls [RE model]. 
Odds ratios and 95% confidence interval, overall and in 15 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death. 
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6.6 Discussion 
The results from the current study suggest marginally significant increased risks 
for cancer overall with use of CCB in both FE (OR 1.08, 95% CI 1.03-1.13) and RE 
model (OR 1.09, 95% CI 1.00-1.19). Both FE and RE meta-analyses were used in 
the remaining sensitivity and subgroup analyses because of the substantially high 
heterogeneity between studies as indicated by a significant chi-square test (P-
value = 0.002) and I2 index of 51%. Also, sensitivity analyses showed trends towards 
a positive association between CCB and cancer risk. However, this meta-analysis 
showed that CCBs have no impact on cancer-related death.  
The association between CCB and cancer incidence from this study is similar to 
the most recent meta-analysis published by Bangalore et al. (2011). They have 
included 22 RCTs using CCB as one of its study drugs and reported a summary OR 
of 1.06 (95% CI 1.01-1.11) with a moderate index of heterogeneity observed (I2 = 
27.8%). Additionally, Bangalore and colleague have conducted a network meta-
analysis including altogether 70 trials and 324,168 participants. Multiple indirect 
comparisons showed no significant relationship to risks of cancer when compared 
to other antihypertensive agents or controls, except for beta-blockers (OR 1.08, 
95% CI 1.01-1.15). An identical network meta-analysis of 27 RCTs using major 
antihypertensive classes was applied by Coleman et al. (2008). Compared to 
Bangalore, this study has more relaxed inclusion criteria because they have 
included study with a shorter duration of follow-up (six months).  The overall OR 
for CCB was reported as 0.95 (95% CI 0.79-1.13) with the remaining pairwise 
comparison demonstrated a lack of significant association between treatment and 
cancer.  Nevertheless, network meta-analysis is more subject to erroneous 
conclusions than a routine meta-analysis and tends to only be valid for very similar 
studies. Besides, one of the included studies in the meta-analysis by Bangalore 
and colleagues was identified as non-RCT (Gong et al., 1996) and inaccurate 
cancer data was imputed for the MIDAS study. Both cancer incidence and cancer-
related deaths from this study were used in the meta-analysis of CCB and cancer 
risk.          
A review by Frishman (2007a) has outlined the differences between DHP and non-
DHP CCBs in term of pharmacological effects which may translate into differences 
in clinical outcomes for certain conditions. Although both subclasses share a 
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common mechanism of action, DHP CCBs tend to be a more potent vasodilator 
whereas non-DHP CCBs has a marked negative inotropic effect. These differences 
in clinical effects also may contribute to the varying safety profile. Due to the 
DHP CCBs’ potent peripheral vasculature vasodilatory effects, patients on these 
agents are more predisposed to experience a headache, facial flushing, and ankle 
oedema compared to non-DHP CCBs. Likewise, patients on non-DHP CCBs are more 
likely to experience atrioventricular (AV) conduction disturbances due to its 
negative chronotropic effects. Numerous literature published to date have shown 
interest in the potential risk of cancer with CCB use, but limited data were 
available for the difference in risk between DHP and non-DHP subclass.  The 
subgroup analyses from the current review demonstrated a positive relationship 
between DHP CCBs and the risk of cancer with OR 1.11 (95% CI 1.00-1.23) at 
borderline significance (P-value = 0.05). However, a considerable disagreement 
between the FE model (OR 1.08 (95% CI 1.03-1.13; P-value = 0.002) and RE model 
estimates reflect the heterogeneity present between the studies, therefore 
pooling of studies is not recommended. Lack of significant difference was 
observed for non-DHP CCBs (OR 1.01, 95% CI 0.90-1.14). Bangalore and colleagues 
(2011) also observed a comparable association in their meta-analysis of 18 DHP 
and four non-DHP CCB trials. They reported an OR of 1.06 (95% CI 1.01-1.12) and 
OR 1.02, 95% CI 0.90-1.15) for the former and latter respectively. These findings 
support the hypothesis that, unlike DHP CCBs, non-DHP CCBs do not affect risks of 
cancer. This is also supported by a much earlier meta-analysis of 39 RCTs using 
verapamil published two decades ago (Dong et al., 1997). The authors have 
reported a lack of significant associations between verapamil and active 
treatment or placebo for cancer incidence and cancer deaths. However, this study 
exercised less strict inclusion criteria in which they allowed studies with 10 
participants enrolled and lasted for at least seven days duration.  
Additionally, when compared to the different type of comparators, the subgroup 
analysis from the current review showed increased risk of cancer for patients in 
the CCB group versus any active controls (OR 1.08, 95% CI 1.02-1.13; P-value = 
0.004) and renin-angiotensin system (RAS) inhibitors (OR 1.14 95% CI 1.04-1.25; P-
value 0.005). Majority of these studies used DHP CCBs as their study drug and all 
studies, except one, have shown trends toward a positive association with OR 
more than 1 which may have contributed to the significant increase in cancer risk. 
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In the RAS inhibitors subgroup, all the studies have used DHP CCB as a comparator. 
These results corroborate the other findings as discussed in the previous chapters 
(See Chapter 4, Section 4.6.5 and Chapter 5, Section 5, Section 5.6.2) where the 
comparison between ARB or ACEI versus CCB showed reduced or no difference 
respectively in risk for cancer in the RAS inhibitors group. Concern regarding 
cancer risk associated with antihypertensive agents particularly the ARB and CCB 
has been constant in recent years. A meta-analysis of nine RCTs by Sipahi et al. 
(2010) has sparked a controversy with the safety of ARB use. This study reported 
a moderate increased in new cancer incidence, especially lung cancer, in those 
using ARB. However, a subsequent meta-analysis of 15 major ARB trials (Teo, 2011) 
did not confirm this and has alternatively concluded that ARB treatment was not 
associated to the risk of any or specific cancer incidence as well as cancer deaths. 
The only hypothesis that could be drawn from this finding is that treatment with 
RAS inhibitors in general and ARB specifically in comparison to CCB is safer in term 
of cancer risk. Though still unclear, the cellular effect exerted by CCB mechanism 
of action may have some impact on cancer risk. 
Conversely, a meta-analysis of 21 observational studies has shown a lack of 
association for both CCB subclasses (Ni et al., 2017). The authors investigated the 
use of major antihypertensive drug classes and risk of breast cancer and found no 
differences in either DHP or non-DHP CCB use. Alternatively, the authors 
suggested that prolonged use of ACEI or ARB therapy has a beneficial effect on 
breast cancer risk. However, this meta-analysis was limited by potential bias and 
confounders inherent in observational studies.  A much earlier pre-clinical 
experimental study has assessed the carcinogenic potential of DHP CCBs in rodents 
for two years (Ahr et al., 1998). Groups of 50 male and 50 female rats each were 
treated with nifedipine, nisoldipine, nimodipine, or nitrendipine and were 
compared to control. The investigators have found no evidence for the 
carcinogenic potential of DHP CCBs.  
Age has long been established as one of the risk factors for cancer with incidence 
rates increasing with age for most cancers. An American statistic in 2009 has 
shown that more than half of cancers occurred in adults aged 65 years or older 
(U.S. Cancer Statistics Working Group, 2017). Likewise in the UK, the peak age for 
cancer occurrence ranged between 65 to 75 years for both males and females 
between the year 2012 and 2014 (Cancer Research UK, 2017). A subgroup analysis 
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assessing age and risk of cancer has yielded a positive association in patients age 
65 years or older (OR1.08 95% CI 1.01-1.15) which agrees to the aforementioned 
evidence. It has been suggested that some of the biologic mechanism in ageing 
may be involved in the pathogenesis of certain age-related diseases such as 
cancer. Some of the hallmarks for aging are also shared by cancer which includes 
genomic instability and epigenetic alteration (Collado et al., 2007, Hanahan and 
Weinberg, 2011, López-Otín et al., 2013). Aging is also commonly implicated in 
chronic diseases where stress and inflammation plays an important role. A 
subgroup analysis in this review has shown that different health settings do not 
significantly affect the risk of cancer. Although all the different subgroups showed 
trends toward increased cancer risk, lack of significance suggests the effect of 
CCBs are independent of patients’ health background and illness severity.   
Previous epidemiological studies have also linked prolong use of CCB to increased 
cancer risk. A population-based case-control study by Li et al. (2013) investigated 
the risk of breast cancer among females aged 55 to 74 in a tri-county metropolitan 
area. The investigators have found that long-term use of CCB for ten years or more 
was associated with increased risk for ductal and lobular breast carcinoma. 
Following this, a meta-analysis of 17 observational studies reported an OR of 1.71 
(95% CI 1.01-2.42) for breast cancer in patients taking CCB for more than 10 years 
(Li et al., 2014b). In a subgroup analysis based on follow-up duration, studies with 
a follow-up of three years or longer have shown an increased risk for cancer (OR 
1.08, 95% CI 1.01-1.15). This evidence suggests that CCB may exhibit a cumulative 
dose relationship with cancer. However, the association was not significant for 
studies followed for five years or longer. The most likely reason was due to only a 
few numbers of studies (n=3) were available. Two of the three included studies 
reported an OR more than 1 though their 95% CI crossing 1. Quite the contrary, a 
recently published study using the Women's Health Initiative cohort reported no 
association to cancer was observed when CCBs were considered by the duration 
of use, length of action, or drug class (Brasky et al., 2017). Yet, this study showed 
an elevated risk for triple-negative breast cancer (HR 1.60, 95% CI, 1.04–2.48) 
which warrants further consideration. The underlying mechanism by which CCB 
affects breast cancer development is not clear. It is possible that breast tissue is 
more prone to alteration in apoptotic activity than other tissues. Moreover, the 
growth and differentiation of mammary gland are independently modulated by 
Chapter 6 CCB and risk of cancer 250 
 
hormones such as oestrogen and progesterone thus suggests a feasible interaction 
between apoptosis and hormonal activity. Therefore, more related studies are 
required to clarify this hypothesis. 
In another aspect, many studies have shown beneficial effects of CCBs in general 
when used in conjunction with standard chemotherapy in cancer patients. The 
notion that CCB increases antineoplastic sensitivity has been explored since the 
1980s and has been solely focused on verapamil. In one of the earliest study, 
Tsuruo et al. (1981) used a mice model with leukaemia to assess the effect of 
verapamil when used concomitantly with antineoplastic agents. Verapamil has 
been showed to increased cytotoxicity of both vincristine and vinblastine by 
increasing cellular uptake and inhibiting the efflux of these agents from tumour 
cells. Subsequently, a review of in-vitro and in-vivo studies has reported the 
sensitivity of various types of tumour cells resistant towards several cytotoxic 
therapies including doxorubicin and thiotepa was augmented by verapamil 
(Simpson, 1985). Also, verapamil improves patients survival by reversing multidrug 
resistance (MDR) in patients with breast cancer (Timcheva and Todorov, 1996, 
Belpomme et al., 2000), and multiple myeloma (Salmon et al., 1991). In a recent 
experimental study, Chiu and team (2010) have assessed the efficacy of 
verapamil, diltiazem, and nifedipine to reverse vincristine- and doxetacel-induced 
resistance in human lung cancer lines. Verapamil was reported to only sensitize 
cell lines but has no effect on parent cancer cells. They also found that diltiazem 
and nifedipine also sensitize cell lines but with lower efficacy than verapamil. 
Hence, inhibition of calcium channels may provide a potential target in cancer 
chemotherapy.        
 Study strengths and limitations 
The main strength of this review is that only RCTs were included and this study 
design is regarded as the gold standard for evaluating the effectiveness of an 
intervention. Apart from strong internal validity, RCTs also balances both measure 
and unmeasured confounders. To the best of found knowledge, this is the largest 
systematic review and meta-analysis of RCTs associating CCB and cancer risk. In 
addition, this systematic review search spans over a period of 60 years which 
eventually adds and updates the most recent review which was published in 2011 
(Bangalore et al., 2011). Cancer outcomes data from the CASE-J Ex, NHS, and 
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INTACT were only incorporated in this meta-analysis of CCB trials and risk of 
cancer.  
Nevertheless, this review has its limitations. Firstly, the majority of the studies 
included in this review were not designed to detect cancer incidence as one of 
their endpoints. The inclusion of patients with baseline cancer in the analysis is 
possible as not all studies stated whether such patients were excluded and this 
could lead to a spurious result. However, incorporating such patients in the meta-
analysis where applicable did not significantly impact the summary effect as 
demonstrated in the sensitivity analysis. Then again, the diagnosis of malignancy 
was adjudicated variably across the different studies. Second, only aggregate data 
were available for all the studies. Therefore, time-to-event analyses were not 
performed. Additionally, the majority of the cancer outcomes available were 
limited to cancer incidence, not to the incidence of a different type of cancers.  
The longest study follow-up was nine years with the majority of the studies follow-
up lasted approximately five years or less. Therefore, the chance to detect a pro-
cancer or anti-cancer effect of the study drug within this short period of time 
could be decreased. Additionally, the results of this study could only reflect late-
detected cancers. Furthermore, this meta-analysis is limited to evaluation CCB as 
a drug class, not individual CCBs. 
 Conclusion 
There is evidence suggesting that CCB use, particularly DHP CCB, is associated 
with an elevated risk for cancer as a whole. However, the disagreement between 
FE and RE meta-analyses suggests further evaluation of trials with minimal 
heterogeneity between studies where possible. Additionally, a properly designed 
further research into the risk of a specific type of cancer with the use of DHP CCB 
is warranted.   
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7 Association between beta-adrenergic blockers 
(BB) and risks of cancer 
7.1 Introduction 
The adrenergic nervous system (ANS) or also known as the sympathetic nervous 
system is mainly mediated by neurotransmitters released by adrenergic neurones 
known as epinephrine and norepinephrine (NE). These neurotransmitters are also 
collectively termed as catecholamines. The receptors these catecholamines 
stimulate are called adrenergic receptors or adrenoceptors. There are two distinct 
types of adrenoceptor classified as alpha (α)- and beta (β)-adrenergic receptors. 
Beta-adrenergic receptors (β-AR) exists as three distinct subtypes: β1, β2, and β3 
(Figure 7-1). Meanwhile, two α-adrenergic receptor major subtypes are α1 and α2. 
Both α- and β-adrenergic receptors belong to the G-protein-coupled receptor 
superfamily and utilize a variety of second messenger pathway to modulate 
cellular function. The β-AR are mostly involved in the relaxation of effector cells 
and dilatation of blood vessels. However, stimulation of β1-adrenoceptor in the 
heart increases the force and rate of myocardial contractility causing the heart to 
beat faster while stimulation of β1-AR in the kidney increases renin secretion from 
the juxtaglomerular cells. Once the β-AR has been described, blockade of this 
receptor became feasible. 
In general, BB antagonises the effect of sympathetic nerve stimulation or action 
of catecholamines on the β-AR which is widely distributed all over the human body 
system. The β1-AR are primarily distributed in the heart and kidney while the β2-
AR are predominant in other organs such as the lung, vascular smooth muscle, and 
skeletal muscles. BP lowering effect of BB involves the following mechanism 
(Rang, 2016):[1] reduction in cardiac output by blockade of the β1-AR located in 
the sino-atrial node and myocardium, [2] reduction of renin release from the 
juxtaglomerular cells by blockade of the β1-AR located in the kidney, and [3] 
reduction of sympathetic activity where blockade of the β-AR located in the 
central and peripheral nervous system inhibits the release of sympathetic 
neurotransmitters 
Table 7-1 showed some of the properties possessed by individual BB which includes 
β1-blockade potency ratio, relative β1-AR selectivity, and intrinsic 
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sympathomimetic activity (ISA). The β1-blockade potency ratios are compared to 
propranolol which has a ratio of one. The BBs are further categorised into β1-AR 
selective or cardioselective BB and β1-AR non-selective or non-cardioselective BB, 
according to their abilities to antagonize sympathetic amines in low doses at some 
tissues than in other tissues. Furthermore, the BBs also differs in term of ISA which 
means some of the BB such as pindolol mimics the effect of catecholamines and 
may cause an increase in BP and heart rate. In general, cardioselective BBs 
antagonise the β1-AR in the heart at low doses but have less effect on β2-AR in the 
bronchial and vascular locations. At higher doses, cardioselective BB can block β2-
AR causing bronchospasm in susceptible patients. However, cardioselective BB is 
safer in patients with bronchospastic diseases because the β2-adrenergic receptors 
can still be stimulated by β2-adrenergic agonist to facilitate bronchodilation.    
 BB and cancer 
Previous studies have found that the use of BB is associated with a lower risk of 
cancer (Perron et al., 2004, Monami et al., 2013). The proposed underlying 
mechanism is related to the inhibition of stress mediators such as catecholamines 
from activating β-AR signalling to inhibit cellular proliferation and cellular 
migration and invasion (Fitzgerald, 2009, Guo, 2009b). Sood and colleagues (2006) 
have conducted an in-vitro study using ovarian cancer cells that were exposed to 
increasing levels of epinephrine, NE, and cortisol. They reported that both 
catecholamines had significantly enhanced cell invasiveness. As for cortisol, 
although cell invasiveness significantly increased, the effect of cortisol was 
substantially smaller than that observed in catecholamines. This finding was 
further supported by another experimental study by Guo (2009b) using human 
pancreatic cell lines. The investigators demonstrated that both β-AR subtypes 
were expressed in the human pancreatic cancer cells and cells pre-treated with 
NE displayed significant cellular invasion at an average ~2.5 fold increase 
compared to control. Guo and colleague also found that propranolol inhibits NE-
mediated increase in matrix metalloproteinases (MMP) and vascular endothelial 
growth factor (VEGF) which are thought to play a role in cell proliferation, 
migration, differentiation, and angiogenesis (Duffy, 2000-2013, Rodríguez et al., 
2010). Using a different cancer cell type, Liao (2010) evaluated the involvement 
of β-AR, nuclear factor κB (NF-κB), MMP-2 and -9, VEGF, and cyclooxygenase-2 
(COX-2) in modulating cell apoptosis and cell cycle arrest by propranolol in human 
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gastric adenocarcinoma cell lines. In addition to decrease production of pro-
angiogenic and pro-proliferation cytokines, the author also found that pro-
inflammatory cytokines (NF-κB and COX-2) were also reduced after treatment with 
propranolol. Propanolol also induced arrest of the resting and mitotic cell cycle in 
gastric cancer cells. Therefore, experimental studies discussed earlier have 
indicated that BB affects cancer development by inhibiting the β-AR signalling 
pathway and subsequently decrease the release of pro-inflammatory, pro-
angiogenic and pro-mitotic mediators. Evidence from observational studies is 
discussed in Chapter 1, Section 1.9.5 (page 50). 
This chapter aims to systematically review and report the meta-analysis of RCTs 
using BB as one of its treatment and its association with risks of cancer. 
Table 7-1 : Pharmacodynamic effects of β-adrenergic blocking drugs 
  β1 - Blockade Potency 
Ratio  (Propanolol = 
1.0) 
Relative β1 
Selectivity 
Intrinsic Sympathomimetic 
Activity (ISA) 
Acebutolol 0.3 + + 
Atenolol 1.0 ++  0 
Betaxolol 1.0 ++  0 
Bisoprolol 10.0 ++  0 
Carteolol 10.0 0  + 
Carvedilol* 10.0 0  0 
Esmolol 0.02 ++  0 
Labetolol* 0.3 0  + 
Metoprolol 1.0 ++  0 
Nadolol 1.0 0  0 
Penbutolol 1.0 0  + 
Pindolol 6.0 0  ++ 
Propanolol 1.0 0  0 
Sotalol 0.3 0  0 
Timolol 6.0 0  0 
+ indicates modest effect; ++, strong effect; 0, no effect. 
* possess additional α1-adrenergic blocking activity.  
Adapted from Frishman and Saunders (2011). 
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Figure 7-1 Adrenergic receptors.  
β-adrenoceptors are coupled with the stimulatory G-protein subunit (Gs) that activates adenylyl cyclase when stimulated by cateholamines and leads to an increase in 
cAMP. Modified from Frishman (2007b).  
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7.2 Methodology 
 Systematic review 
Full descriptions of the methods used have been described previously in Chapter 
2, Section 2.1 (page 57).  
Except for the MERIT-HF study (MERIT-HF Study Group, 1999), cancer outcomes 
for all of the included studies were published and available publicly. Cancer data 
for the MERIT-HF trial was provided by one of the trial investigator (Professor John 
Wikstrand of Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska 
University Hospital, Göteborg University, Sweden). However, the cancer data 
provided comprised both benign and malignant neoplasms and were not specified 
whether these data were for fatal or non-fatal cancers. Therefore, all data were 
treated as incident cancer with only malignant data were included. 
 Meta-analysis 
For data synthesis, see Chapter 2 Section 2.1.7.4 (page 66). 
For BB and risk of incident cancer, sensitivity analyses were performed by 
excluding trials with the following criteria: [1] small sample size with the number 
of total participants less than 1000 which; [2] poor methodological quality; [3] 
studies with different add-on therapy protocol;and [4] studies with ambiguous 
cancer outcomes. With regard to BB and risk of cancer-related death, a sensitivity 
analysis was conducted by excluding the MRC (MRC Working Party, 1985) and 
MRCOA (MRC Working Party, 1992) due to high risk of attrition bias. Additionally, 
a sensitivity analysis was conducted by the inclusion of the CONVINCE (Black et 
al., 2003) and STOP-HTN2 (Lindholm et al., 2001) trials. These two studies 
randomised patients to either BB or diuretics as one treatment arm versus other 
antihypertensive agents and have reported cancer outcomes collectively. 
Subgroup analyses were conducted on the following theme: [1] cardio-selectivity; 
[2] comparator; [3] clinical setting; [4] mean age; and [5] duration of follow-up. 
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7.3 Results 
The searching and identification process of trials is summarised in Figure 3-1 (Page 
74). Altogether, 74 of the 90 studies were excluded mainly because they do not 
consist of BB treatment arm.  
In general, the search conducted has identified 16 studies enrolling 90,956 
patients with an average follow-up of 3.9 years (range 1 to 9 years). The average 
age of participants across all trials is 60.5 years. The full description of the studies’ 
characteristics is described in Chapter 3, Section 3.2.2.1 whereas the 
methodological quality is described in Chapter 3, Section 3.3.6. The oldest eligible 
study was published in 1975 while the latest was 2005. No difference In term of 
study size was observed between old or recent studies. The largest trial was 
INVEST (Pepine et al., 2003), followed by ASCOT-BPLA (Dahlöf et al., 2005) and 
MRC where these studies recruited more than 10,000 participants.  
Overall, hypertensive patients accounted for the highest proportion (85.8%) of the 
population studied, followed by patients with underlying CVD (13.6%) comprising 
CHD and HF. All of the studies enrolled patients with mean age older than 50 
years. Most of the included trials were males predominant with two studies, 
MAPHY (Wikstrand, 1988)  and VA COOP II, enrolled only male participants. Also, 
the proportion of smokers was exceptionally high in the Practolol Study 
(Anonymous, 1975a) exceeding more than half of its study population. Most of the 
trials’ participants were followed for less than five years except for APSIS 
(Rehnqvist et al., 1996), ASCOT-BPLA, MRCOA, and UKPDS-38 (UKPDS 
Investigators, 1998) with the longest duration of follow-up was nine years.   
All of the included studies are RCTs that have used BB as one of its treatment 
arms. Majority of the eligible studies (75%) used cardioselective BB as one its 
treatment. The remaining RCTs used propranolol (four studies), a non-
cardioselective BB whereas Wilcox (1980) used both BB subtypes for its BB 
treatment arm. Nine of the RCTs compared BB to active controls which include 
RAS inhibitors (ACEI or ARB), CCB, and TZ. The remaining studies compared BB to 
placebo or no treatment. 
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All of the eligible studies instigated two parallel treatment arms, except for three 
trials. These trials have an additional treatment arm where they also randomised 
participants to placebo (MRC and MRCOA) or another non-specified 
antihypertensive agent (UKPDS-38). Most of the included studies have 
implemented a double-blind design. Only two RCTs (MRC and MRCOA) were single-
blinded whereas the remaining three studies (ASCOT-BPLA, HEP, and INVEST) used 
the PROBE design. 
Table A-3 (Page 321) shows the selected characteristics of interest extracted from 
individual trials. Overall, only one study (INVEST) reported enrolment of patients 
with baseline cancer while three studies (MAPHY, MRCOA, and VA COOP II) have 
excluded such patients in their study protocol. Only four trials aimed to identify 
malignancy as one of their outcomes whereas most of the eligible studies were 
not designed to detect cancer as their primary or secondary endpoints. Report of 
cancer adjudication varied across studies with only one study (Wilcox) established 
cancer diagnosis from study site reports. 
With regard to treatment adherence, the ASCOT-BPLA, LIFE (Dahlöf et al., 2002), 
and SMT (Olsson, 1985) have shown good adherence (80% or more) while the rest 
displayed moderate adherence (more than 50%). Furthermore, the reporting of 
loss to follow-up was not reported consistently across studies. However, it is 
important to note that the MRC and MRCOA trials have reported a considerably 
high rate of participants’ loss to follow-up at 19% and 25% respectively.  
According to the risk of bias assessment as described in the general method (see 
Chapter 2, Section 2.4.1.3), only seven of the included trials (ASCOT-BPLA, BHAT, 
INVEST, LIFE, MERIT-HF, PAT, and UKPDS-38 ) were deemed to have a low risk of 
bias. 
7.4 BB and risks of incident cancer 
 Overall 
In total, seven RCTs were eligible and data from 60,132 participants enrolled was 
available for BB and risk of cancer. Cancer incidence was 4.88% in patients 
assigned to BB versus 5.19% assigned to control. In the FE model as shown in Figure 
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7-2, the overall result was mainly driven by the ASCOT-BPLA study as it weighted 
the most at 60.6% followed by LIFE and INVEST at 23.0% and 13.1% respectively. 
Three studies showed an increased odds of cancer incidence with OR ranging from 
1.03 to 2.01 and wide 95% CI traversing 1. On the other hand, VA COOP II showed 
a marked decrease in cancer incidence estimate with OR 0.16 and 95% CI 0.01 to 
3.20.  
Visually, the ASCOT-BPLA study’s influence in the analysis was apparent as it was 
represented by the largest box which corresponds to its weight. The 95% CI of all 
the studies overlaps 1 as all the CI crossed the line of no effect indicating no 
statistical significance at the study level. Although the diamond representing the 
combined estimate was located to the left of the forest plot, the 95% CI of the 
overall effect estimate overlaps 1 indicating no statistical significance at 5% 
significance level.      
Meanwhile, the RE model as shown in Figure 7-3 depicted comparable individual 
studies’ weightage and effect estimates. Both FE and RE models agree on the 
pooled effect estimate of OR 0.93 and 95% CI 0.87-1.01(P-value = 0.07) indicating 
no significant difference in odds of cancer between treatment and control group. 
The chi-square statistic for heterogeneity recorded a P-value of 0.81 indicating no 
statistical evidence for a difference between the seven included studies. 
Additionally, the I2 statistics observed at 0% suggests no heterogeneity. 
Finally, assessment of the funnel plot (Appendix Figure A-1, Page 323) 
demonstrated missing studies in the upper- and mid-left area of non-significance 
indicating clear asymmetry. 
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Figure 7-2: Forest plot of cancer incidence by BB vs non-BB controls [FE model]. 
Odds ratios, and 95% confidence interval, overall and in 7 trials. The overall effect represents the 
pooled estimate of odds for cancer incidence.  
 
 
Figure 7-3: Forest plot of cancer incidence by BB vs non-BB controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 7 BB trials, The overall effect represents 
the pooled estimate of odds for cancer incidence. 
 
 Sensitivity analyses 
As shown in Figure 7-4, elimination of the MERIT-HF study from the analysis did 
not significantly affect the overall combined estimate with OR 0.93 and 95% CI 
0.86-1.00 (P-value = 0.06).  Similarly, exclusion of the HEP and VA COOP II trials 
with small sample size (N < 1000) resulted in OR of 0.93 with 95% CI 0.87-1.01 (P-
value = 0.08, Figure 7-5).  
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Meanwhile, exclusion of four studies with inadequate blinding of personnel, 
patients and/or outcome assessors (ASCOT-BPLA, HEP, INVEST, and VA COOP II) 
slightly decrease the overall estimate giving an OR of 0.90 with marginally wider 
95% CI between 0.77 to1.04. Exclusion of these studies left only three trials and 
the meta-analysis was largely driven by the LIFE study where it carries the most 
weight at 90.8% (Figure 7-6). Likewise, exclusion of studies with different add-on 
therapy (ASCOT-BPLA and INVEST) generated an OR of 0.90 with 95% CI 0.78 – 1.04 
with most of the weightage given to the LIFE study at 87.2% (Figure 7-7). 
Conversely, the inclusion of two trials with inadequate information on cancer 
outcomes for BB (CONVINCE and STOP-HTN2) increase the availability of data for 
cancer incidence (Figure 7-8). Cancer incidence was 4.84% in the BB treatment 
group versus 5.39% in the control group. The weight given to the ASCOT-BPLA 
study was reduced from 60.6% to 43.6% in the FE model. Nearly equal weight was 
given to the CONVINCE and LIFE studies (15.0% and 16.5% correspondingly) and 
12.9% of the overall study weight was given to the STOP-HTN2 study. The two 
included studies, CONVINCE and STOP-HTN2, reported a decrease in odds for 
cancer incidence with OR 0.95 (95% CI 0.85-1.12) and OR 0.93 (95%CI 0.78-1.11) 
respectively.  
Furthermore, the 95% CI for all the studies overlap 1 suggesting no statistical 
significance at the study level. However, the summary effect lies to the right side 
of the forest plot with its 95% CI impinging 1 (OR 0.94, 95% CI 0.88-1.00) and a P-
value of 0.04 indicating the overall effect is statistically significant at the 5% 
significance level. Heterogeneity assessment by chi-square statistics yields a P-
value of 0.93 while the I2 statistics of 0%.  
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Figure 7-4: Forest plot of incident cancers by BB vs controls [Sensitivity analysis: Exclusion 
of study with ambiguous cancer outcome]. 
The overall effect represents the pooled estimate of odds for incident cancers.  
 
 
Figure 7-5 Forest plot of incident cancers by BB vs non-BB controls [Sensitivity analysis: 
Study size].  
The overall effect represents the pooled estimate of odds for incident cancers.  
 
 
Figure 7-6: Forest plot of incident cancers by BB vs controls [Sensitivity analysis: Study 
design]. 
The overall effect represents the pooled estimate of odds for incident cancers.  
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Figure 7-7: Forest plot of incident cancers by BB vs controls [Sensitivity analysis: Exclusion 
of studies with different add-on therapy protocol]. 
The overall effect represents the pooled estimate of odds for incident cancers. 
 
 
Figure 7-8: Forest plot of incident cancers by BB vs controls [Sensitivity analysis: Inclusion 
of the CONVINCE and STOP-HTN2 trials]. 
The overall effect represents the pooled estimate of odds for incident cancers.  
 
 Subgroup analyses 
Table 7-2 summarises the results for subgroup analyses that were conducted for 
BB and the risk of cancer. 
7.4.3.1 By receptor selectivity 
Data for cardioselective BB was available from five RCTs enrolling 55,901 patients. 
Cancer incidence was 5.23% in the BB treatment group versus 5.57% in the control 
group. The combined effect estimate resulted in OR 0.93 with 95% CI 0.87-1.01 
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(P-value = 0.07). The I2 test for heterogeneity of 0% indicates that all studies were 
evaluating the same effect.  
On the other hand, only two RCTs (BHAT and VA COOP II) were available for non-
cardioselective BB with the total number of participants was 4,231. Cancer 
incidence was 0.19% in the BB treatment group versus 0.23% in the control group, 
OR 0.87 with 95% CI 0.25-3.06 (P-value= 0.83). The test for heterogeneity was 53% 
suggesting moderate heterogeneity between studies (see Figure 7-9).  Participants 
recruited in the BHAT study have the worst health condition (post-MI) compared 
to those in the VA COOP II study.   
7.4.3.2 By type of comparator 
As shown in Figure 7-10, data were available from four RCTs for comparison 
between BB and active controls which include ARB (LIFE), CCB (ASCOT-BPLA, 
INVEST), and TZ (VA COOP II) enrolling a total of 51,420 participants.  Cancer 
incidence was 5.51% in the BB treatment group versus 5.90% in the active controls 
treatment group, OR 0.93 with 95% CI 0.86-1.00 (P-value = 0.06). At the study 
level, when compared to ARB, the OR for cancer incidence was 0.88 (95% CI 0.75-
1.03). For the two studies that compared BB to CCB, the overall OR for cancer was 
0.93 with 95% CI between 0.87 and 1.03. Meanwhile, comparison to TZ showed the 
OR for cancer was 0.16 (95% CI 0.01-3.20). The I2 test for heterogeneity of 0% 
indicates that all studies were evaluating the same effect.     
For comparison with placebo or no treatment, data were available from three 
RCTs (BHAT, HEP, and MERIT-HF) with a total number of 8,712 patients. Cancer 
incidence was 1.03% in the BB treatment group versus 1.07% in the control group. 
The combined OR gave an estimate of 1.08 with 95% CI 0.72-1.61 (P-value = 0.72). 
The I2 test for heterogeneity of 0% indicates that all the studies were evaluating 
the same effect.  
7.4.3.3 By population clinical setting 
A total of five studies (ASCOT-BPLA, HEP, INVEST, LIFE, and VA COOP II) enrolled 
52,304 participants with underlying hypertension.  Cancer incidence was 5.46% in 
the BB treatment group versus 5.84% in the control group, OR 0.93 (95% CI 0.86-
1.00; P-value = 0.06). The I2 test for heterogeneity was measured at 0%.  
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As for patients with high CVD risk (ASCOT-BPLA) comprising CHD (BHAT and 
INVEST) and HF (MERIT-HF), data were available from 49,661 participants. Cancer 
incidence was 4.58% in the BB treatment group versus 4.80% in the control group 
(OR 0.95, 95% CI 0.87-1.04; P-value = 0.25). Likewise, the test for heterogeneity 
was assessed at 0% (See Figure 7-11). 
7.4.3.4 By mean age groups 
For studies with mean patients’ age of 65 years old or older, data were available 
from 32,653 patients enrolled in three studies (HEP, INVEST, and LIFE). Cancer 
incidence was 3.14% in the BB treatment group versus 3.43% in the control group. 
The combined OR was observed at 0.91 with 95% CI ranged between 0.81 and 1.03 
(P-value = 0.15; Figure 7-12). The I2 test for heterogeneity was measured at 0%.  
On the other hand, data for studies with mean patients’ age younger than 65 years 
was available from four RCTs (ASCOT-BPLA, BHAT, MERIT-HF and VA COOP II) 
enrolling 27,479 patients. Cancer incidence was 6.94% in the BB treatment group 
versus 7.28% in the control group with OR 0.95 and 95% CI 0.86-1.04 (P-value = 
0.24). Heterogeneity was observed at I2 of 0%. 
7.4.3.5 By duration of follow-up 
For studies followed for three years or longer, data were available from three 
trials (ASCOT-BPLA, HEP, LIFE) with a total of 29,334 participants. Cancer 
incidence was 8.49% in the BB treatment group versus 9.08% in the control group 
yielding an OR of 0.93 with 95% CI ranged between 0.85 and 1.00 (P-value = 0.06). 
Heterogeneity was observed at I2 of 0%.   
Meanwhile, data for studies with follow-up less than three years was available 
from four RCTs (BHAT, INVEST, MERIT-HF, VA COOP II) enrolling 30, 798 
participants. Cancer incidence was 1.45% in the BB treatment group versus 1.49% 
in the control group with OR 0.97 (95% CI 0.81-1.17; P-value = 0.77). Heterogeneity 
was observed at I2 of 0% (see Figure 7-12).      
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Table 7-2 : Beta-blockers and risk of cancer: Subgroup analysis 
Subgroup analysis No. of study 
No. of 
participants
Cancer incidence 
(%) OR (95% CI) P-value I2 (%) 
BB Control 
Overall 
effect FE model 7 60132 4.88 5.19 0.93 (0.87-1.01) 0.07 0 
Receptor 
selectivity 
Cardioselective 5 55901 5.23 5.57 0.93 (0.87-1.01) 0.07 0 
Non-
cardioselective 2 4231 0.19 0.23 0.87 (0.25-3.06) 0.83 53 
Type of 
comparators 
Active 4 51420 5.51 5.9 0.93 (0.86-1.00) 0.06 0 
Placebo or no 
treatment 3 8712 1.13 1.07 1.08 (0.72, 1.61) 0.72 0 
Clinical 
setting 
Hypertension 5 52304 5.46 5.84 0.93 (0.86-1.00) 0.06 0 
High CVD risk 4 49661 4.58 4.8 0.95 (0.87-1.04) 0.25 0 
Age 
≥ 65 years 4 32653 3.14 3.43 0.91 (0.81-1.03) 0.15 0 
< 65 years 3 27479 6.94 7.28 0.95 (0.86-1.04) 0.24 0 
Duration of 
follow-up 
≥ 3 years 3 29334 8.49 9.08 0.93 (0.85-1.00) 0.06 0 
< 3 year 4 30798 1.45 1.49 0.97 (0.81-1.17) 0.77 0 
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Figure 7-9: Forest plot of cancer incidence by BB receptor selectivity [FE model]. 
1) Cardioselective BB vs controls in 4 trials; 2) Non-cardioselective BB vs controls in 2 trials. The 
subtotal effect represents the pooled estimate of odds for cancer incidence for each subclass.  
 
 
Figure 7-10: Forest plot of cancer incidence by comparators [FE model]. 
1) Active controls; 2) Placebo or no treatment. The subtotal effect represents the pooled estimate 
of odds for cancer incidence for each comparator.  
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Figure 7-11: Forest plot of cancer incidence by clinical setting [FE model]. 
1) Hypertension; 2) High-risk CVD. The subtotal effect represents the pooled estimate of odds for 
cancer incidence for each clinical setting.  
 
 
Figure 7-12: Forest plot of cancer incidence by Mean age and duration of follow-up [FE 
model]. 
1) Mean age ≥ 65 years;  2) Mean age < 65; 3) Follow-up ≥ 3 years ; 4) Follow-up < 3 years. The 
subtotal effect represents the pooled estimate of odds for cancer incidence for each criterion... 
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7.5 BB and cancer-related death 
Overall, 12 RCTs were included in the meta-analysis of BB and its association to 
risk of cancer-related mortality. Data were available from 49,683 (82.6%) 
participants out of 60,160 patients enrolled in the 12 trials. Based on treatment 
assignment, cancer-related death was 2.41% in the BB treatment group versus 
2.34% in the control group.  
As shown in Figure 7-13, the meta-analysis was mainly influenced by the ASCOT-
BPLA study as it carries the heaviest weight overall (53.9%) and this was followed 
by the LIFE study at 20.0%. Only the UKPDS-38 study showed a statistically 
significant increase in the odds for cancer with OR 2.04 and its 95% CI ranged 
between 1.06 and 3.90. Yet, the UKPDS-38 study did not have a huge influence on 
the overall pooled effect estimate as it only carries 2.1% of the overall weight. 
Also, three other studies with increased odds for cancer (ASCOT-BPLA, HEP, and 
MRCOA) were not statistically significant as their 95% CI crossed 1. Conversely, the 
APSIS study yielded the lowest effect estimate, OR 0.49 with 95% CI ranged 
between 0.12 and 1.98 and it only carries 1.1% of the overall weight. The study 
by Wilcox showed no statistical difference between the BB treatment group and 
control with OR equivalent to 1 and 95% CI ranged between 0.09 and 11.09.  
From the forest plot, the point estimate and 95% CI for the UKPDS-38 study lies on 
the right side of the plot that favours the control group. Meanwhile, the 95% CI of 
the remaining studies overlaps 1 as all the CI crossed the line of no effect 
indicating no statistical significance at the study level. The diamond representing 
the combined estimate was located to the right side of the forest plot, but the 
95% CI of the overall effect estimate overlaps the line of no effect indicating no 
statistical significance at 5% significance level. Based on the FE model, the overall 
pooled OR for BB and cancer-related death was 1.04 with 95% CI ranged between 
0.93 and 1.17. 
The chi-square statistic for heterogeneity recorded a P-value of 0.64 indicating no 
statistical evidence for a difference between the eligible studies 12. Additionally, 
the I2 statistics observed at the value of 0% suggests no statistical difference 
between the studies.   
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In the RE model meta-analysis, as shown in Figure 7-14, the UKPDS-38 study was 
given slightly more weightage compared to the FE model (2.1% versus 3.2% 
respectively). The weight assigned to ASCOT-BPLA and LIFE has reduced by 0.5% 
and 0.7% respectively. The overall combined effect has marginally increased with 
OR 1.05 (95% CI 0.93-1.17; P-value = 0.46).  
Heterogeneity test evaluated using chi-square test showed a P-value of 0.64 in 
both FE and RE model. Likewise, the I2 statistics described the proportion of 
variances across studies that is due to heterogeneity was 0%. The Tau2 indicated 
that Tau is equivalent to 0 which means that most of the true effects fall within 
0.93 and 1.17.  
The funnel plot as shown in Appendix Figure A-2 (Page 324) indicated missing 
studies in the middle and bottom right and left side of the plot. No outlier was 
detected. In general, the funnel plot appeared symmetrical. 
 
Figure 7-13 Forest plot of cancer-related death by BB vs non-BB controls [FE model]. 
Odds ratios, and 95% confidence interval, overall and in 12 trials. The overall effect represents the 
pooled estimate of odds for cancer-related death.  
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Figure 7-14 Forest plot of cancer-related death by BB versus non-BB controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 12 trials The overall effect represents the 
pooled estimate of odds for cancer-related death.   
 
7.6 Discussion 
From the results, there is little evidence of significant association between BB use 
and cancer incidence although the summary effect is less than unity (OR 0.93, 95% 
CI 0.87-1.01). This is supported by the marginally wide 95% CI which contains 1 
and a P-value of 0.07 just short of significance. Furthermore, both FE and RE meta-
analysis agrees on the summary effect estimates.  
Subgroup analyses performed showed BB has no significant effect on cancer when 
compared to active controls overall (OR 0.93, 95% CI 0.86-1.00) or placebo (OR 1.08, 
95% CI 0.72, 1.61). Analysis at the study level has demonstrated that odds for cancer 
are less for BB when compared to ARB and CCB, the two drug classes that have 
been implicated with increased cancer risk in previous studies (Sipahi et al., 2010, 
Li et al., 2013). A meta-analysis of  nine RCTs using ARBs by Sipahi et al. (2010) 
reported a significantly increased risk of new cancer occurrence in patients 
assigned to ARB (RR 1.08, 95% CI 1.01–1.15; p=0.016) with a specific concern to 
risk of lung cancer (RR 1·25, 1.05–1.49; p=0.01).  
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Common risk factors shared by CVD and cancer such as smoking, obesity, 
hyperglycaemia, hypertension, and hyperlipidaemia induced inflammation and 
this can lead to expression and release of pro-inflammatory mediators 
subsequently fostering proliferation, survival, and migration (Coussens and Werb, 
2002, Libby, 2006). Especially hypertension, a well-established CVD risk factor, 
has been related to malignancy in previous studies. The most current study has 
reported that the risk of cancer increased correspondingly for every 10 mmHg BP 
increment (Stocks et al., 2012) To assess whether underlying CVD or hypertension 
affect the risk for cancer, a subgroup analysis was performed based on study 
population clinical settings. This subgroup analysis has found that the risk for 
cancer was independent of treatment indication where a comparable association 
was observed between the population with underlying hypertension (OR 0.93, 95% 
CI 0.86-1.00; P-value = 0.06) and high CVD risk (OR 0.95, 95% CI 0.87-1.04). 
Overall, the current study’s results corroborated the results of two recent meta-
analyses (Bangalore et al. (2011), (Monami et al., 2013). In the most recent study, 
Monami et al. (2013) conducted a meta-analysis of RCTs using BB in addition to an 
observational study looking at the risk of cancer in T2DM on insulin. The eligibility 
criteria for this study were more relaxed because the authors have allowed the 
inclusion of studies with smaller sample sizes (n participants < 100). Their meta-
analysis of nine RCTs concluded that BB was associated with a non-significant 
trend towards a reduced risk of cancer overall (OR 0.93, 95% CI 0.86-1.01; P-value 
= 0.07). In another study, Bangalore et al. (2011) have conducted a network meta-
analysis of antihypertensive drugs and risk of cancer which includes BB. Their 
direct meta-analysis of seven BB trials yielded an OR of 0.94 with 95% CI ranged 
between 0.88 and 1.00 (P-value = 0.10). However, this meta-analysis included two 
studies, CONVINCE (Black et al., 2003) and STOP-HTN2 (Lindholm et al., 2001) that 
were excluded from the current review because of inadequate information on 
cancer outcomes for the BB treatment arm. Both studies have randomised patients 
to either BB or diuretics as one treatment arm versus other antihypertensive 
agents and reported cancer outcomes collectively. Incorporation of these data 
could introduce bias and may lead to a spurious result as the observed effects may 
have equally resulted from administration of either drug. This was demonstrated 
in the current study sensitivity analysis where inclusion of these two studies in the 
meta-analysis has shifted the combined treatment effect from non-significant to 
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statistically significant (OR 0.94, 95% CI 0.88-1.00; P-value = 0.04). Similar 
precaution was also taken in a much earlier network meta-analysis. The meta-
analysis by Coleman et al. (2008) has assessed the impact of major 
antihypertensive medication classes on cancer incidence and reported no 
significant difference in risk of cancer in relation to BB with OR 1.00 (95% CI 0.78-
1.32). Compared to the current study, the eligibility criteria for this meta-analysis 
was less strict because they allowed smaller studies (n participants < 100 per 
treatment arm) and shorter duration of patients’ follow-up (minimum six months).  
In addition, the effect of different BB receptor selectivity on the risk of cancer 
was evaluated. From the subgroup analysis, there is little evidence of an 
association when analyses were restricted to cardioselective BB (OR 0.93, 95% CI 
0.87-1.01; P-value = 0.07) and non-cardioselective BB (OR 0.87, 95% CI 0.25-3.06) 
although the trend is toward a reduced risk of cancer in both subtypes. The only 
other meta-analysis that has considered BB receptor selectivity was by Bangalore 
et al. (2011). They have observed an OR of 0.15 (95% CI 0.02-1.50) from one non-
cardioselective BB study whereas an OR of 0.94 (95% CI 0.88-1.00) for 
cardioselective BB, which is similar to the present study result. Many prior studies 
have not considered the different BB agents subtypes in analysis and this, may in 
part, have led to the continuous reporting of conflicting results.  
Studies that have considered the effects of the different BB subtypes mainly 
looked at cancer patients’ survival as their main outcome. One earlier study 
(Barron et al., 2011) conducted an observational study following 5,333 women 
with breast cancer between 2001 and 2006. The author observed significantly 
lower odds of terminal stage breast cancer (OR 0.24, 95% CI 0.07-0.85) and breast-
cancer specific mortality (OR 0.19, 95% CI 0.06-0.60) in propranolol users 
compared to the non-BB user. Conversely, there was no difference in tumour 
spread or breast-cancer specific mortality in atenolol users compared to matched-
controls. Quite recently, a study by Watkins et al. (2015) investigated the impact 
of selective and non-selective BB on survival in 1,425 medical records of women 
with ovarian cancer. The investigators found that those receiving non-selective BB 
had a median overall survival (OS) of 94.9 months versus 38 months for those 
receiving β1-adrenoceptor selective agents (P-value < 0.001) and this effect was 
independent to the effect of the drug on hypertension. A similar result was 
reported in another study (Renz et al., 2017) looking at the survival of 595 patients 
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with post-pancreatic ductal adenocarcinoma resection. Renz and colleague 
reported the median OS of patients receiving BB was 40 months versus 23 months 
in non-BB user (P-value = 0.0007) and 21 months in those receiving cardioselective 
agents (P-value = 0.0396). They also found that microtumours treated with either 
non-selective BB or β2-adrenoceptor selective agents showed significantly lower 
residual metabolic activity (P-value = 0.032). Although the present study analysis 
for non-cardioselective BB resulted in a non-significant association and showed 
significantly high evidence of heterogeneity (I2 = 53%), the effect magnitude and 
direction supports the outcome reported by both Watkins et al. (2015) and Renz 
et al. (2017). As for cancer-related death, only the MRC study used the non-
selective BB and has shown a non-significant lower odds of cancer-related death 
(OR 0.98, 95% CI 0.63-1.51). However, the reverse outcome was reported by one 
previous analysis using an established UK primary care database (Shah et al., 2011) 
following 3,462 patients aged 40 to 85 with a new common cancer diagnosis for 
up to ten years. Compared with cancer patients receiving other antihypertensive 
therapy, this study found that users of BB overall experienced poorer survival with 
HR 1.21 (95% CI 0.94-1.55) for the non-selective BB. Still, findings from previous 
studies combined with the result from the present study suggest targeted therapy 
of the adrenergic beta-2 pathway could potentially be promising in the 
therapeutic strategy of cancer patients and merits further research. 
Furthermore, the meta-analysis conducted in the present study also found no 
significant association between BB and the risk of overall cancer-related mortality 
with OR 1.04 (95% CI 0.93-1.17; P-value = 0.47). Results from the present study to 
a certain extent agree with the findings reported by Bangalore et al. (2011) where 
their meta-analysis of seven BB studies and cancer-related deaths have 
demonstrated an OR of 1.02 (95% CI 0.92-1.14; P-value = 0.51). Compared to this 
study, the present meta-analysis is larger and more precise because five additional 
studies were included and the CONVINCE study which does not contain adequate 
information on cancer outcomes for the BB treatment arm was excluded. Of the 
included studies in the analysis, only the MAPHY and MRCOA have reported the 
exclusion of patients with baseline cancer. For this reason, the treatment effect 
derived could not be determined if it was confounded by underlying cancer 
diagnosed prior to the study randomisation. 
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Nonetheless, the use of BB in cancer patients has been shown to reduce cancer-
specific mortality in some studies. In one observational study(Botteri et al., 2013), 
treatment with BB showed significantly lower breast-cancer death in menopausal 
women with triple-negative breast cancer (TNBC). The researcher identified 800 
patients operated between 2007 and 2008 with TNBC and found the risk of breast-
cancer specific mortality favoured those on BB treatment with HR 0.42 (95% CI 
0.18-0.97). Apart from breast cancer, BB use was also associated with a lower risk 
of prostate cancer-specific (Grytli et al., 2014), ovarian cancer-specific (Watkins 
et al., 2015), and melanoma –specific mortality (Wrobel and Le Gal, 2015).  
On the contrary, a number of studies have found that BB use was not associated 
with improved survival for common cancers. Some of the studies (Shah et al., 
2011) have been described earlier in this discussion. In another large United 
Kingdom (UK) study (Cardwell et al., 2014), a cohort of 6,339 prostate cancer 
patients identified from the UK Clinical Practice Research database (CPRD) was 
followed for an average follow-up of six years. The researchers found little 
evidence of a reduction in risk of prostate cancer-specific mortality in BB users 
compared to non-users (OR 0.94, 95% CI 0.81-1.09). Furthermore, this finding was 
supported by a recent systematic review and meta-analysis of 30 observational 
studies enrolling  88,026 cancer patients (Weberpals et al., 2016). The authors of 
this meta-analysis concluded that there was no significant clinical evidence 
associating BB use and survival. They have also proposed that the beneficial effect 
of BB on cancer survival might be based on immortal time bias (ITB) which refers 
to a period of follow-up during which, by design, the event or outcome of interest 
cannot take place (Lévesque et al., 2010). Most cohort studies are susceptible to 
ITB when they fail to account for appropriate follow-up time and treatment status 
in the design and analysis.           
 Strengths and limitations 
The main strength of this review is that only RCTs were included where this study 
design is the gold standard for evaluating the effectiveness of the intervention. 
Additionally, only studies with cancer data for BB were incorporated for this meta-
analysis, hence resulting in a more precise association for the drug class studied. 
Cancer outcomes from the BHAT and MERIT-HF study were only incorporated in 
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this review of BB trials. Also, a comprehensive search was conducted spanning a 
period of over 60 years.  
The present review has a number of shortcomings. One limitation is that all of the 
RCTs were not designed to detect incident cancer and/ or cancer-related 
mortality as a primary end-point. Apart from cancer-deaths, diagnosis of 
malignancy was variably adjudicated across the different studies. Second, only 
aggregate data reported as raw number (n/N) were available for most of the 
studies. Due to the unavailability of individual-patient data, the time-to-event 
analysis was not performed. Availability of such information could better estimate 
the association of drug class studied to the occurrence of site-specific and overall 
cancer. Moreover, most of the studies were followed for an average short period 
of time ranging from one to five years.  As cancer development is a slow process, 
the results from the present study could only reflect late-detected cancers. Also, 
the risk of cancer from this meta-analysis could not be inferred to individual BB 
as only atenolol, metoprolol, practolol, and propranolol were used in the included 
trials. Finally, the number of trials included in the meta-analysis for cancer 
incidence was too small (n= 7 for incident cancer). Although only five or more 
trials are all that is needed to give some confidence that the result is valid 
(Herbison et al., 2011), the conclusion drawn from these reviews is not possible 
to predict as estimates could still differ substantially following the addition of 
studies in the future.   
 Conclusion 
BB use is not significantly associated with the risk of cancer or cancer-related 
death overall. Results from this review and meta-analysis add to the growing body 
of evidence suggesting this drug class does not affect the risk for malignancy. 
Finally, further research investigating the use of non-cardioselective BB as part of 
a treatment strategy for cancer therapy is warranted.
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8 Association between Thiazide diuretics (TZ) and 
risks of cancer 
8.1 Introduction 
A diuretic is any substance that increases production of urine thereby promoting 
the removal of body salt, mainly sodium, and water. There are different types of 
diuretics and various diuretic agents are used in medicine for specific purposes. 
Prior to the advent of modern day’s diuretics, only intravascular and intramuscular 
mercurial agents were available and effective, though their use was difficult and 
restricted. Understanding the mechanism of a renal tubular mechanism for 
acidifying the urine has led to the development of carbonic anhydrase inhibitor 
(Pitts, 1945). In the process of refining and producing a more potent carbonic 
anhydrase inhibitor, exploration of several key compounds and addition of a 
benzene ring to sulfonamide has resulted in chlorothiazide, a first for its class 
(Novello and Sprague, 1957, Beyer, 1982). Members of this drug class are derived 
from benzothiadiazine with a benzothiadiazine ring as a parent structure and are 
collectively termed as ‘thiazide’ diuretics. Drugs that act on the same co-
transporter in the distal tubules of the kidney but do not have the chemical 
structure of a TZ are known as ‘TZ-like’ diuretics. 
The pharmacokinetics of TZ varies between subclasses and individual drugs. The 
comparison between TZ-type and TZ-like diuretics are outlined in Table 8-1 (page 
280). Although these drugs are collectively known as TZ, significant differences 
in chemical structure exist. The only common structure between the two 
subclasses is the sulphonamide group (SO2NH2), the chemical compound that 
inhibits carbonic anhydrase activity. All TZs are absorbed orally and have a volume 
of distribution equal to or greater than total body weight. The oral bioavailability 
is relatively high and varies between individual TZ. All TZs are highly protein-
bound, hence limit its filtration by the renal glomeruli and allow its delivery to 
secretory sites of the renal proximal tubular cells. Among the TZs, chlorthalidone 
has the longest elimination half-life of 50 to 60 hours. Most TZs are renally 
excreted except for indapamide which is metabolized by the liver and excreted 
via the biliary system. 
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In general, the main action of diuretics is to promote diuresis by the kidney which 
is achieved by altering how the kidney handles sodium. Different diuretic acts on 
a different segment of the renal tubular system. Figure 8-1 depicts a unit of 
nephron with sites of action for major diuretic groups. The primary site of action 
for TZ is at the distal convoluted tubule (DCT) of the nephron. Inset is a molecular 
level depiction of TZ exerting its effect on the epithelial cells of the renal distal 
tubule. Approximately 10% of the filtered sodium chloride (NaCl) is reabsorbed in 
the distal tubule (Ives, 2012) and sodium (Na) returns into the circulation via the 
adenosine triphosphate (ATP)-activated sodium-potassium pump. Inhibition of the 
Na/Cl co-transporter (NCC) by TZ at the luminal side of the epithelial cells in the 
DCT prevents reabsorption of NaCl. The resulting low intracellular sodium (Na) in 
turn lowers intracellular calcium (Ca) mediated by the Na/Ca exchanger (NCX1). 
Low intracellular Ca subsequently enhanced the diffusion of Ca through calcium 
ion channels expressed on the luminal membrane and therefore increases Ca 
reabsorption. The hypocalciuric effect caused makes TZ useful in patients with 
kidney stones produced by hypercalciuria. Moreover, the unabsorbed NaCl is 
consequently delivered to the collecting duct where only 2-5% is reabsorbed by 
the kidney (Ives, 2012) while the remaining is excreted with excess water as urine.  
 TZ and cancer 
One of the postulated mechanisms where TZ could alter the risk for cancer is that 
TZ, such as HCTZ, as a cyclic amide can be converted to a nitroso derivative in 
the stomach which is mutagenic (Andrews et al., 1984). An experimental study 
using rats have shown that rats treated with HCTZ  developed chronic nephropathy 
and renal adenomas (Lijinsky and Reuber, 1987). Treatment with TZs has also been 
shown to alter the epithelial structure of the nephron distal tubule. Loffing et al. 
(1996) have demonstrated in an animal study where rats treated with TZ such as 
HCTZ or metolazone for three days provoked apoptosis and most of the DCT 
epithelial cells have thickened resembling a stratified epithelium. Findings from 
these experimental studies led to the speculation that the continuous 
bombardment of the DCT with TZ may lead to neoplastic changes and possibly give 
rise to renal cancer. For evidence from epidemiological studies, see Chapter 1, 
Section 1.9.6 (page 53). 
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This chapter aims to systematically review and report the meta-analysis of RCTs 
using TZ diuretic as one of its treatment and its association with risks of cancer. 
 
 
Figure 8-1 Site of diuretics action in the nephron. 
TZ block the Na/Cl cotransporter that is selectively expressed in the distal convoluted tubule, 
inhibiting its ability to transport ions. The inhibition of Na transport in this segment results in greater 
delivery of sodium to the collecting duct. KCC, potassium chloride c-transporter; NCC, sodium 
chloride co-transporter; NCX1, sodium calcium exchanger 1. Modified from Ives (2012). 
 
Thiazide diuretics mechanism of 
action 
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Table 8-1: Pharmacokinetic characteristics of thiazide diuretics 
Diuretic  Thiazide Thiazide-like
Drug name Chlorothiazide HCTZ Bendroflumethiazide Chlorthalidone Indapamide Metolazone
Chemical compound Benzothiadiazine derivative 
Benzothiadiazine 
derivative 
Benzothiadiazine 
derivative 
Benzophenones 
derivative 
Chlorosulphonamide 
derivative 
Quinazoline 
derivative 
Relative carbonic 
anhydrase inhibition* ++ 
 
+ 
 
0 
 
+++ 
 
++ + 
 
Oral bioavailability (%) 
 
15-30 
 
60-70 
 
90 
 
65 
 
93 65 
 
Volume of distribution 
(litres per kilogram) 
 
1 
 
2.5 
 
1.0-1.5 
 
3-13 
 
25† 113† 
Protein binding (%) 70 40 94 99 75 95 
Half-life (hour) 1.5-2.5 9-10 9 50-60 14 8-14 
Route of elimination 100% renal 95% renal 30% renal 65% renal 
Hepatically 
metabolised 
80% renal 
* Plus signs indicates inhibition with greater number of plus signs reflecting increased inhibition. The zero indicates the inhibition constant of 0.  
† The volumes of distribution for indapamide and metolazone are given for the total volume in litres. Data on litres per kilogram were not available. 
Table adapted from Ernst and Moser (2009). 
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8.2 Methodology 
 Systematic review 
Full descriptions of the methods used have been described previously in Chapter 
2, Section 2.1. Except for the ALPINE (Lindholm et al., 2003) and PREVER-
Treatment study (Fuchs et al., 2016), all cancer outcomes were published in the 
individual primary study or post-hoc analyses. Cancer data for the ALPINE study 
was retrieved from a meta-analysis published by Bangalore et al. (2011). 
Meanwhile, cancer input for the PREVER-Treatment study was provided by the 
study’s primary author, Dr Flávio D. Fuchs of Hospital de Clinicas de Porto Alegre, 
Rio Grande do Sul, Brazil. Furthermore, the PHYLLIS study has four treatment arms 
consisted of TZ, ACEI, TZ plus statin, and ACEI plus statin. However, only the TZ 
and ACEI monotherapy were considered in this review. 
 Meta-analysis 
For data synthesis, see Chapter 2, Section 2.1.7.4 (page 66). 
Sensitivity analyses for TZ and risk of cancer were conducted by the exclusion of 
studies based on the following criteria: [1] small sample size with the number of 
total participants less than 1000, and [2] poor methodological quality. 
Additionally, the ALPINE study was excluded from the overall meta-analysis due 
to a different add-on therapy between the TZ diuretic treatment arm and control. 
Subgroup analyses were also conducted on the following groups and treatment 
comparisons: [1] subclass; [2] comparator; [3] clinical setting; [4] mean age; and 
[5] duration of follow-up. 
8.3 Results 
The searching and identification process of trials is summarised in Figure 3-1 (page 
74). From the 90 studies eligible for the systematic review, only 18 studies were 
included in the analysis for TZ. The 72 eligible studies excluded from this review 
were primarily because they do not consist of a TZ diuretic treatment arm.  
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As a whole, the search result has identified 18 studies enrolling 79,058 participants 
with an average follow-up of 3.4 years. The average age for patients across all 
trials is 59.5 years. The full characteristics and risk of bias of the 18 studies 
included in this review have been described previously (See Chapter 3, Section 
3.2.2.1 and Section 3.3.6). 
Majority of the studies were published in the1980s and 1990s with the oldest study, 
ANBP (The ANBP Study Commitee, 1980), published in 1980 whereas only five 
studies were published after the 20th century. The largest study is the ALLHAT 
trial enrolling 33,357 patients and all studies have recruited at least 300 
participants in total. All studies, except one, recruited patients with underlying 
hypertension. The trial conducted by LaCroix (2000) has targeted healthy elderly 
men and women who were normotensive with baseline bone mineral density at 
the total hip that was within two standard deviations of the normal value for their 
age.  
Overall, 41.2% of the participants across all the studies were randomised to TZ 
diuretic. Of these, slightly over half (56.1%) of the participants were assigned to 
TZ-like diuretics including chlorthalidone and indapamide. Majority of the studies 
have compared TZ to active controls such as RAS inhibitors, CCB, and BB. The 
remaining five studies compared TZ to either placebo or no treatment. 
Most of the studies consist of two parallel treatment arms and only four studies 
consist of an additional one or two treatment arms. The ALLHAT study has 
compared TZ to ACEI and CCB whereas the MRC and MRCOA study has compared 
TZ to BB and placebo. Except for three studies, the majority of the studies have 
implemented the double-blind methods. Treatment assignment in both the MRC  
and MRCOA studies were single-blind while the OSLO study was open-label with 
blinded end-points assessors.   
All the participants in the studies were followed for at least one year with the 
longest mean duration of follow-up was 5.8 years. The mean or median age of 
patients recruited into most of the studies is above 50 years except in the OSLO 
study whose patients were slightly younger with a mean age 45.3 years. Four 
studies, EWPHE, MRCOA, NICS-EH, and SHEP, were designed to investigate the 
effect of TZ in older patients with a mean or median age ranged between 69 and 
Chapter 8 TZ and risk of cancer 283 
 
72 years. Furthermore, the proportion of male and female participants was 
comparatively equally distributed across all studies except in seven studies where 
male (MAPHY, MIDAS, OSLO, VA COOP II) or female (EWPHE, LaCroix, NICS-EH) 
participants were predominant. The proportion of smokers ranged from small to 
moderate across all studies. 
Table A-3 (Page 321) shows the selected characteristics of interest extracted from 
individual trials. The reporting of all these variables was inconsistent across all 
studies. None of the studies has reported the status of cancer patients’ enrolment 
but eight studies have stated cancer or malignancy as their exclusion criteria from 
their protocol. Also, only four studies (ALLHAT, MIDAS, MRC, MRCOA) were 
designed to detect cancer incidence and/ or cancer-related deaths as one of their 
primary or secondary outcomes. The remaining 18 studies did not mention cancer 
incidents or cancer-related death as one of their primary or secondary endpoints. 
Method for arbitration of cancer diagnosis and other major adverse events were 
not described in many of the included studies. Only seven studies reported that 
cancer and/or cancer-related deaths were centrally adjudicated. Similarly, 
reporting of patients’ adherence to study treatment was lacking in many except 
for eight studies. In these studies, patients’ adherence was reported to be 
between good to excellent ranging from 65% to 100%. Most of the studies have 
reported the proportion of participants who were lost to follow-up. No patients 
were lost to follow-up in three studies (ALPINE, NESTOR, OSLO) while two studies, 
MRC and MRCOA have a high attrition rate of 19% and 25% respectively. Cancer 
outcomes were available publicly for all studies except for one.  
8.4 TZ and risks of incident cancer 
 Overall 
Altogether, 12 RCTs were included and data were available from 44,768 (99.4%) 
of the total 45,039 patients enrolled. Cancer incidence was 6.36% in the TZ 
treatment group versus 6.74% in the control group. In the FE model as shown in 
Figure 8-2, the ALLHAT study had the highest weight at 86.6% overall which is 
clearly indicated by the largest blue square in the forest plot. The weight 
assignment between the heaviest and the second heavy study is very wide with a 
difference of 76.5%. The remaining studies only carry a small portion of weight 
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each ranging from 0.1% to 1.5%. Only four studies (LaCroix, MIDAS, NESTOR, VA 
COOP II) had recorded an increased risk with OR more than 1, however, the 95% 
CI for these studies overlaps 1. The remaining studies recorded an OR equivalent 
or less than 1 with the 95% CI includes 1. Confidence intervals for all the studies 
crossed the line of no effect indicating a lack of statistical significance at the 
study level. As a result, the combined OR is 0.97 with 95% CI ranged between 0.90 
and 1.05 (P-value = 0.43). The diamond that represents the pooled effect 
estimates impinges the line of no effect, hence indicating the absence of 
statistical significance at the meta-analysis level.    
Figure 8-3 depicts the RE model meta-analysis of the 18 RCTs included in the 
assessment of cancer risk. Likewise, the ALLHAT study was given the heaviest 
weightage at 87.4% overall while the majority of the remaining studies carries a 
weight of less than 1%. The combined effect estimate yields an OR of 0.97 with 
95% CI ranged between 0.90 and 1.05 (P-value = 0.43), unequivocally similar to 
the FE model.  
Assessment of heterogeneity in both FE and RE model showed a chi-square P-value 
of 0.80 and an I2 statistics of 0% indicating no statistical differences between 
studies. 
Visual assessment of the funnel plot as shown in Appendix Figure A-1(Page 323) 
demonstrated missing studies on the middle right side of the plot but no outlier is 
detected. Overall, the funnel plot appears relatively symmetry on both sides of 
the plot indicating the risk of publication bias is unlikely.  
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Figure 8-2: Forest plot of incident cancers by TZ vs non-TZ controls [FE model]. 
Odds ratios and 95% confidence interval, overall and in 18 trials. The overall effect represents the 
pooled estimate of odds for incident cancers.  
 
 
Figure 8-3: Forest plot of incident cancers by TZ vs non-TZ controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 18 trials. The overall effect represents the 
pooled estimate of odds for incident cancers. 
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 Sensitivity analysis 
Exclusion of 16 studies enrolling less than total 1000 participants resulted in OR 
0.97 with 95% CI ranged between 0.90 and 1.05 (P-value = 0.41; Figure 8-4). This 
result is largely driven by the ALLHAT study because it was assigned 89.5% of the 
overall weight. Chi-square test for heterogeneity yields a P-value of 0.23 and I2 
statistics is observed at 30% indicating low heterogeneity between studies. The 
heterogeneity observed is most likely due to the methodological diversity of the 
ALLHAT (a three-arm parallel study) and INSIGHT (used a different type of TZ drug) 
study.  
Figure 8-5 shows the meta-analysis of five studies after exclusion of studies 
judged to be of low methodological quality. The combined effect estimates yield 
an OR of 0.98 with 95% CI ranged between 0.91 and 1.06 (P-value = 0.66). This 
result was mainly influenced by the ALLHAT study because it was assigned 99.5% 
of the overall weight. Assessment of heterogeneity showed a chi-square test P-
value of 0.93 and I2 statistics of 0% indicating a lack of statistical significance in 
differences between studies.  
Finally, the exclusion of the ALPINE study from the overall-meta-analysis resulted 
in OR 0.97 with 95% CI ranged between 0.90 and 1.05 (P-value = 0.43; Figure 8-6). 
The weighting of the studies in this meta-analysis is comparable to the primary 
meta-analysis analysis with the ALLHAT study assigned the most weight (86.7%). 
Assessment of heterogeneity showed a chi-square test P-value of 0.72 and I2 
statistics of 0% indicating a lack of statistical significance in differences between 
studies.  
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Figure 8-4 Forest plot of incident cancers by TZ vs controls [Sensitivity analysis: Study 
size]. 
The overall effect represents the pooled estimate of odds for incident cancers. 
 
 
Figure 8-5 Forest plot of incident cancers by TZ vs controls [Sensitivity analysis: 
Methodological quality]. 
The overall effect represents the pooled estimate of odds for incident cancers. 
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Figure 8-6 Forest plot of incident cancers by TZ vs controls [Sensitivity analysis: Exclusion 
of the ALPINE trial]. 
The overall effect represents the pooled estimate of odds for incident cancers.  
 Subgroup analyses 
Table 8-2: summarises the results for subgroup analyses performed for TZ and 
cancer risk.  
8.4.3.1 By Subclass 
Data for TZ-type diuretics were available from nine RCTs with a total study 
population of 10,187. Cancer incidence was 3.21% in the TZ-type treatment groups 
versus 3.69% in the control group. The combined effect estimate resulted in OR 
0.89 with a rather wide 95% CI ranging from 0.72 to1.10 (P-value = 0.28). As shown 
in Figure 8-7, the INSIGHT study has the biggest influence as it carries the heaviest 
weight overall (77.4%) and is depicted as the largest blue square in the forest plot.  
The chi-square test resulted in a P-value of 0.66 and the I2 statistics of 0% indicates 
no statistical difference between studies. 
For TZ-like diuretics, data were available from 34,581 patients enrolled in three 
RCTs. Cancer incidence was 7.39% in the TZ-like diuretics treatment group versus 
7.56% in the control group with OR 0.98 (95% CI 0.91-1.07; P-value = 0.67). This 
result was largely driven by the ALLHAT study as it was assigned 99.7% of the 
overall weight (Figure 8-7). Assessment of heterogeneity showed a chi-square P-
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value of 0.84 and I2 statistics is observed at 0% indicating no statistical difference 
between studies.  
8.4.3.2 By type of comparator 
Altogether, ten RCTs have compared TZ to active controls with data available 
from 43,608 patients. Cancer incidence was 6.46% in the TZ-diuretics treatment 
group versus 6.79% in the active control group. Pooling of effect estimates from 
the ten studies yields an OR of 0.97 (95% CI 0.90-1.05) with P-value = 0.44 (Figure 
8-8). The ALLHAT study had the biggest influence in this analysis as it carries 88% 
of the overall weight. The chi-square test resulted in a P-value of 0.64 and the I2 
statistics of 0% indicates no statistical heterogeneity between studies. 
Five RCTs compared TZ to RAS inhibitors comprising ACEI and ARB and data were 
available from 26,179 patients. Cancer incidence was 7.25% in the TZ treatment 
group versus 7.10% in the RAS inhibitors treatment group. Combined effect 
estimates resulted in OR 0.98 (95% CI 0.89-1.08; P-value = 0.75). This result was 
mainly influenced by the ALLHAT study as it carries the most weight overall at 
99.2% (Figure 8-8). Assessment of heterogeneity showed a chi-square P-value of 
0.75 and I2 statistics observed at 0% indicating no statistical difference between 
studies. 
Similarly, five RCTs have compared TZ to CCB with data available from 32,290 
patients. Cancer incidence was 6.81% in the TZ treatment group versus 6.66% in 
the CCB treatment group with OR 0.96 (95% 0.88-1.05; P-value = 0.40). The 
ALLHAT study was assigned the heaviest weight of 84% overall and consequently 
has a major influence in the direction of the combined OR (Figure 8-8). The chi-
square test resulted in a P-value of 0.33 and the I2 statistics observed at 13% 
signifies low heterogeneity between studies. The observed heterogeneity is most 
likely due to methodological and clinical diversity of the MIDAS study 
(predominant male participants).  
For placebo, data were available from 1,160 patients enrolled in two RCTs. Cancer 
incidence was 3.33% in the TZ treatment group versus 4.16% in the placebo group 
with OR 0.94 and a relatively wide 95% CI ranging from 0.51 to 1.73 (P-value = 
0.84). From Figure 8-8, it is clear that the EWPHE study has influenced the 
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direction of the pooled effect estimates with assigned study weight of 96.9% 
overall. Assessment of heterogeneity showed a chi-square P-value of 0.78 and I2 
statistics observed at 0% indicates no statistical difference between studies.  
8.4.3.3 By population health setting 
Data for patients with uncomplicated hypertension were available from 3,947 
enrolled in seven RCTs. Cancer incidence was 2.16% in the TZ treatment group 
versus 2.10% in the control group. The combined effect estimates resulted in OR 
1.05 with a rather wide 95% CI ranged between 0.68 and 1.61 (P-value = 0.83). 
The overall result was mainly driven by the EWPHE  study (51.2%) followed by the 
MIDAS study (21.4%) as demonstrated by the weight assigned to each study (Figure 
8-9). Assessment of heterogeneity showed a chi-square P-value of 0.54 and I2 
statistics is observed at 0% indicates no statistical difference between studies. 
For hypertensive patients with one or more risk factor for CV events, data were 
available from 40,902 patients enrolled in four RCTs. Cancer incidence was 6.81% 
in the TZ treatment group versus 7.13% in the control group with OR  0.97 (95% CI 
0.90-1.04; P-value = 0.40). This analysis was mainly driven by the ALLHAT study 
as it carries the greatest weight of 89.2% overall. The chi-square test resulted in 
a P-value of 0.63 and the I2 statistics of 0% signifies no statistical heterogeneity 
between studies. 
8.4.3.4 By mean age groups 
For studies with patients’ mean age of 65 years or older, data were available from 
41,252 enrolled in five RCTs. Cancer incidence was 6.84% in the TZ treatment 
group versus 7.19% in the control group. The pooled effect estimates resulted in 
OR 0.97 (95% CI 0.90-1.04; P-value = 0.38). The analysis was mainly influenced by 
the ALLHAT study as it was assigned the most weight of 87.8% overall (Figure 
8-10). The chi-square test resulted in a P-value of 0.73 and the I2 statistics of 0% 
signifying no statistical heterogeneity between studies.  
On the other hand, data for studies with younger mean age (< 65 years) were 
available from 3,516 patients enrolled in seven RCTs. Cancer incidence was 1.24% 
in the TZ treatment group versus 0.98% in the control group with combined OR of 
1.26 and a wide 95% CI ranging from 0.68 to 2.32 (P-value = 0.47; Figure 8-10). 
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This result was mainly influenced by the MIDAS study which carries the most 
weight overall (47.6%). Assessment of heterogeneity showed a chi-square P-value 
of 0.63 and I2 statistics observed at 0% indicates no statistical difference between 
studies. 
8.4.3.5 By duration of follow-up 
Data for studies with mean patients’ follow-up three years or longer were 
available from 42,135 patients enrolled in six RCTs. Cancer incidence was 6.76% 
in the TZ treatment group versus 7.09% in the control group. Combined effect 
estimates resulted in OR of 0.97 (95% CI 0.90-1.05; P-value = 0.45). This analysis 
was mainly driven by the ALLHAT study which was assigned the greatest weight 
overall (87.2%; Figure 8-11). Assessment of heterogeneity showed a chi-square P-
value of 0.59 and I2 statistics observed at 0% indicates no statistical difference 
between studies. 
Meanwhile, studies with patients’ mean follow-up duration of less than three years 
were available from 2,633 patients enrolled in six RCTs. Cancer incidence was 
0.52% in the TZ group versus 0.62% in the control group. Combined effect 
estimates resulted in OR of 0.86 with a very wide 95% CI ranged between 0.34 and 
2.18 (P-value = 0.74; Figure 8-11). Weights were fairly distributed between 
studies with almost equivalent weight was assigned to the VERDI, PREVER-
Treatment, and NESTOR study (26.5%, 21.2%, and 20.7% respectively). The chi-
square test resulted in a P-value of 0.67 and the I2 statistics of 0% signifies no 
statistical heterogeneity between studies. 
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Table 8-2: Thiazide diuretics and risk of cancer: Subgroup analyses 
Subgroup analysis No. of study 
No. of 
participants
Cancer incidence 
(%) OR (95% CI) P-value I2 (%) 
TZ Control 
Overall 
effect FE model 12 44768 6.36 6.74 0.97 (0.90-1.05) 0.43 0 
Subclass 
TZ 9 10187 3.21 3.69 0.89 (0.72-1.10) 0.28 0 
TZ-like diuretics 3 34581 7.39 7.56 0.98 (0.91-1.07) 0.67 0 
Type of 
comparator 
Active 10 43608 6.46 6.79 0.97 (0.90-1.05) 0.44 0 
RAS inhibitors 5 26179 7.25 7.10 0.98 (0.89-1.08) 0.75 0 
CCB 5 32290 6.81 6.66 0.96 (0.88-1.05) 0.40 13
Placebo 2 1160 3.33 4.16 0.94 (0.51-1.73) 0.84 0
Clinical 
setting 
Hypertension 7 3947 2.16 2.10 1.05 (0.68-1.61) 0.83 0 
High- risk 
hypertensive 4 40902 6.81 7.13 0.97 (0.90-1.04) 0.40 0 
Age 
≥ 65 years 5 41252 6.84 7.19 0.97 (0.90-1.04) 0.38 0 
< 65 years 7 3516 1.24 0.98 1.26 (0.68-2.32) 0.47 0 
Duration of 
follow-up 
≥ 3 years 6 42135 6.76 7.09 0.97 (0.90-1.05) 0.45 0 
< 3 year 6 2633 0.52 0.62 0.86 (0.34-2.18) 0.74 0 
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Figure 8-7: Forest plot of cancer incidence by TZ subclass [FE model]. 
1)TZ vs controls in 9 trials; 2) TZ-like vs controls in 3  trials The subtotal effect represents the 
pooled estimate of odds for cancer incidence for each subclass. 
 
 
Figure 8-8: Forest plot of cancer incidence by comparators [FE model]. 
1) Active controls; 2) RAS inhibitors; 3) CCB; 4) Placebo. The subtotal effect represents the pooled 
estimate of odds for cancer incidence for each comparator.  
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Figure 8-9: Forest plot of cancer incidence by clinical setting [FE model]. 
1) Hypertension; 2) High-risk hypertension. The subtotal effect represents the pooled estimate of 
odds for cancer incidence for each clinical setting. 
 
 
Figure 8-10: Forest plot of cancer incidence by study population’s mean age [FE model]. 
1) Mean age ≥ 65 years; 2) Mean age < 65 years. The subtotal effect represents the pooled 
estimate of odds for cancer incidence for each criterion.  
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Figure 8-11: Forest plot of cancer incidence by study mean duration of follow-up [FE 
model]. 
1) Follow-up ≥ 3 years; 2) Follow-up < 3 years. The subtotal effect represents the pooled estimate 
of odds for cancer incidence for each criterion.
 
8.5 Thiazide diuretics and cancer-related death 
Overall, 10 RCTs were included in the meta-analysis of TZ-diuretics and cancer-
related death. Data were available from 69,241 (99.9%) patients out of total 
69,256 patients enrolled in the ten studies. Based on randomly assigned therapy, 
cancer-related deaths were 2.58% in the TZ group versus 2.35% in the control 
group. 
Figure 8-12 shows the meta-analysis 10 TZ-diuretic trials in an FE model. The 
main analysis was mainly influenced by the ALLHAT study as it was assigned the 
most weight overall at 67.4% which is clearly depicted as the largest blue square 
in the forest plot. This is followed by the SHEP, MRCOA, and MRC study which carry 
10%, 9.8% and 8.5% of the overall weight correspondingly. Five studies have 
recorded an OR more than 1 ranging from 1.06 to 4.90. On the other hand, the 
five remaining studies observed an OR less than 1 ranging from 0.32 to 0.96. The 
95% CI of all the studies includes 1 which is displayed as CI crossing the vertical 
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line of no effect in the forest plot. Therefore, none of the individual studies is 
statistically significant at the study level. When the results of all the ten studies 
were pooled together, the combined effect showed an OR of 1.03 with 95% CI 
ranged between 1.03 and 1.14 (P-value = 0.56) and the diamond that represents 
the combined effect estimate in the forest plot is located on the line of no effect. 
This result indicates that no statistical significance is observed at the meta-
analysis level. 
Figure 8-13 showed the meta-analysis of the ten studies in a RE model. In 
comparison to the FE model, an additional 1.2% weight was assigned to the ALLHAT 
study whereas the remaining 17 studies carry less than 10% weight individually. 
Nevertheless, both FE and RE model meta-analyses arrive at an identical combined 
OR of 1.03 (95% CI 0.93-1.14) and a relatively similar overall effect P-value of 
0.57. 
Assessment of heterogeneity in both FE and RE model showed a chi-square test P-
value of 0.97 and I2 statistics of 0%. These values indicate no evidence of 
statistically significant heterogeneity between the difference studies.   
Evaluation of the funnel plot as shown in Appendix Figure A-2 (Page 324) 
demonstrates missing study on the right side of the plot. All the studies fall within 
the area of non-significance and no outlier is detected. Otherwise, the funnel plot 
appears fairly symmetrical indicating the presence of bias is unlikely. 
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Figure 8-12 Forest plot of cancer-related death by TZ vs non-TZ controls [FE model]. 
Odds ratios, and 95% confidence interval, overall and in 10 trials The overall effect represents the 
pooled estimate of odds for cancer-related death.  
  
 
Figure 8-13 Forest plot of cancer-related death by TZ vs non-TZ controls [RE model]. 
Odds ratios, and 95% confidence interval, overall and in 10 trials The overall effect represents the 
pooled estimate of odds for cancer-related death. 
 Sensitivity analysis 
Figure 8-14 shows the meta-analysis of eight studies after exclusion of the MRC 
and MRCOA. The combined effect estimates yield an OR of 1.05 with 95% CI ranged 
between 0.94 and 1.17 (P-value = 0.40). This result was mainly influenced by the 
ALLHAT study because it was assigned 82.5% of the overall weight. Assessment of 
heterogeneity showed a chi-square test P-value of 0.95 and I2 statistics of 0% 
indicating a lack of statistical significance in differences between studies. 
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Figure 8-14 Forest plot of cancer-related death by TZ vs controls [Sensitivity analysis: 
Exclusion of trials with high attrition rate].  
The overall effect represents the pooled estimate of odds for incident cancers 
8.6 Discussion 
The result of the present meta-analyses showed that TZ is not significantly 
associated with any cancer risk with OR 0.97 (95%CI 0.90-1.05; P-value = 0.43). 
The results of sensitivity analyses also suggest a similar direction to the combined 
effect estimates. Likewise, no significant association was seen between TZ and 
risks of cancer-related deaths (OR 1.03, 95% CI 0.93 and 1.14). The magnitude and 
direction of the association are comparable even after exclusion of the two trials 
with high attrition bias (MRC and MRCOA) with OR 1.05 (95% CI 0.94-1.17). 
Consistently, both TZ and TZ-like diuretics showed decreased cancer risk although 
the association is not statistically significant with OR 0.89 (95% CI 0.72-1.10) and 
OR 0.98 (95% CI 0.91-1.07) respectively. Previous systematic reviews and meta-
analyses of RCTs have not reported the risk for cancer between TZ and TZ-like 
diuretics (Coleman et al., 2008, Bangalore et al., 2011). Generally, both TZ and 
TZ-like diuretics are safe and well tolerated and their use is interchangeable. In 
practice, however, TZ-like diuretics such as chlorthalidone is preferred over HCTZ  
because the former is 1.5 to 2.0 times as potent and has a much longer duration 
of action than the latter. The main concern when prescribing diuretics would be 
electrolyte disturbance due to its mechanism of action at the distal tubules of the 
kidney. Blockade of the Na+/Cl- cotransporter at the distal tubule by TZ prevents 
reabsorption of Na+ which subsequently increases Na+ delivery to the collecting 
duct. Since Na+ reabsorption is coupled to K+ secretion in the collecting duct, TZ 
can lead to hypokalaemia by excessive secretion of potassium into the urine. 
Hyponatraemia is also a typical complication seen in TZ users especially in 
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elderlies and existing hypokalaemia (Fuisz et al., 1962, Chow et al., 2003). 
Additionally, studies have also reported lower insulin sensitivity following 
treatment with TZ (The ALLHAT Collaborative Research Group, 2002, Eriksson et 
al., 2008). A recent meta-analysis of 12 RCTs has assessed HCTZ and TZ-like 
diuretics (indapamide or chlorthalidone) effects on biochemical properties (Liang 
et al., 2017). The authors reported that the risk for hypokalaemia, hyponatraemia, 
or changes in serum glucose or total cholesterol is not different between the two 
TZ. Due to lack of head-to-head comparative trial between HCTZ and TZ-like 
diuretics, the authors have included data with a combination of diuretics and 
other antihypertensive class agents which could make an assessment of diuretics’ 
attributes on metabolic effects challenging. Nonetheless, these negative 
metabolic disturbances only occur at high doses and can be minimized by shifting 
to a low-dose strategy (Sica et al., 2011). 
Though insignificant, TZ to some extent appeared to have a protective effect 
against cancer incidence when compared to other antihypertensive agents or 
placebo. Subgroup analyses conducted in the present review have demonstrated 
an OR less than 1 with 95% CI overriding 1 for all comparisons using any active 
controls, RAS inhibitors, CCB or placebo (Table 8-2:). The most recent network 
meta-analysis of 70 RCTs with 148 comparator arms have reported an OR of 1.01, 
0.99,0.96, and 0.95 for TZ in direct comparison to ARB, ACEI, CCB, and placebo 
correspondingly for cancer incidence (Bangalore et al., 2011). In an earlier 
network meta-analysis of 27 RCTs with 56 comparator arms assessing the odds for 
cancer in major antihypertensive class agents, the OR for diuretics was 0.94 (95% 
CI 0.73-1.19) with placebo or untreated control group as the referent comparison 
(Coleman et al., 2008). Despite this evidence, many earlier epidemiological 
studies demonstrated the opposite.  
The most common malignancy to be associated with diuretics is the RCC. A 
retrospective cohort study by Yu et al. (1986) was one of the earliest studies to 
linked diuretics as one of the risk factors for RCC. The investigators assessed 
obesity, cigarette smoking, coffee consumption and diuretic use as a risk factor in 
160 pairs of RCC cases and controls. They have found that diuretics use is a 
significant risk factor for RCC in female but not in men with RR of 4.5 (95% CI 1.6-
14.5) and this relationship has remained even after controlling for hypertension 
(RR 4.0, 95% CI 1.3-12.5). Apart from diuretics, Yu and colleague also reported a 
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positive association with the other factors studied which are shared with another 
type of malignancy. This discovery had prompted a case-control study enrolling 
495 RCC cases and 697 controls assessing the odds for RCC with the use of diuretics 
(McLaughlin et al., 1988). A consistent association was seen in females but just in 
those without hypertension (16 cases, 6 controls) with OR 5.3 (P value <0.01) and 
not in those with hypertension (OR 0.7). Consistently, a 518 RCC cases and 1,381 
population-based controls study in Canada has also reported a significant increase 
in odds of RCC in women who used diuretics after adjusted for high BP with OR 
2.3 (95% CI 1.3-4.0)(Kreiger et al., 1993). These studies, however, are likely to be 
subjected to recall bias as they have used the interview-questionnaire method. In 
addressing this problem, an all-women cohort study in the US used a medical-
record database as a source of information on prescription diuretic use (Finkle et 
al., 1993). After adjusting for potential confounding factors, the investigators 
reported a significant association between RCC and diuretics (OR 2.9, 95% CI 1.7-
4.7). All the same, none of these studies specified the type of diuretics 
investigated. In another historical case-control study, the risk of RCC was assessed 
in relation to the use of TZ (Hiatt et al., 1994). Hiatt and team had reported a 
significant excess risk in women ever having used TZ with OR 4.00 (95% CI 1.5-
10.8) after adjusting for hypertension, body mass index (BMI), smoking, and kidney 
infection. Alternatively, they found that hypertension is not significantly linked to 
risk of RCC after adjustment to TZ therapy. 
While kidney cancer is more common in men than women with a male: female 
ratio of around 17:10 (Cancer Research UK, 2016), the fact that most of these 
studies have documented that women are at higher risk of RCC than men suggests 
a specific cause. A cross-sectional study of the Netherland population from 1987 
to 1995 reported that women used diuretic two to three times more than men 
(Klungel et al., 1998) possibly because women have a greater tendency for oedema 
than men. Another explanation could be related to the differences in the level of 
sex hormone present in both men and women. In an experimental study using the 
ovariectomized rat model, Verlander et al. (1998) demonstrated that oestrogen 
has an effect on TZ diuretic in the kidney. After comparing between 
ovariectomized and control rats, the authors concluded that the presence of 
oestrogen is necessary to maintain the complexity and density of TZ-sensitive NaCl 
cotransporter (TSC1) in the DCT. Unfortunately, due to a lack of individual-patient 
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data, the difference between gender in odds of RCC and other cancer types was 
not assessed in the present study. 
Nevertheless, findings from these studies also suggest that the presence of high 
BP does not affect the risk of cancer which agrees with a subgroup analysis in the 
present study. Assessment of odds for cancer in hypertensive patients and in 
patients with higher risk for CV events showed a non-significant association with 
OR 1.05 (95% CI 0.68-1.61) and OR 0.97 (95% CI 0.90-1.04) respectively. The 
primary meta-analysis of TZ and odds of cancer incidence in the present review is 
not restricted to only patients with hypertension which render any association by 
indication unsupported.    
More recent epidemiological studies have tried linking diuretics and risk of another 
cancer type. Li et al. (2003) conducted a population-based study assessing elderly 
women for risk of breast cancer in association to the use of antihypertensive 
medications. They found that together with immediate release CCBs, TZ and 
potassium-sparing diuretics modestly increased breast cancer risk with OR 1.4 
(95% CI 1.1-1.8) and OR 1.6 (95% CI 1.2-2.1) correspondingly. In another 
population-based case-control study, Largent et al. (2006) assessed the risk of 
breast cancer in association with hypertension and diuretic use among middle-
aged and elderly women using a cancer surveillance programme database. This 
study reported an increased risk for breast carcinoma in women ever treated for 
hypertension (OR 1.77, 95% CI 1.04-3.03) and in women who were exposed to 
diuretics irrespective of the indication (OR 1.79, 95% CI 1.07-3.03). In both studies, 
the cases reported more risk factor for breast cancer than controls such as family 
history of breast cancer, older age at first pregnancy, and menopause. 
Additionally, the results of these studies could only be inferred to older and 
menopausal women. A subsequent larger case-control study assessed breast 
cancer risk among women aged between 18 and 75 years using 30 years of data 
from hospital-based surveillance study (Coogan et al., 2008). On the contrary, this 
study found no significant association between breast cancer and TZ use 
regardless of the duration of exposure. The proposed mechanism by which TZ 
could affect breast cancer risk is by increasing insulin resistance as a result of TZ-
induced hypokalaemia. Bruning et al. (1992) conducted a case-control study 
among 223 women aged between 38 to 75 years presenting with early stage breast 
cancer and 441 age-matched women with no cancer. A second control group 
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comprised patients with malignant lymphoma, melanoma, or uterine breast 
cancer. This study measured the level of non-fasting serum C-peptide, a 31-amino 
acid that is released simultaneously with insulin from the pancreatic beta cells 
following cleavage of proinsulin. The authors reported that post-menopausal and, 
to a lesser extent, pre-menopausal breast cancer patients have a higher serum 
level of C-peptide compared to controls indicating specificity for breast 
malignancy. However, a recent meta-analysis of 22 observational studies has 
found no differences between fasting insulin and fasting/non-fasting C-peptide 
levels in women with and without breast cancer (Hernandez et al., 2014).          
Studies looking into the overall survival of cancer in relation to TZ diuretic are 
comparably limited. In a cohort study of 14,166 patients aged between 45 to 74 
years with history of CHD and over 5.6 years follow-up, Tenenbaum et al. (2001) 
reported a significantly increased risk for colon cancer mortality in patients 
treated with diuretics (HR 3.7, 95% CI 1.7–8.3), while mortality difference for 
other cancer types were not observed. This association, however, was not 
specified to the type of diuretic and was only observed among non-aspirin user. 
This study was further limited by the lacked information on drug doses which is 
crucial in distinguishing the undesirable effect of the drug and those related to 
the degree of metabolic derangements. One mechanistic hypothesis linking TZ to 
colon cancer is that TZ diuretic such as HCTZ as a cyclic imide can be converted 
to a mutagenic N-nitroso derivative in the stomach (Andrews et al., 1984). In time, 
accumulation of these mutagenic compounds could potentially be carcinogenic in 
the gastrointestinal tract. In a more recent population-based cohort study using a 
cancer registry linked to a prescription database, Holmes et al. (2013) assessed 
the five major antihypertensive class and survival in patients with cancer. They 
reported a significantly increased mortality in colorectal (HR 1.28, 95% CI 1.15–
1.42), lung (HR 1.10, 95% CI 1.01–1.19), and prostate cancer (HR 1.41, 95% CI 1.20–
1.65) related to TZ diuretic when compared to non-user. Nonetheless, the 
indication for TZ in cancer patients may have been related to fluid retention 
problem rather than hypertension. For this reason, it is possible that patients 
taking TZ have additional comorbidities which may adversely affect survival.       
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 Study strengths and limitations 
To the best of author’s knowledge, this is the largest meta-analysis of RCTs 
investigating the association between TZ and the risk of cancer. On that account, 
RCTs included also ensured internal validity by minimizing selection bias and 
confounding bias. Cancer outcomes from the ANBP, MAPHY, NESTOR, and PREVER-
Treatment study which has never been incorporated in the most recent review 
available (Bangalore et al., 2011) was also included in the present study.  
However, like any review, this study has a number of limitations. Firstly, the RCTs 
included in this review were not designed to detect cancer as one of their study 
endpoints. Accordingly, not all of the studies had mentioned whether patients 
with baseline cancer were enrolled in the trials leading to the possibility of an 
augmented association. However, the negative association observed in both 
cancer incidence and cancer-related death meta-analyses are reassuring. 
Secondly, only aggregate cancer data were available from the majority of the 
included studies thus limiting potential cancer-specific and time-to-event 
analysis. Also, the associations derived from this review are only applicable to TZ 
as a class and not as individual drugs.  
The general impression remains that most human malignancies grow at a slow rate 
for long periods of time during the clinical and measurable phase. In this review, 
the longest study follow-up was 6.5 years with the majority of studies were 
followed for less than five years. For a tumour to be detectable clinically would 
require at least five years of observation based on the kinetics and growth rate of 
malignant cells (Friberg and Mattson, 1997). Moreover, the result of this review 
could only reflect late-detected cancers.    
8.7 Conclusion  
There is no evidence that use of TZ affects the risk of cancer or cancer-related 
death. Low dose TZ probably remain a good choice for initial treatment of 
hypertension in the elderly. Unless indicated, avoid starting treatment with TZ 
diuretic in younger and/or pre-menopausal women as there is evidence of higher 
risk for RCC in women compared to men.   
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9  General discussion and prospects 
9.1 General overview 
Hypertension accounts for around 5% of the current global disease burden because 
of increasing life-expectancy and concomitant factors such as obesity, physical 
inactivity, and high salt diet. Antihypertensive drugs are prescribed to help 
prevent detrimental outcomes of hypertension including stroke, CHD, and HF. 
There is a continuous relationship between BP and risk and this is reflected in the 
changing BP targets over time in hypertension treatment guidelines. The recent 
SPRINT trial has precipitated an update in hypertension guidelines by lowering 
target BP to 130 systolic. An important message from SPRINT was that it was 
possible to attain target BP in treated patients and this required on-average one 
extra drug in the intensive arm control. Whilst the use of antihypertensive drugs 
has increased, the shift to lower target BP will result in greater exposure to 
antihypertensive drugs for patients and for longer periods of time. Thus it is 
important to establish potential long-term adverse reactions of these commonly 
used drugs. The carcinogenic potential of antihypertensive drugs have been under 
scrutiny for a while and results have not been conclusive. It is on this background 
that this project was developed to determine through a comprehensive systematic 
review, the risk of cancer for all major antihypertensive drug classes. Most reviews 
of primary studies focused on the beneficial effect and clinical efficacy of 
antihypertensive drugs without adequately addressing adverse effects (Ernst and 
Pittler, 2001, Baguet et al., 2007, Fretheim et al., 2012). A balanced assessment 
of benefit and harm is crucial in assisting healthcare providers and patients in 
making an informed decision about its application. However, this can be difficult 
to achieve due to the massive amount of information generated from a great 
number of individual studies which may be biased, methodologically flawed, time 
and context dependent, and can be misinterpreted and misrepresented (Wilson 
and Petticrew, 2008). Hence, a systematic review of adverse effects within 
reviews of effectiveness could provide the much needed evidence to guide 
practitioners in decision-making.  
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 Strengths of the review 
The main strength of this review is described in each individual result chapter. 
Most of the studies included in this review have good methodological quality. To 
the best of author’s knowledge, this is the largest, most comprehensive and 
updated systematic review and meta-analysis of RCTs of its kind. Additionally, this 
review has the potential to contribute important insight into the risk of cancer in 
relation to exposure to major antihypertensive drug classes in an indicated 
population. The comprehensive search strategy implemented allowed me to 
capture as many relevant citations and articles as possible. Secondly, the strict 
entry criteria ensure sufficiently large sample size which is necessary to produce 
results between different interventions that are significantly different. Finally, 
the inclusion of the population from various clinical health settings consequently 
increased external validity particularly in those who are indicated for the studied 
antihypertensive drug class. At the same time, stratified analyses were also 
performed to assess potential confounding by indication in a population with 
different health settings. This is important to obtain valid measures of the effects 
of antihypertensive agents on risks of cancer outcomes.  
 Limitations of the review 
Most of the limitations described in the individual result chapters are associated 
with the included RCTs design weaknesses and the lack of individual-patient-level 
data which hinders the analysis of specific drug within a class in association to a 
specific type of cancer. This review is limited to the assessment of drug classes 
and as such, the potential of any of the individual drugs to alter the risk of cancer 
cannot be confirmed. Nonetheless, evaluation of subclasses for every drug class 
in subgroup analyses have demonstrated lack of significant association to risk of 
cancer except for CCB. This review also did not take into account the cumulative 
dose of drugs exposed to participants, therefore it is impossible to report whether 
exposure to a small or high cumulative dose of antihypertensive drugs could alter 
the risk for cancer. However, results from subgroup analyses conducted based on 
the duration of follow-up are comparable to the primary meta-analysis across all 
antihypertensive classes.  
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Meanwhile, a long duration of observation is essential to detect pro- or anti-cancer 
effect of interventions studied as most cancer has a long latency period. Latency 
period in this review is defined as the length of time between exposure to 
antihypertensive therapy and diagnosis of cancer. Most of the studies included 
were followed for an average short period of time ranging from one to five years. 
As cancer development is a slow process, this review could only reflect late-
detected cancers. All the included studies also failed to describe the time interval 
between initiation of treatment and cancer diagnosis. Cancer incidence diagnosed 
in the early stage of studies may have developed long before exposure to the study 
intervention, thus the inclusion of these patients in the meta-analyses potentially 
lead to overestimation of effect. Despite this inadequacy, sensitivity analyses in 
this review have demonstrated that inclusion of patients with established cancer 
did not affect the result of the primary meta-analysis.  
At the same time, the software used for this review is not built to run certain 
analysis such as meta-regression which can supplement and support the primary 
meta-analysis. Nevertheless, the subgroup analyses conducted is sufficient to 
assess moderator variables.      
 Comparison with other reviews 
Appraisal of the literature has shown a number of studies similar to the present 
review where such studies either assessed all the major antihypertensive drug 
classes together or individually with regards to any or specific type of cancer. Only 
studies that are very similar to the present review are described and discussed in 
this section. Studies focusing on one class of antihypertensive agents were 
discussed in individual antihypertensive drug class chapters. Altogether, two 
reviews have been identified to have a comparable study objective, design, and 
outcome of the present study. Both studies have conducted a network meta-
analysis, a complex method of combining both direct and indirect effect estimates 
concurrently. This approach enables observation of indirect comparisons 
constructed from two trials that contain one common treatment (e.g. comparison 
of treatment A versus C with trials comparing A versus B and B versus C) (Song et 
al., 2011). The validity for both meta-analysis and network meta-analysis is 
dependent upon the adequacy of the evidence and similarity of trials. The recently 
published PRISMA Extended Statement for reporting of systematic review requires 
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that all network meta-analyses are based on a systematic review (Hutton et al., 
2015).     
The first study to assess major antihypertensive drug classes and their impact on 
cancer incidence in RCTs was a network meta-analysis by Coleman et al. (2008). 
The reviewers have searched four electronic databases as well as trial references, 
reports and registries through June 2007. The Jadad score was used for quality 
assessment which evaluates randomisation, masking, and accountability of all 
participants (Jadad et al., 1996). No other restrictions were applied. This 
publication, however, did not supplement readers with the study flow chart 
describing the screening, eligibility, inclusion and exclusion of studies. Hence, it 
is difficult to determine the burden of the study selection process and to compare 
with the present review. Overall, 27 RCTs with a total of 126,137 patients enrolled 
were included in the final meta-analysis. Due to the relaxed inclusion criteria, 
study with less than one year treatment follow-up (Borghi and Ambrosioni) was 
also included in the network meta-analysis. Only results from multiple comparison 
and pairwise analysis were reported in which Coleman and team have 
consequently concluded that these drug classes are not associated with increased 
risk of cancer.  
A much similar network meta-analysis was published by Bangalore et al. (2011). 
The objective of Bangalore and team was to assess the association of 
antihypertensive drug classes with the risk of cancer incidence and cancer-related 
death. In addition to electronic databases and trials reference list, they also 
reviewed grey literature and hand-searched the FDA database up to August 2010. 
Authors of studies were contacted for additional information as required. They 
also restricted the inclusion criteria to only trials with at least one year follow-up 
and enrolled a minimum of 100 patients. The study flow describing the process of 
trials selection presented in this review demonstrated that the authors have 
conducted the search discretely for each drug class. Methodological qualities of 
included trials were assessed in accordance with the Cochrane Collaboration risk 
of bias tool. Altogether, they included 70 RCTs enrolling 324,168 participants. 
Bangalore and team have analysed individual drug classes directly by also 
stratifying them according to subclasses. Apart from monotherapy, they also 
assessed ACEI and ARB combination on the risk of cancer. For the ONTARGET 
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study, cancer data for the ARB monotherapy treatment group had been compared 
to ACEI monotherapy and then to ACEI and ARB combination treatment groups in 
the same meta-analysis. Double-counting of the same study is an inappropriate 
method for combining patient outcome data (Senn, 2009) as this could introduce 
bias leading to inaccurate effect estimate. In keeping to the PRISMA guideline of 
reporting systematic review, the meta-analysis of cancer outcomes was conducted 
in an intention-to-treat manner for both direct and multiple comparisons. Apart 
from network meta-analysis, they also conducted trial sequential analysis (TSA) 
to assess for consistency of effect between the direct and multiple comparisons. 
TSA, similar to interim analyses, is a method that combined the sample sizes of 
all included trials for a meta-analysis with monitoring boundaries of statistical 
significance. 
From direct comparisons, Bangalore reported a significant increase in odds of 
cancer incidence for CCB overall and DHP CCB in particular, but not for cancer 
deaths. Meta-analysis of two trials using ACEI and ARB combination as one of its 
treatment group in the FE model has shown a significant increased risk for cancer 
incidence, but not in the RE model. No significant association was observed with 
other class of antihypertensive drugs. Results from multiple comparisons were 
largely similar to the direct comparisons except they found no increased risk of 
cancer incidence with use of CCB in both FE and RE model. As for ARB and ACEI 
combinations, comparison with placebo, ARB or ACEI monotherapy, BB and TZ 
increased cancer risk only in the FE model. Meanwhile, results from the TSA 
suggested evidence for at least a 10% relative risk increase of cancer with ACEI 
and ARB combination.    
In comparison to the Bangalore study, a similar search strategy was employed in 
the present review. Instead of PubMed, a search using Medline was performed 
because it enabled a more focused search. The ClinicalTrials.gov, a registry of 
clinical trials and is the largest of its kind, was also hand-searched for relevant 
trials. In addition, the search was extended up to December 2015. Due to the 
massive volume of citations generated from the three databases and time-
constraint, the search for grey literature was not performed. Nonetheless, this 
search strategy did cover all the RCTs included in the Bangalore review and more. 
The literature searching was also performed collectively for all drug classes as this 
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method is more efficient in the process of study selection. Where possible, the 
primary or secondary author of the respective trials was contacted though not 
many have responded. The eligibility criteria for this review is stricter. A similar 
approach has been used in assessing the methodological quality of each included 
RCT. In comparison to Bangalore, an additional 20 RCTs were included in the 
present review in which 14 of the studies were published prior to 2010 and only 
nine studies were published after 2010 (the latest 2016). Seven studies (APRES, 
GISEN, GLANT, HSCSG, JIKEI, KYOTO Heart Study, and STONE) included in the 
Bangalore review were excluded from this study for reasons described in Chapter 
3, Section 3.2.1 (page 73). 
Unlike Bangalore, trials with two types of antihypertensive drug used in one group 
where the exact number of patients receiving the treatment and the number of 
cancer incidence according to drug class was not specifically stated were not 
incorporated in the meta-analysis of either class of drug. For example, the 
CONVINCE study randomised patients to verapamil in one group and atenolol or 
HCTZ in another group. Therefore, cancer data from this study was only included 
in the meta-analysis for CCB and risk of cancer, but not for BB or TZ. Whenever 
possible, patients with baseline cancer were excluded in the present study. 
Excluding these patients could introduce the risk of bias into the result as it was 
not an ITT analysis and the treatment groups may be unbalanced. However, 
sensitivity analyses performed by including these patients showed the measured 
effects did not differ.   
9.2 Implication for research 
It is recognized that safety must be monitored in all clinical trials; therefore a 
standardized formal procedure to identify adverse events and to conduct an 
interim analysis for safety reason should always be considered. Since many studies 
had attempted to implicate antihypertensive drugs to the risk of cancer, better 
designed RCTs with cancer pre-specified as one of the safety endpoint is 
warranted. Pre-identification of cancer as an outcome with careful monitoring can 
ensure early diagnosis and credibility of the results. Moreover, it is not uncommon 
for trials to not publish outcomes measured during clinical trials upon completion 
of the trial regardless of funding sources or the journals in which they are 
published (Jones et al., 2015). The presence of outcome reporting bias prevents 
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the classification of RCTs merely as either published or unpublished. Despite the 
availability of data from 390,750 trial participants in this review, it is difficult to 
determine the true effect of antihypertensive drugs, mainly CCBs, on the risk of 
cancer incidence. Preventing underestimation of the intervention effect on 
undesirable events such as cancer entails reporting of all serious adverse events 
especially in future long term clinical trials. Trials with adverse events collection 
deficiencies led to inadequate cancer ascertainment.  
An individual participant data (IPD) meta-analysis use the same basic methodology 
as any traditionally conducted systematic review and meta-analysis. Moreover, 
this approach is preferred whenever possible as this method can improve the 
quality of both data and analyses, hence the reliability of the results. For this 
method to be successful, extensive collaboration between researchers is essential 
in ensuring the validity of trial data consequently avert outcome reporting bias. 
9.3 Implication for practice 
The implication for practice in this review can be described under two themes- 
the safety of antihypertensive agents and general drug safety. 
 Antihypertensive agents safety   
Evidently, all the antihypertensive agents class are deemed to be effective in 
lowering BP thereby recommended as first or second-line therapy for hypertension 
by  NICE, JNC 8, and ESH/ESC guidelines. This review supports the continuous use 
of ACEI, ARB, and BB as recommended by these established guidelines. Low dose 
TZ probably remain a good choice for initial treatment of hypertension in the 
elderly. Unless indicated, avoid starting treatment with TZ diuretic in younger 
and/or pre-menopausal women as there is evidence of higher risk for RCC in 
women compared to men. More importantly, this review found a significantly 
increased risk for cancer associated to use of DHP CCBs which merits further 
assessment. In the meantime, it is probably best to start with low dose CCB and 
followed by combination therapy with other antihypertensive class where 
indicated. 
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 General drug safety 
The current available ICH guidelines for carcinogenicity testing is only indicated 
for any pharmaceutical product whose expected clinical use is continuous for at 
least 6 months or if there is concern about their carcinogenic potential (EMA, 
1996). For such agents, a two year carcinogenicity evaluation is undertaken using 
rodents. However, a call for revision to this guidance had been proposed quite 
recently to introduce better way to address the risk of cancer in human of small 
molecule pharmaceuticals and to define the conditions under which the two year 
rodent carcinogenicity studies add value to the assessment (EMA, 2016); negative 
predictions can be made when negative carcinogenic signals are present and vice 
versa. In doing so, use of animals, drug development resources and timelines to 
market authorization can be reduced without compromising patients’ safety. 
Nonetheless, continuous pharmacovigilance is key in early identification of any 
adverse events that may cross the line of a drug’s efficacy. Documentation of new 
cancer cases should take into consideration any medicinal substance exposure 
regardless of prescription status and duration of use.  
9.4 Future works 
Firstly, the plan is to conduct a network meta-analysis using data from the current 
review. Subsequently, I would like to conduct a trial sequential analysis (TSA) to 
evaluate the reliability of the association between CCB and cancer risk as observed 
in this study. Eventually, the results of this systematic review highlighting the risks 
of cancer associated with individual drug class will be published to add to the 
growing body of evidence. I have also identified the need for observational studies 
carefully adjusted for all potential confounders to assess cancer risk linked to 
CCBs. Future studies are recommended to focus on identifying the type and dose 
of CCB that may alter the risk for cancer and the type of cancer that CCB is likely 
to cause.  
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9.5  Conclusion 
In summary, the present study found no evidence of increased risk of cancer or 
cancer-related mortality with the use of ACEI, ARB, BB, or TZ. However, increased 
risk of cancer with CCB use cannot be ruled out. Further study is warranted in 
verifying the risk of any cancer and specific type of cancer associated with CCB, 
particularly DHP-CCB. 
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Appendix 
Table A-1:Keywords use for electronic database search. 
MP indicates multi-purpose search terms in the title, original title, abstract, subject heading, the 
name of substance and registry word fields; “tw” indicates that the term is a text word meaning and 
title and abstract; “Pt.” Indicates publication types, such as reviews, clinical trials, directories, and 
letters; “Ab” indicates all searchable words from the abstract; “/” indicates that it is a Medical 
Subject Heading (MeSH) term; “$” indicates all possible suffix variations of the root words; “?” 
indicates the retrieval of documents with British or American word variants; “adj” plus a number 
between any two terms returns records that contain both terms within the specified number of 
words from each other. 
 Keyword searches
1. Ace inhibitors.mp.
2. angiotensin converting enzyme inhibitors/
3. (Benazepril or captopril or enalapril or cilazapril or delapril or fosinopril or imidapril or 
Lisinopril or moexipiril or perindopril or quinapril or ramipril or spirapril or temocapril 
or trandolapril or zofenopril).tw 
4. Or/1-3 
5. angiotensin receptor antagonists/
6. angiotensin II receptor antagonist$.mp or Angiotensin Receptor antagonists/
7. angiotensin II receptor blocker$.tw
8. (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or 
forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or 
tasosartan or telmisartan or valsartan or zolasartan).tw
9. Or/ 5-8 
10. calcium channel blockers/
11. (calcium adj2 (inhibit$ or block?)).tw.
12. Calcium channel antagonis$.mp
13. (Amlodipine or benidipine or diltiazem or felodipine or isradipine or manidipine or 
nicardipine or nifedipine or nisoldipine or nitrendipine or verapamil).tw 
14. Or/10-13 
15. adrenergic beta-antagonists.mp.
16. (beta adj2 (inhibit$ or block?)).tw.
17. Beta block$.mp 
18. Beta-receptor antagonist$.mp
19. (Acebutolol or atenolol or bisoprolol or carvedilol or celiprolol or esmolol or labetolol 
or metoprolol or nadolol or nebivolol or propranolol or sotalol or timolol).tw
20. Or/15-19 
21. Diuretics.mp 
22. thiazides.mp. 
23. (Chlorothiazide or hydrochlorothiazide or bendroflumethiazide or hydroflumethiazide 
or methylchlothiazide or polythiazide or trichlormethiazide or chlorthalidone or 
metolazone or indapamide).tw
24. Or/21-23 
25. 4 or 9 or 14 or 20 or 24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab. 
29. Drug therapy.tw. 
30. randomly.ab. 
31. trial.ti 
32. Or/26-31 
33. animals/ not (humans/ and animals/)
34. 32 not 33 
35. 25 and 34  
36. limit 35 to (humans and yr.="1950 - 2015" and "all adult (19 plus years)" and humans 
and randomized controlled trial) 
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Table A-2 : Characteristics of included studies 
Trial Year N Cohort Treatment n Control n Average 
follow-
up 
(years) 
Age 
(years) 
Proportion 
male (%) 
Trial design and 
methods 
ABCD 1998 470 Normotension 
and HTN with 
type 2 DM 
Enalapril 235 Nisoldipine 235 5.6 57.5 
(8.3) 
67.5 Parallel groups, 
double blind 
ACTION 2004 7665 CAD Nifedipine 3825 Placebo 3840 4.9 (1.1) 63.5 
(9.3)
79.4 Parallel groups, 
double blind
ACTIVE I 2011 9016 AF plus one risk 
factor for stroke 
Irbesartan 4518 Placebo 4498 4.1 69.6 
(9.7) 
60.7 Parallel groups, 
double blind 
AIPRI 1996 583 CKD Benazepril 300 Placebo 283 3* 51 (13) 72.2 Parallel groups, 
double blind
ALLHAT 2002 3335
7 
HTN with at least 
1 risk factor for 
CHD event 
Lisinopril 9054 a) 
Chlorthalidone 
1525
5 
4.9 (1.4) 67 53 Parallel groups, 
double blind 
b) Amlodipine 9048
ALPINE 2003 393 HTN  Candesartan 196 HCTZ 196 1 55 (9.5) 48 Parallel groups, 
double blind
ANBP 1980 3427 Mild HTN Chlorothiazi
de
1721 Placebo 1706 4 50.5 (9) 63.3 Parallel groups, 
double blind
ANTIPAF 2011 430 AF Olmesartan 214 Placebo 211 1 61.5 
(10.7)
58.6 Parallel groups, 
double blind
APSIS 1996 809 CHD (stable 
angina pectoris) 
Verapamil 403 Metoprolol 408 9.1* 59 (7) 69.5 Parallel groups, 
double blind 
ASCOT-
BPLA 
2005 1925
7 
HTN with at least 
3 other CVD risk 
Amlodipine 9639 Atenolol 9618 5.5 63 (8.5) 77 PROBE
BHAT 1982 3837 Post-MI Propanolol 1916 Placebo 1921 2.1 54.8 85.5 Parallel groups, 
double blind 
CAMELO
T  
2004 1991 Normotension 
with CAD 
Enalapril 675 a) Amlodipine 665 2 57.7 72 Parallel groups, 
double blind 
b) Placebo 657
CASE-J 
Ex 
2011 4703 High risk HTN Candesartan 2354 Amlodipine 2349 4.5 (1.9) 63.9 55.2 PROBE
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CHARM 
Added 
2003 2548 HF Candesartan 1276 Placebo 1272 3.4* 64.1 
(11) 
78.7 Parallel groups, 
double blind 
CHARM 
Alternati
ve 
2003 2028 HF Candesartan 1013 Placebo 1015 2.8* 67 (11) 68.2 Parallel groups, 
double blind 
CHARM 
Preserve
d 
2003 3023 HF Candesartan 1514 Placebo 1509 3.1* 67.2 
(11.1) 
59.9 Parallel groups, 
double blind 
CONVIN
CE 
2003 1660
2 
HTN Verapamil 8179 Atenolol 680 3 (2-
4.25)
65.6(7.4
)
44 Parallel groups, 
double blind    
HCTZ 7617
DAVIT II 1999 1775 CHD post MI Verapamil 878 Placebo 897 1.3 60.7 
(9.2) 
79.8 Parallel groups, 
double blind 
DEMAND 2011 380 HTN with T2DM 
and albuminuria 
Delapril 126 a) Delapril + 
manidipine 
127 3.8 (3.1-
4.7)* 
61.2 
(7.7) 
66.9 Parallel groups, 
double blind 
b) Placebo 127
DIABHYC
AR 
2004 4912 Type 2 DM with 
albuminuria 
Ramipiril 2443 Placebo 2469 4 (3-6)* 65.1 
(8.4) 
70 Parallel groups, 
double blind 
DIRECT- 
Prevent 
1 
2008 1421 T1DM without 
retinopathy 
Candesartan 711 Placebo 710 4.7 (4.2-
5.1)* 
29.7 56.7 Parallel groups, 
double blind 
DIRECT- 
Protect 
1 
2008 1905 T1DM with 
retinopathy 
Candesartan 951 Placebo 954 4.8 (4.4-
5.3)* 
31.7 
(7.75) 
57.3 Parallel groups, 
double blind 
DIRECT- 
Protect 
2 
2008 1905 T2DM with 
retinopathy 
Candesartan 951 Placebo 954 4.7 56.9 49.8 Parallel groups, 
double blind 
E-COST 2005 2048 HTN Candesartan 1053 Conventional 995 3.1(0.4) 67 48 Parallel groups, 
open-label
ESPIRAL 2001 241 HTN with CKD Nifedipine 
GITS
112 Fosinopril 129 3 56 (24-
74)
59 Parallel groups, 
open-label
EWPHE 1991 840 Elderly with HTN HCTZ plus 
Triamterene 
416 Placebo 424 72 (8) 30.3 Parallel groups, 
double blind 
FACET 1998 380 HTN with T2DM Fosinopril 189 Amlodipine 191 2.9 63.1 
(0.5)
60 PROBE
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FEVER 2005 9711 HTN on thiazide 
therapy 
Felodipine 4841 Placebo 4870 3.3 (1) 61.5 
(7.2) 
61 Parallel groups, 
double blind 
GISSI-AF 2009 1442 AF Valsartan 722 Placebo 720 1 68 (9.2) 62 Parallel groups, 
double blind 
HEP 1896 884 HTN Atenolol 419 Control 465 4.4 68.8 
(5.2)
31 PROBE
HIJ-
CREATE 
2009 2049 HTN with CAD Candesartan 1024 Non-ARB 1025 4.2 (3.5-
4.9)
64.8 
(9.2)
80.2 PROBE
HOPE 2000 9297 Patients high risk 
of cardiovascular 
events 
Ramipiril 4645 Placebo 4652 5 66 (7) 73.3 Factorial, double-
blind 
IDNT  2003 1715 HTN with T2DM 
nephropathy 
Amlodipine 567 Irbesartan 579 2.6 59(7.5) 66 Parallel groups, 
double blind 
Placebo 569
INSIGHT 2000 6321 HTN Nifedipine 3157 Co-amilozide 3164 4.5 65(6.5) 46.3 Parallel groups, 
double blind 
INTACT 1990 348 Mild CHD Nifedipine 173 Placebo 175 3 53.1 
(7.6) 
NR Parallel groups, 
double blind 
INVEST 2003 2257
6 
HTN with CHD Verapamil 
SR
1126
7
Atenolol 1130
9
2.7 (0-
5.4)
66.1 
(9.8)
48 PROBE
I-
PRESERV
E 
2010 4128 HF with 
preserved EF 
Irbesartan 2067 Placebo 2061 4.1 72(7) 60 Parallel groups, 
double blind 
IRMA-2 2001 608 HTN with type 2 
DM and 
microalbuminuria 
Irbesartan 402 Placebo 206 2 58 (8) 69 Parallel groups, 
double blind 
Kanamas
a et al 
1998 1054 CAD post MI Nifedipine 425 Non-CCB 488 2.2 (2.3) 60 
(11.5)
80 Parallel groups, 
open-label    
Diltiazem 141
LaCroix 2000 320 Healthy adult HCTZ 215 Placebo 105 3 68 (4.5) 36 Parallel groups, 
double blind 
LIFE 2002 9193 HTN Losartan 4605 Atenolol 4588 4.8 (0.9) 67 (7) 46 Parallel groups, 
double blind 
MAPHY 1988 3234 HTN HCTZ 1625 Metoprolol 1609 4.2* 52.6 (7) 100 Parallel groups, 
double blind
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MERIT-
HF 
2001 3991 HF Metoprolol 1990 Placebo 2001 1 63.8 
(9.7) 
77.5 Parallel groups, 
double blind 
MIDAS 1996 883 HTN Isradipine 442 HCTZ 441 3 58.5 
(8.5) 
78 Parallel groups, 
double blind 
MRC 1985 1735
4 
Mild HTN Bendrofluazi
de
4297 Propranolol 4403 4.9 52 (8) 52.2 Parallel groups, 
single blind    
Placebo 8654
MRC-OA 1992 4396 HTN HCTZ plus 
amiloride 
1081 Atenolol 1102 5.8 70.3 41.8 Parallel groups, 
single blind 
    
Placebo 2213
NAVIGAT
OR 
2010 9306 IGT with 
established CVD 
or CV risk factors 
Valsartan 4631 Placebo 4675 5 63.7 50.6 Factorial 2-by-2, 
double-blind 
NESTOR 2004 570 HTN with T2DM Indapamide 283 Enalapril 286 1 60 (9.9) 64 Parallel groups, 
double blind
NHS 2012 1150 HTN with Type 2 
DM or IGT 
Valsartan 575 Amlodipine 575 3.2 (2.6-
4.7)* 
63 (8) 66 PROBE
NICOLE 2003 819 CHD underwent 
PCI 
Nisoldipine 408 Placebo 411 3 60 ((9) 79 Parallel groups, 
double blind 
NICS-EH 1999 429 Elderly HTN Nicardipine 215 Trichlormethia
zide 
214 4.6* 69.8 
(6.5) 
33 Parallel groups, 
double blind 
OCTOPU
S 
2013 469 HTN with ESRD Olmesartan 235 Non-ARB 234 3.5 59.5 
(12) 
62 PROBE
ONTARG
ET  
2008 2562
0 
CVD or DM with 
end-organ 
damage 
Telmisartan 8542 a) Ramipiril 8576 4.7 66.4 
(7.2) 
73 Parallel groups, 
double blind 
    
b) Telmisartan 
+ ramipiril 
8502
OPTIMAA
L 
2002 5477 HF with CAD (MI) Captopril 2733 Losartan 2744 2.7 (0.9) 67.4(9.8
)
71.2 Parallel groups, 
double blind
OSLO 1980 785 HTN HCTZ 406 No treatment 379 5.5 (5-
6.5)
45.3 
(2.9)
100 PROBE
Otsuka 
et al 
2004 253 CAD post PCI Quinapril 131 Control 122 4.8 (4.2-
5.1)*
63 72 Parallel groups, 
open-label
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PARADIG
M-HF 
2014 8442 HF with EF ≤ 40% Enalapril 4229 LCZ696 4203 2.25 63.8(11.
4) 
78.2 Parallel groups, 
double blind 
PAT 2002 548 Asymptomatic 
small AAA 
Propanolol 276 Placebo 272 2.5 (1.1) 68.9 
(7.9) 
84 Parallel groups, 
double blind 
PHARAO 2008 1008 Pre-HTN Ramipiril 505 Non-ACEi 503 3 62.3 
(8.1)
48 PROBE
PHYLLIS 2004 508 HTN with 
hypercholesterol
aemia 
Fosinopril 127 HCTZ 127 58.4 
(6.7 
40 Parallel groups, 
double blind 
Practolo
l Study 
1975 3038 Post-MI Practolol 1524 Placebo 1514 1.2 55 86.5 Parallel groups, 
double blind 
PRAISE 1996 1153 HF Amlodipine 571 Placebo 582 1.2 (0.5-
2.75) 
64.7 
(0.5) 
76 Parallel groups, 
double blind 
PREVEN
T 
2000 825 CHD Amlodipine 417 Placebo 408 3 56.9 
(30-78)
80.1 Parallel groups, 
double blind
PREVER-
Treatme
nt 
2016 655 HTN Losartan 322 Chlorthalidone
/ amiloride 
333 1.5 54 51 Parallel groups, 
double blind 
PRoFESS 2008 2033
2 
CVA Telmisartan 1014
6 
Placebo 1018
6 
2.5 (1.5-
4.3) 
66.2 
(8.6) 
64 Factorial 2-by-2, 
double-blind 
REIN 2 2005 335 CKD Felodipine 167 Conventional 
AHT 
168 1.6* (1-3) 53.4 
(15.3) 
74.9 PROBE
RENAAL 2001 1513 T2DM with 
nephropathy 
Losartan 751 Placebo 762 3.4 60 (7) 63.2 Parallel groups, 
double blind 
SAVE 1992 2231 HF with CAD 
(post-MI) 
Captopril 1115 Placebo 1116 3.5 (0.8) 59.4 82.5 Parallel groups, 
double blind
SCAT 2000 460 CAD Enalapril 229 Placebo 231 4 61 (10) 89.1 Factorial, double-
blind
SCOPE 2003 4964 HTN with MMSE 
score ≥ 24 
Candesartan 2477 Placebo 2460 3.7 76.4 35.5 Parallel groups, 
double blind
SHEP 1991 4736 Elderly with HTN Chlorthalido
ne
2365 Placebo 2371 5 71.6 
(6.7)
43 Parallel groups, 
double blind
SMT 1985 301 Post-MI Metoprolol 154 Placebo 147 3 59.7 (7) 80.4 Parallel groups, 
double blind
SOLVD-P 1992 4228 HF with LVEF ≤ 
35% 
Enalapril 2111 Placebo 2117 3.1 (1.2-
5.2)
59.1 88.6 Parallel groups, 
double blind
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SOLVD-T 1991 2569 HF with LVEF ≤ 
35% 
Enalapril 1285 Placebo 1284 3.5 (1.2-
5.2) 
60.9 80.4 Parallel groups, 
double blind 
SPRINT 1998 2127 CHD post-MI Nifedipine 1059 Placebo 1068 5 57.5 (9) 85 Parallel groups, 
double blind 
STOP-
HTN2 
1999 6614 HTN Felodipine/ 
isradipine 
2196 ACEI 2205 5 76 33.2 PROBE
    
BB /TZ 2213
Suzuki 2008 366 ESRD on dialysis Valsartan/ 
Losartan/ 
Candesartan 
183 Non-ARB 183 3 59.6(10) 59 Parallel groups, 
open-label 
Syst-
China 
1998 2394 HTN Nitrendipine 1253 Placebo 1141 4 (0.1-
7.8) 
66.5 
(5.5) 
64 Parallel groups, 
double blind 
Syst-Eur 1997 4695 HTN Nitrendipine 2398 Placebo 2297 2 (0.1-
8.1) 
70.3 
(6.7) 
33 Parallel groups, 
double blind 
TRACE 2005 1749 HF with LVEF ≤ 
35% 
Trandolapril 876 Placebo 873 5.6 67.5 71.5 Parallel groups, 
double blind
TRANSC
END 
2008 5926 CVD or DM with 
end-organ 
damage 
intolerant to 
ACEi 
Telmisartan 2954 Placebo 2972 4.7 
(4.25-
5.3) 
66.9(7.4
) 
57 Parallel groups, 
double blind 
TROPHY 2006 772 Pre-HTN Candesartan 391 Placebo 381 3.6 (1.1) 48.5 (8) 59.6 Parallel groups, 
double blind 
UKPDS 
38 
1998 758 HTN with T2DM Captopril 400 a) Atenolol 358 9 56 (8) 55 Parallel groups, 
double blind
b) 
Conventional 
therapy  
390
VA COOP 
II 
2004 394 HTN Propanolol 182 HCTZ 212 1 50 (9.8) 100 Parallel groups, 
double blind 
Val-
HeFT 
2001 5010 HF Valsartan 2511 ACEI 2499 1.92 (0-
3.2) 
62.7 
(11.1) 
80 Parallel groups, 
double blind 
VALIANT 2003 1470
3 
HF or LVSD post 
MI 
Valsartan 4909 a) Captopril 4909 2.1* 64.8 68.9 Parallel groups, 
double blind 
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b) Valsartan + 
captopril 
4885
VALUE 2004 1524
5 
HTN with high 
risk cardiac 
events 
Valsartan 7649 Amlodipine 7596 4.2 (1.2) 67(8.2) 58 Parallel groups, 
double blind 
VERDI 1989 167 HTN Verapamil 182 HCTZ 187 1 50.5 
(10.7)
54 Parallel groups, 
double blind
Vheft II 1991 804 HF Enalapril 403 Hydralazine-
isosorbide 
401 2.5 (0.5-
5.7) 
60.5 100 Parallel groups, 
double blind 
Wilcox 
et al 
1980 388 Suspected MI Propanolol 132 Placebo 129 1 NR NR Parallel groups, 
double blind 
        Atenolol 127
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Table A-3: Selected characteristics of included trials 
Trial Histor
y of 
cance
r 
Cancer pre-
specified as 
outcome 
Adjudication Data source Men 
(%) 
Curren
t 
smoker 
(%) 
Adherence 
(%) 
Loss to 
follow-
up (%) 
ABCD NR No NR Published 67.5 NR NR NR
ACTION 4.4 No NR Published 79.4 17.7 79 NR
ACTIVE I NR No NR Published 60.7 7.7 70 0.4
AIPRI 0 No NR Published 72.2 NR NR NR
ALLHAT  NR Yes Central Published 53 22 78 2.8
ALPINE NR No NR Published 48 13 100 0
ANBP NR No NR Published 63.3 25 64.7 2.6
ANTIPAF NR No NR Published 58.6 NR NR NR
APSIS NR No NR Published 69.5 22 NR NR
ASCOT-
BPLA 
NR No Central Published 77 33 81 0.3
BHAT NR No Central Published 85.5 57.2 60 0.3
CAMELOT NR No NR Published 72 26.5 NR 2.8
CASE-J Ex 0 No NR Published 55.2 21.8 96.3 10
CHARM 
Added 
6 No NR Published 78.7 16.8 75 0.2
CHARM 
Alternative 
6.6 No NR Published 68.2 13.6 77 0.1
CHARM 
Preserved 
7.5 No NR NR 59.9 13.5 75 0.1
CONVINCE NR Yes Central Published 44 23 60.5 7
DAVIT II NR Yes NR Published 79.8 NR 87 NR
DEMAND NR No NR Published 66.9 10.2 NR 0
DIABHYCAR NR No NR Unpublished 70 15.4 59.3 3.2
DIRECT- 
Prevent 1 
NR No NR Unpublished 56.7 25.5 NR 1.3
DIRECT- 
Protect 1 
NR No NR Unpublished 57.3 26.4 NR 1.4
DIRECT- 
Protect 2 
NR No NR Unpublished 49.8 27 NR 1
E-COST NR No NR Published 48 NR 77 NR
ESPIRAL NR No NR Published 59 NR NR NR
EWPHE 0 No NR  Published 30.3 NR NR 15
FACET NR Yes Central Published 60 6 77 1
FEVER NR No Site 
reported 
Published 61 29 86 0.3
GISSI-AF 3.1 No NR Published 62 8.5 83.1 4.5
HEP NR No NR Published 31 24.5 70 NR
HIJ-CREATE 0 No NR Published 80.2 38 NR 0.4
HOPE NR No NR Published 73.3 14.2 78.8 0.1
IDNT NR No Central Published 66 17 79 0.5
INSIGHT NR No Central Published 46.3 28.4 NR 2.4
INTACT 0 No NR Published NR 84 NR NR
INVEST 3.4 Yes Central Published 48 12.4 79.5 2.5
I-PRESERVE NR No Central Published 60 NR 64 1.5
IRMA-2 0 No NR Published 69 18.6 85 0.5
Kanamasa 0.4 Yes NR Published 80 NR NR NR
LaCroix 0 No NR  Published 36 7.5 82 1.6
LIFE NR Yes Central Published 46 16 82 0.1
MAPHY No No Central Published 100 2.1 NR NR
MERIT-HF NR No NR Unpublished 77.5 14.5 79 0
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MIDAS NR Yes Central Published 78 20 55 NR
MRC NR Yes Central Published 52.2 28.8 68 19
MRCOA 0 Yes Central Published 41.8 18.2 69 25
NAVIGATOR NR No NR Published 50.6 11 74 9.7
NESTOR NR No NR Published 64 14 88 0
NHS NR No Central Published 66 18.3 NR 2.6
NICOLE NR No NR Published 79 71.2 75 2
NICS EH NR No NR Published 33 9.9 NR NR
OCTOPUS 5.3 No NR Published 62 16.8 51 0.2
ONTARGET  NR Yes Central Published 73 12.4 81.3 0.2
OPTIMAAL NR No Central Published 71.2 NR 82 0.02
OSLO 0 No NR Published 100 41.7 NR 0
Otsuka et 
al 
NR No Site 
reported 
Published 72 NR 31 0
PARADIGM-
HF 
NR No Central Unpublished 78.2 NR 81.2 0.2
PAT NR No Central Published 84 34.7 65.3 1.1
PHARAO NR No NR Published 48 45.5 80 0
PHYLLIS NR No NR Published 40 16.2 NR NR
Practolol 
Study 
NR No Central Published 86.5 70 NR NR
PRAISE NR No NR Published 76 NR 90 0
PREVENT NR No Central Published 80.1 24.7 79 0
PREVER-
Treatment 
NR No NR Unpublished 51 7.3 NR 3.1
PRoFESS NR No NR Published 64 21.2 68.3 0.6
REIN 2 0 No NR Published 74.9 NR NR 2
RENAAL NR No NR Published 63.2 18.3 53.5 0.2
SAVE NR No NR Published 82.5 53 70 0.3
SCAT NR Yes NR Published 89.1 15 95 NR
SCOPE NR No Central Published 35.5 8.7 49 0.2
SHEP 0 No Central Published 43 12.7 NR NR
SMT NR No NR Published 80.4 56.8 96.7 NR
SOLVD-P NR No NR Published 88.6 23.5 75 0.2
SOLVD-T 0 No NR Published 80.4 22.1 65 0.1
SPRINT 0 No NR Published 85 46.6 83 0.5
STOP-HTN2 NR No NR Published 33.2 9 63.3 0
Suzuki NR No NR Published 59 22 NR 0
Syst-China NR No Central Published 64 31 NR 9.9
Syst-Eur NR No Central Published 33 7.3 NR 5
TRACE 0 No NR Published 71.5 74 63.5 0.3
TRANSCEN
D 
4.9 Yes Central Published 57 9.8 81 0.3
TROPHY NR No NR Published 59.6 NR NR NR
UKPDS 38 NR No NR Published 55 22.5 77 NR
VA COOP II 0 No NR Published 100 NR NR NR
Val-HeFT NR No NR Published 80 NR NR NR
VALIANT NR No NR Published 68.9 32 83 0.9
VALUE NR No NR Published 58 NR 74 0.6
VERDI 0 No NR Published 54 NR NR NR
VHeFT II NR No Site-
reported
Published 100 33 86 NR
Wilcox et 
al 
NR No Site-
reported 
Published NR NR NR NR
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Funnel plot of comparison: ACEI vs. non-ACEI, outcome: 4-5 Incident 
cancers 
 
Funnel plot of comparison: ARB vs. non-ARB, outcome: 5-5 Incident cancers 
 
Funnel plot of comparison: CCB vs. non-CCB, outcome: 6-4 Incident 
cancers 
 
Funnel plot of comparison: BB vs. non-BB, outcome: 7-5 Incident 
cancers 
 
Funnel plot of comparison: TZ vs. non-TZ, outcome: 8-5 Incident 
cancers 
Figure A-1 Funnel plots of antihypertensive drug classes’ comparison: outcome: Incident 
cancers
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Funnel plot of comparison: ACEI vs. non-ACEI, outcome: 4-7 Cancer-
related death 
 
Funnel plot of comparison: ARB vs. non-ARB, outcome: 5-7 Cancer-
related death 
 
Funnel plot of comparison: CCB vs. non-CCB, outcome: 6-6 
Cancer-related death 
 
Funnel plot of comparison: BB vs. non-BB, outcome: 7-7 
Cancer-related death 
 
Funnel plot of comparison: TZ vs. non-TZ, outcome: 8-7 
Cancer-related death 
Figure A-2 Funnel plots of antihypertensive drug classes’ comparison: outcome: Cancer-
related deaths 
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